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Abstract 
NK cells secrete a variety of immune-regulatory cytokines and chemokines 
such as interferon - γ (IFN-γ) and tumour necrosis factor- α (TNF-α). However, in 
some of infections where NK cells have an important role in the defence mechanism, 
IL-6 appears to play a significant anti-viral role. Considering the role of both IL-6 and 
NK cells in these infections raises the possibility that IL-6 secretion by NK cells could 
be a main defence mechanism against them. Morover, NK cell-mediated IL-6 
secretion may provide a critical link between the innate and adaptive immune response 
of the host. Furthermore, changes in this pathway in various autoimmune diseases, for 
example rheumatoid arthritis (RA) may be relevant for the pathogenesis of these 
disorders. 
The results presented in this thesis demonstrated that peripheral blood NK 
cells from healthy individuals have the ability to secrete IL-6 after co-culture with 
target cells against which these cells are known to exhibit direct cytotoxicity (either 
K562 or HeLa cells). The described secretory response was rapid, with IL-6 being 
significantly higher as early as 1 hour in HeLa co-cultures compared to 6 hours in case 
of K562 co-cultures. These findings were further confirmed when NK cells were 
activated alone with high doses of IL-2 or with non specific chemical activators 
(PMA+ ionomycin). These experiments clearly showed that NK cells have the 
potential to secrete IL-6 following activation. To analyse whether IL-6 secretion in the 
co-culture experiments was the result of direct cell-cell interactions between NK cells 
and the target cells or was induced by the presence of soluble mediators, co-culture 
experiments were set up where the target cells were separated from NK cells using a 
0.4 µm pore size inserts. Separating NK cells and target cells abolished increases in 
cytokine production proving that direct interaction between NK cells and target cells is 
necessary for triggering IL-6 production by NK cells, as the semi-permeable 
membrane of Transwell chambers allows for the free passage of soluble factors but 
prevents direct cell-cell contact. 
Investigating the activating pathway which triggers the secretion of IL-6 by 
NK cells was the next step. This aim was achieved by inducing NK cell activation 
with immobilized antibodies against NK cell activating receptors and assessing the 
effect of the engagement of these receptors on peripheral blood NK IL-6 gene 
expression and protein secretion by quantitative real time PCR and ELISA.The results 
demonstrated that NKG2D and NKp46 were the two main receptors involved in the 
IL-6 mRNA expression and secretion by NK cells.  
The final aim of this thesis was to evaluate the biological significance of this 
secretion through an in vitro experimental model. We hypothesized that IL-6 secreted 
by NK cells could contribute to the migration of other inflammatory and immune cells 
to the site of inflammation. This hypothesis was based on the observations of others 
that IL-6 could induce direct CD4
+
 T cell migration. To test this hypothesis, an in vitro 
transmigration assay using Transwell inserts with 8 and 3 µm pore size were used. Our 
results demonstrated that CD4
+
 T cell migration in response to NK cells was inhibited 
by about 30% in the presence of neutralizing antibody to IL-6. These results signify 
the relative biological importance of IL-6 induced secretion by NK cells. 
In conclusion NK cells can contribute to IL-6 secretion. Given that NK cells 
appear at inflammation sites at the earliest stages of the process, where the number of 
other cells with a potential to secrete IL-6 is low, it is possible that NK cell-mediated 
IL-6 secretion is essential in orchestrating and potentiating the later stages of the 
adaptive immune response. 
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1.1 Natural killer (NK) cells   
Human natural killer (NK) cells are large granular lymphocytes that 
function predominantly as cytotoxic effector cells of the innate immune system. They 
comprise about 5-15 % of all circulating lymphocytes and play a major role in the 
early host defence against tumours and viruses prior to initiation of the adaptive 
immune response (Biron and Brossay, 2001; Zamai et al, 2007; Fietta and Delsante, 
2009). They were named “natural killers” because of the initial notion that they did not 
require any previous immunisation or prior sensitisation in order to exert their 
cytotoxic functions. In addition NK cells also function as regulators of immune 
responses, via the secretion of immune-regulatory cytokines and chemokines and / or 
interaction with other immune cells to trigger an adaptive, or antigen-specific, immune 
response (Lünemann et al, 2009). In contrast to T- lymphocytes, natural killer cells do 
not express T-cell antigen receptor (TCR) or the pan T cell marker (CD3) (Ritz et al, 
1988 ; Murphy et al, 1992). They also fail to express surface immunoglobulins (Ig) 
which characterise B cells (Murphy et al, 1992). Instead, human natural killer cells 
express the surface marker (CD56), a neural cell adhesion molecule (NCAM) isoform 
found on NK cells and a minority of T cells, and CD16 (FcγRIII). Based on the 
surface expression of CD56 and CD16, peripheral blood NK cells can be divided into 
at least two functional subsets. CD56 
dim 
CD16 
bright
 NK cells constitute about 90% of 
total blood NK cells and CD56 
bright 
CD16 
dim/–  
cells make up <10% of NK cells in the 
blood, but they are enriched in secondary lymphoid tissues (Cooper et al, 2001a).  
 
1.1.1  Origin and development of NK cells 
It has been generally accepted that NK cell development primarily occurs 
within the bone marrow (BM) from the same hematopoietic CD34
+
 progenitor cells 
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(HPCs) as B and T cells but then they diverge from other lymphocyte lineages fairly 
early in their development (Fietta and Delsante, 2009). In the bone marrow NK cells 
develop from CD34
+ 
progenitor cells and express the phenotype CD34
+
 CD45RA
+
 
(Figure1.1). In mice, CD122 co-expression in the absence of other mature NK cell 
markers identifies these pre-NK cells Freud and Caligiuri, 2006). In humans, pre-NK 
cells do not express CD122 and therefore identification of these pre-NK cells is more 
difficult (Freud and Caligiuri, 2006). Some studies suggested that co-expression of 
CD7, CD10, CD117 and CD45RA on CD34
+
 cells are associated with a significant 
restriction toward NK cell development (Freud and Caligiuri, 2006; Caligiuri, 2008). 
Nevertheless, this phenotype is not specific for the NK cell lineage as B cells, T cells, 
and dendritic cells (DCs) can all be derived from this cell population (Galy et al, 
1995). Functional NK cells can be derived in vitro following culture of CD34
+
 cells in 
the presence of either interleukin-2 (IL-2) or IL-15, which signal through the shared 
IL-2 / IL-15 receptor β chain and the common γ chain (Mingari et al, 1997). These 
functional NK cells phenotypically and functionally resemble CD56 
bright
 NK cells 
(Carson et al, 1997). The expansion and differentiation of CD34
+
 CD45RA
+
 pre-NK 
cells is sustained by growth factors within the BM micro-environment including c-kit 
(KL) ligand, flt-3 (FL) ligand and cytokines such as IL-2, IL-7, IL-15 and IL-21 
(Fietta and Delsante, 2009). c-kit and flt-3 ligands  are crucial in the early commitment 
of CD34
+
 progenitor cells (HPCs) towards the NK cell lineage. They also up-regulate 
the expression of IL-15 receptor complex on NK cell precursors (Yu et al, 1998).  
Current evidence indicates that only the very early stages of NK cells 
development occur exclusively within the BM and the thymus and secondary 
lymphoid tissues (SLTs) are the fundamental sites for NK lymphocyte maturation (Di 
Santo and Vosshenrich, 2006; Fietta and Delsante, 2009). CD34
+
 CD45RA
+
 NK cells 
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are not only found in the BM, but also in thymus (Sánchez et al, 1994), cord blood 
(Canque et al, 2000) and SLTs (Freud et al, 2005) in concentrations even higher than 
those found in the BM. This enrichment of CD34
+
 CD45RA
+
 pre-NK cells together 
with immature NK (iNK) cells within SLT relative to BM or blood, along with an 
abundance of dendritic cells (DCs) and other antigen presenting cells (APCs) that 
express membrane bound IL-15, which is required for NK-cell maturation, suggested 
that SLTs may be a site for NK-cell development in vivo (Caligiuri, 2008).  
Since the discovery of the CD56 
bright / dim
 NK cell subsets it has been 
postulated that CD56 
dim
 NK cells may represent a subsequent stage of CD56 
bright
 NK 
cell maturation (de Toledo et al, 2010). This hypothesis is supported by some data as 
only CD56 
bright  
(but not CD56 
dim
)
 
cells have convincingly been generated in vitro 
from CD34
+
 CD45
+
 pre-NK cells following treatment with IL-2 and/or IL-15 (Mrózek 
et al, 1996; Carson et al, 1997) , and only CD56 
bright
 NK cells express the c-kit 
immature cell marker (Cooper et al, 2001a). It is important to note that CD56 
bright
 NK 
cells appear to be the only lymphocytes with constitutive expression of the high-
affinity IL-2R, while CD56 
dim
 NK cells express only the intermediate affinity IL-2R 
and do not express c-kit marker (Cooper et al, 2001a). This could explain, in part, why 
CD34
+
 HPCs in LN differentiate preferentially into CD56 
bright
 NK cells, and why 
CD56 
dim
 NK cells proliferate weakly in response to high doses of IL-2 or IL-15 (de 
Toledo et al, 2010). CD56 
bright
 NK cells have been found to be predominantly present 
within SLTs (Freud and Caligiuri, 2006). Since CD56 
dim 
NK cells are more abundant 
in peripheral blood, it had been postulated that the CD56 
bright 
NK population is less 
mature than the CD56 
dim 
subset and activation of CD56 
bright 
NK cells within SLTs 
increased the expression of NK receptors that are characteristic of the CD56 
dim
 subset.  
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Figure 1.1: Different stages of human NK cell development. CD34
+
CD45RA
+
 
HPCs pro- NK cells leave BM circulate in the blood and then enter secondary 
lymphoid tissues (SLTs) through extravasation. Here, pro-NK cells are activated 
through contact with dendritic cells (DCs) and progress through distinct stages of 
maturation, namely immature NK (iNK), CD56 
bright
 and CD56 
dim
 NK cells. Mature 
CD56 
dim
 NK cells return to the circulation via the efferent lymph whereas most CD56 
bright
 NK cells remain within the SLTs. Illustration by Debra T. Dartez. Reproduced 
from Caligiuri MA (2008). 
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1.1.2  NK cell subsets: 
1.1.2.1  Phenotypic properties  
NK cells are large granular lymphocytes possess a prominent kidney shaped 
nucleus and numerous granules, many of which are secretory granules containing the 
lytic effector molecules involved in NK cell-mediated cytotoxic activity. In addition, 
they have extensive and well developed endoplasmic reticulum and Golgi networks 
suggesting a significant level of constitutive protein synthesis. 
Human NK cells selectively express CD56, an isoform of the human neural 
cell adhesion molecule (NCAM) that is generally not expressed by other 
haematopoietic cells or lymphocytes (Lanier et al, 1989). The function of CD56 on 
human NK cells is controversial. Early studies suggested that this molecule might 
mediate interactions between human NK cells and target cells (Nitta et al, 1989; 
Suzuki et al, 1991). However, mouse NK cells do not express CD56 suggesting that 
this functional role on NK cells is not conserved (Hayakawa et al, 2006). Recent 
studies suggested a role for CD56 in promoting the terminal maturational step of NK 
cells (Caligiuri, 2008). Using an in vitro co-culture system consisting of purified CD56 
bright
 NK cells and human fibroblasts, Chan et al (2007) demonstrated that antibody 
blockade of the interaction between CD56 and fibroblast growth factor receptor-1 
significantly inhibited the generation of CD56 
dim
 NK cells. Nevertheless, CD56 is 
particularly useful as a pan NK cell marker in humans. 
 The other widely used marker for the characterisation of NK cells is CD16, 
a low-affinity receptor for the Fc portion of IgG isotypes (Schumann et al, 1994). It is 
also found on monocytes / macrophages and neutrophils (Selvaraj et al, 1988; 
Wirthmueller et al, 1992). NK cell and macrophage isoforms of CD16 (FcγRIIIa) are 
integral membrane proteins in contrast to the GPI-linked isoform of neutrophils 
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(FcγRIIIb) (Fossati et al, 2001). CD16 is a potent activator of NK cell cytotoxicity, 
allowing NK cells to recognize and bind Ab-coated (opsonized) targets (Mandelboim 
et al, 1999). This mechanism is termed antibody-dependent cellular cytotoxicity 
(ADCC). Differences in the level of expression of CD16 have functional consequences 
for ADCC by NK-cell subsets, as will be discussed later.  
Based on the cell surface density of CD56 and CD16, human NK cells have 
been phenotypically divided into at least two subsets with different functional patterns 
and tissue locations (Figure1.2). In the peripheral blood of healthy individuals the 
majority (90%) of NK cells belong to the CD56 
dim
 CD16 
bright
 subset while a minority 
(10%) are CD56 
bright
 CD16 
dim/-
 (Cooper et al, 2001a). However, CD56 
bright
 CD16 
dim/-
 
cells prevail in SLTs representing more than 75% of NK cells in these tissues 
(Moretta, 2010). It is also noteworthy that the infiltrating NK cells in a number of 
human inflammatory lesions were found to be mainly CD56 
bright 
CD16 
dim/– 
NK cells 
(Dalbeth et al, 2007) suggesting a prominent role for these cells both in secondary 
lymphoid tissues as well as at sites of infection and inflammation. In contrast to the 
CD56 
dim
 CD16 
bright
 NK cell subset, which efficiently kill target cells and secrete only 
low levels of cytokines, activated CD56 
bright
 CD16 
dim/-
 cells produce large amounts of 
cytokines including interferon-γ (IFN-γ), tumer nicrosis factor-α (TNF-α) and 
granulocyte monocyte-colony stimulating factor (GM-CSF), but acquire cytotoxicity 
after prolonged activation (Strowig et al, 2008). Recent studies revealed that CD56 
dim
 
CD16 
bright 
cells can also be a potent source of cytokines (Moretta, 2010). CD56 
bright 
CD16 
dim/- 
and CD56 
dim
 CD16 
bright
 NK cells also differ from each other in the 
expression of inhibitory and activating NK cell receptors as well in the expression of 
adhesion molecules and chemokine receptors which facilitate homing to lymphoid 
tissues and the sites of inflammation. These will be discussed later on in this chapter. 
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Figure 1.2: NK cell subsets. NK cells are not a homogenous group of cells. Instead 
they are generally divided into two subsets based on the surface expression of CD56 
and CD16 markers. A) CD56 
bright
 CD16 
dim/-
 NK cells account for ~ 10% of peripheral 
blood NK cells but they are enriched in SLTs. B) CD56 
dim
 CD16 
bright
  cells account 
for ~ 90% of peripheral blood NK cells.  In addition to the differences in their 
localization, the two groups also differ in their surface expression of activating and 
inhibitory receptors, and adhesion molecules. Reproduced from Cooper et al (2001c). 
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1.1.2.2  Cytokine and chemokine receptors 
All NK cells express the low-intermediate affinity interleukin-2 receptor 
(IL-2Rβγ), whereas the high affinity heterodimeric receptor, IL-2Rαβγ (CD25), is 
exclusively expressed on the CD56 
bright
 cells (Caligiuri, 1990). This subset has a high 
proliferative response to low doses of IL-2 alone and can be expanded in vitro and in 
vivo in response to picomolar concentrations of IL-2 in contrast to resting CD56 
dim 
NK cells which show almost no proliferation in response to high doses of IL-2 in vitro 
(Cooper et al, 2001a). High level of expression of some of monokine receptors 
including IL-1RI and IL-18R has also been noted in the CD56 
bright
 subset (Cooper et 
al, 2001a; Poli et al, 2009) suggesting that these cells probably receive some of their 
earliest activation signals from monocytes during the innate immune response. 
The two subsets of NK cells also differ in terms of chemokine receptors and 
adhesion molecule expression, suggesting that they have different homing properties. 
CD56 
dim
 cells express high level of the chemokine receptors CXCR1, CXCR3, 
CXCR4 and CX3C-chemokine receptor 1 (CX3CR1) but lack the expression of CCR7 
(Robertson, 2002). In contrast, CD56 
bright
 cells show little expression of CXC 
receptors but they do express high levels of CCR7 (Robertson, 2002). None of the NK 
cell subsets express CXCR2, CXCR5, or CCR5. These different chemokine profiles 
suggest the existence of differential trafficking for both CD56 
bright
 and CD56 
dim 
NK 
cell subsets, influencing their functions in innate and adaptive immunity. 
CD56 
bright 
CD16 
dim/- 
NK cells also constitutively express the adhesion 
molecule CD62L (L-selectin) (Frey et al, 1998). This molecule, together with CCR7, 
allows the recruitment of CD56 
bright 
subset from the blood into lymphoid tissues and 
site of inflammation. CD56 
bright
 NK cells also display a stronger expression of CD2, 
CD11c, CD44, CD49e and CD54 adhesion molecules, whereas CD56 
dim
 NK cells 
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express more CD11a (Poli et al, 2009). At sites of inflammation, CD56 
bright
  CD16 
dim/- 
cells display an activated phenotype (CD69), and  undergo reciprocal stimulatory 
cell-to-cell interactions with monocytes/macrophages and DCs (Fietta and Delsante, 
2009). Such a NK/DC “stimulatory synapse” promotes the DC secretion of IL-12, 
crucial not only for inducing the release of IFN-γ by NK cells, but also for increased 
cytotoxicity (Fietta and Delsante, 2009).  
 
1.1.2.3  Functional properties 
1.1.2.3.1  Response to and production of cytokines and chemokines  
Although interleukin 15 (IL-15) has no sequence homology with IL-2, it 
interacts with components of the IL-2 receptor (IL-2R) (Carson et al, 1994; Freud and 
Caligiuri, 2006). High concentrations of IL-15 (nanomolar) can induce proliferation of 
CD56 
bright
 NK cells via signalling through the IL-2 receptor β and γ subunits that are 
common to both the IL-2 and IL-15 receptors (Carson et al, 1994). The proliferative 
effects of IL-15 on CD56 
bright
 NK could be abrogated by anti-IL-2R β and anti-IL-2R 
γ but not by anti-IL-2R α antibodies. IL-15 is produced by activated monocytes 
/macrophages thus these cells may regulate NK cell function (Ferlazzo et al, 2004). 
Resting human NK cells constitutively express the IL-10 receptor (Carson et al, 1995). 
Although IL-10 does not induce proliferation of CD56 
bright
 or CD56 
dim
 NK cells, low 
concentrations of IL-10 significantly augment IL-2-induced proliferation of CD56 
bright 
NK cells (Carson et al, 1995). IL-10 is also able to induce significant NK cytotoxic 
activity against NK-resistant tumour cell targets in both subsets of NK cells in a dose-
dependent fashion. Furthermore, the combination of IL-10 and IL-2 had an additive 
effect on NK cytotoxic activity (Carson et al, 1995). Production of IFN-γ, TNF-α and 
GM-CSF by IL-2-activated NK cells was also significantly enhanced by IL-10 
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(Carson et al, 1995). It is noteworthy that CD56 
bright 
cells require no co-stimulus to 
initiate their proliferative response to IL-2 or IL-15. This is in sharp contrast to both T-
cells and B-cells which require additional signals from CD28 and CD40 respectively 
(Langley, 2005). This observation is consistent with an early effector role of NK cells 
in the innate immune response.  
Freshly isolated CD56 
bright
 human NK cells are the primary source of NK-
cell-derived immune-regulatory cytokines. These include IFN-γ, TNF-α, and GM-CSF 
(Diefenbach and Raulet, 2001). During the innate immune response, when 
macrophages encounter pathogens, they produce a variety of monocyte-derived 
cytokines (monokines) which include IL-2, IL-12, IL-15 and IL-18. These monokines 
can then activate the production of cytokines by CD56 
bright
 NK cells. Studies have 
shown that IL-12 combined with IL-18 is the optimal stimulus for the production of 
IFN-γ while IL-15 together with IL-18 results in optimal production of GM-CSF 
(Cooper et al, 2001a). These data suggest that the qualitative and quantitative 
production of monokines following infection of the host is probably important in 
determining the cytokine response of CD56 
bright
 NK cells. The production of these 
cytokines is also differentially regulated by IL- 4 and IL-12. Whereas production of 
IFN-γ in response to IL-2 is significantly inhibited or induced by IL-4 and IL-12 
respectively, the production of other cytokines remains relatively unaffected (Perussia, 
1996). Secretion of IFN-γ by CD56 dim NK cells is negligible when co-cultured with 
recombinant monokines. However, these cells seem to be a potent source for IFN-γ 
and TNF-α when they come in contact with target cells (Fauriat et al, 2010).  
Resting NK cells have been shown to express mRNA for different 
chemokines. These include macrophage inflammatory protein 1α (MIP-1α; CCL3), 
monocyte chemoattractant protein-2 (MCP-2; CCL8) and activation-induced, T cell–
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derived, and chemokine-related (ATAC; XCL1) (Roda et al, 2006). Following 
activation, however, NK cells have been shown to dramatically up-regulate their 
expression of chemokine transcripts and to secrete chemokines with the capacity to 
recruit T cells, B cells, neutrophils, and other activated NK cells. These include MIP-
1α, MIP-1β, IL-8, macrophage-derived chemokine (MDC; CCL22), and regulated on 
activation, normal T-cell expressed and secreted (RANTES; CCL5) (Fehniger et al, 
1999; Diefenbach and Raulet, 2001; Roda et al, 2006). NK cells produce these 
chemokines after activation with IL-2 or IL-12, or following activation of their 
receptors during interactions with target cells (Roda et al, 2006; Fauriat et al, 2010). 
However, differential secretion of chemokines by specific NK cell subsets has not 
been fully evaluated.  
 
1.1.2.3.2  NK cell cytotoxicity 
Unlike cytotoxic T lymphocytes (CTLs), NK cells do not require antigen-
specific recognition to kill target cells, and as such are capable of limiting infection 
prior to the induction of adaptive immune response. Consistent with their more 
granular appearance, the cytotoxic activity of CD56 
dim 
NK cells is significantly higher 
than that of CD56 
bright
 cells (Poli et al, 2009). However, after activation with IL-2 
CD56 
bright
 and CD56 
dim
 cells exhibit similar levels of cytotoxicity. The high 
expression level of CD16 on CD56 
dim
 cells makes them efficient mediators of 
antibody-dependent cellular cytotoxicity (ADCC), whereas CD56 
bright
 CD16 
dim/-
 NK 
cells perform ADCC only weakly or not at all (Poli et al, 2009). NK cell cytotoxicity 
is initiated via two main pathways, the granule - exocytosis pathway and the receptor 
mediated (ligation of death receptors) pathway (Cullen et al, 2008). In the granule - 
exocytosis pathway, several cytotoxic secretory granules are released from the 
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cytoplasm of NK cell into the immunological synapse between it and the target cell. 
These cytotoxic granules are formed during development and therefore, NK cells are 
equipped to respond rapidly to the threat of tumourigenicity or infection. The granule 
components are numerous powerful proteases together with other lytic molecules 
which, upon delivery to the target, cause rapid cell death in less than 20  min (Cullen 
et al, 2008). Of the proteases, perforin and granzymes are the most abundant. Upon 
release by NK cells, perforin integrates into the membrane of the target cell and 
disrupts its integrity allowing entry of granzymes to the inside of target cell. When 
delivered to the target cell, granzymes promote programmed target cell death 
(apoptosis) either indirectly through the activation of a family of death-inducing 
proteases called caspases or directly by fragmentation of the target cell DNA (Trapani 
and Smyth, 2002). Therefore, even if caspases are inhibited by viral proteins or are 
inactivated through mutation in an attempt from the pathogens to prolong the life of 
the infected cell, the granzyme-mediated proteolysis of other cellular substrates 
remains rapid, powerful and multi-faceted, and cell death follows in minutes, thereby 
limiting pathogen replication and spread.  
Natural killer (NK) cell cytotoxicity was initially thought to be only 
dependent on perforin and granzymes. However, granzyme - deficient NK cells were 
also shown to retain potent in vivo antitumour activity despite the fact that these cells 
can not cause cell death by DNA fragmentation (Cullen et al, 2008). This suggests that 
the NK cells can employ another killing mechanism(s). Although many studies, 
including studies in perforin - deficient animals, have led to the conclusion that 
perforin / granzyme-mediated induction of cell death is still a principal pathway used 
by NK cells to eliminate virus-infected or transformed cells (Van den Broek er al, 
1995; Kägi et al, 1996; Smyth et al, 1999; Pardo et al,2002), it is now clear that NK 
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cells are also capable of using death ligands like Fas ligand (FasL) or tumour necrosis 
factor-related apoptosis-inducing ligand (TRAIL) to induce cytotoxicity (Oshimi et 
al,1996; Eischen and Leibson, 1997; Kayagaki et al,1999; Wallin et al, 2003). 
However, still relatively little is known about the control of the "perforin and 
granzyme-independent" cytotoxicity, for example, the regulation of FasL expression 
on NK cells.  
 
1.1.3  Regulation of NK cell functions 
1.1.3.1  Missing self hypothesis (role of MHC-class I molecules) 
The first important clue as to the regulation of NK cell function came in 
1986 from the observation that major histocompatibility complex (MHC) - class I 
deficient tumour cells were attacked by NK cells in vivo (Kärre et al, 1986). Since 
then, a ”missing self” hypothesis was introduced proposing that NK cells discriminate 
target cells according to the level of self MHC-class I expression (Kärre et al, 1986; 
Ljunggren and Kärre, 1990). Thus, the absence or altered expression of MHC class I 
molecules would render target cells susceptible to NK cell attack while normal levels 
of MHC class I molecules would inhibit NK cells. Further support for the “missing 
self” hypothesis was shown in allogeneic BM grafts and T-cells lymphoblasts from 
β2-microglobulin deficient mice that were attacked by NK cells from syngeneic wild-
type (WT) mice and this rejection could be prevented by expressing a H-2 transgene 
(MHC-class I antigen) in the donor mice (Ohlén et al, 1989). In addition, the 
phenomenon of hybrid resistance, where a (A x B) F1 host rejects A or B grafts (A and 
B refers to MHC genotype), was known to be dependent on NK cells (Davenport et al, 
1995; Kumar et al, 1997). Moreover, the notion that the rejection of class I MHC 
deficient bone marrow cells by NK cells from MHC-matched mice was a strong 
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suggestion that susceptibility to NK cell lysis of the parental graft was, at least in part, 
linked to the absence of specific MHC class I products in the donor (Ohlén et al, 1989; 
Yu et al, 1992; Borrego, 2006). Based on the ”missing self” hypothesis  NK cells 
survey the surface of host cells for the expression of autologous MHC class I 
molecules via surface receptors that deliver signals inhibiting NK cell functions. The 
failure to express one or more MHC-class I alleles by target cells represents a major 
threat to host integrity rendering them more susceptible to NK cell lysis. Certain 
viruses including herpesviruses and adenoviruses induce MHC-class I down regulation 
as strategies to evade HLA-class I- restricted CTLs (Petersen et al, 2003).  However, 
this down regulation of MHC- class I molecules makes them more susceptible to NK 
cells lysis. This is particularly important in the early stages of viral infection when 
CTLs are unable to mediate protection and may represent a general mechanism by 
which NK cells limit virus spreading during the early phases of infection. Regarding 
MHC-class I expression in tumour cells, these often express low levels of these 
molecules and over 85% of human metastatic carcinomas display deficient HLA-class 
I expression (Garrido and Ruiz-Cabello, 1999; Moretta et al, 2004). This could reflect 
a loss of a single allele, or a general down regulation of all class I alleles. This 
regulatory mechanism has been demonstrated experimentally where NK cells lysed 
MHC-class I deficient EBV-transformed B-lymphoblastoid cell lines, whereas 
transfection of MHC-class I alleles into target cells inhibited lysis (Storkus et al, 1989; 
Shimizu and DeMars, 1989; Farag et al, 2002). 
 
1.1.3.2  MHC - class I independent regulation of NK cell function 
Some studies have demonstrated that NK cells are still able to efficiently 
attack some target cells that express normal levels of MHC - class I molecules. For 
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example, some virus-infected cells that maintain expression of MHC class I at the cell 
surface can still be killed by autologous NK cells (Routes, 1992; Malnati et al, 1993; 
Farag et al, 2002). On other hand, some other cells are not sensitive to NK cell lysis 
despite low or absent class I MHC expression. For example, NK cells are unable to 
reject MHC class I–deficient non hematopoietic tissues, such as skin grafts, and in 
vitro they fail to lyse fibroblasts, even from β2-microglobulin null mice that lack class 
I expression (Zijlstra et al, 1992; Farag et al, 2002). NK cells are also unable to attack 
human erythrocytes despite low or abscent MHC class I expression by these cells 
(Lanier, 2003). Furthermore, ligation of NK activating receptors with membrane-
bound molecules of target cells or monoclonal antibodies results in NK cell 
cytotoxicity and cytokine production (André et al, 2004). These observations point to 
the additional importance of activating receptors in regulating NK cell effector 
function. Therefore  the regulation of NK functions appears to be more complicated 
than it was thought, and it is now largely accepted NK cell cytotoxicity and cytokine 
secretion are ultimately regulated by a balance of signals from activating and 
inhibitory receptors that interact with MHC class I and non class I–like molecules on 
target cells.  
 
1.1.4  NK cell receptors (NKRs) 
Three major superfamilies of NKRs have been described in humans (Lanier, 
1998; Cooper et al, 2001a): the killer cell immunoglobulin - like receptor (KIR) 
superfamily, which primarily recognizes classical MHC-class I molecules (HLA-A, -B 
and -C); the C-type lectin superfamily, which includes CD94 and NKG2 receptors 
recognizing non classical MHC class I molecules (HLA-E); and natural cytotoxicity 
receptors (NCRs) whose ligands are unknown. In general, triggering KIRs as well as 
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the CD94/NKG2A receptor on NK cells by classical and non-classical MHC class I 
molecules respectively delivers negative signals that prevent target cell killing (Lanier, 
2005), although some activating KIRs are also available. In contrast, engagement of 
activating receptors such as NCRs by naturally occurring ligands provides an NK cell 
activating signal, which can also be mimicked by stimulating these receptors with 
appropriate antibodies (Moretta et al, 2001). 
   
1.1.4.1  MHC class I receptors  
1.1.4.1.1  Killer-cell immunoglobulin-like receptors (KIRs) 
KIRs, originally known as natural killer associated transcripts (NKATs),  
are a family of protein molecules found on the surface of the NK and T cells that 
specifically recognize HLA-A, HLA-B and HLA-C alleles. They are encoded by a 
diverse and rapidly evolving family of genes located on chromosome 19p13.4 and 
different individuals differ in the number and type of inherited KIR genes (Trowsdale, 
2001; Vilches and Parham, 2002). The KIR family of proteins has also been 
designated CD158 a-k (André et al, 2001). 
KIRs are named according to whether they have two extracellular domains 
(2D) or three extracellular domains (3D) and whether they possess a short (S) or long 
(L) cytoplasmic tail (Colonna and Samaridis, 1995; Long et al, 1996). KIRs with long 
cytoplasmic tails contain immunoreceptor tyrosine-based inhibition motifs (ITIMs) 
and have inhibitory functions (Colonna and Samaridis, 1995; Long et al, 1996; 
Trowsdale, 2001; Vilches and Parham, 2002). Therefore, NK cells expressing KIR 
with ITIM sequences in their cytoplasmic domains (KIR2DL and KIR3DL) are 
inhibited from lysing target cells that express MHC class I molecules. This interaction 
usually also inhibits cytokine production by the effector cells (D'Andrea et al, 1996). 
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In contrast, expression of KIRs with short cytoplasmic tails without an ITIM (e.g. 
KIR2DS) have a potentially activating function through interactions with the adaptor 
molecule DAP12 and NK cells expressing such receptors  appear to promote cytolysis 
against target cells expressing an appropriate MHC class I molecules (Moretta et al, 
1995; Vilches and Parham, 2002). Despite the functional differences, activating and 
inhibitory variants of KIR molecules share the same MHC class I ligand due to the 
almost identical extracellular domain (Borrego et al, 2002). CD56 
bright
 CD16 
dim/-
 cells 
have low to absent expression of KIRs which are, in contrast, expressed by CD56 
dim
 
CD16 
bright
 NK cells (Cooper et al, 2001a). The differential expression of the more 
complex inhibitory and activating KIR receptor repertoire by the latter subset of 
human NK cells probably enables the unique regulation of cytotoxic properties by 
these cells (Lünemann et al, 2009).  
 
1.1.4.1.2  CD94/NKG2 receptors 
In humans CD94/NKG2 receptors are a group of molecules structurally 
characterized by c-type lectin extracellular domain that require Ca2+ for carbohydrate 
recognition (Drickamer, 1988). These receptors are type II integral proteins expressed 
as disulphide-linked heterodimers composed of an invariant common sub-unit, CD94, 
linked to a distinct glycoprotein member of NKG2 family (Lazetic et al, 1996; Brooks 
et al, 1997; Cantoni et al, 1998). It appears that the NKG2 glycoproteins are usually 
unable to be expressed on the cell membrane unless they are disulphide-linked to 
CD94. CD94 has very short cytoplasmic tail and by itself is unable to transduce 
signals, but is necessary for expression of NKG2 on the cell surface (Lanier, 1998).  
CD94 and NKG2 genes are closely linked on human chromosome 12 in the 
NK gene complex (Houchins et al, 1991; Renedo et al, 1997). Whereas CD94 is 
 
 
20 
 
encoded by a single gene with limited or no allelic polymorphism, the NKG2 family is 
encoded by five genes designated NKG2A, NKG2C, NKG2E (Houchins et al, 1991), 
NKG2F (Plougaste and Trowsdale, 1997) and NKG2H which is an alternative splice 
variant of NKG2E (Bellón et al, 1999). Although NKG2D is encoded within the NK 
gene complex on human chromosome 12 but it is distantly related to NKG2 and shows 
only 20% sequence homology with other NKG2 family members (Houchins et al, 
1991) and does not interact with CD94 (Wu et al, 1999). Apart from the NKG2F, 
NKG2 genes show some degree of sequence homology with each other within same 
species for example; NKG2C and NKG2E genes in humans are 92% identical 
indicating that, like the KIRs, they probably arose from recent duplication events 
(Middleton et al, 2002). Similar to KIRs, the CD94/NKG2 family of receptors has 
individual members with activating and inhibitory features that correlate with ITAMs 
or ITIMs subunits in their transmembrane and intracytoplasmic tails respectively.  
The inhibitory members of this family are NKG2A and an isoform of 
NKG2A generated by alternative spliced pre-mRNA referred to as NKG2B (Houchins 
et al, 1991). NKG2A and NKG2B express two cytoplasmic ITIMs capable of 
interacting with SH2 containing phosphatase (SHP)-1 and SHP-2. CD94/NKG2A (B) 
heterodimers bind HLA-E, a non-classical MHC class I molecule in humans (Braud et 
al, 1998; Lee et al, 1998b; Navarro et al, 1999; López-Botet et al, 2000). The 
interaction of CD94/NKG2A (B) with HLA-E is a central mechanism by which NK 
cells indirectly monitor the expression of other classical MHC class I molecules within 
a target cell. To be expressed, HLA-E needs to bind conserved sequences derived from 
the leader sequences of classical MHC-class I molecules (Braud et al, 1998; Lee et al, 
1998a). In other words, optimum expression of HLA-E molecules on target cells is 
dependent on the expression of other classical MHC-class I molecules. Thus NK cells 
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expressing CD94/NKG2A (B) are able to monitor indirectly the integrity of the 
expression of other MHC class I molecules.  
The activating forms of NKG2 receptors are NKG2C, NKG2E and NKG2H 
with NKG2E and NKG2H being generated by alternative splicing of the same pre-
mRNA transcript (Bellón et al, 1999). These molecules have intracellular tails without 
ITIM motifs and a charged amino acid in the transmembrane region necessary for the 
association with DAP-12, an immuno-receptor tyrosine-based activation motif 
(ITAM) - bearing adaptor molecule (Lanier et al, 1998; Braud et al, 1998; Vance et al, 
1999; López-Botet et al, 2000). The ligand for these receptors is HLA-E (Braud et al, 
1998; López-Botet et al, 2000). An interesting member of the NKG2 family is 
NKG2F. It differs from other NKG2 genes in that it has a shortened extracellular 
domain because of two additional nucleotides that lead to a premature stop codon but 
the transcripts of this gene have been detected in most NK clones (Plougaste and 
Trowsdale, 1997; Middleton et al, 2002). The putative NKG2F protein has a charged 
residue in the transmembrane region, a mock ITIM-like motif in the cytoplasmic tail 
and does not contain any C-type lectin domain (Kim et al, 2004). However, it can be 
associated with DAP12 in its transmembrane regeion thereby providing activation 
signaling potential (Kim et al, 2004). A conserved 24-amino acid sequence, present in 
all members of the NKG2 family, suggests that NKG2-F could form heterodimers 
with CD94 (Borrego et al, 2002). Regarding the expression of CD94/NKG2 receptors 
on different subsets of NK cells, CD56 
bright
 NK cells preferentially express the 
inhibitory CD94/NKG2A complex (de Matos et al, 2007; Lünemann et al, 2009).  
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1.1.4.2  Non - MHC class I specific receptors  
1.1.4.2.1  NKG2D 
The stimulatory natural killer group 2 D (NKG2D) receptor, also known 
CD314, is a type II trans-membrane protein (Houchins et al, 1991) with an 
extracellular C-type lectin-like domain (Li et al, 2001; Wolan et al, 2001). It was 
originally identified in 1991 as an orphan activating receptor expressed on human NK 
cells (Houchins et al, 1991). Subsequently, mouse, rat, and porcine homologues have 
also been identified. NKG2D is also expressed on CD8
+
 T cells and subpopulations of 
γδ T cells (Bauer et al, 1999). The NKG2D gene is encoded within the "NK complex" 
(Figure 1.3) on human chromosome 12 (Glienke et al, 1998) and mouse chromosome 
6 (Ho et al, 1998). Despite its name and its genomic location, NKG2D differs 
dramatically in sequence from the other NKG2 proteins (only 21% identity in amino 
acid sequence) (Houchins et al, 1991), does not associate with CD94 and does not 
recognize Qa-1/HLA-E (Wu et al,1999; Diefenbach and  Raulet , 2001). 
 
 
Figure 1.3: The human and mouse NKG2D gene. The NKG2D gene is located 
within the NK cell complex on chromosome 6 in mouse and chromosome 12 in 
human. Other genes found in the human “NK complex” include CD69, CD94, NKR-
P1A, and the NKG2 family while the mouse “NK complex” includes the NKG2 
family, the Ly49 family, the NKR-P1 family, CD94 and CD69. Reproduced from 
Raulet DH (2003). 
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1.1.4.2.1.1 NKG2D structure and distribution 
Crystal structures of human and mouse NKG2D revealed that NKG2D 
retains an overall structure that is surprisingly homologous to other members of the C-
type lectin family including CD94, Ly49A, and CD69, despite the relatively low 
sequence identity (Diefenbach and  Raulet , 2001). NKG2D itself is more closely 
related to CD94 than other members of the C-type lectin family and it does not contain 
a putative carbohydrate binding site or any of the features that are characteristic of the 
Ca2+ binding sites of C-type lectins (Middleton et al, 2002). Kinetic analysis indicated 
that the NKG2D interaction with its ligands such as MICA might be more stable than 
TCR - ligand and other NK receptor - ligand complexes (Li et al, 2001; Middleton et 
al, 2002). Although there is little obvious sequence similarity between human and 
mouse NKG2D ligands, there appears to be considerable structural similarity as shown 
by the ability of mouse NKG2D to react with human ligands, MICB, ULBP1, and 
ULBP2 (Kubin et al, 2001). Structural conservation is also indicated by the fact that, 
although the MICA and MICB proteins of various primate species are highly diverse, 
they are readily recognized by receptors on human intestinal epithelial γδ cells (Groh 
et al, 1998).  
There are significant differences in the expression pattern of NKG2D 
receptors between mice and humans. In mice, NKG2D is expressed on the cell surface 
of almost all NK cells (Raulet, 2003). Increased expression is observed when NK cells 
are treated in vitro with IL-2 or IL-15 (Kubin et al, 2001). Resting peripheral blood 
CD4
+ 
and CD8
+
 T cells do not express significant levels of NKG2D, but the 
expression of the receptor is up-regulated by T-cell receptor (TCR) cross-linking in all 
CD8
+
 but not in CD4
+
 T cells (Diefenbach et al, 2000). Co-stimulation with anti-CD28 
does not increase further NKG2D expression by CD8
+
 T cells (Diefenbach et al, 2000; 
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Diefenbach and  Raulet, 2001; Raulet, 2003). Approximately 25% of mouse splenic γδ 
T cells, all of which also express CD44, express NKG2D (Raulet, 2003). In vivo 
treatment of severe combined immunodeficeny syndrome (SCID) mice with IL-15 
leads to up-regulation of NKG2D on splenocytes (Kubin et al, 2001). Almost all of the 
γδ T cells in the mouse epidermis (dendritic epidermal T cells) also express NKG2D, 
whereas most mouse intestinal intraepithelial γδ T cells do not (Raulet, 2003). In 
humans, virtually all NK cells also express NKG2D, and the levels are increased by 
exposure to IL-15 (Sutherland et al, 2002). In contrast to resting mouse CD8
+
 T cells 
that do not express NKG2D, almost all human peripheral blood CD8
+
 T cells express 
this receptor constitutively without activation, including those that lack expression of 
the co-stimulatory molecule CD28 (Diefenbach and  Raulet, 2001; Raulet, 2003). 
Expression of NKG2D receptors by these cells is maintained after activation.  As in 
mice, human CD4
+ 
T cells do not express NKG2D (Bauer et al, 1999; Diefenbach and  
Raulet, 2001). All human γδ T cells express NKG2D in contrast to mouse γδ T cells 
whose expression appears to be primarily restricted to the subset of cells that expresses 
CD44 (Diefenbach and  Raulet, 2001; Raulet, 2003). In addition, although intestinal 
intraepithelial γδ T cells lack NKG2D expression in mice, almost all human intestinal 
intraepithelial γδ T cells express NKG2D at low levels, which can be increased by 
incubation with IL-15 (Raulet, 2003).  
 
1.1.4.2.1.2 NKG2D ligands 
Several families of ligands have been described for NKG2D in humans, all 
of which are distantly related to MHC class I molecules.  
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1.  The MIC family of proteins (MICA and MICB) 
MICA (MHC class I chain-related gene A) is a heavily glycosylated 
transmembrane glycoprotein that functions as a ligand for human NKG2D (Bauer et 
al, 1999). A closely related protein, MICB, shares 85% amino acid identity with 
MICA (Bahram and Spies, 1996, Bahram et al, 1996b). Although they share some 
structural similarity with MHC-class I molecules in that they possess three 
extracellular Ig-like domains (α1, α2, and α3 domains) there is only 27% amino acid 
identity with human MHC class I, they do not associate with ß2-microglobulin and 
have no capacity to bind peptide (Li et al, 1999). The genes encoding these proteins 
are found within the MHC locus in most but not all mammalian species (Groh et al, 
1996; Steinle et al, 1998). However, they are absent in mice where no MIC 
homologues have been identified. Instead, in this species NKG2D binds to H60 
(Cerwenka et al, 2000; O'Callaghan et al, 2001, Cerwenka et al, 2002) and the 
members of the Rae-1 family (O'Callaghan et al, 2001). Both MICA and MICB loci 
are highly polymorphic with more than 50 and 12 recognized human alleles 
repectively (Petersdorf et al, 1999; Stephens, 2001). The functional significance of this 
polymorphism remains unclear. Because of MICA's proximity to HLA-B, which is 
associated to a number of autoimmune diseases, most efforts to study the role of 
MICA in human diseases are mainly focused on the potential associations with 
autoimmune diseases (Choy and Phipps, 2010). For example, Behçet's disease was 
among the first to be associated with a MICA polymorphism (Choy and Phipps, 2010). 
However, several later studies concluded that the disease is instead associated with 
HLA-B*51 and the perceived association with MICA alleles was due to linkage 
disequilibrium (Choy and Phipps, 2010). Ankylosing spondylitis is another disease 
known to be primarily associated with HLA-B*27, whereas MICA association appears 
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secondary. Therefore, more refined disease studies on MICA polymorphism, 
independent of HLA association, need to be undertaken to confirm its pathological 
role. 
Under normal circumstances, the expression of MIC proteins is highly 
restricted to the human intestinal epithelium, endothelial cells, and fibroblasts (Groh et 
al, 1996; Groh et al, 1998; Zwirner et al, 1999). Additionally, in the sub-capsular 
cortex of infant thymi a population of stellate MIC expressing epithelial cells could be 
identified (Groh et al, 1996; Diefenbach and Raulet, 2001). Expression is up-regulated 
in various transformed cells, particularly those of epithelial origin such as tumours of 
lung, breast, kidney, ovary, prostate and colon (Groh et al, 1999; Dunn et al, 2004). In 
thymomas, it is over-expressed in cortical and medullar epithelial cells (Hüe et al, 
2003). Expression of the MIC proteins can also be up-regulated under conditions of 
“stress” such as heat shock (Groh et al, 1996; Stern-Ginossar and Mandelboim, 2009), 
viral infections such as CMV, Sendai and influenza A viruses (Groh et al, 2001; Das et 
al, 2001; Siren et al, 2004) and some bacterial infections such as Mycobacterium 
tuberculosis (Das et al, 2001) and diarrhoeagenic E.coli (Tieng et al, 2002). 
Expression was also observed in kidney and pancreatic allografts undergoing rejection 
episodes (Hankey et al, 2002; Racca et al, 2009) and after oxidative stress (Yamamoto 
et al, 2001). Exposure to DNA damaging conditions such as high doses of ionizing 
radiation or genotoxic stress (Gasser et al, 2005) and proteasome inhibitors (Valés-
Gómez et al, 2008) can also increase MIC expression by target cells. Therefore MIC 
expression can thus be viewed as an “identification system” that cells use to provoke 
attack by the immune system. 
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2.  The ULBP family of NKG2D ligands  
UL16 binding proteins (ULBPs) are another group of human NKG2D 
ligands first identified for their ability to bind UL16, a type I glycoprotein expressed 
by CMV infected cells (Sutherland et al, 2001). UL16 also binds to a member of the 
MIC family of proteins, MICB but not to MICA (Sutherland et al, 2001; Cosman et al, 
2001). ULBP1 was the prototype of this family while the ULBP2 and ULBP3 were 
subsequently identified as proteins encoded by ULBP1-related expressed sequence 
(Cosman et al, 2001). All three ULBPs are distantly related to members of the 
extended MHC class I family with amino acid sequences that are 55– 60% identical 
(Cosman et al, 2001; Sutherland et al, 2001; Sutherland et al, 2006). The extracellular 
domain structure shows similarity to the α1 and α2 domains of MHC class I molecules 
but they lack the α3 domain (Cosman et al, 2001). They comprise an overall amino 
acid identity of < 25% to human HLA molecules and only 23-26% identity with the 
MIC proteins (Diefenbach and  Raulet, 2001). ULBPs also do not associate with ß2-
microglobulin and they lack many of the conserved amino acids that are known to be 
important for peptide binding by classical MHC class I and are therefore unlikely to 
present peptide antigens (Cosman et al, 2001; Sutherland et al, 2002). Unlike the MIC 
family, which are true transmembrane proteins, ULBPs are anchored to the membrane 
via a GPI- linkage (Cosman et al, 200l). However, two family members, ULBP4 
(RAET1E) and ULBP5 (RAET1G), have transmembrane domains (Chalupny et al, 
2003; Eagle et al, 2009).  
Unlike most members of the extended MHC class I family and MIC family, 
which map to chromosome 6p21 the ULBP genes map outside the MHC region to 
chromosome 6q25 (Sutherland et al, 2001). The ULBP gene family is homologous to 
the mouse Rae1/H60/Mult1 gene family (Raulet, 2003). This is why ULBP proteins 
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are sometimes referred to as RAET1 proteins in recognition of their relatedness to the 
mouse proteins. This also might explain why human ULBP1 and ULBP2 can interact 
with mouse NKG2D (Kubin et al, 2001). Polymorphism in ULBP genes and its impact 
on NK cell functions is still under analysis. Cao et al (2007) demonstrated that a 
soluble form of ULBP4 (RAET1E) protein produced in COS-7 tumour cell lines from 
selective splicing of the ULBP4 gene resulted in inhibition of NKG2D - mediated NK 
cytotoxicity.  
The ULBPs are broadly expressed in a number of tissues and high levels of 
expression were observed on normal human epithelial and endothelial cells of various 
origin. These include the heart, brain, lung, liver, testis, lymph node, thymus, tonsil 
and bone marrow (Diefenbach and  Raulet, 2001). ULBP transcripts were also 
abundant in foetal heart, brain, lung and liver (Diefenbach and  Raulet, 2001). 
However, in some tissues / cells where high ULBP mRNA was detected, such as the 
Raji cell line, no cell surface ULBP expression was detected with a monoclonal 
antibody. ULBPs are also widely expressed on transformed cells including 
neuroblastomas (Raffaghello et al, 2004), malignant gliomas (Friese et al, 2003), 
leukemias (Poggi et al, 2004) and ovarian carcinomas (Conejo-Garcia et al, 2004). 
Correlations have been made between ULBP expression and good tumour prognosis 
suggesting that ULBPs may have a role in mediating antitumour immune responses in 
vivo (Poggi et al, 2004; Conejo-Garcia et al, 2004).   
 
1.1.4.2.1.3 NKG2D signalling pathway 
Many NK cell activating receptors consist of ligand recognition subunits 
that are non-covalently associated with transmembrane signalling „adaptor‟ subunits. 
Most of these adaptor subunits, including CD3δ, FcεRIγ and DAP12, possess 
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immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic tails 
(Mistry and O'Callaghan, 2007). Receptor engagement by their ligands induces 
tyrosine phosphorylation of the ITAMs, recruitment and activation of Syk or δ-chain-
associated protein 70 kDa (ZAP70) tyrosine kinases, and phosphorylation of 
downstream effectors that trigger cell activation (Raulet, 2003). Human NKG2D has 
two charged residues in the transmembrane domain leading to the prediction that 
NKG2D is a stimulatory receptor that uses these residues to associate with an adapter 
molecule (Diefenbach and  Raulet, 2001). However, none of the known adapter 
molecules involved in NK-cell signalling (CD3δ, FcεRIγ and DAP12) was known to 
be associated with human NKG2D. Instead, the receptor was shown to associate with 
a new adaptor molecule known as DAP10, which is unusual as it lacks an ITAM in its 
cytoplasmic domain but contains a different tyrosine-based motif (YxxM) that is 
similar to those found in co-stimulatory receptors such as CD28, inducible co-
stimulatory molecule (ICOS) and CD19 (Raulet, 2003). Engagement of NKG2D in 
human NK cells results in tyrosine phosphorylation of DAP10 and recruitment and 
activation of the p85 subunit of phosphatidylinositol 3- kinase (PI3K) and the anti-
apoptotic kinase AKT (Wu et al, 1999; Raulet, 2003). DAP10 is expressed by several 
human NK-cell lines, a myeloid cell line (U937) and in CD8
+
 T cells (Chang et al, 
1999). Despite their gene similarities, DAP10 and DAP12 form distinct receptor 
complexes with their ligand-binding partners in NK cells and transfectants, activate 
different kinase pathways and contain different tyrosine based motifs (Chang et al, 
1999; Wu et al, 2000).  
Depending on the length of their intracellular cytoplasmic tail, two isoforms 
of NKG2D receptor are present in the mouse. These are NKG2D short (NKG2DS) 
which can be associated with both DAP 10 and DAP 12 and NKG2D long (NKG2DL) 
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which can only associate with the DAP10 molecule (Rosen et al, 2004). Cross-linking 
of either DAP10- or DAP12- associated receptors has been shown to be sufficient to 
trigger NK cell-mediated cytotoxicity in both mouse and humans (Wu et al, 2000). 
Regarding the cytokine secretion cross-linking of mouse NKG2D on the surface of 
NK cells by monoclonal antibodies (mAbs) is known to trigger IFN-γ secretion by NK 
cells and TNF-α and nitric oxide production by macrophages (Diefenbach et al, 2002; 
Raulet, 2003). In humans, NKG2D cross-linking by mAbs failed to induce IFN-γ and 
GM - CSF secretion by NK cells in some studies (Billadeau et al, 2003; Castriconi et 
al, 2003; Andre et al, 2004). This secretion was only induced when soluble 
recombinant ligands to NKG2D were used (Sutherland et al, 2001; Sutherland et al, 
2002; Andre et al, 2004). This leads to the assumption that NKG2D in humans might 
function as a co-stimulatory receptor rather than as a primary recognition receptor. 
Studies of CD8
+
 T-cell activation stimulated by NKG2D-ligand-transfected target cells 
or by antibody cross-linking supported the conclusion that NKG2D functions as a co-
stimulatory receptor that amplifies TCR-mediated activation of CD8
+
 T cells (Raulet, 
2003). However, further clarification of the role of NKG2D in humans is needed 
before this conclusion can be made.  
 
1.1.4.2.1.4 Functions of NKG2D  
Engagement of human NKG2D on the surface of NK cells and γδ T cells by 
its ligands can trigger cytolytic activity as demonstrated in transfectants that express 
MIC and the ULBP proteins (Bauer et al, 1999; Cosman et al, 2001). This lytic 
activity is strongly inhibited by antibodies against NKG2D receptors (Bauer et al, 
1999). Similar results were observed in mouse transfectants expressing the mouse 
NKG2D ligands (Rae-1 proteins, and H-60) (Cerwenka et al, 2000). Moreover, 
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expression of human MIC or murine RAE-1 on epithelial tumour cells causes NKG2D 
dependent rejection of tumour cells by NK cells and primed cytotoxic T cells (Groh et 
al, 1999; Cerwenka et al, 2000). Overall, these findings signify the potential role of 
NKG2D in innate and adaptive immune responses against tumours.  
NKG2D appears to function in some cells as a co-stimulatory molecule. 
When CD8
+
 CD28
-
 αß-T cell clones, specific for HCMV antigens, were tested for 
their capacity to kill HCMV-infected fibroblasts the interaction between NKG2D and 
MIC strongly augmented T cell responses under conditions of suboptimal TCR 
stimulation (Groh et al, 2001). Thus, induced expression of MIC may overcome the 
interference of viral gene products with antigen processing and presentation and the 
down modulation of MHC class I that is frequently associated with tumours. NKG2D 
can also trigger T cells in a TCR- independent manner (González et al, 2006). Normal 
freshly isolated intestinal intraepithelial lymphocytes (IEL) exhibit markedly 
diminished expression of NKG2D, which may be down modulated to prevent chronic 
T cell stimulation and autoreactive bystander T cell activation. High levels of NKG2D 
can be induced by IL-15 (Roberts et al, 2001), which is produced by intestinal 
epithelial cells on external stimuli and infection. In patients with active celiac disease, 
however, NKG2D is strongly expressed because of high local levels of IL-15 and MIC 
is up-regulated in intestinal epithelial cells (Hüe et al, 2004). Under these conditions, 
freshly isolated intraepithelial CD8
+
 αβ T cells lyse intestinal epithelial cell lines 
independent of TCR engagement. 
NKG2D signalling can also elicit cytokine secretion. Cross-linking of 
mouse NKG2D receptors by monoclonal antibody (mAb) on the surface of NK cells 
can induce IFN-γ secretion by these cells (Diefenbach et al, 2002). In human, NK cell 
stimulation with soluble recombinant NKG2D ligands such as MICA or ULBP1 (but 
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not with mAbs) induces IFN-γ and GM-CSF secretion by these cells (Kubin et al, 
2001; Sutherland et al, 2001; Sutherland et al, 2002; Andre et al, 2004). This effect is 
accompanied by increased expression of IL-2 receptor (CD25) and proliferation of NK 
cells (Kubin et al, 2001; Andre et al, 2004). Similarly, secretion of IFN-γ, TNF-α, IL-
2, and IL-4 secreted by HCMV-specific αß-T cells is strongly enhanced when exposed 
to target antigen presented by MICA-transfected C1R cells (Groh et al, 2001). 
Infection by Mycobacterium tuberculosis induces expression of MIC on dendritic and 
epithelial cells, resulting in NKG2D-mediated co-stimulation of Vγ2/Vδ2 T cell 
cytotoxicity, proliferation, and release of IFN-γ and IL-2 (Das et al, 2001).  
 
1.1.4.2.2  Natural cytotoxicity receptors (NCRs)  
The search for receptors responsible for NK-cell triggering in non-MHC-
restricted natural cytotoxicity identified three novel NK-cell-specific triggering surface 
molecules. These molecules are termed natural cytotoxicity receptors (NCRs) and 
appeared to play a critical role in the induction of NK-cell-mediated cytotoxicity. All 
NCRs (except NKp80) are type I transmembrane proteins with one or two 
extracellular immunoglobulin domains, a transmembrane domain and a short 
cytoplasmic tail (Moretta et al, 2000). The transmembrane region of NCRs contains a 
positively charged amino acid residue that is crucial for their association with distinct 
signal-transducng adaptor molecules bearing ITAM sequences (DAP12, CD3 δ and 
FcεRIγ). A putative NCR should satisfy the following requirements (Moretta et al, 
2000): 1) its expression should be restricted to NK cells. 2) its mAb in a redirected 
killing assay should trigger NK-cell cytotoxicity. 3) mAb-mediated masking of the 
NCR should inhibit the NK-cell-mediated cytotoxicity. Three NCRs were discovered: 
NKp46 (NCR1), NKp44 (NCR2) and NKp30 (NCR3) (Moretta et al, 2000). NKp80 is 
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type II transmembrane protein that may acts as a co-receptor rather than a primary 
recognition receptor (Vitale et al, 2001). Little is known about the expression of NCRs 
by NK-cell subsets. Although some reports suggest that NCRs are not expressed 
differentially on NK-cell subsets (Moretta et al, 2000; Moretta and Moretta, 2004), 
other studies demonstrated that their expression is significantly up-regulated in CD56 
bright 
compared to CD56 
dim
  in some diseases such as in women with recurrent 
spontaneous abortions and implantation failures (Fukui et al, 2006). Both NKp46 and 
NKp30 are expressed by all NK cells irrespective of their activation status (Sivori et 
al, 1997; Sivori et al, 1999; Moretta et al, 2000; Moretta and Moretta, 2004). However, 
NKp44 is absent in freshly isolated peripheral blood NK cells but is progressively 
expressed by NK cells in vitro upon culture in the presence of IL-2 (Vitale et al, 1998; 
Moretta et al, 2000; Moretta and Moretta, 2004). Therefore, NKp44 appears to be a 
marker specific for activated human NK cells. 
 
1.  NKp46 (NCR1 or CD335)  
NKp46 is a 46 kDa type I transmembrane glycoprotein, characterised by 
two C2 - type immunoglobulin-like domains in the extracellular portion (Sivori et al, 
1997; Pessino et al, 1998; Biassoni et al, 1999). NKp46 lack the intrinsic signalling 
motifs and instead it associates with the ITAM-bearing CD3δ or FCεRIγ adaptor 
subunits (Pessino et al, 1998). The NKp46 gene is expressed in human on 
chromosome 19 (Pessino et al, 1998). The mouse homolog has been identified 
independently as MAR-1 (mouse-activating receptor 1) and is expressed on 
chromosome 7 (Biassoni et al, 1999). Since NKp46 expression is confined only to NK 
cells (both resting and activated) therefore it is a true NK-specific molecule, and 
probably the most reliable surface marker to identify NK cells. The engagement of this 
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receptor with activating mAbs induces cytotoxicity, calcium mobilization and 
synthesis of cytokines (Sivori et al, 1999; Moretta et al, 2000; Moretta et al, 2005). 
This receptor appears to have a central role in the lysis of different targets including 
normal and tumour-transformed cells (Sivori et al, 1999). NKp46 masking by specific 
blocking mAbs inhibits lysis of the majority of human tumours belonging to different 
histotypes, including lung, liver and breast carcinomas, melanoma, and Epstein Barr 
virus (EBV)-transformed cell lines (Moretta et al, 2000). In particular, the use of 
murine-tumour target cells (including Bw1502 and YAC cells) provided direct 
evidence that NKp46 is sufficient to mediate NK cytolytic anti-tumour activity that 
does not necessarily require co-engagement of other triggering receptors (Moretta et 
al, 2000; Moretta et al, 2005). In addition, Vankayalapati et al (2002) have reported 
that NKp46 can also contribute to NK-cell lysis of mononuclear phagocytes infected 
with an intracellular bacterium. The surface density of NKp46 seems to be important 
in determining the magnitude of the cytotoxic response from NK cells (Moretta et al, 
2005). In a control population, < 20% donors display the NCR 
dull
 phenotype while 
most donors express a high density of NCRs on NK cells, NCR 
bright
 phenotype (Sivori 
et al, 1999).  In general, NCR 
dull
 individuals displayed low cytolytic activity against a 
variety of NK-susceptible tumour targets. De Maria et al (2003) have also reported 
that the reduced cell surface expression of NKp46 and other NK-cell receptors is 
associated with the impaired NK-cell cytolytic function in viraemic HIV-1 infection. 
Decreased NKp46 expression on NK cells has also been reported in the elderly, 
potentially impacting on susceptibility to infectious, inflammatory, and neoplastic 
diseases (Almeida-Oliveira et al, 2011).  
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2.  NKp44 (NCR2 or CD336)  
NKp44 is a 44 kDa protein first identified by Vitale et al (1998) and its gene 
has then been cloned by Cantoni et al in 1999. It is type I transmembrane glycoprotein 
with one immunoglobulin- like domains in the extracellular portion. The NKp44 gene 
is only found in humans and shows three different splice forms varying in their stalk 
and intracellular domains (Hollyoake et al, 2005). The crystal structure of NKp44 
shows structural homology with a number of other immunoglobulin-like structures 
including TREM-1 (triggering receptor expressed on myeloid cells); TREM-like 
transcript-1, and sialoadhesin (Joyce and Sun, 2011). NKp44 also lacks the intrinsic 
signalling motifs. However, unlike NKp46 (associates with CD3δ or FCεRIγ adaptor 
subunits) and NKp30 (associates with CD3δ adaptor subunit), NKp44 is associated 
with another adaptor molecule (DAP12) and is expressed only on the surface of 
activated NK cells (Vitale et al, 1998; Cantoni et al, 1999). Furthermore, in contrast to 
other markers of lymphocyte activation, NKp44 is absent from activated T cells or T- 
cell clones and therefore, NKp44 appears to be the first marker specific for activated 
human NK cells (Bottino et al, 2000). Cross-linking of NKp44 by mAbs strongly 
activates tumour target cell lysis by NK cells in a redirected killing assay indicating 
that NKp44 can mediate triggering of NK cell non-MHC restricted cytotoxicity (Vitale 
et al, 1998). mAb-mediated masking of NKp44 resulted in partial inhibition of 
cytolytic activity against certain MHC - class I FcγR negative NK-susceptible target 
cells. Remarkably, the degree of inhibition was greatly increased by the simultaneous 
masking of NKp46 (Vitale et al, 1998). In addition to tumour lysis, NKp44 is also 
reported to be involved in triggering NK-cells‟ cytolytic activity against virus infected 
cells. These include influenza virus (Arnon et al, 2001; Arnon et al, 2006; Ho et al, 
2008), Sendai virus (Arnon et al, 2001; Arnon et al, 2006) and flavivirus (Hershkovitz 
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et al, 2009). Therefore, NKp44 appears to function as an NCR that is selectively 
expressed by activated NK cells and that might cooperate with other NCRs in the 
process of non-MHC-restricted lysis of tumour and virus-infected cells. 
 
3.  NKp30 (NCR3 or CD337)  
NKp30, the third NCR molecule, was first discovered by Pende et al in 
1999. It is a 30 kDa glycoprotein that contains only one immunoglobulin-like 
extracellular domain, (Moretta et al, 2000; Joyce et al, 2011). Its transmembrane 
portion contains an arginine residue which is involved in the association with the 
CD3δ chain for transduction of downstream activating signals (Pende et al, 1999). 
With the exception of NK cells in lymph nodes and in the endometrium during the 
menstrual cycle (Manaster et al, 2008) NKp30 is selectively expressed by all human 
NK cells, both freshly isolated and cultured in IL-2. However, it is present as a non-
expressed pseudogene in mouse (Hollyoake et al, 2005). The crystal structure of 
NKp30 displays strong structural similarity to the CD28 family of receptors (Joyce 
and Sun, 2011). CD59 is physically and functionally associated with NKp30 and 
NKp46 and therefore may act as a co-receptor to trigger NCRs -mediated cytotoxicity 
by NK cells (Marcenaro et al, 2003). NKp30 was found to co-operate with NKp46 and 
NKp44 in the induction of cytotoxicity against a variety of normal and transformed 
cells (Pende et al, 1999). Moreover, NKp30 is the major receptor responsible for the 
killing of some tumour target cells that are relatively resistant to NKp46/NKp44 
mediating killing such us MEL-15 melanoma cells suggesting that NKp30 probably 
recognizes distinct ligands (Pende et al, 1999). Depending on the type of target cells, 
mAb masking of NKp30 results in partial to complete inhibition of NK-cell mediated 
cytotoxicity. NKp30 is also shown to recognize an unknown ligand expressed on the 
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surface of immature dendritic cells (iDCs) suggesting that NKp30 may be involved in 
the NK cell mediated killing of iDCs (Fauriat et al, 2005; Farag, 2005). Furhtermore, 
NK- mediated induction of DC maturation is also dependent on NKp30. Vitale et al 
(2005) showed that upon NK/DC interaction NK cells produced TNF-α and IFN-γ 
that, in turn, promoted DC maturation. Masking of NKp30 with specific monoclonal 
antibodies (mAbs) strongly reduced maturation of DCs co-cultured with NK cells.  
The surface expression of NKp30 parallels that of NKp46, as NK cells displaying an 
NKp46 
dull
 or an NKp46 
bright
 phenotype were also characterized by dull or bright 
NKp30 fluorescence (Pende et al, 1999; Moretta et al, 2000). The demonstration that 
NK cells express parallel densities of different triggering receptors might explain the 
existence of NK-cell subsets displaying different natural cytolytic activity.  
 
4.  NKp80  
NKp80, also known as killer cell lectin-like receptor subfamily F member 1 
(KLRF1), is the last discovered member of NCR receptors. It is a type II 
transmembrane protein with a C-type lectin domain in its extracellular region and 
encoded by the human NK cell gene complex region (Vitale et al, 2001; Biassoni et al, 
2001). No mouse homologue to human NKp80 has been yet identified. NKp80 is 
shown to be expressed on the cell surface of virtually all fresh or activated NK cells, a 
minor subset of T cells that express CD56 (Vitale et al, 2001) and a small fraction of 
CD8
+
 effector memory cells (Kuttruff et al, 2009) as a dimer of 80 KDa. NKp80 
surface expression was also detected in all CD3
-
 and in a proportion of CD3
+
 
lymphoproliferative diseases of large granular lymphocytes (Vitale et al, 2001). The 
transmembrane region is characterized by non-polar amino acids and therefore 
disfavouring association with classical adaptor molecules such as DAP12, CD3 δ and 
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FcεRIγ (Biassoni et al, 2001). The signal transduction pathway of NKp80 is still 
largely unknown although some recent reports demonstrated that NKp80 uses an 
atypical hemi-ITAM and Syk kinase to trigger cellular cytotoxicity (Dennehy et al, 
2011). There was some controversy regarding the role of NKp80 as activating or 
inhibitory receptor. One early study suggested that NKp80 functions as an inhibitory 
receptor for NK cells based on the  presence of two immunoreceptor tyrosine-based 
inhibitory-like motifs (ITIMs) within the cytoplasmic tail of NKp80 (Roda-Navarro et 
al, 2000). However, subsequent studies clearly indicated that NKp80 displays an 
activating function. mAb- mediated cross-linking of NKp80 in NK cells resulted in 
induction of cytolytic activity  and Ca2+ mobilization (Vitale et al, 2001; Welte et al, 
2006). In fact, Vitale et al (2001) suggested that NKp80 functions as a co-receptor that 
cooperates with other NCRs rather than acting as a primary recognition receptor. 
Moreover, Welti et al (2006) demonstrated that when NKp80 comes in contact with its 
proposed ligand, activation induced C type lectin (AICL), pro-inflammatory cytokine 
secretion is stimulated. 
 
1.1.4.2.2.1 NCR ligands 
Very little is known regarding the cellular ligands of NKp46, NKp44 and 
NKp30. However, haemaglutinin molecules of different influenza and Sendai viruses 
and neuraminidase of Sendai viruses were suggested as the first specific NKp46 and 
NKp44 ligands (Mandelboim, 2001; Arnon et al, 2001; Arnon et al, 2004). In these 
studies, recognition of the haemagglutinin of influenza and haemagglutinin / 
neuraminidase of Sendai viruses by NKp46 and NKp44 was needed to kill the infected 
cells. Vimentin, a surface marker expressed by Mycobacterium tuberculosis-infected 
human monocytes, was also proposed as a ligand for NKp46.  NKp30 is suggested to 
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interact with heparan sulphate proteoglycans (HSPGs) (Bloushtain et al, 2004). This 
binding may be critical for tumour cell killing but its relevance to virally infected cell 
killing is unclear. However, both NKp46 and NKp30 bind to this molecule (Bloushtain 
et al, 2004). Keeping in mind the differential susceptibility of targets to the killing 
mediated by NKp46 and NKp30, and the likelihood that these receptors recognize 
different cellular ligands HSPG is probably a co-ligand for both these receptors rather 
than a specific ligand for NKp30. The HCMV tegument protein (pp65) was found to 
antagonize NKp30 activation by causing a dissociation of the adaptor molecule CD3 δ 
from NKp30. pp65 is an intracellular protein and it is therefore suggested that soluble 
pp65 derived from direct lysis of virally infected cells or from apoptotic cells may 
bind to NKp30 and hamper its activity (Arnon et al, 2005). NKp30 is also suggested to 
recognize intracellular ligands. This is supported by the finding that the nuclear factor 
HLA-B associated transcript 3 (BAT3) released from tumour cells can directly bind to 
NKp30 and initiate NKp30 cytotoxicity. BAT3 is thus the first cellular ligand 
identified for NKp30 (Pogge von Strandmann et al, 2007). Most recently, NKp30 was 
shown to recognize a B7 family homolog (B7-H6) as its ligand (Brandt et al, 2009). 
Unlike other proposed NKp30 ligands, B7-H6 expression is confined to tumour cells 
and is not expressed by normal cells (Brandt et al, 2009). B7-H6 is expressed on a 
number of tumour cell lines, such as K562 and Raji, as well as on primary cancer cells 
(Joyce and Sun, 2011). However, the role of NKp30 in cancer immunity against these 
cell lines is still unclear. The activation-induced C-type lectin (AICL) (which is also 
encoded in the NK-gene complex) was identified as a ligand of NKp80 (Welte et al, 
2006). AICL is a myeloid-specific receptor expressed by monocytes, macrophages and 
granulocytes. Interaction between NK cells and monocytes resulted in a cytokine 
release that was partially dependent on NKp80 engagement. Hence, it seems that 
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NKp80-AICL interaction is involved in the crosstalk between NK cells and myeloid 
cells and thus may influence the initiation and maintenance of immune responses in 
humans (Welte et al, 2006). 
 
1.1.4.2.3 CD16 
CD16 or Fc-gamma receptor III (Fc-γ RIII) is another activating receptor of 
NK cells that recognizes non-MHC class I molecules (Diefenbach and Raulet, 2001). 
It is one of the three subtypes of Fc-IgG receptors that bind to the Fc region of IgG 
antibody (Kimberly et al, 1995). All these receptors belong to the immunoglobulin 
superfamily and are distributed widely on many cells of the immune system (Ivan and 
Colovai, 2006). They are 1) FcγRI (CD64), a high affinity receptor capable of binding 
monomeric IgG and expressed on monocytes and activated neutrophils. 2) FcRγII 
(CD32), a low-intermediate affinity receptor that binds multimeric IgG and is 
expressed on the surface of B cells, monocytes, neutrophils, and non-hematopoietic 
cells such as epithelial cells. 3) FcγRIII (CD16), also a low affinity receptor capable of 
binding multimeric IgG. They can also contribute to the pathogenesis of immune 
complex and auto-antibody mediated disorders such as vasculitis, rheumatoid arthritis, 
idiopathic thrombocytopaenic purpura, or autoimmune neutropaenia (Takai T, 2005; 
Ivan and Colovai, 2006). Human CD16 is expressed in two distinct (CD16a and 
CD16b) isoforms, which are products of two different highly homologous genes 
(Schumann et al, 1994). CD16a (Fc-γRIIIa) is a 50-65 kDa polypeptide-anchored 
transmembrane protein that is expressed on the surface of NK cells (Lanier et al, 1989; 
Anderson et al, 1990), activated monocytes or macrophages (Wirthmueller et al, 1992)  
and mast cells (Kurosaki et al, 1992). CD16b (Fc-γRIIIb) or HNA (human neutrophil 
antigen) is a GPI-linked monomeric receptor that is over 95% homologous to CD16a 
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in its extracellular domain and is expressed specifically on neutrophils (Selvaraj et al, 
1988; Huizinga et al, 1988; Huizinga et al, 1989). CD16a requires association of the 
gamma subunit of Fc epsilon (FcεRIγ) or TCR-CD3δ for cell surface expression 
(Nagarajan et al, 1995). Engagement of CD16 induces phosphorylation of ITAMs on 
the adaptor chains CD3δ and FcεRγ, which in turn recruit and activate Syk and ZAP70 
tyrosine kinases for downstream signalling (Ting et al, 1995; Nagarajan et al, 1995). 
Activation of CD16 on the surface of NK cells by IgG aggregates or IgG-antigen 
complexes or mAb induces the release of cytokines such as IFN-γ (Márquez et al, 
2010) and cytotoxic mediators like perforin and granzymes (Werfel et al, 1989; 
Mandelboim et al, 1999). The latter is known as antibody-dependent cell-mediated 
cytotoxicity (ADCC). Ligation of CD16 can also induce highly activated NK cells to 
undergo Fas ligand induced apoptosis (Eischen et al, 1996).  
 
1.1.4.3  Other NK cell receptors 
Several other receptors and co-receptors have been identified to be 
expressed on the surface of NK cells such as DNAX accessory molecule-1 (DNAM-
1), CD69, and 2B4. DNAM-1 is a transmembrane glycoprotein with two 
immunoglobulin-like domains expressed on the surface NK and T cells in association 
with lymphocyte function antigen-1 (LFA-1) (Shibuya et al, 1996). It is a signal 
transducing adhesion molecule that is involved in the adhesion of certain tumour cells 
to CTLs and NK cells and mediates their cytotoxicity (Shibuya et al, 1996; 
Lakshmikanth et al, 2009). Anti-DNAM-1 mAbs inhibits T and NK cell-mediated 
cytotoxicity against a variety of tumour cell targets and blocks cytokine production by 
alloantigen-specific T cells (Shibuya et al, 1996). Recent studies also demonstrated 
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that DNAM-1 can synergize with other activating NK cell receptors in the pro-
inflammatory cytokine secretion by these cells (Fauriat et al, 2010).  
CD69, also known as activation inducer molecule or early T- cell activation 
antigen (P60), is a type II transmembrane glycoprotein with a C-type lectin-binding 
domain encoded by the CD69 gene located on chromosome 12 (Borrego et al, 1999). 
NK cells can express CD69 after activation by different stimuli such as phorbol 12-
myristate 13-acetate (PMA), IL-2, IL-12, IFN-γ or anti-CD16 mAbs (Borrego et al, 
1999). It is commonly used as quantitative measure of NK cell or T cell activation. 
Ligation of this molecule with activating anti-CD69 mAbs results in triggering of NK-
cell-mediated cytolytic activity (Borrego et al, 1999). However, this activity can be 
abrogated by simultaneous stimulation of CD94/NKG2A inhibitory receptors.  
2B4 is a glycoprotein that belongs to the signalling lymphocyte activation 
molecule (SLAM) family of receptors (Velikovsky et al, 2007). It is expressed on NK 
cells, monocytes, basophils, TCRγδ+ T cells, and a subset of CD8+ T cells (Roda-
Navarro et al, 2004). Engagement of 2B4 by mAb induces its phosphorylation and 
recruitment of SLAM-associated protein (SAP) through cytoplasmic tyrosine-based 
motifs (Chen et al, 2004). The ligand of 2B4 is CD48, which is expressed on 
hematopoietic cells (Bryceson et al, 2006). 2B4 may function as a co-receptor in 
human NK-cell mediated cytotoxicity, leading to induction of cytokine (IFN-γ) and 
matrix metalloproteinase (MMP-2) production (Chuang et al, 2001).  
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1.2  Interleukin-6 (IL-6) 
Interleukin-6 (IL-6) together with other interleukins such as IL-1 and IL-10 
are pleiotropic in their effect (Kishimoto, 2006; Apte and Voronov, 2002; Commins et 
al, 2008). However, the IL-6 is considered the prototypic pleiotropic cytokine among 
them. This is reflected in the variety of names originally assigned to IL-6 based on its 
various functions. These include interferon beta 2 (IFN-B2) (Zilberstein et al, 1986), B 
cell stimulatory factor- 2 (BCSF-2) (Hirano et al, 1985; Hirano et al, 1986), B-cell 
differentiation factor (BCDF) (Kishimoto, 1989), plasmacytoma / hybridoma growth 
factor (P/HGF) (Van Damme et al, 1987;  Van Snick  et al,1988), 26 kDa protein 
(Haegeman et al, 1986), hepatocyte stimulating factor (HSF) (Baumann et al, 1987), 
monocyte-granulocyte inducer type 2 (MGI-2) (Shabo et al, 1988), and cytotoxic T-
cell differentiation factor (CDF) (Uyttenhove et al, 1988; Ming et al, 1989). 
Sequencing the cDNA clones have shown that all these molecules were identical and 
are encoded by a single gene (Poupart et al, 1987). The name IL-6 was proposed for 
this molecule in December 1988 (Shegal et al, 1989; Sehgal et al, 1995). This protein 
has been proven to play important roles in acute phase reactions (Heinrich et al, 1990), 
inflammation (Hodge et al, 2005), haematopoiesis (Rodríguez et al, 2004), bone 
metabolism (Ishimi et al, 1990; de la Mata et al, 1995) , and cancer progression 
(Hodge et al, 2005; Bomberg and Wang, 2009).  
 
         1.2.1  Structure of IL-6  
IL-6 is a member of a family of cytokines called the IL-6 cytokine family. 
This family also includes interleukin 11 (IL-11), interleukin 27 (IL-27), ciliary 
neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), cardiotrophin-like cytokine 
(CLC), leukemia inhibitory factor (LIF), oncostatin M (OSM) and Kaposi's sarcoma 
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associated herpes virus interleukin-6 like protein (KSHV-IL6) (Kishimoto et al, 1995; 
Taga and Kishimoto, 1997). All known members of the IL-6 cytokine family have 
similar helical structure (Somers et al, 1997), induce hepatic expression of acute phase 
proteins (Somers et al, 1997) and signal through transducing receptors containing the 
gp 130 subunit (Boulanger et al, 2004).  
Human IL-6 cDNA encodes a polypeptide of 212 amino acids with 28 
amino acids as signal sequence and a 184 amino acids as mature segment (Hirano et 
al, 1986; Simpson et al, 1997; Li et al, 2004). The mature protein is N-glycosylated at 
positions 73 and 172 respectively. Due to different degrees of glycosylation and 
phosphorylation, IL-6 has a molecular weight ranging between 21-28 kDa (Park and 
Philinger, 2007). An alternative splice variant of IL-6 was identified in monocytes and 
lymphocytes (Kestler et al, 1995). This form is 17 kDa (148 amino acids long) and 
appears to lack a binding site for the IL-6 signal transducing molecule gp 130. The 
human IL-6 molecule contains four conserved cysteine residues involved in the 
formation of two disulphide bonds (Boulanger et al, 2003). A region containing nine 
amino acids between two of these cysteine residues are identical which led to the 
proposition that these cysteines were essential for the IL-6 activity. However, the 
biological activity of recombinant IL-6 lacking the cysteine residues suggests that 
these cysteines may be not necessary (Park and Philinger, 2007). Mouse and rat IL-6 
also have been cloned and are approximately 65% identical to human IL-6 at cDNA 
level and about 40% identical at the protein level (Chiu et al, 1988; Van Snick, 1990). 
Unlike human IL-6, mouse and rat IL-6 lack potential N-linked glycosylation sites but 
may be O-glycosylated (Van Snick, 1990). Although human IL-6 is active on mouse 
and rat cells, mouse IL-6 is not active on human cells (Chiu et al, 1988; Northemann et 
al, 1989; Hammacher et al, 1994).  
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1.2.2  Gene structure 
The human IL-6 genomic DNA segment has a length of approximately 5 kb 
and contains five exons and 4 introns (Li et al, 2004; Park and Philinger, 2007). It 
maps to human chromosome 7p14 and contains a c-fos serum responsive enhancer 
element and sequences for cAMP induction, activator protein-1 binding and 
glucocorticoid –responsive elements (Park and Philinger, 2007). The wide range of 
regulatory pathways involved in controlling IL-6 transcription confirms the central 
role of IL-6 in inflammatory responses.  The murine gene also consists of five exons 
and 4 introns, but it maps to chromosome 5 (Tanabe et al, 1988).  The comparison 
between human and mouse IL-6 genomic segments reveals highly homologous regions 
extending approximately 350 bp upstream of the cap site (Tanabe et al, 1988). The 
nucleotide sequences of IL-6 and GM-CSF genes also resemble each other in a way 
suggesting a possible evolutionary relationship. Four polymorphisms in the IL-6 gene 
have been described, with possible functional consequences (Brull et al, 2001). For 
example the common G C polymorphism at position -174 results in lower stimulated 
IL-6 promoter activity in vitro and lower circulating IL-6 concentrations in healthy 
individuals compared with the G allele (Fishman et al, 1998). Ferrari et al (2001) 
demonstrated that postmenopausal women homozygous for the -174 C allele have low 
serum levels of C-terminal cross-linking of type I collagen (sCTx), a marker of bone 
resorption. 
 
1.2.3  Expression and secretion of IL-6 
Various cell types  are capable of IL-6 expression / or synthesis including T-
lymphocytes (Sad et al, 1995), monocytes (Kestler et al,1995), macrophages (Stowet 
et al, 2009), eosinophils (Melani et al, 1993), mast cells (Gagari et al,1997) fibroblasts 
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(Cichy et al, 1996),  synoviocytes (Miyazawa et al, 1998) , hepatocytes (Panesar et al, 
1999), endothelial cells (Xin et al, 1995) , skeletal and smooth muscle cells (Keller et 
al, 2003; Bouchelouche et al, 2006), chondrocytes (Guerne et al, 1990), keratinocytes 
(Jiang et al, 1994) glial cells (Sun et al, 1997), astrocytes (Lafortune et al, 1996) and 
adipocytes (Fried et al, 1998; Lyngsø et al, 2002). Production and expression of IL-6 
is also up-regulated by numerous signals including viral infections (Sharma et al, 
2005; Jiang et al, 2008; Cai et al, 2008), lipopolysaccharide (Grimaldi et al, 1998; 
Zhang et al, 2009), calcium ionophore (Holmes et al, 2004), interleukins (IL-1, IFN, 
TNF) (Sancéau et al, 1995; Flower et al, 2003),  platelet derived growth factor (PDGF) 
(Franchimont et al, 1999),  bacterial toxins (Onogawa et al, 2002), and hormones (Bell 
et al, 2003). In contrast, IL-4 inhibits IL-6 expression in monocytes (Donnelly et al, 
1993).  In fibroblasts the synthesis of IL-6 is enhanced by treatment with TNF-α, IL-
1i, prostaglandin E2, and various activators of the intracellular signalling pathways 
acting through proteinkinase A (PKA) or protein kinase C (Baumann and Kushner, 
1998). In epithelial and endothelial cells the secretion of IL-6 is also induced by IL-17 
(Laan et al, 2001). IL-6 is not constitutively expressed. Some studies suggest that IL-6 
is secreted in circadian pattern with two peaks at about 19.00 and 05.00 hrs and its 
circadian secretion correlates with sleep (Vgontzas et al, 2005; Burgos et al, 2006). 
Vgontzas et al concluded that IL-6 is a mediator of sleepiness and its circadian pattern 
reflects the homeostatic drive for sleep. Finally, IL-6 can also stimulate or inhibit its 
own synthesis, depending upon the cell type.  
 
1.2.4  Normal IL-6 concentration  
Circulating IL-6 can be found in the blood of normal individuals in the 1 
pg/ml range (D'Auria et al, 1997) with slight elevations during the menstrual cycle 
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(Angstwurm et al, 1997), and large elevations (up to 430 pg/ml) after surgery 
(Sakamoto et al, 1994). There is a controversy regarding the major source of 
circulating IL-6 in healthy individuals. While Keller et al (2003) demonstrated that 
skeletal muscle is a major source of blood-borne IL-6, Mohamed-Ali et al (1997) 
demonstrated  that one third of total circulating concentrations of IL-6 originate from 
adipose tissue. Plasma IL-6 concentrations may be influenced by a person‟s age with 
higher concentrations detected in the elderly. Weight, disease conditions, medications/ 
supplements, alcohol consumption, composition of the last meal eaten, and activity 
level can all influence IL-6 levels (Picotte et al, 2009). Despite these sources of 
variation, a positive association between circulating IL-6 levels and increased 
mortality rate has been described (Fernandez-Real et al, 2001). Yudkin et al (2000) 
speculated that IL-6 is the link among obesity, inflammation, stress, and coronary 
heart disease.  
 
1.2.5  IL-6 receptors and signalling pathway  
IL-6 induces signalling through a cell surface heterodimeric receptor 
complex composed of a ligand binding subunit (IL-6 R) and a signal transducing 
subunit, gp130 (Kamimura et al, 2003). Both are members of the class I cytokine 
receptor superfamily. Although IL-6 binding to gp130 has been described, it is 
generally accepted that the IL-6 R is the actual IL-6 binding protein (Hibi et al, 2003). 
IL-6 can signal via two different pathways (Figure 1.4): classical signalling via the 
membrane bound IL-6R and IL-6 trans-signalling via a naturally occurring soluble IL-
6R (sIL-6R). In classical signalling, IL-6 engagement of membrane bound IL-6R 
results in association of the intracellular segment of IL-6R with the gp130. The 
resulting complex is a hexamer comprised of two IL-6 molecules, two IL-6R and two 
 
 
48 
 
gp130. Dimerized gp130 activates intracytoplasmic Janus tyrosine kinases (JAK) 
which in turn induce tyrosine phosphorylation of STAT3. STAT-3 is a member of 
STAT family of cytoplasmic latent transcription factors which consists of seven 
members: STAT-1-4, STAT-5a, STAT-5b, and STAT-6. Once STAT 3 is activated, it 
translocates to the nucleus. The translocation of STAT3 to the nucleus then induces 
IL-6 regulated changes in gene expression (Park and Philinger, 2007). These changes 
include up-regulation of expression of genes that control cell proliferation, survival, 
differentiation, and development, and new gene expression of acute phase proteins, 
which subsequently are secreted (Heinrich et al, 2003; Brantley and Benveniste, 
2008). The membrane bound IL-6R is only expressed on hepatocytes, neutrophils, 
macrophages and some lymphocytes (Drucker et al, 2010). Accordingly, the effect of 
IL-6 through the classical signalling pathway is restricted to these cells. However, this 
pathway does not explain the wide biological effect of IL-6 on a broad spectrum of 
cells that do not express IL-6R. Therefore, the alternative IL-6 pathway is trans-
signalling pathway in which IL-6 binds to a naturally occurring soluble IL-6R (sIL-
6R) and this IL-6/sIL-6R complex activates gp130 (Rose-John et al, 2006). Since 
gp130 is expressed on all cells of the body, therefore most cells can respond to IL-6 by 
this way. However, IL-6 trans-signalling affects also cells that express membrane 
bound IL-6R, e.g. hepatocytes. In this setting an activation of the IL-6 trans-signalling 
can enhance stimulatory effects of IL-6 classical pathway (Drucker et al, 2010). It is 
also noteworthy to mention that two soluble splice forms of gp130, lacking the 
transmembrane segment, also exist (Sharkey et al, 1995; Diamant et al, 1997). When 
bound to the IL-6/IL-6R complex, these soluble gp130 block trans-signalling from the 
IL-6/IL-6 R but not from other cytokines that utilize gp130 as a co-receptor (Narazaki 
et al, 1993). 
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Figure 1.4: IL-6 receptors and signalling pathways. A) Classic IL-6 signalling 
pathway: IL-6 binds to membrane bound IL-6R resulting in dimerization of gp130. 
The actual complex is comprised of two IL-6 molecules, two IL-6Rs and two gp130. 
Dimerized gp130 activates intracytoplasmic Janus tyrosine kinases (JAK) which in 
turn induce tyrosine phosphorylation of STAT3 which translocates into the nucleus 
and initiates IL-6 induced changes in gene expression. B) IL-6 trans-signalling 
pathway: sIL-6R is generated either by limited proteolysis of the membrane-bound 
IL-6R or by alternative mRNA splicing. IL-6 binds to soluble IL-6R (sIL-6R) and this 
IL-6/sIL-6R complex activates gp 130. Reproduced from Dayer and Choy (2010)  
 
 
 
 
A Classic signalling B Trans-signalling 
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1.2.6  Functions of IL-6 
As mentioned before, IL-6 is a pleiotropic cytokine with diverse biological 
activities. These include: 
 
1.  Acute phase response 
IL-6 is one of the most important mediators of acute phase responses 
(Heinrich et al, 1990). These include induction of hepatic acute phase proteins, fever, 
increased erythrocyte sedimentation rate (ESR), increased secretion of glucocorticoids 
and the activation of the complement and clotting cascades. Similarly to IL-1, IL-11 
and LIF, IL-6 can induce the synthesis of hepatic acute phase proteins both in vivo and 
in vitro by regulating changes in the gene transcription rate of these proteins 
(Moshage, 1997; Akira and Kishimoto, 2004). These are C - reactive protein (CRP), 
serum amyloid A (SAA), alpha-1-antichymotrypsin and haptoglobin (Moshage, 1997; 
Akira and Kishimoto, 2004). It also increases the synthesis of fibrinogen, an important 
clotting agent but decreases the synthesis of albumin and transferrin (Park and 
Philinger, 2007). When secreted by T-cells and macrophages, it stimulates the immune 
response to trauma, especially against burns or other tissue damage leading to 
inflammation (Vindenes et al, 1998).  
 
2.  T-cells  
Interleukin-6 has a prominent regulatory role in T-cell proliferation, 
differentiation and survival (Dienz and Rincon, 2009). In the early stages of T-cell 
differentiation, it activates resting T-cells by inducing both IL-2 production and IL-2 
receptor expression and thus with IL-2, drives the differentiation of naïve T-cells cells 
into cytotoxic T cells (Garman et al, 1987; Noma et al, 1987). IL-6 also functions as 
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the required second signal in both antigen- or mitogen-activated T-cells and induces 
the proliferation of mitogen-activated T cells and thymocytes (Park and Philinger, 
2007). Details of the effect of IL-6 on T cells will be discussed in the following 
chapters.  
 
3.  B-cells 
Interleukin-6 is very important in the stimulation of differentiation of B cells 
into plasma cells and it was first described as a B-cell activation or differentiation 
factor (Schwarting et al, 1985; Hirano et al, 1986; Muraguchi et al, 1988). It is 
involved in the induction of B-cell activation and enhances the production of 
antibodies by activated B-cells, but not their proliferation (Hirano, 1998). Here this 
cytokine stimulates mostly the release of IgG and IgA antibodies from these cells.  
   
4.  Haematopoiesis  
The IL-6 is a promoter of haematopoiesis. It has blast cell growth factor 
activity and can synergize with IL-3 to shorten the G0 period of early haematopoietic 
progenitors (Park and Philinger, 2007). In addition, IL-6 has been found to synergize 
with IL-3 in increasing the number, size and average ploidy value of megakaryocyte 
colonies formed from mouse or human bone marrow cells in vitro (Ishibashi et al, 
1989; Kimura et al, 1990). IL-6 was also found to increase platelet numbers (Gutierrez 
et al, 1995; Clarke et al, 1996).  
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5.  Bones 
IL-6 is a modulator of bone resorption (Ishimi et al, 1990; Palmqvist et al, 
2002). Osteoclast formation is increased in the presence of IL-6, apparently through 
the activation of gp130 (Heymann and Rousselle, 2000). Given the recent interest in 
osteoclasts as mediators of bony erosion in RA, these observations suggest a possible 
direct role for IL-6 in RA joint destruction (Lipsky, 2008). 
 
6.  Muscles and fatty tissues 
IL-6 stimulates energy mobilization from muscles and fatty tissues, which 
leads to increased body temperature (Petersen et al, 2005). It is also a „Myokine‟ a 
cytokine produced from the muscle, and it is elevated in response to muscle 
contraction (Febbraio et al, 2005; Pedersen et al, 2007).   
 
7.  Hybridomas and malignancy  
IL-6 has growth factor activities and stimulates the growth of hybridomas 
(Van Damme et al, 1987), plasmacytomas (Pattengale, 1997; Schirmacher et al, 1998) 
and multiple myelomas (Hitzler et al, 1991; Lokhorst et al, 1994; Pattengale, 1997). 
Multiple studies have documented high IL-6 levels in the serum of patients with 
certain carcinomas such as breast (Sansone et al, 2007; Knupfer and Preiss, 2007; 
Schafer and Brugge, 2007), lung (Schafer and Brugge, 2007; Pine et al, 2011), colon 
and rectum (Becker et al, 2005) and lymphoma (Kurzrock et al, 1993; Schafer and 
Brugge, 2007). In these patients high IL-6 levels correlated with a poor clinical 
prognosis. IL-6 also appears to be especially important in some sarcomas such as 
AIDS-related Kaposi‟s sarcoma (Miles et al, 1990; Yang et al, 1994) glioblastomas 
(Van Meir et al, 1990) and later stages of melanomas (Francis et al, 1996). However, 
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in contrast to its growth stimulatory activities, it is interesting to know that IL-6 is also 
a growth inhibitor for a number of carcinomas such as hepatocellular carcinoma 
(Moran et al, 2008); and early stages of melanoma (Lu et al, 1992).  
 
8.  Chronic inflammation and autoimmune diseases 
IL-6 has shown to be an important key player in several chronic and 
autoimmune diseases. It not only maintains inflammation, but also modifies the 
immune responses. It has been suggested that IL-6 can change the direction of immune 
responses to self or non-self, or activation or tolerance, by modifying the quality of 
peptide presentation by dendritic cells (Ishihara and Hirano, 2002). An overproduction 
of this protein has been reported to be involved in the pathology of rheumatoid 
arthritis (Lipsky, 2006; Nishimoto, 2006 ; Park and Philinger, 2007), Castleman‟s 
disease (Yoshizaki et al, 1989), juvenile idiopathic arthritis (Lepore et al, 1994), 
ankylosing spondylitis (Gratacós et al, 1994), systemic lupus erythematosus (Gröndal 
et al, 2000), psoriasis (Arican et al, 2005) and Crohn‟s disease (Ito, 2003). On the 
other hand, defective production of this protein has been proposed in the pathogenesis 
of other autoimmune disorders, such as liver autoimmune diseases (Tovey, 1989).  
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1.3  Aims and objectives of this study 
The aims of this study were: 
1. To investigate the secretion and expression of interleukin-6 (IL-6) by 
human peripheral blood natural killer (PBNK) cells from healthy individuals by 
triggering NK cells with different stimuli, including co-cultures with K562 and HeLa 
cells, incubation with cytokines and non-specific chemical activators (PMA+ 
ionomycin). 
 
2. To study which NK receptors are involved in the induction of IL-6 
expression and secretion. 
  
3. To evaluate the biological significance of IL-6 secretion by PBNK cells 
through an in vitro model.  
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2.1  Cells  
2.1.1  Healthy donors 
Ethical approval from the South Sefton Ethics Committee was obtained for 
this study. Blood samples from healthy volunteers without previous history of 
autoimmune diseases or current infections were obtained at the University of 
Liverpool. All donors signed forms of consent to participate in the research project. 
Their age varied from 30-65 years and the M/F ratio was 2/5. 
 
2.1.2  Mononuclear cell separation 
Heparinized venous blood of healthy volunteers was collected in sterile 
universal tubes. The amount of blood varied between 15 – 20 ml per donor. The blood 
was then diluted with equal volume of 1X Phosphate Buffered Saline (PBS) and the 
mixture was then slowly layered on top of 10 ml Ficoll Paque 
TM PLUS
 (Amersham 
Bioscience, Sweden). The samples were centrifuged at 400g (1800 rpm) for 20-25 
minutes at 22 
o
C without braking during deceleration. Thus, the blood cells are 
distributed in the solution in layers based on the differences in their density/size. 
Resultant layers from top to bottom are: plasma – platelets – peripheral blood 
mononuclear cells (PBMCs) – Ficoll – red blood cells (with granulocytes). The 
PBMCs become visible as buffy coat between the plasma and the Ficoll, which was 
carefully removed with a pastette and transferred into new universal tube and washed 
twice with 1X PBS. After washing, the PBMCs were counted using a haemocytometer 
and the viability of the cells were assessed by staining with 0.4% trypan blue.  
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2.1.3  Cell Counting using a haemocytometer 
 For the cell counting procedure, a haemocytometer of 0.1 mm depth was 
used. The mononuclear cells were suspended in 10 ml culture medium. Ten µl aliquots 
of the cell suspension were then placed in a suitably-sized conical centrifuge tube 
(Eppendorf tube) and mixed with equal volume of 0.4 % trypan blue in PBS. A Gilson 
pipette was used to transfer the mixture of cells and trypan blue to the chambers of the 
haemocytometer by carefully touching the edge of the cover slip with the pipette tip 
and allowing each chamber to fill by capillary action. The cells were then viewed 
under a microscope at 100 X magnification. Under the microscope, a grid of nine 1mm 
squares should be seen (Figure 2.1). The central 1mm square (big red circle) is divided 
into 25 groups of 0.25 mm small squares (small blue circle). All the viable cells in the 
central 1mm square were counted. The non-viable cells stained blue by trypan blue 
and were excluded from the total. Each large square of the haemocytometer, with 
cover-slip in place, represents a total volume of 0.1 mm
3
 (1.0 mm x 1.0 mm x 0.1mm) 
or 10
-4
 cm
3
. Since 1 cm
3
 is equivalent to approximately 1 ml, the total number of cells 
per ml was then determined using the following formula: 
Number of cells/ml = Total number of viable cells in 1mm central square x (dilution factor for trypan blue) x 104 
 
Total cell number   = cells per ml x the original volume of fluid from which cell sample was removed. 
 
 
                      
Figure 2.1: Cell counting using a haemocytometer. 
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2.1.4  Freezing cells 
After cell counting, the PBMCs were re-suspended in freezing medium that 
consisted of 90% foetal calf serum (FCS) and 10% dimethyl sulphoxide (DMSO). The 
cells were then  transferred into small cryogenic vials at a concentration of 1 x 10
7
 
viable cells/ 1ml freezing medium / vial  and frozen at - 80 
o
C overnight. On the next 
day, they were transferred into liquid nitrogen and stored for further use. 
 
2.1.5  Effector cells (peripheral blood natural killer cells) 
The frozen cells (PBMCs) were taken out from the liquid nitrogen on the 
day of the experiment, warmed to 37 
o
C in a water bath and then transferred into a  
universal tube and  warm culture medium (complete RPMI 1640 or DMEM medium) 
was added to fill the universal tube. Complete RPMI 1640 medium and Dulbecco‟s 
modified medium (DMEM) from (Sigma-Aldrich, UK) were supplemented with 10% 
foetal calf serum (FCS), 2 mML-glutamine (GIBCO, Invitrogen), 100 U of penicillin 
and 100 mg of streptomycin (GIBCO, Invitrogen) per ml. The cells were then spun at 
400g (1800 rpm) for 10 minutes at 22 
o
C and the pellet re-suspended with culture 
medium (CM) in a plastic petri dish and incubated at 37 
o
C in atmosphere of 5% CO2 
for 2 hours. After incubation, the adherent cells containing the monocytes were 
discarded while the non-adherent cells containing the lymphocytes were collected and 
their cell number was determined. The peripheral blood natural killer (PBNK) cells 
were isolated from the other lymphocytes by negative magnetic separation using a 
commercial NK cell isolation kit (Miltenyi Biotec, Germany). Using this kit, the non 
NK cells, i.e. T cells, B-cells, stem cells, dendritic cells, monocytes, granulocytes and 
erythrocytes were magnetically labelled with biotin conjugated antibodies and a 
cocktail of micro beads. Upon passing the cells over a MACS® column (Miltenyi 
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Biotec, Germany) that is placed in a magnetic field, the magnetically labelled non-NK 
cells were retained on the column while the unlabeled NK cells passed through 
(negative selection). The procedure was carried out according to the manufacturer‟s 
instructions. Briefly, PBMCs cells were centrifuged at 400g (1800 rpm) for 10 minutes 
and the supernatant was removed completely. The cell pellet was re-suspended in 40 
µl of MACS buffer per 10
7
 total cells and 10 µl of NK cell selection biotin antibody 
cocktail was added. The cells were incubated for 10 minutes on ice. After this 
incubation, 30 µl of MACS buffer and 20 µl of micro bead cocktail were added to 10
7
 
total cells. The cells were incubated again for 15 minutes on ice. Following the second 
incubation, the cells were washed with 2 ml of MACS buffer /10
7
 cells and 
centrifuged at 400g (1800 rpm) for 10 minutes. The supernatant was then removed 
completely and the cells were re-suspended in 500 µl of MACS buffer and passed 
through an LS MACS column placed in a MACS separator. After three washings with 
3 ml of MACS buffer, the total effluent was collected. This fraction represents the 
enriched NK cells. For higher purity, the cell suspension resulting from this selection 
process was applied to a second LS column. 
  
Figure 2.2: Diagram to illustrate purification of NK cells by immunomagnetic depletion. 
Magnetic labelling: Non target cells (non-NK 
cells) were magnetically labelled with biotin 
antibody cocktail and anti-biotin micro beads. 
Magnetic separation: Undesired cells were 
retained in MACS column placed in MACS 
separator. The desired cells (NK cells) passed 
through the column and were collected as 
enriched, untouched cell fraction depleted of 
non-target cells.  
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2.2  Cell lines  
2.2.1  Target cell lines 
For the purposes of activating resting peripheral blood natural killer cells 
(PBNK) cells, two different NK cell sensitive tumour cell lines were used as target 
cells: 
 
2.2.1.1  K562  
This is an erythroleukemia cell line derived from a 53-year-old female with 
chronic myeloid leukaemia in blast crisis (Lozio and Lozio, 1975). The cells are non-
adherent and rounded with some morphology similar to undifferentiated granulocytes 
and erythrocytes (Gahmberg and Andersson, 1981). These cells do not express major 
histocompatibility complex (MHC) class I molecules and therefore can be easily killed 
by NK cells as they lack the MHC class I complexes required to inhibit NK activity 
(Zamai et al, 1998).  
 
2.2.1.2  HeLa 
HeLa cells are large adherent immortal cervical cancer cells derived from 
Henrietta Lacks, who died from her cancer in October, 1951 (Lucey et al, 1991). They 
are larger than K562s and divide in unlimited number of times in culture. These cells 
do express MHC class I molecules. However, they are known to be susceptible to NK 
cell lysis through a mechanism mediated by NKG2D, a dominant NK cell stimulatory 
receptor. 
Both K562 and HeLa tumour cell lines were gifts from the Inflammation 
Research Unit/ Teaching Hospital Aintree, University of Liverpool. The K562 cells 
were maintained in 75 cm
2
 tissue culture flask (Corning) in complete RPMI 1640 
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medium (Sigma-Aldrich, UK) supplemented with 10% foetal calf serum (FCS), 2 
mML-glutamine (GIBCO, Invitrogen), 100 U of penicillin and 100 mg of 
streptomycin (GIBCO, Invitrogen) per ml. HeLa cells were maintained in 75 cm
2
 
tissue culture flask (Corning) in Dulbecco‟s modified medium (DMEM) from Sigma-
Aldrich supplemented with 10% foetal calf serum (FCS), 2 mML-glutamine, 100 U of 
penicillin, and 100 mg of streptomycin per ml. The flasks were kept in a tissue culture 
incubator at 37 
o
C, 5% CO2 and a humid atmosphere. Every 2-3 days, the non-
adherent cells were centrifuged, washed once with 1 X PBS and the pellet re-
suspended in a fresh CM. The adherent cells were trypsinized with trypsin (Sigma-
Aldrich, UK) to detach them from the wall of culture flask, centrifuged and washed 
once with 1 X PBS. The pellet was then re-suspended in fresh CM. Aliquots of both 
K562 and HeLa cells were cryo-preserved in liquid nitrogen at a concentration of 1 x 
10
7 
cells / vial for future use. 
 
2.2.2  Other cell lines 
Several other cell lines were used for the purposes of transfection and for 
studying the signalling pathways involved in the secretion of IL-6 by human NK cells. 
These included: 
 
2.2.2.1  CHO cells 
Chinese hamster ovary (CHO) cells are the most widely used mammalian 
cells for transfection, protein expression, and large-scale recombinant protein 
production. CHO cells were purchased from European Collection of Cell Cultures 
(ECACC). Upon receipt these cells were maintained in Ham′s F12 medium (Sigma-
Aldrich, UK) supplemented with 10% foetal calf serum (FCS), 2 mML-glutamine 
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(GIBCO, Invitrogen), 100 U of penicillin and 100 mg of streptomycin (GIBCO, 
Invitrogen) per ml. Since these cells were prepared from low passage cell bank 
cultures, they were frozen in multiple cryo vials to ensure having an adequate supply 
of early-passage cells. Culturing CHO cells was also attempted in serum free EX-
CELL™ 302 medium (SAFC Biosciences, UK) supplemented with 2 mM L-glutamine 
(GIBCO, Invitrogen), 100 U of penicillin and 100 mg of streptomycin (GIBCO, 
Invitrogen) per ml. The latter is a serum free medium specifically developed for long 
term growth and maintenance of transfected and untransfected CHO cells.   
 
2.2.2.2  HEK - 293 cells 
HEK - 293 is an adherent cell line derived from human embryonic kidney 
cells (Graham et al, 1977). The source of these cells was a healthy, aborted foetus. 
Like CHO cells, HEK cells are easy to grow and transfect and have been widely used 
for cell biology research and also used by the biotechnology industry to produce 
therapeutic proteins and viruses for gene therapy. HEK - 293 cells were a gift from the 
Inflammation Research Unit/ Teaching Hospital Aintree, University of Liverpool.  
 
2.2.2.3  Caco-2 cells 
 The Caco-2 cell line is a continuous line of heterogeneous human epithelial 
colorectal adeno carcinoma cells (Trainer et al, 1988). They are adherent and known to 
express ligands for NKG2D receptors, namely MICB and ULPBs (Butler et al, 2009) 
and therefore their RNA was used to synthesize the cDNA necessary for amplification 
of these ligands. Both HEK- 293 and Caco-2 cells were grown and maintained in 75 
cm
2
 tissue culture flasks containing complete DMEM medium.  
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2.3  Activation of resting PBNK cells  
Different methods were used for activating the resting PBNK cells after 
isolation. These included co-culturing the NK cells with target cells (K562 or HeLa 
cells), stimulation with cytokines (IL-2) at different concentrations and using phorbol 
diesters (e.g. Phorbol Myristate Acetate [PMA]) together with ionomycin).  
 
2.3.1  Co-cultures of PBNK cell with target cells 
2.3.1.1  NK cells and K562 
After isolation, 1x10
5
 NK cells from each healthy donor were co-cultured 
with 10
5
 K562 cells in a 96-well round bottom tissue culture plate. Cell concentrations 
were adjusted to obtain effector: target (E: T) ratios of 1:1. Additionally, two sets of 
controls were prepared. The first control was containing only target cells (same 
concentration as in the co-cultures), and the other containing only 1x10
5
 NK cells in 
culture medium. All wells were prepared in duplicates whenever sufficient numbers of 
effector cells were available. The plate was then placed in a humidified incubator with 
5% CO2 atmosphere at 37 
o
C for up to 24 hrs. Supernatants from this co-culture as 
well as from the controls were collected at 1, 3, 6, 18 and 24 hrs. The supernatants 
were then stored at - 80 
o
C for further analysis. 
 
2.3.1.2  NK cells and HeLa 
Co-culturing of PBNK cells with HeLa cells was carried out in a similar 
way to co-culturing NK cells with K562 cells. The only difference was that the cell 
concentrations were adjusted to obtain effector: target (E: T) ratios of 5: 1 due to the 
fact that HeLa cells are significantly larger than K562s.  
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2.3.2  Stimulation of resting PBNK cells with PMA and ionomycin 
Isolated PBNK cells, at the same concentrations as those in the co-cultures, 
were washed twice with 1X PBS and incubated at 37 
o
C in a humidified atmosphere 
with 5% CO2 in the presence of 10 ng/ml of PMA (Sigma-Aldrich, UK) and 
ionomycin (1µg/ml). Supernatants were collected at 1, 3, 6 and 18 hrs (depending on 
the numbers of the effector cells) and stored at - 80 
o
C.  
 
2.3.3  Activation of resting PBNK cells with IL-2 
Resting NK cells collected from healthy donors were washed twice with 1X 
PBS and then activated with 500 U / ml of recombinant human IL-2 (R & D Systems, 
UK). Another sample was activated with only 100 U / ml of IL-2. The cell 
concentration was the same in these co-cultures. Cells were then incubated at 37 
o
C 
with 5% CO2.  Aliquots of tissue culture supernatants were collected at different time 
points i.e. 1, 3, 6 and 18 hrs and stored at - 80 
o
C until further analysis. 
 
2.4  Analysis of isolated PBNK cells for CD56 surface antigen expression 
The purity of the enriched PBNK cells after negative magnetic selection was 
assessed by flow cytometry. Four aliquots of 100 µl of the enriched PBNK cell 
fraction were taken from each sample in Falcon tubes and washed twice with FACS 
buffer. The first aliquot was stained with PE-conjugated antibody against the NK cell 
marker (CD56). The second one was stained with FITC - conjugated antibody against 
a T - cell marker (CD3) and the third one was dual labelled with both CD56 PE and 
CD3 FITC. A fourth unstained sample was used as a control. The aliquots were then 
incubated on ice in the dark for 45-60 minutes. Following the incubation, the cells 
were washed twice and re-suspended in 500 µl of FACS buffer and run on a Cyan 
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ADP flow cytometer (DakoCytomation Coulter, USA). Analysis was carried out using 
the Summit software package (DAKO). The samples were acquired until 20,000 target 
cells had been counted. Gates on the NK cell populations were set manually whereby 
the cell debris and dead cells were excluded to assess NK cell purity (CD3
−
 CD56
+
). 
All flow cytometry reagents and antibodies were from BD bioscience.  
 
2.5  Measurement of IL-6 secretion by ELISA  
The IL-6 concentration in the co-cultures, IL-2 and PMA - activated 
supernatants was assessed using the „Human IL-6 ELISA Ready-SET-Go‟ ELISA Kit 
(eBioscience, USA). This kit has a detection limit as low as 2 pg/ml; the procedure 
was done according to the manufacturer‟s instructions. 100 µl of monoclonal antibody 
specific for IL-6 (at a dilution of 48 µl/12 ml coating buffer) has been coated onto a 
96-well ELISA micro plate (Corning) and incubated overnight at 4 
o
C. The wells were 
then washed with washing buffer. 100 µl of the standards in serial dilutions (from 200 
to 0 pg / ml) and the samples were pipetted into the wells and incubated for 2 hrs. IL-
6, if present in a sample, was bound to the wells by the immobilized antibody. The 
wells were washed and 100 µl of biotinylated anti-human IL-6 antibody (concentration 
of 48 µl/12 ml assay buffer) was added for 1 hr. After washing to remove any unbound 
biotinylated antibody, 100 µl of HRP-conjugated streptavidin was pipetted into the 
wells and the plate was incubated further for 30 minutes. After a further washing step 
100 µl of a 3, 3′, 5, 5′-Tetramethylbenzidine (TMB) substrate solution was added to 
the wells. A blue colour developed in proportion to the amount of IL-6 bound. The 
colour development was stopped by adding Stop solution which changed the colour 
from blue to yellow. Finally, the intensity of the colour was measured at 450 nm and a 
calibration curves is plotted on semi log paper and values of optical density (OD) of 
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samples calculated from the standard. A TECAN plate reader was used to measure the 
absorbance (optical density) at 450 nm. The generation of standard curve and 
measurement the concentration of unknowns were done by using Microsoft Excel. 
 
2.6  Assessment of IL-6 secretion using Transwell plates  
In this assay, a 24-well polycarbonate Transwell plates (Corning) with 0.4 
µm pore size inserts were used. In the first well, resting PBNK cells from healthy 
donors were added at a concentration of 1 x 10
5
 cells / 100 µl of culture medium in the 
upper chamber of the Transwell plate. 1 x 10
5
 K562 (or 2 x 10
4
) HeLa cells suspended 
in 600 µl of culture medium were added to the lower chamber to act as target cells 
(Figure 2.3A). In the second well, 1x 10
5
 NK cells and an identical number of K562 
cells (or 2 x 10
4
 HeLa cells) were placed in the lower compartment of the Transwell 
plate and adjusted to a total volume of 600 µl of culture medium. 100 µl of culture 
medium, containing no cells was added to the upper compartment (Figure 2.3B). A 
third well was used as a negative control in which 100 µl of culture medium was 
added to the upper compartment while the lower compartment received 1 x 10
5
 K562 
(or 2 x 10
4
 HeLa cells) (Figure 2.3C). The wells were incubated at 37 
o
C with 5% CO2 
for 24 hrs and the supernatants were collected from the lower compartments. IL-6 was 
then measured in the supernatants by ELISA. 
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Figure 2.3A: 1 x 10
5
 resting PBNK cells from healthy donors in 100 µl of culture 
medium were added to the upper chamber of the Transwell well. The K562 with same 
concentration as the PBNK cells (or 2 x 10
4
 HeLa cells) suspended in 600 µl of 
culture medium were added to the lower chamber to act as target cells. 
Figure 2.3B: The NK cells in a concentration of 1 x 10
5
 cells were co-cultured with 
same concentration of K562 (or 2 x 10
4
 HeLa cells) in the lower compartment of the 
Transwell plate and adjusted to a total volume of 600 µl of culture medium. 100 µl of 
culture medium without cells was added to the upper compartment. 
 
 
Figure 2.3 C: Control sample in which 100 µl of culture medium was added to the 
upper compartment while the lower compartment received 1 x 10
5
 K562 (or 2 x 10
4
 
HeLa) cells. Pictures were reproduced from www.corning.com  
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2.7  Reverse transcription–polymerase chain reaction (RT-PCR) 
2.7.1  RNA handling 
Obtaining high quality, intact RNA is the first and often the most critical 
step in performing many molecular biology experiments, such as Northern analysis, 
RT-PCR, and quantitative PCR (qPCR). As RNA is very unstable all reagents and 
materials for its handling were treated to remove possible Ribonucleases (RNAse) 
activity. RNAses are very stable and are difficult to inactivate. Therefore, throughout 
the extraction, measures were taken to minimize RNAse activity. These included 
working in a dedicated RNA room, changing gloves regularly, and using previously 
un-opened RNAse-free tips and dedicated pipettes.     
 
2.7.2  Total RNA extraction from NK cells and cell lines 
Total RNA was extracted from NK cells and cell lines (HeLa and Caco-2 
cells) using the QIAmp RNA Blood Mini Kit (Qiagen, UK) according to the 
manufacturer‟s instructions. The purified NK cells and cell lines were disrupted or 
lysed using Buffer RLT to which β-Mercaptoethanol was added. The lysate was then 
added into a QIAshredder
TM
 spin column in a 2 ml collection tube and centrifuged for 
2 minutes at maximum speed (14,000 rpm) to homogenize. The QIAshredder
TM
 spin 
column was then discarded and the homogenized lysate was saved. One volume of 
70% ethanol was then added to the homogenized lysate to maximize the binding 
capacity and mixed by pipetting. The sample was then carefully pipeted into QIAamp 
spin column in a 2 ml collection tube without moistening the rim, and centrifuged for 
15 seconds at 10,000 rpm. This step is necessary to bind the RNA to silica membrane. 
The QIAamp spin column was then transferred into a new 2 ml collection tube and 
Buffer RW1 was added into the QIAamp spin column and centrifuged for 15 seconds 
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at 10,000 rpm to wash .The QIAamp spin column was then transferred into a new 2 ml 
collection tube and washed with 500 μl buffer RPE (with ethanol) and centrifuged for 
15 seconds at 10,000 rpm. The flow-through was discarded. This washing step was 
repeated again with the same buffer at full speed (14,000 rpm) for a longer period (3 
minutes) to dry the membrane. The QIAamp spin column was placed in a new 2 ml 
collection tube and the old collection tube was discarded. The column then centrifuged 
at full speed for 1 minute to remove any excess of ethanol. The total RNA was then 
eluted from the membrane by adding 30 - 50 μl of RNAse-free water directly onto the 
QIAamp spin column followed by centrifugation for 1 minute at 10,000 rpm. The 
eluted RNA was then either used immediately or stored in a - 80°C freezer for further 
use. 
 
2.7.3  Measuring RNA concentration 
The following formula was used for measuring RNA concentration: 
                                           
 
2.7.4  Determining RNA purity   
The ratio between the readings at 260 nm and 280 nm (A260/A280 ratio) 
provides estimates of the purity of RNA.  
 
2 
 
 
Ratios more than 1.8 were taken to indicate good RNA purity (Manchester, 1996).  
 
RNA conc. = Optical Density at 260 nm x Dilution Factor x 40µg/ml 
Total RNA yield = Concentration x Volume of stock in ml 
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2.7.5  Determining the RNA integrity 
The integrity of RNA is a major concern for gene expression studies and 
traditionally has been evaluated by comparing the intensity of the 28S and 18S rRNA 
bands on agarose gel. A denaturing gel system is suggested because most RNA forms 
extensive secondary structure via intra-molecular base pairing, and this prevents it 
from migrating strictly according to its size. Formaldehyde is usually used for analysis 
of RNA on gels and to keep the RNA denatured.  
 
2.7.6  Formaldehyde - Denaturing Agarose Gel Electrophoresis 
The electrophoresis tank and comb were cleaned with a detergent solution, 
thoroughly rinsed with 70% ethanol and left overnight in DEPC 
(diethylpyrocarbonate) treated RNAse-free water. On the next day, 1 g agarose was 
melted in 82 ml of 1X TAE buffer prepared using DEPC treated water. The mixture 
was heated in microwave until dissolved and then allowed to cool to 50°C.  After that, 
18 ml of 37% formaldehyde and 1 µl of ethidium bromide were added to the gel 
mixture.  The gel was mixed gently and then poured carefully onto the casting tray 
with the combs already inserted and left to set at room temperature for 30 - 45 
minutes. When fully set, the gel was assembled in the electrophoresis tank and the 
comb was carefully removed. 1X TAE buffer was then poured to cover the gel surface 
and used as running buffer. 4 volumes of RNA sample was mixed with 1 volume of 
5X RNA sample buffer. The mixture was then heated at 65°C for 15 minutes and then 
immediately chilled on ice for 1 minute to denature the RNA. The RNA sample was 
then loaded onto the formaldehyde agarose gel. The gel was run at 1-5 V/ cm until the 
dye front has migrated the appropriate distance. The gel was visualized under UV light 
and digitally recorded. 
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2.7.7  Reverse transcription (cDNA synthesis) 
The AMV (Avian Myeloblastosis Virus) Reverse Transcription System 
(Promega, UK) was used to synthesize single-stranded complementary DNA (cDNA) 
from the isolated total RNA. Since this system uses the AMV polymerase enzyme, a 
short double-stranded sequence is needed at the 3' end of the mRNA which acts as a 
start point for the polymerase.  This is provided by poly (A) tail found at the 3' end of 
most eukaryotic mRNAs to which a short complementary synthetic oligonucleotide 
(oligo dT primer) is hybridized (polyT-polyA hybrid). The total RNA template and all 
other reaction components were thawed and stored on ice. The optimal amount of 
starting RNA varied from 100 ng up to 1µg depending on each experimental design 
and the concentration of target cells. The RNA was heated at 70 °C for 10 minutes, 
centrifuged briefly and then placed on ice. A 20 µl reaction master mix was then 
prepared as follows: 
Reagent Volume 
Final 
Concentration 
10 X AMV RT Buffer  
 
2 1X 
MgCl2(25mM) 
 
4 5mM 
Deoxyribonuclease triphosphates (dNTPs),10mM 
 
2 1Mm 
Oligo dt(15) Primer 
 
0.5  0.5 µg 
RNase inhibitor 
 
0.5 µl 1u/µl 
AMV reverse Transcriptase 
 
1 µl 15 u 
RNAse –free water 
 
variable  
Template RNA 
 
variable 100 ng up to 1 µg 
Total 
 
20 µl  
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The reverse transcription reaction was incubated in a thermal cycler 
(Eppendorf Mastercycler, Germany) at 42°C for 15 minutes. During this step the oligo 
dT primer anneals to poly-A tail of mRNA and the AMV reverse transcriptase 
synthesizes a complementary DNA strand on the mRNA template (RNA-DNA 
hybrid). At the same time the AMV reverse transcriptase enzyme has a strong 
ribonuclease activity (RNase H) which recognises the RNA component of the RNA: 
DNA hybrid. This results in the cleavage of the RNA at a number of non-specific sites 
leaving a single stranded cDNA copy of the RNA template. After the completion of 
the reverse transcription the sample was heated at 95°C for 5 minutes, and then 
incubated at 0 - 5°C for 5 minutes. This inactivates the AMV reverse transcriptase and 
prevents it from binding to the cDNA. The first-strand cDNA was then stored at - 
20°C until use. 
 
2.8  PCR based DNA cloning 
2.8.1  General primer design considerations 
The most vital step in the development of a PCR reaction is the design of 
suitable primers. A PCR primer pair consists of two oligonucleotides that hybridize to 
complementary stands of the DNA template, and thus identify the region to be copied. 
The following considerations were taken into account when designing the primers for 
PCR reactions: 
1.  Primer length 18-30 bp 
2.  Primers should be in 5‟ to 3‟ orientation 
3.  Primer melting temperature (Tm) 55 °C -65 °C. 
4.  Tm difference between forward and reverse primers ≤ 5°C 
5.  Guanine-Cytosine (GC) content 40 - 60 % 
6.  No secondary structures such us self dimers or hairpin. 
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2.8.2  Fc-Fusion protein primers  
The human NKG2D (hNKG2D) ligands were planned to be expressed as 
Fc-fusion proteins to investigate the role of NKG2D signalling in the initiation of IL6 
production by NK cells. This can be achieved by the use of overlap extension PCR.  In 
the first round (PCR1) the genes encoding for the extracellular portions of hNKG2D 
ligands (MICA, MICB, ULBP1, ULBP2 and ULBP3) were amplified. In PCR2, the 
genes encoding the hinge region, CH2 and CH3 domains of heavy chain of mouse IgG 
(m IgG) were amplified. The primers were specifically designed so that the 3‟ ends of 
PCR1 and PCR2 were overlapped. This was followed by third round of PCR (PCR3) 
in which these two intermediate products were hybridized together and were extended 
to generate the full length recombinant gene using the forward primer of NKG2D 
ligand and the reverse primer of the Fc fragment respectively. These primers also 
included restriction enzyme sites for inserting the product into an expression vector for 
cloning purposes. The following primers were used to generate hNKG2D - mFc fusion 
proteins throughout this study (Table 2.1). All of them were purchased from 
Invitrogen and their designs are discussed in more details in Chapter 5: 
 
Table 2.1: Primers used to generate hNKG2D ligands - mFc fusion proteins 
 
Primer name Primer sequence Primer length 
EcoRI – MICA forward 
primer1-  sense 
5‟ TCTGAATTCATGGGGCTGGGCCCGGTC 3‟ 27 bp 
EcoRI – MICB forward 
primer1-  sense 
5‟ TCTGAATTCATGGGGCTGGGCCGGGTC 3‟ 27 bp 
EcoRI – ULBP1 forward 
primer1-  sense 
5‟TCTGAATTCATGGCAGCGGCCGCCAGC 3‟ 27 bp 
EcoRI – ULBP2 forward 
primer1-  sense 
5‟ TCTGAATTCATGGCAGCAGCCGCCGCT 3‟ 27 bp 
 
 
76 
 
EcoRI – ULBP3 forward 
primer1 -  sense 
5‟ TCTGAATTCATGGCAGCGGCCAGCCCC 3‟ 27 bp 
EcoRI – MICA forward 
primer2 -  sense 
5‟ TCTGAATTCGGAGCCCCACAGTCTTCGTTA3‟  30 bp 
EcoRI – MICB forward 
primer2 -  sense 
5‟TCTGAATTCGGAGCCCCACAGTCTTCGTTA3‟  30 bp  
EcoRI – ULBP1 forward 
primer2 -  sense 
5‟TCTGAATTCGTGTGAAGTTCAAGGCCTGGT 3‟ 30 bp 
EcoRI – ULBP2 forward 
primer2-  sense 
5‟ TCTGAATTCGTGTGCGGTTCAAGGCCAGGT 3‟ 30 bp 
EcoRI – ULBP3 forward 
primer2-  sense 
5‟TCTGAATTCGTGTGAGGTCCAGAGCCAGGT 3‟ 30 bp 
MICA reverse (pFUSE 
overlap) - antisense 
5‟ TGTGGGCCCTCTGGGAGAGGGCACAGGGTG 3‟ 30 bp 
MICB reverse (pFUSE  
overlap) - antisense 
5‟ TGTGGGCCCTCTGGGAGGGTGAGTGCCGTG 3‟ 30 bp 
ULBP1 reverse (pFUSE  
overlap)-antisense 
5‟ TGTGGGCCCTCTGGGTTGTTCCCAGTACAT 3‟ 30 bp 
ULBP2 reverse (pFUSE 
overlap) - antisense 
5‟ TGTGGGCCCTCTGGGGCTGTCCATGCCCAT 3‟ 30 bp 
ULBP3 reverse (pFUSE 
overlap)-antisense 
5‟ TGTGGGCCCTCTGGGCTTCTTCCTGTGCAT 3 ‟ 30 bp 
pFUSE forward (MICA 
overlap) - sense  
5‟ CACCCTGTGCCCTCTCCCAGAGGGCCCACA 3‟                                                                      30 bp
pFUSE forward (MICB 
overlap) - sense  
5‟ CACGGCACTCACCCTCCCAGAGGGCCCACA 3‟ 30 bp 
pFUSE forward (ULBP1 
overlap) -sense  
5‟ ATGTACTGGGAACAACCCAGAGGGCCCACA 3‟ 30bp 
pFUSE forward (ULBP2 
overlap) - sense  
5‟ATGGGCATGGACAGCCCCAGAGGGCCCACA 3‟ 30bp 
pFUSE forward (ULBP3 
overlap) - sense  
5‟ATGCACAGGAAGAAGCCCAGAGGGCCCACA3‟ 30bp 
pFUSE reverse (anti- 
sense) 
5‟ CTGGGTCATCCTCGCTCACATCCACCA 3‟ 27 bp 
BglII - MICA reverse-
antisense   
5‟GTTAGATCTAGAGGGCACAGGGTGAGTGCT 3‟ 30 bp 
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2.8.3  Setting up the overlap extension PCR reaction 
2.8.3.1  PCR1 for the amplification of genes encoding the extracellular portion 
of hNKG2D ligands (MICA, MICB, ULBP1, ULBP2 and ULBP3)  
Whenever these PCR1 reactions were conducted, two 50 µl PCR reactions 
(one for the sample and other for negative control) were set up.  All components were 
thawed and kept on ice and all the work was carried out in a clean, aseptic 
environment using gloves and clean RNAse free disposable pipettes.  Phusion® High 
Fedility polymerase (Finnzymes) was used for this step to decrease error rate. The 
master mix was prepared as follows: 
 
Reagent Volume Final concentration 
5X Phusion HF buffer 
(Finnzymes) 
10 µl 1X 
dNTPS, 10mM (Promega)  1 µl 200 µM each 
Sense  primer*                                                      1 µl 0.5 µm 
Anti-sense primer*                                                       1 µl 0.5 µm 
cDNA**   1 µl  
Phusion® High-Fidelity DNA 
polymerase (Finnzymes)  
0.5 µl 0.02 U/µl 
H2O Up to 50 µl  
Total 50 µl  
 
*    H2O was used instead of the sense and anti-sense primers for the negative control. 
** HeLa cDNA was used as a template to amplify the genes encoding for the extracellular portion 
of MICA. 
      Caco-2 cDNA was used as a template to amplify the genes encoding for the extracellular 
portion of MICB and ULBPs.  
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After setting up the reaction mix, the tubes were spun down briefly to bring 
all the components of PCR reactions to the bottom and then incubated in a 
Thermalcycler (Eppendorf, Germany). The cyclic parameters were as follows: 
 
Cycle step Temperature Time Cycles 
Initial denaturation 98°C 30 seconds 1 
Denaturation 
Annealing 
Extension 
98°C 
* 
72°C 
5-10 seconds 
10-30 seconds 
1 minute 
 
 
30 cycles 
 
Final extension  72°C 
4°C 
5 minutes 
hold 
1 
 
*MICA/B = 62°C 
 *ULBP1 = 60°C 
 *ULBP2 = 62°C 
 *ULBP3 = 60 °C 
 
 
2.8.3.2  PCR 2 for the amplification of genes encoding for the Fc portion of 
mouse IgG 
The pFUSE mIgG2A-Fc plasmid (Invivogen) was used as a template to 
amplify the Fc portion of the mouse IgG2A. pFUSE-Fc plasmids are  family of 
plasmids specifically developed to facilitate the construction of Fc-Fusion proteins by 
fusing a sequence encoding a given protein to the Fc region of an immunoglobulin. 
Two set of reaction mixes (sample and negative control) were prepared as follows: 
 
 
 
 
 
79 
 
Reagent Volume Final concentration 
5X Phusion HF buffer (Finnzymes) 10 µl 1X 
dNTPS, 10mM (Promega)  1 µl 200 µM each 
Sense  primer*                                                      1 µl 0.5 µm 
Anti-sense primer*                                                       1 µl 0.5 µm 
cDNA**   1 µl  
Phusion®High-Fidelity 
DNApolymerase (Finnzymes)  
0.5 µl 0.02 U/µl 
H2O Up to 50 µl  
Total 50 µl  
 
*    H2O was used instead of the sense and anti-sense primers for the negative control. 
** pFUSE-mIgG2A-Fc plasmid was used as a template to amplify the Fc portion of mIgG2A. 
 
 
The thermocyclic parameters were as follows: 
  
Cycle step Temperature Time Cycles 
Initial denaturation 98°C 30 seconds 1 
Denaturation 
Annealing 
Extension 
98°C 
* 
72°C 
5-10 seconds 
10-30 seconds 
1 minute 
 
 
30 cycles 
 
Final extension  72°C 
4°C 
5 minutes 
hold 
1 
 
* pFUSE (MICA overlap)  = 62 
* pFUSE (ULBP1 overlap) = 60              
* pFUSE (ULBP2 overlap) = 62 
* pFUSE (ULBP3 overlap) = 60 
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After amplification, the PCR1 and PCR2 were purified using Qiagen 
MinElute PCR Purification Kit (Qiagen, UK). In brief, one volume of PCR1 or PCR2 
products was mixed with 5 volumes of Qiagen PB buffer. The mixture was added to 
Qiagen MinElute column and centrifuged for 1 minute at miximum speed (14,000 
rpm). Following centrifugation, the column was washed with 750 µl of PE buffer 
(with ethanol) and centrifuged again for 1 minute at maximum speed. After discarding 
the flow-through, the column was centrifuged for additional 1 minute to get rid of any 
residual ethanol from PE buffer. Finally, the column was placed in a clean 1.5 ml 
microcentrifuge tube and 50 µl of elution buffer (EB buffer) was added to the centre of 
the column membrane. The DNA was then eluted from the column membrane by 
centrifugation for 1 minute at maximum speed.  
A 1% agarose gel in 1X TAE buffer was used to analyze and visualise the 
DNA fragments generated during PCR1 and PCR2 reactions. 1.5 g of agarose powder 
(Web Scientific, UK) was mixed with 150 ml of 1X TAE buffer and heated in a 
microwave oven until completely melted. After melting, the gel was cooled to about 
50 °C and 1 µl of ethidium bromide was added to the gel at this point to facilitate the 
visualization of DNA after electrophoresis. The gel was then poured into a casting tray 
containing a comb and allowed to solidify at room temperature. After the gel set the 
comb was removed, and the gel (still in its plastic tray), was inserted horizontally into 
the electrophoresis chamber and just covered with 1X TAE buffer. 5µl DNA samples 
from the PCR1 and PCR2 products were mixed with 6X loading buffer (NEB, UK) 
and pipetted into the sample wells along with 10000 bp DNA ladder (Web Scientific, 
UK ; NBS Biologicals, UK). After electrophoresis, the amplified fragments were 
checked for their size and approximate concentration and a picture was taken by 
digital camera. 
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 2.8.3.3 PCR3 for fusing hNKG2D ligand - mFc recombinant genes  
In this PCR, a recombinant DNA construct for hNKG2D ligands was 
generated by fusing the sequence encoding for the extracellular portion of NKG2D 
ligand proteins (MICA/B, ULBP1, ULBP2 and ULBP3) to the Fc region of mouse 
IgG2A. The PCR3 reaction was set up in 2 steps:  
In the first step 15µl of PCR 1 were mixed with 15 µl of PCR 2 in 0.5 ml 
PCR tube and the reaction was allowed to run on Thermocycler (Eppendorf, Germany) 
for 10 cycles without primers. During this step the annealing temperature of the 
overlap area was determined and the extension time increased to allow the annealing 
of PCR1 with PCR2. The reaction was set as follows:   
 
Reagent Volume 
Final 
concentration 
5X Phusion HF buffer 
(Finnzymes) 
10 µl 1X 
dNTPS, 10mM (Promega)  1 µl 200 µM each 
Sense  primer                                                      - - 
Anti-sense primer                                                       - - 
cDNA   15µl of PCR1+15 µl of PCR 2  
Phusion®High-Fidelity 
DNApolymerase (Finnzymes)  
0.5 µl 0.02 U/µl 
H2O Up to 50 µl  
Total 50 µl  
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The cycling parameters were as follows: 
Cycle step Temperature Time Cycles 
Initial denaturation 98°C 30 seconds 1 
Denaturation 
Annealing 
Extension 
98°C 
* 
72°C 
5-10 seconds 
10-30 seconds 
1.5 minutes 
 
 
10 cycles 
 
Final extension  72°C 
4°C 
5 minutes 
hold 
1 
 
*MICA/B fusion = 66 
*ULBP1 fusion = 61 
*ULBP2 fusion = 65 
*ULBP3 fusion = 62 
 
Following this step, 1µl of the forward primer (either MICA/B or ULBP1 or 
ULBP2 or ULPB3 forward primer) and 1 µl of the pFUSE-mIgG2A-Fc reverse primer 
were added to the reaction. More Phusion® Polymerase enzyme (0.3 µl) was also 
added to the PCR mix at this step and the reaction was run for another 25 cycles using 
the following cycling conditions:  
Cycle step Temperature Time Cycles 
Initial denaturation 98°C 30 seconds 1 
Denaturation 
Annealing 
Extension 
98°C 
* 
72°C 
5-10 seconds 
10-30 seconds 
1.5 minutes 
 
 
25 cycles 
 
Final extension  72°C 
4°C 
5 minutes 
hold 
1 
 
*MICA/B fusion = 66 
*ULBP1 fusion = 61 
*ULBP2 fusion = 65 
*ULBP3 fusion = 62 
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2.8.4  Visualization and extraction of the fused PCR products  
After analysing on 1% agarose gel/1X TAE buffer, the PCR3 (recombinant 
DNA products) were then gel purified using PureLink 
TM
 Quick Gel Extraction Kit 
(Invitrogen) according to the manufacturer‟s instructions. In brief, the gel area 
containing the correct size recombinant DNA fragment was carefully excised using a 
clean, sharp razor blade. The excised gel was then placed in a 1.5 ml polypropylene 
micro-centrifuge tube and weighed. Three volumes of Quick Gel Solubilisation Buffer 
were then added to the gel and allowed to melt at 50 °C for at least 10 minutes. After 
complete dissolution of the gel, 1 volume of 100% isopropanol was added to the 
DNA-gel mixture and the mixture was then loaded onto Quick Gel Extraction column 
and centrifuged at 10,000 rpm for 1 minute. This step is necessary to bind the DNA to 
silica membrane. Following centrifugation, the flow-through was discarded and the 
membrane was washed with 500 ml of Quick gel Wash Buffer (with ethanol) and 
centrifuged at 10,000 rpm for another 1 minutes. To remove any residual ethanol and 
Wash Buffer, the Quick Gel Extraction column was centrifuged again for 2-3 minutes. 
The wash tube was then discarded together with the flow-through and the Quick Gel 
column was placed in a new 1.5 ml eppendorf tube. Finally, the DNA was eluted from 
the membrane by adding 30 - 50 μl of Quick Gel Elution Buffer directly onto the 
column followed by centrifugation for 1 minute at 13,000 rpm. The eluted DNA was 
either used immediately or stored in a - 80°C freezer until further use. 
 
 
 
 
 
 
 
84 
 
2.9  Cloning and sequencing of the recombinant gene products 
2.9.1   Restriction enzyme digestion and T4 ligation 
The recombinant DNA products (hNKG2D ligand- mFc recombinant genes) 
were cloned into pFUSE-mIgG2A - Fc1 and pFUSE-mIgG2A - Fc2 plasmids 
(Invivogen, San Diego, USA). These plasmids are cloning plasmids with Zeocin 
selection specifically engineered to facilitate the generation and secretion of Fc fusion 
proteins. Both the recombinant genes and plasmids were double digested for 2 hours 
by EcoRI and BspHI endonucleases (NEB) according to manufacturer‟s instructions. 
The double digest was possible because both enzymes are 100% active in the same 
buffer (Buffer 4 from NEB). The digested plasmid and overlap PCR products were gel 
purified as described above and then ligated overnight at 4 °C by T4 ligase enzyme 
(Promega) according to manufacturer‟s instructions.  The equation described by 
Alexei Gratchev (www. methods.info / Methods / RNA_DNA / ligation) was used to 
calculate the volume of the insert needed for the ligation reaction.   
 
 
Li = volume of the insert in µl. 
Lv = volume of the vector in µl to be used. 
Si= Size of the insert 
Sv= Size of the vector 
Iv/Ii= approximate intensity of the vector to the intensity of the insert on agarose 
gel. 
Vi/Vv= volume of the insert to volume of the vector loaded on the gel. 
 
 
                  Li = 3     x     Lv      x              x              x  
Si 
Sv 
Iv Vi 
Ii Vv 
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2.9.2   Transformation 
C2925I dam
-
/dcm
- 
competent E. coli was first purchased from NEB and 
maintained and re-prepared using the protocol described by Chung et al (1989). In this 
method, the E. coli were grown in LB (Luria-Bertani) broth to the early exponential 
phase (OD600 0.3-0.4), pelleted by centrifugation at 1000 x g for 10 min at 4 °C and 
then re-suspended at one-tenth of their original volume in ice-cold transformation and 
storage solution (TSS). A 0.1 ml aliquot of E. coli was then transferred into 15 ml cold 
polypropylene tube, mixed with the ligation mix, and incubated for 30 min at 4 °C. 
After incubation, 0.9 ml of TSS with 20 mM glucose was added, and the bugs were 
grown at 37 °C with shaking (225 rpm) for 1 hr to allow expression of the antibiotic-
resistance gene. 1 µl of empty pFUSE-mIgG2A-Fc vector was also transformed and 
used as positive control to check for transformation efficiency. Transformants were 
then selected by plating transformed E.coli on LB agar plates containing Zeocin (50 
µg/ml), and incubated overnight at 37 °C. On next day, at least 3 colonies were picked 
and screened for the presence of the recombinant vector by colony PCR or by
restriction endonuclease digestion and gel electrophoresis of minipreps. 
 
2.9.3  Colony PCR protocol 
Colonies were picked up, suspended in 3 ml of LB broth + Zeocin and 
incubated at 37 °C for 2-3 hours with vigorous shaking. After incubation, the cells 
were centrifuged at maximum speed at 4 °C for 10 minutes and the supernatant was 
discarded.  The cell pellet was then re-suspended in 50 µl of 10 mM EDTA and heated 
at 100 °C for 5 minutes. After heating, the lysate was vortex and briefly centrifuged. 1-
2 µl of the lysate was taken and used as template for colony PCR. The PCR master 
mix was set up as follows: 
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Reagent Volume Final concentration 
10 X Taq Buffer (Qiagen) 10 µl 1X 
dNTPS, 10mM (Promega)  1 µl 200 µM each 
Sense  primer*                                                      1µl 0.5 µM 
Anti-sense primer*                                                       1 µl 0.5 µM 
cDNA**   1 µl  
TaqDNApolymerase (Qiagen) 0.5 µl 0.02 U/µl 
H2O Up to 50 µl  
Total 50 µl  
 
*Sense Primer = Forward primer for MICA, MICB, ULBP1, ULBP2 or ULBP3. 
 
*Anti-sense primer = Reverse primer for pFUSE-mIgG2A-Fc vector. 
 
**cDNA = colony lysate 
 
 
 
 2.9.4  Purification of pFUSE-mIgG2A-Fc plasmids containing recombinant 
DNA (miniprep) 
pFUSE plasmids containing the recombinant (fusion) DNA were purified 
using  Qiaprep Spin Miniprep Kit (Qiagen) according to the manufacturer‟s 
instructions. Using this kit, the positive colonies on colony PCR were collected and re-
suspended in 6 ml of LB broth containing Zeocin and incubated overnight at 37 °C 
with shaking at 225 rpm. The next day the bacterial cells were centrifuged at 1000 x g 
at 4 °C for 10 minutes and the pellet was re-suspended in 250 µl of Buffer P1. After 
re-suspension, the bacterial cells were lysed with gentle mixing in 250 µl of Buffer P2 
in the presence of RNAse A. Buffer P2 is a NaOH/SDS buffer in which the SDS 
(sodium dodecyl sulphate) solubilises the components of the cell membrane, leading to 
lysis and release of the cell contents while NaOH denatures the chromosomal and 
plasmid DNAs, as well as proteins. The lysate was then neutralized and adjusted to 
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high-salt binding conditions in one step by the addition of 350 µl of Buffer N3. The 
high salt concentration of Buffer N3 causes denatured proteins, chromosomal DNA, 
cellular debris, and SDS to precipitate, while the smaller plasmid DNA re-natures 
correctly and stays in solution. After clearing the lysate by centrifugation at 14,000 
rpm for 10 minutes, the supernatant containing the plasmid DNA was applied to the 
QIAprep Spin Column by decanting or pipetting and centrifuged for 1 minute at 
10,000 rpm. The QIAprep Spin Column is a silica membrane column that allows only 
the DNA to adsorb to the membrane under optimized buffer conditions. After 
centrifugation, the flow-through was discarded and the column was washed with 500 
µl of Buffer PB and centrifuged again for 1 minute. The salts were removed by a wash 
step with 750 µl of buffer PE. Any residual wash Buffer should be removed from the 
column and this can be achieved additional centrifugation for 1 minute. Plasmid DNA 
was then eluted from the QIAprep column with 50 µl of Buffer EB or water and the 
purified plasmid DNA was then checked for the presence of recombinant (fusion) 
DNA by endonuclease digestion and gel electrophoresis.  
 
2.9.5  Plasmid Maxi-prep and DNA sequencing 
Bulk cultures of pFUSE-mIgG2A-Fc plasmids containing recombinant 
NKG2D ligands - Fc genes (MICA/B, ULBP1, ULBP2 and ULBP3 recombinant 
genes) were purified using the QIAGEN Plasmid Maxi Kit (Qiagen) according to 
manufacturer‟s instructions. The purified plasmids were quantified by 
spectrophotometry and sent to Source BioScience LifeSciences (Cambridge, UK) for 
DNA sequencing. The resulting sequences were then verified with the NCBI BLAST 
programme.  
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2.9.6  Transfection  
After DNA sequence verification, CHO cells and HEK - 293 cells were 
transfected with hNKG2D ligand - mFc fusion plasmid constructs and the positive 
clones were selected. Transfectants were generated using non liposomal reagents, 
electroporation or a combination of cell - specific reagent and electroporation. With 
non liposomal reagents, CHO or HEK - 293 cells were cultivated in 75 cm
2
 tissue 
culture flasks as described in Section 2.2.2. 1-2 days after, when the cells reached 90% 
confluence, transfection was performed using 20 μg of plasmid DNA and 20 μl of 
jetPRIME (Polyplus transfection
TM
, USA) for 4 hours according to the manufacturer's 
recommendations. The transfection medium was then removed and cells were 
incubated at 37 °C with 20 ml fresh culture medium for 72 - 96 hours. Cell 
supernatants were harvested and kept stored at - 20°C. Stable transfectants were also 
selected after plasmid linearization with NotI enzyme (NEB) and purification by 
phenol extraction and ethanol precipitation in 12-well tissue culture plate in a medium 
containing 400 μg/ml of Zeocin (Invitrogen). The selective medium was changed 
every 2-3 days and clones resistant to the Zeocin antibiotic emerged after 2-3 weeks. 
These resistant clones were transferred into 75 cm
3
 tissue culture flasks and allowed to 
grow and expand in the Zeocin selective medium. Cell supernatants were then 
collected and stored at - 20 °C until used. 
Electroporation was used for transient transfection of CHO cells. After 
trypsinization, a suspension of 1x 10
6
 cells/ sample in 500 µl Ham‟s F-12 culture 
medium alone (without FCS and antibiotic) was placed in 4 mm electroporation 
cuvettes (Bio-Rad). This culture medium was used as electroporation buffer. 100 µg of 
Maxi-prep purified plasmid DNA was then added to the cell suspension and the 
cuvette was connected to the electroporator (Bio-Rad). The cells were subjected to a             
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high-voltage electrical pulse of 290 V and 960μF capacitance. After electroporation, 
the cells were then allowed to recover briefly on ice for 5 minutes before they were 
placed in 20 ml of normal growth medium. The cell supernatant was collected 72 - 96 
hours later and stored at - 20 °C until used. 
 The combination of cell - specific reagent and electroporation was another 
method used for transfection of CHO cells. 1-2 days prior to transfection the CHO 
were cultivated in 75 cm
2
 tissue culture plates in complete Ham‟s F-12 medium until 
reaching 80-90 % confluency. On the day of transfection, these cells were trypsinized, 
counted and aliquoted into 1x10
6
 cells / sample. These aliquots were then centrifuged, 
the supernatant removed completely and the cells re-suspended in 100 µl of 
nucleofactor® Solution (Lonza, UK) / sample. The nucleofactor® Solution was made 
of 4.5 volumes of nucleofactor® Solution to one volume of nucleofactor® 
Supplement. The cell suspension was then mixed with 2µg of recombinant pFUSE-
mIgG2A-Fc plasmid containing the recombinant hNKG2D ligand – mFc gene and 
transferred into a certified 2 mm electroporation cuvette (Lonza, UK). The cuvette was 
then placed into the electroporator (Bio-Rad) and the appropriate pulse (960 µF 
capacitance, 290 V) was applied.  Following electroporation, the cells were transferred 
with sterile pipettes into a 75cm
2
 tissue culture flask containing 20 ml complete Ham′s 
F12 medium. 72-96 hours later, the cell supernatant was collected and stored at - 20°C 
until used.  
 
2.9.7  Purification of NKG2D ligand-Fc fusion proteins 
NKG2D ligand-Fc fusion proteins were purified from cell supernatants by 
affinity chromatography using a Pierce® Chromatography Protein A/G Cartridge 
(Thermo Fischer, USA) according to the manufacturer‟s protocol. Using a 20 ml 
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syringe, the cartridge was first washed with 5-10 ml of Thermo Fisher 
Washing/Binding Buffer, pH 7.2 (BupH™ Phosphate Buffered Saline) at a flow rate 
of ~ 1ml/minute. Supernatant from transfectant CHO or HEK - 293 cells was then 
taken out from the -20 °C freezer, warmed to 37 °C in a water bath and transferred into 
a clean 50 ml tube and diluted with an equal volume of BupH™ Phosphate Buffered 
Saline. This adjusts the sample to the ionic strength and pH of the Washing/ Binding 
Buffer and allows maximum binding when applying to the protein A/G resin. The 
supernatant was then pumped through the protein A/G cartridge at a flow rate of 1 
ml/minute and the effluent was discarded. Supernatant taken from untransfected CHO 
or HEK-293 cells was also used as negative control. Following the addition of the 
supernatant, the cartridge was washed again with 5-10 ml of Thermo Fisher 
Washing/Binding Buffer at a flow rate of ~1 ml/minute and then eluted with 
approximately 2-5 ml of Thermo Fisher ImmunoPure® IgG Elution Buffer (pH 2.8). 
Eluted  fractions of 0.5-1 ml were collected and immediately adjusted to physiological 
pH by adding 100 μl of the Neutralization Buffer (1 M Tris at pH 8.7) per 1 ml of 
elute. The eluted fractions were stored at -20 °C until use. The integrity of the proteins 
was then verified by SDS-PAGE on 10 % acrylamide gels and staining with 
Coomassie Blue or by Western blotting.  
 
2.10  SDS-PAGE and Western blot  
The eluted fractions collected from the supernatant of transfected cell lines 
were analysed for the NKG2D-fusion proteins secretion. On the day of experiment the 
samples were thawed to room temperature and their volume was reduced to ~ 10-15 µl 
by centrifuging in vacuum, and mixed with equal volume of 1X SDS sample buffer. 
The mixture was then heated to 100 °C for 5-10 minutes, sonicated 3-4 times and then 
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loaded onto an SDS-PAGE gel. The SDS-PAGE gel was made up as 10 % resolving 
gel and 4.5% stacking gel and prepared as follows: 
Reagent 10% resolving gel 4.5% stacking gel 
De-ionized H2O 2816 µl 3575 µl 
1M Tris HCl, pH 8.7 3750 µl - 
1M Tris HCl, pH 6.7 - 625 µl 
Polyacrylamide (30% stock) 3333 µl 750 µl 
10% (w/v) SDS (sodium dodecyl sulphate)  100 µl 50 µl 
10% (w/v) ammonium persulphate 
(Sigma)  
100 µl 50 µl 
TEMED (Tetramethylethylenediamine), 
Sigma 
15 µl 8 µl 
 
The resolving gel was poured into the gel cassette (Invitrogen) and the 
cassette was filled with SDS-PAGE resolving gel to a level which allows the comb to 
be inserted with about 5mm between the bottom of the wells and the top of the 
resolving gel. 0.5 ml of H2O was overlaid the gel to ensure a flat interface between the 
resolving and stacking gels. The gel was then left for about 30 minutes to solidify. 
After setting the gel, cassette was inverted to drain the H2O and the stacking gel was 
poured into the gel cassette to the top. The comb was inserted and the stacking gel was 
allowed to polymerize for at least 1 hour at room temperature or left overnight at 4 °C. 
The comb was carefully removed to prevent the disruption of the gel and the gel 
cassette was put in an XCell SureLock
TM
 Mini-cell (Invitrogen) containing SDS 
running buffer. Using special gel loading tips or a micro-syringe the samples, the 
controls and protein ladder (NEB, UK) were loaded into the wells. The gel was then 
electrophoresed at 180 V until the dye molecules (the “migration front”) reached the 
bottom of the gel. If only SDS-PAGE was used, the acrylamide gels were analysed for 
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the secretion of hNKG2D ligands - mFc fusion proteins by staining with Coomassie 
Brilliant Blue. If Western blotting carried out, the gels were transferred to PVDF 
(Polyvinylidine fluoride) membrane (Millipore) in 1X western blot transfer buffer at 
30 V for 1 hour. Good electrophoretic transfer was confirmed by the complete transfer 
of molecular weight markers below 100 kDa when the membrane was stained with 
0.1% (w/v) Ponceau S stain in 5% (v/v) acetic acid. Pre-stained markers of greater 
than 100 kDa may not transfer completely from the gel onto the membrane. After 
staining with Ponceau S, the PVDF membrane was washed with 1X TBS with 0.075% 
Tween 20 (Sigma-Aldrich) to remove the stain and then blocked with Western blot 
blocking buffer (1X TBS, 5% milk and 0.075% Tween 20 ) for 1 hour at room 
temperature. The membrane was briefly washed 2 times with 1X TBS with 0.075% 
Tween 20 for 30 seconds to remove excess blocking buffer and then incubated with 
the primary mouse anti-MICA monoclonal antibodies (Santa Cruz biotechnology, 
USA) overnight at 4 °C with shaking. Antibodies were diluted to the recommended 
concentration in a 1% milk/1X TBS incubation solution. On the next day the 
membrane was washed two times in Western blot washing buffer for 5 minutes on a 
shaker and then incubated with biotinylated monoclonal secondary antibody (goat 
anti-mouse HRP-labelled streptavidin, Sigma-Aldrich, UK) at the recommended 
dilution of (1:10000) in a 1% milk/1X TBS for 1 hour at RT with agitation and then 
washed as above. For the detection of blotted proteins, enhanced chemiluminescence 
(ECL) Kit (Millipore) was used. This kit consists of two detection reagents which are 
mixed in equal quantities just before use e.g. 800 μl of each. Any excess washing 
solution is shaken off the blot and 1.6 ml volume of working reagent was added to 
protein surface of the membrane and incubated for 1-5 minutes. The membrane was 
then blot dried and sealed in a plastic wrap and the outside corners of membrane were 
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marked with pen and the covered membrane was placed in a developing cassette. 
Membranes were exposed to X-ray film in a dark room and developed. Exposure times 
were determined by experience and they varied between 2 seconds and 5 minutes. 
 
2.11  Real -time IL-6 PCR quantification 
IL-6 mRNA expression was analysed using semi-quantitative real-time PCR 
with GAPDH mRNA as the internal reference gene. Total RNA (100 ng) from PBMCs 
or purified NK cells was reverse transcribed into cDNA using the method described 
previously. Primer sequences used in this experiment for the real-time amplification of 
IL-6 and GAPDH were acquired from published sequences (Table 2.2). 
 
Table 2.2: Oliginucleotides used in real-time PCR 
Primer Name Sequence 
Primer 
length 
Product 
size 
Reference 
IL-6  primer (1) sense 
 
5‟ GGTACATCCTCGACGGCATCT3‟ 21 bp  81 bp 
Keller et 
al,2003 
IL-6  primer (1) anti-sense 5‟ GTGCCTCTTTGCTGCTTTCAC3‟ 21 bp  81 bp 
Keller et 
al,2003 
IL-6  primer (2) sense 5‟ CATTTGTGGTTGGGTCAGG 3‟ 19 bp  99 bp 
Liebertz et 
al, 2010 
IL-6  primer (2) anti-sense 5‟ AGTGAGGAACAAGCCAGAGC3‟ 20 bp  99 bp 
Liebertz et 
al, 2010 
IL-6  primer (3) sense 5‟ CTGCAGCCACTGGTTCTGT 3‟ 19 bp 143 bp 
Lechner et 
al, 2010 
IL-6  primer (3) anti-sense  5‟ CCAGAGCTGTGCAGATGAGT 3‟   20 bp 143 bp 
Lechner et 
al, 2010 
IL-6  primer (4) sense 
 
5‟ TCTCCACAAGCGCCTTCG 3‟ 18 bp 193 bp 
Verhoog 
et al, 2011 
 
 
IL-6  primer (4) anti-sense 
 
5‟ CTCAGGGCTGAGATGCCG 3‟ 18 bp 193 bp 
Verhoog 
et al, 2011 
 
Pre-optimized IL-6 
primers 
  107 bp 
Qiagen 
(QT00083
72) 
GAPDH sense 
 
5‟ CATGGGTGTGAACCATGAGAA 3‟ 21 bp 133 bp 
Iwuchukwu 
et al, 2011 
GAPDH anti-sense 
 
5‟ GGTCATGAGTCCTTCCACGAT 3‟ 21 bp 133 bp 
Iwuchukwu 
et al, 2011. 
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Both the IL-6 and GAPDH reactions were set up using SensiMix
TM 
SYBR 
Green NO ROX kit (BioLine, UK). This kit consists of a 2X master mix, contains hot 
start DNA polymerase, SYBR Green I dye, MgCl2, dNTPs, and buffer. The cDNA 
and primers were added to this mix before transfer to the real-time PCR tubes. 20 µl 
PCR reactions were prepared as follows: 
Reagent Volume Final Concentration 
2X SensiMix 
TM 
SYBRGreen NO ROX 10 µl 1x 
25 µM IL-6 sense primer 0.5 µl 250 nM 
25 µM IL-6 anti-sense primer 0.5 µl 250 nM 
Template (PBMCs or NK cell cDNA) 2 µl 100 ng and more 
H2O Up to 20 µl  
 
Using a Corbett Research loading block, the real-time PCR reactions were 
manually loaded into 0.1 ml real-time PCR tubes (Qiagen, UK). The reactions where 
then run on a Rotor Gene 2000 Real-Time cycler (Corbett, Australia). After using 
different PCR parameters to set up the sample/or machine-specific protocols, the 
following optimised cycling conditions were used for the PCR reactions: 
Cycles Temperature Time  Notes 
1 95 °C 10 minutes Initial activation of polymerase 
 
50  
95 °C 
60 °C 
72 °C 
15 seconds 
15 seconds 
20 seconds 
 
Tm of primers 
Acquiring at the end of the step 
 
At the end of the reaction, PCR products were mixed with 6X orange G 
loading dye (NEB, UK) and ran on a 2% agarose gel stained with ethidium bromide. 
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Fluorescence graphs and melting curves were obtained from each sample via Rotor 
Gene 5 software accompanying the Rotor Gene 2000 Cycler. Only those primers with 
only one band in the gel picture and one peak in the melting curve were used for 
further experiments.  
 
2.12  Transmigration assays 
A modified Boyden chamber was used to study CD4
+
 T lymphocyte 
migration in response to IL-6 secreted by NK cells. CD4
+
 T lymphocytes and NK cells 
from healthy donors were purified from PBMCs by positive selection using a CD4
+
 
positive selection kit (Stem Cell® Technologies) and NK isolation kit (Miltenyi 
Biotec) respectively. After purification, NK cells were activated by co-culture with 
HeLa cells in a ratio of 5:1 plus IL-2 in a dose of 100 U /ml as described in Section 
2:3. Both NK and CD4
+
 T cells were then incubated at 37 °C overnight in RPMI 
medium containing 10% FCS. On the next day, 24-well Transwell plates (Corning) 
with two different pore size inserts (8 micron and 3 micron) were used. Transwell 
inserts were coated first with 100 µl fibronectin in 1X PBS (Sigma-Aldrich) / well at a 
density of 5µg/cm
2 
for at least 45-60 minutes before seeding the cells. In the first well, 
CD4
+
 T lymphocytes were seeded into the upper compartment at a density of 2 x 10
5
 
cells /100 µl of culture medium. The purified NK cells from same donor (same 
concentration as the CD4
+
 cells) suspended in 600 µl of culture medium were then 
placed in the lower compartment. In the second well, the CD4
+
 T cells were seeded in 
the upper compartment and NK cells from same donor and same concentration as 
CD4
+
 T cells were placed in the lower compartment but in the presence of human anti-
IL-6 antibody (clone # 6708, R & D System) at a dose of 0.15 μg / ml for each 2.5 ng / 
ml of human IL 6 as recommended by manufacturer). In the third well, 2 x 10
5
 CD4
+
 T 
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cells were added to the upper compartment and 20 ng / ml of IL-6 (ebioscience) in 600 
µl culture medium was placed in the lower compartment of Transwell well (positive 
control). In the last well, the CD4
+
 T lymphocytes were placed in the upper 
compartment and only culture medium in the lower chamber. This well acts as a 
negative control. Transwell plates were then incubated in tissue culture incubator at 37 
°C for 4 hours. Following incubation, CD4
+
 T lymphocyte migration in response to 
NK cells was assessed by counting the absolute number of CD4
+
 T lymphocytes in the 
lower compartment by flow cytometry using flow count beads and the results were 
presented as the percentage of migration of CD4
+
 T cells. 
 
2.12.1  Calculation of the absolute number of migrated CD4
+
 T lymphocytes 
Absolute cell counts can be obtained by adding a known number of flow 
cytometry cell counting beads to the sample analysed by flow cytometry. These beads 
are derived from a calibrated suspension of microspheres that are brightly fluorescent 
across a wide range of excitation and emission wavelengths and contain a known 
concentration of microspheres. For absolute counts of the migrated CD4
+
 T -
lymphocytes, all the cells in the lower compartment of the Transwell wells were mixed 
with 25 µl of CountBright Absolute Counting Beads (Invitrogen) prior to the 
collection. The cells and the beads were then collected, washed twice with 1X PBS 
and stained with mouse anti-CD4
+
 FITC antibody. After 45-60 minutes incubation on 
ice, the cells were washed twice with FACS buffer. Following the final wash the 
supernatant was discarded and the cells were re-suspended in 1 ml of FACS buffer. 
The samples were then run on the flow cytometer. The forward scatter threshold was 
set low enough to include the microspheres on the forward scatter vs linear side scatter 
plot. By gating the CountBright™ absolute counting beads and the cells in lower 
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compartment separately, the absolute counts of CD4
+
 T lymphocytes after the 
migration could be calculated using the following formula:  
 
  
 
Where: 
 
A = number of cell events 
B = number of bead events 
C = assigned bead count of the lot (25000 beads/25 μl) 
D = volume of sample (μl) 
 
Therefore, the total number of migrating CD4
+
 T cells in the lower compartment: 
 
 
 
2.13  Statistical analysis 
None parametric version of the paired t - test, Wilcoxon signed rank test, 
was employed to compare means. This test does not assume a Gaussian (normal) 
distribution of the data. In all experiments presented in this thesis the sample sizes 
were small (< 12) where the parametric tests (t test and paired t test) are not 
recommended and may be misleading. However, it should be taken into considerations 
that the non parametric tests are less powerful than parametric tests and this must be 
considered when interpreting the statistical differences between samples. P values < 
0.05 were regarded as statistically significant.  
 
 
x = concentration of sample as cells/μl 
A 
B   
         C 
       D 
Absolute number of CD4
+
 T cells in lower compartment/ µl x volume of 
sample in lower compartment (600 µl) 
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2.14  Compositions of solutions, buffers and stains 
1X Phosphate Buffered Saline (PBS) 
8 g of NaCl. 
0.2 g of KCl. 
1.44 g of Na2HPO4. 
0.24 g of KH2PO4. 
distilled water (ddH2O) to a total volume of 1 litre. 
pH to 7.4 with HCl. 
Sterilized by autoclave. 
 
FACS Buffer 
1X PBS 
0.5- 1% Bovine Serum Albumin (BSA)  
0.1% Sodium Azide 
 
MACS Buffer 
1X PBS 
0.5% BSA 
2mM EDTA 
Filtered through 0.22 µm filter  
 
50X TAE (Tris-Acetate-EDTA) Buffer  
242 g Tris Base  
100ml 0.5M EDTA pH 8.0  
57.2ml Glacial acetic acid  
Up to 1000 ml with distilled water (ddH2O) 
 
1X TAE Buffer 
20mL 50X TAE buffer  
980mL ddH2O 
 
SDS-PAGE Running Buffer (10X) 
10 g SDS 
144 g Glycine 
30.3 g Tris 
Up to1000 ml with ddH2O 
 
SDS-PAGE Running Buffer (1X) 
100 ml 10X SDS-PAGE Running Buffer 
900 ml ddH2O 
 
Western Blot Transfer Buffer  
7.2 g Glycine   
1.53 g Tris 
100 ml Methanol 
Up to 500 ml ddH2O 
 
TBS (10X)  
12.1 g Tris 
87.7 g NaCl 
pH 8.0 with HCl 
Up to 1000 ml with ddH2O 
 
 
 
 
 
 
99 
 
Western Blot Washing Buffer (1X TBS, 0.075% Tween 20) 
100 ml 10X TBS 
750 µl Tween 20 
Up to 1000 ml with ddH2O 
 
Western Blot Blocking Buffer (1X TBS, 5% (W/V) Marvel, 0.075% Tween 20) 
20 ml of Western Blot Washing Buffer 
1 gm Marvel (Cow milk) 
 
Western Blot Antibody Buffer 
20 ml of Western Blot Washing Buffer 
0.1 g Marvel 
 
1X SDS Sample Buffer 
63 mM Tris HCl 
10% Glycerol 
2% SDS 
0.1% 2-Mercaptoethanol 
0.0025% BromophenolBlue 
pH 6.8 
 
5X RNA Loading Buffer  
8 µl saturated aqueous Orange G solution  
40 µl 0.5 M EDTA, pH8.0  
360 µl 37% formaldehyde  
1ml 100% glycerol  
1542 µl formamide  
2ml 10x FA Gel Buffer  
RNAse-free water to 5 ml 
 
ELISA Wash Buffer 
1X PBS 
0.05% Tween 20 
 
ELISA Stop Solution 
2N H2SO4 
 
Ponceau S Staining Solution (0.1%(w/v) Ponceau S in 5%(v/v) acetic acid) 
1g Ponceau S 
50ml acetic acid 
Up to 1000 ml with ddH2O 
 
Coomassie Brilliant Blue Staining solution  
40% methanol 
10% acetic acid  
0.025% Coomassie Brilliant Blue R-250  
filtered through Whatman #1 paper.  
 
Freezing Solution 
90% foetal calf serum (FCS)  
10% dimethyl sulphoxide (DMSO) 
 
TSS (Transformation and Storage Solution)  
85% LB broth (autoclaved) 
10% (w/vl) PEG (polyethylene glycol) 
5% (v/v) DMSO 
20-50 mM Mg2+ (MgSO4 or MgCl2), final pH of 6.5 
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3.1 Introduction 
3.1.1 The significance of IL-6 secretion by NK cells in inflammation and 
autoimmunity 
Interleukin-6 (IL-6) has attracted considerable interest in the study of the 
pathobiology of many chronic inflammatory and autoimmune disorders. Up-regulation 
of IL-6 production has been observed in a variety of chronic inflammatory and 
autoimmune diseases such as rheumatoid arthritis Nishimoto, 2006 ;  Lipsky, 2006 ; 
Park and Pillinger, 2007 ; Cronstein, 2007), systemic sclerosis (Hasegawa  et al, 1998 ; 
Sato et al , 2000 ; Barnes et al, 2011) , systemic lupus erythematosus (SLE) (Linker-
Israeli et al, 1999) , ankylosing spondylitis (Falkenbach et al, 2000) ,  thyroiditis 
(Bartalena et al, 1993 ), type I diabetes, (Jain et al, 2001) , mesangial proliferative 
glomerulonephritis (Horii et al, 1989), and psoriasis (Grossman, 1989). In Rheumatoid 
arthritis (RA), several studies have reported that the blood as well as the affected 
tissues of these patients contains highly elevated levels of IL-6 and it has been shown 
that increased IL-6 serum levels indicate a poor prognosis (Madhok et al, 1993; Stuart 
et al, 1995; Usón et al, 1997; Nishimoto et al, 2004). The source of IL-6 in these 
patients has been a matter of intensive investigation. Many studies have proposed that 
type II synoviocytes are the primary source of IL-6 in the synovial fluid of patients 
with RA (Guerne et al, 1989; Miyazawa et al, 1999). However, there is increasing 
evidence that other cells such as natural killer (NK) cells could contribute to the 
production of this cytokine (Barakonyi et al, 2004; Jost, 2007). Since these cells 
appear very early at the inflammation site, as cells contributing to innate immunity, the 
production of IL-6 cytokine by NK cells during the early stage of the immune 
response has the potential of influencing the later stages of the immune response. Thus 
NK cell-mediated IL-6 secretion may provide a critical link between the innate and 
 
 
104 
 
adaptive immune response of the host. Furthermore, changes in this pathway in 
various autoimmune diseases, for example RA, may be relevant for the pathogenesis 
of these disorders. 
Recent findings clearly indicate that IL-6 is a key factor involved in the 
regulation of T cell differentiation and activation (Dienz and Rincon, 2009). IL-6 can 
act as a co-stimulatory molecule for resting T- cell activation and proliferation through 
a mechanism independent of IL-2 gene expression (Lotz et al, 1988). Antigen specific 
CD4
+ 
T lymphocytes have been shown to expand more vigorously in vivo when IL-6 is 
present due to reduced apoptosis suggesting that IL-6 may have anti-apoptotic 
properties thus increasing effector/memory T cell survival (Rochman et al, 2005; 
Dienz and Rincon, 2009). In addition, IL-6 activates T-helper 2 (Th2) cytokine 
production in CD4
+
 T lymphocytes via the transcription factor CREB (Rincón et al, 
1997). These include IL-4, IL-5, IL-6 and IL-13. It also promotes autocrine IL-4 
production which further enhances Th2 differentiation through an auto-feedback loop 
(Rincón et al, 1997). Furthermore, IL-6 stimulation has been linked to increased 
migration of activated CD4
+
 T cells in vitro which could explain their inability to enter 
the infected tissues in the absence of IL-6 during an infection (Weissenbach et al, 
2004; Dienz and Rincon, 2009). Other studies have shown that the de novo 
differentiation of Th17 cells from naïve mouse CD4
 
T cells is achieved by the 
simultaneous treatment with IL-6 and low doses of transforming growth factor (TGF)β 
during antigen stimulation (Bettelli et al , 2006 ; Mangan et al , 2006 ; Veldhoen et al, 
2006). In particular, IL-6 trans-signalling appears to promote the maintenance of IL-
17-secreting T lymphocytes in inflamed tissues (Jones et al, 2010 ; Neurath et al, 
2011) and regulates chronic inflammation in vivo (Rabe et al, 2008 ; McLoughlin et al, 
2005 ; Neurath et al, 2011). 
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NK cells were first described as cytotoxic cells eliminating transformed and 
virally infected cells (Kiessling et al, 1975; Herberman et al, 1975; Messina et al, 
1985). However, it has become clear that NK cells interact with various components 
of the immune system and therefore have the potential to function as regulatory cells. 
These regulatory functions include assisting in dendritic cell (DC) maturation (Moretta 
et al, 2006; Lünemann et al, 2009; Lucas et al 2010), regulating T-cell functions and 
proliferation (Bell, 2007; Lünemann et al, 2009), limiting adaptive immune responses 
and regulating autoimmune responses in a variety of experimental models as well as in 
humans with common autoimmune diseases (Lünemann et al, 2009). Several studies 
have shown that NK cells constitute a significant fraction of the infiltrating cells in a 
range of CD4
+
 driven autoimmune diseases and these cells are predominantly of CD56 
bright
 phenotypes (Pridgeon et al, 2003; Schepis et al, 2009; Poli et al, 2009 ; Conigliaro 
et al, 2011). Taking into consideration that cells with this phenotype are mainly 
cytokine secretors (Cooper  et al, 2001a; Strowig et al, 2008) , together with the fact 
that IL-6 is a powerful regulator of CD4
+
 T cell response (Dienz and  Rincon, 2009) 
one can speculate that these NK cells could be a source of secretion of IL-6 in these 
patients. Furthermore, the preliminary findings in our laboratory that the NK cells 
isolated from the blood of patients with autoimmune diseases produce significantly 
more IL-6 after appropriate stimulation than the NK cells isolated from the blood of 
healthy donors raise the possibility that NK cells could augment the T-cell response in 
these patients via IL-6 secretion.  
The concept of the present study came after a number of preliminary 
observations about IL-6 expression/secretion by NK cells in our laboratory. In DNA 
array experiments, IL-6 mRNA was expressed in NK cells isolated from the peripheral 
blood of healthy individuals and RA as well as the synovial fluid (SF) of the patients 
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(data not published). IL-6 protein was also detected in the supernatants taken from co-
cultures of NK cells and the conventional K562 target cells irrespective of whether the 
NK cells were isolated from the blood of healthy donors or patients, or the SF (Jost, 
2007). It is important to point out that in contrast to peripheral blood NK cells, most 
rheumatoid synovial fluid NK cells are of a CD56 
bright
 CD16 
dim/-
 phenotype (Pridgeon 
et al, 2003). As mentioned earlier, these cells are primarily cytokine secreting cells. As 
a result it has been suggested that cytokine production by these cells may play a role in 
the initiation and maintenance of the disease. 
 
3.1.2 The aims of this chapter 
Based on the preliminary information on the secretion /expression of IL-6 
by NK cells, it was decided to study further the ability of PBNK cells to secrete IL-6 
cytokine following different stimuli. This study was conducted with normal healthy 
donors to gain an insight into IL-6 secretion by NK cells. To approximate 
physiological conditions under which cytotoxicity would occur inside the body, the 
NK cells were stimulated with target cells, K562 and HeLa cells. These two cell lines 
activate NK cells through two different mechanisms. K562 erythroleukemia cells lack 
the expression of MHC class I molecules (Lozzio and Lozzio, 1979) and hence they 
are good targets for the NK cells that can easily recognise and kill them according to 
the “missing self” principles (Kärre et al, 1986; Ljunggren and Kärre, 1990). In 
contrast, HeLa cells express a full set of MHC class I molecules, so they elicit normal 
KIR-mediated inhibitory signals in the NK cells. However, these cells express the 
ligands for the dominant activating NKG2D receptors on NK cells, MICA protein 
(Groh et al, 1999; Zhang et al, 2001). This ligand-receptor interaction activates NK 
cells and induces cytotoxicity despite the presence of MHC class I molecules (Bauer et 
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al, 1999). Using these two cell lines allowed us to study the activating pathway and the 
receptors involved in the IL-6 secretion by NK cells. However, there is a possibility 
that these cell lines also secrete IL-6 as well. To eliminate the possibility of IL-6 being 
derived from the target cells PBNK cells were also stimulated by other methods such 
as using IL-2 and non-specific chemical stimuli such as phorbol diesters. Establishing 
the timing of IL-6 production following triggering of the NK cells was another aim of 
this chapter. The final aim was to investigate if the stimulus for this secretion is via 
soluble mediators or a direct cell-to-cell interaction. This was achieved by using a 
Transwell plate.  
 
3.2 Results 
3.2.1  NK cell magnetic selection (negative vs. positive selection) 
As described in Chapter 2, human PBMCs were isolated from peripheral 
blood by density centrifugation over a step gradient using Ficoll-Paque™ and NK 
cells were purified from the PBMCs by negative (magnetic) selection using the MACS 
MicroBeads system. Briefly, the PBMCs were first stained with a cocktail of biotin-
conjugated monoclonal anti-human antibodies against antigens not expressed by NK 
cells. After 10 minutes incubation on ice, the cells were coupled with a cocktail of 
anti-biotin micro beads. Following a second incubation, the cells were passed through 
a MACS column placed in a strong magnetic field that retained the undesired cells in 
MACS column while NK cells passed through the column and were collected as an 
enriched, untouched cell fraction. This system yields a high purity of untouched NK 
cells as assessed by flow-cytometry (Figure 3.1). Since a high level of NK cell purity 
was required throughout this study, this method was used for purification of NK cells 
from PBMCs to eliminate any potential bystander effect of contaminating cells.  
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Direct magnetic labelling of the NK cell surface antigen CD56 is often used 
for the purification of NK cells from PBMCs (positive selection). Although this 
method is faster than negative selection and can produce high level of pure CD56
+
 
cells, many disadvantages to positive selection limited its use in this study. The main 
disadvantage was that the CD56 surface marker is not only expressed by NK cells but 
also a small proportion of T cells (NKT cells and some CD8
+
 T-cells) also express this 
surface marker. Thus, using positive selection up to 50% of the isolated CD56
+
 cells 
are CD3
+
 T cells (data not shown). In addition beads cannot be removed easily and 
must be carried along with the cells. It was feared that antibody binding to the 
positively selected NK cells may interact with the remaining beads and affect their 
subsequent functional responses. 
 
3.2.2 Assessment of PBNK cell purity after negative selection 
As many cells are capable of IL-6 synthesis, including T-lymphocytes and 
monocytes, and some of these cells might have been trapped during NK cell selection, 
it was necessary to exclude the possibility that IL-6 was produced by these cells and 
not the NK cells. Following isolation, flow cytometric analysis was performed on each 
sample for the quantitation of NK cells (defined as CD56
+
 CD3
-
 cells). The average 
purity of NK cells after isolation was 9 .5 % (range 88.18% - 96.34%). On average, 
the cell pool contained 1.44% CD56
+
CD3
+
 cells (range 0.20%-2.62%). The average T 
cell (CD56
-
 CD3
+
) contamination was 0.74 (range 0.11- 1.99). Purities of ≥ 95% were 
obtained from all the samples after passing the eluted NK cell fractions over a second 
LS MACS column. A summary of the separation performance for the isolation of 
PBNK cells is shown in Figure 3.2.  
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Figure 3.1: Purity of PBNK cells after immunomagnetic negative selection as 
assessed by flow cytometry (dot plot profiles). A: PBMCs before magnetic 
separation. R4 in the top picture represents to total unstained PBMCs fraction. R2 in 
the bottom picture represent the PBNK cell fraction after staining with CD3 FITC 
and CD56 PE monoclonal antibodies. B: PBNK after purification. R4 in the top 
picture represents the PBNK cell fraction in an unstained sample while R2 in the 
bottom picture represent the PBNK cell fraction after magnetic separation. The gate 
was set by forward and side scatter to exclude dead cells, debris, and cell aggregates. 
The purity of PBNK cells after isolation in this sample was 94.  %.                             
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Figure 3.2: Purity of isolated CD56
+
 CD3
-
 PBNK cells after negative selection 
using MACS MicroBeads System expressed as percentage of CD56
+
 CD3
- 
cells 
within the live cell gate. The PBNK cells were isolated by magnetic depletion of non-
NK cells using eight healthy donors. The purity after isolation ranged from 88.13% to 
96.34% (average was 92.59%). However, purity of ≥ 95% was obtained from all these 
samples after passing the eluted NK cells over a second MACS column. 
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3.2.3  Secretion of IL-6 by purified PBNK cells  
After isolation the resting PBNK cells were activated and tested for the 
production of IL-6 using different approaches. These included co-culturing with target 
cells such as K562 or HeLa cells, stimulation with cytokines (IL-2) at 2 different 
concentrations and using non specific chemical mediators (e.g. phorbol myristate 
acetate [PMA]) together with ionomycin). After activation 100 µl of supernatants were 
collected at 1, 3, 6, 18 and 24 hrs and frozen at - 80 
о
C until further analysis. Since the 
aim was to find out how the NK cells contribute to inflammation via the IL-6 secretion 
during the early stages of the immune response, time points as early as 1 and less than 
24 hrs were chosen. Supernatants from target cells alone and from non-activated 
(resting) PBNK cells were also collected at the same time points and compared with 
those taken from the activated NK cells. The IL-6 in the supernatants was then assayed 
using a commercially available IL-6 ELISA kit as described in Chapter 2.  
 
3.2.3.1 Endogenous IL-6 secretion by K562 and HeLa cell lines 
The identification of the cells responsible for cytokine production in 
cultures containing a mixed cell population remains one of the main limitations of 
ELISA experiments. To investigate the possibility that the detected IL-6 was produced 
by K562 or HeLa cells and not the purified PBNK cells during the co-culture 
experiments, supernatants of wells containing these target cells alone were analysed as 
negative controls. The results are shown in Figure 3.3. As can be seen from this figure, 
it is clear that both K562 and HeLa cell lines spontaneously produced IL-6 (Figures 
3.3 A and B). The IL-6 production by these cell lines increased with time as the 
cytokine being detected as early as 1 hr, increasing further at 3 and 6 hrs, and reaching 
significant levels at 18 and 24 hrs (p <0.05). HeLa cells produced significantly more 
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IL-6 than K562 cells at the same duration of culture (Figure 3.3 C). Again, this 
accumulation during the culture period seems to indicate a non-stimulated spontaneous 
IL-6 release by both of the used cell lines. 
 
3.2.3.2 PBNK and target cell co-cultures produce more IL-6 than cultures 
containing target cells or PBNK cells alone  
After conducting these control experiments we then measured the IL-6 
cytokine levels in supernatants taken from co-cultures of effector cells (PBNK) + 
target cells (K562 or HeLa) and compared them with those obtained from effector 
cells or target cells alone. K562 cells were co-cultured at a concentration of 1x10
5
 cells 
with the same number of purified PBNK cells in 96-well round bottom tissue culture 
plates. Since HeLa cells are much larger than K562, the cell concentration was 
adjusted to obtain effector: target (E: T) ratio of 5:1 to compensate for this difference. 
Therefore, only 2 x 10
4
 of HeLa cells were co-cultured with 1x10
5
 purified PBNK 
cells. Cultures of K562 or HeLa cells and PBNK cells alone at the same concentration 
as in the co-cultures were also used as negative controls. Supernatants were then 
collected at 1, 3, 6, 18 and 24 hrs after the plating of the cells and analysed for IL-6 by 
ELISA. The results of these experiments are shown in Figure 3.4. Six hrs after 
initiating the stimulation of PBNK cells with K562 targets the IL-6 concentration 
increased significantly compared with K562 alone (p<0.05) while IL-6 concentration 
in PBNK + HeLa co-cultures was significantly higher as early as 1 hr (p < 0.05).  
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Figure 3.3: Endogenous production of IL-6 protein by K562 and HeLa cell lines. 
1x10
5
 K562 cells and 2x10
4
 HeLa cells were plated in 96 well plates. Supernatants 
were harvested at 1, 3, 6, 18 and 24 hrs and analyzed for IL-6 production by ELISA. 
As shown in Figures A and B both cell lines spontaneously produced IL-6. HeLa cells 
produced significantly more IL-6 than K562 at the same time points (Figure C). All 
measurements were performed in duplicates and presented as means of three 
independent experiments. Statistical analysis was performed using Wilcoxon signed 
rank test. The error bars denote the SD; *, p<0.05. 
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Figure 3.4: Increased production of IL-6 following the activation of NK cells with 
cellular targets. A: The mean IL-6 concentrations (pg/ml) in the supernatants taken 
from wells containing K562, PBNK and NK+ K562 co-cultures at different time 
points. The IL-6 increased significantly in the co-culture supernatants at 6 hrs 
following stimulation with the K562s compared to the supernatants from the K562s or 
PBNK cells alone (n= 8, p <0.05). B: Comparison of the mean IL-6 concentrations 
(pg/ml) in the supernatants in wells containing HeLa, PBNK and HeLa + NK co-
cultures at different time points. IL-6 increased significantly in the co-culture 
supernatants as early as 1 hr following stimulation with the HeLa compared to the 
supernatants from the HeLa or PBNK cells alone (n=8, p <0.05).The measurements 
were performed  in duplicates and the results are representative of three independent 
experiments. Statistical analysis was performed using Wilcoxon signed rank test. The 
error bars denote the SD; *, p<0.05, **, p<0.01. Significant difference at p < 0.05. 
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3.2.3.3 PBNK + HeLa co-cultures produce more IL-6 than PBNK+K562 co-
cultures 
Next IL-6 concentrations were compared in the supernatants taken from the 
co-cultures of purified PBNK and K562 cells with those obtained from co-cultures of 
purified PBNK +   HeLa cells. Again, 1x10
5
 PBNK cells were co-cultured with the 
same number of K562 targets in 96-well round bottom tissue culture plate. Only 2x 
10
4
 HeLa cells were co-cultured with 1x10
5
 PBNK cells. The time points when IL-6 
levels were tested in the supernatants were 1, 3, 6, 18 and 24 hrs after plating the cells. 
The results are shown in Figure 3.5. From this figure it is clear that the IL-6 
concentration in the supernatants taken from PBNK + HeLa co-cultures was 
significantly higher than those taken from PBNK+ K562 co-cultures at the same time 
points. However, we should mention that these results were expressed as means ± SD 
of three independent experiments performed with 8 healthy donors and there were 
some individual variations between the donors regarding the IL-6 secretion in the co-
cultures.  
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Figure 3.5: Comparison of IL - 6 concentrations (pg / ml) in the co-culture 
supernatants (PBNK + K562 vs PBNK + HeLa) as determined by ELISA. NK 
cells were isolated from the PBMCs of eight healthy donors by negative selection and 
co-cultured with K562 cells (E: T ratio was 1:1) or HeLa cells (E: T ratio 5:1). 
Supernatants were taken at 1, 3, 6, 18 and 24 hrs and IL-6 cytokine concentration was 
determined in the supernatants by ELISA. The PBNK + HeLa co-cultures produce 
significantly more IL-6 than PBNK + K562 co-cultures at all time points. Results were 
representative of three experiments and presented as means ± SD. Statistical analysis 
was performed using Wilcoxon signed rank test. The error bars denote the SD; *, 
p<0.05, **, p<0. 01. Significant difference at p < 0.05.  
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3.2.3.4 Secretion of IL-6 by PBNK cells after stimulation with PMA and 
ionomycin 
Utilizing co-cultures it was observed that more IL-6 cytokine was produced 
in co-cultures than the effector (PBNK cells) alone or target cells (K562 cells or HeLa 
cells) alone. This suggested that both PBNK and target cells could contribute to the 
IL-6 production. However, the co-culture experiments cannot exclude the possibility 
that the target cell were the source of IL-6 and not the PBNK cells. To eliminate this 
possibility and prove that NK cells could produce this cytokine, pharmacological 
stimulation of PBNK cells was also carried out. Human PBNK cells from 4 healthy 
donors, at the same density as in the co-cultures (1x10
5
 cells), were washed twice with 
1X PBS, cultured in 96-well round bottom plate and stimulated with potent non-
specific chemical stimulators (PMA in a dose of 10 ng/ml and ionomycin in a dose of 
1 µg/ml). To determine timing of cytokine release, 100 µl of cell-free supernatants 
were collected at 1, 3, 6 and 18 hrs.  The results are depicted in Figure 3.6 A and 
summarized in Figure 3.6 B. IL-6 concentration was significantly increased as early as 
6 hours following stimulation with PMA and ionomycin (p< 0.05) with the 
concentration increasing further at 18 hours. 
   
3.2.3.5  Secretion of IL-6 by PBNK cells after stimulation with IL-2  
It has been observed that stimulation of NK cells with IL-2 promotes their 
cytotoxicity and enhances the production of different cytokines including interferon 
gamma (IFN-γ) (Weigent et al, 1983; Trinchieri et al, 1984; Ortaldo et al, 1984; Kehri 
et al, 1988; Armant et al, 1995; Son et al, 2001). However, little is known about the 
secretion of IL-6 by IL-2 activated NK cells. IL-2 in a dose of 50- 100 U / ml is known 
to induce NK activation in both primary NK cells and NK cell lines. In this study, a 
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preliminary experiment was carried out using 1x10
5
 purified NK cells from a healthy 
donor stimulated with recombinant human IL-2 (rhIL-2) at a dose of 100 U / ml. 100 
µl of supernatants were collected at 1, 3, 6 and 18 hrs and the IL-6 concentration was 
determined by ELISA. Little IL-6 was produced by PBNK cells in response to this 
dose of rIL-2 at all time points with concentrations ranging from 2.7 pg/ml at 1 hr to 
12.4 pg/ml at 18 hrs. These figures were not significantly different from those 
obtained with non-activated (resting) PBNK cells.  
Next, we have examined the ability of IL-2 to enhance IL-6 cytokine 
secretion by PBNK cells at higher doses. Doses from 200 U /ml up to 1000 U/ml have 
been used for activation of resting NK cells in some studies (Kehri et al, 1988; Weil-
Hillman, 1990; Sarina et al, 1997). Stimulating resting PBNK cells from 5 healthy 
donors with 500 U/ml of rhIL-2 was tried next. Supernatants were then collected at 
same time points as in the previous experiment. The results are shown in Figure 3.7 A 
and summarized in Figure 3.7 B. As shown in this figure there was a significant 
amount of IL-6 produced; the concentrations were higher than in the PMA experiment.  
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Figure 3.6: The IL-6 production by PBNK cells following activation with PMA 
and ionomycin. A) PBNK cells were purified from 4 healthy donors by negative 
selection and stimulated with PMA (10 ng/ ml) and ionomycin (1µg g/ml). Following 
incubation, the supernatants were collected at 1, 3, 6 and 18 hrs and analysed for IL-6 
levels. B: The mean ± SD for the 4 samples at each of the four time points was 
calculated. The IL-6 concentration started to increase significantly at 6 hrs after 
stimulation with PMA and ionomycin (P<0.05). Statistical analysis was performed 
using Wilcoxon signed rank test. The error bars denote the SD; *, p<0.05, ***, 
p<0.001. Significant difference at p < 0.05.  
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Figure 3.7: IL-6 secretion by PBNK cells after stimulation with rhIL-2. A) PBNK 
cells were isolated from 5 healthy donors and stimulated with IL-2 at a dose of 500 
U/ml. Following incubation, the supernatants were collected at 1, 3, 6 and 18 hrs and 
analysed for IL-6 protein by ELISA. Despite some inter-individual variability at 6 and 
18 hrs, IL-6 was secreted by NK cells isolated from all donors tested. B) The mean ± 
SD for the 5 samples at each of the four time points was calculated. Again, the IL-6 
concentration started to increase significantly at 6 hrs after stimulation with IL-2 (P 
<0.05). Statistical analysis was performed using Wilcoxon signed rank test. The error 
bars denote the SD; *, p<0.05, ***, p<0.001. Significant difference at p < 0.05. 
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3.2.4 Direct PBNK-target cell contact is necessary for the initiation of IL-6 
production upon target cell recognition   
To analyse whether IL-6 secretion in the co-culture experiments was the 
result of direct cell-cell interactions between PBNK cells and the target cells  or was 
induced by the presence of soluble mediators, the following experiment was devised: 
co-culture experiments were set up where the target cells were separated from PBNK 
cells using Transwell inserts. The pores in the inserts used would allow the free transit 
of soluble mediators, such as cytokines or chemokines, but not the cells themselves. 
The details of this experiment were discussed in Chapter 2. Briefly, a 24-well 
Transwell plate with 0.4 µm pore size insert was used. 1 x 10
5
 of K562 cells (or 2 x 
10
4
 HeLa cells) suspended in 600 µl of complete culture medium (complete RPMI or 
DMEM medium) were placed in the lower compartment. PBNK cells at a 
concentration of 1 x 10
5
 cells suspended in 100 µl culture medium were then placed in 
the Transwell insert and therefore separated from the targets by the membrane. As 
controls, two additional wells were prepared.  One of these, the positive control, had 
the PBNK cells and the targets mixed together (same concentration as in the co-culture 
experiments) in the lower compartment while the upper compartment received only 
100 µl of culture medium. A Transwell insert was still present to eliminate the 
possibility that chemicals eluting from the membrane could inhibit IL-6 production. In 
the negative control well, only the target cells (1 x 10
5
 K562 or 2 x 10
4
 HeLa cells) 
were added to the lower compartment and the upper insert compartment received only 
culture medium. These controls would indicate if the insert could affect IL-6 
production due to the presence of chemicals in the membrane/insert. The experiment 
was conducted with cells from 3 healthy donors. Supernatants from the lower 
compartment were collected and assayed for the induction of IL-6 secretion after 24-
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hour incubation. The results are shown in Figures 3.8 and 3.9. As can be seen from 
these Figures, when the PBNK and target cells were separated from each other (i.e. no 
direct physical contact between them), the concentration of IL-6 in the K562 or HeLa 
cells compartments was not significantly different from that of the negative controls 
(target cells alone) (p > 0.05). However, in the co-cultures of NK cells and K562 or 
HeLa cells, where cellular contact was maintained, the levels of IL-6 production were 
significantly increased (p < 0.01). These results clearly indicate under normal or 
physiological conditions soluble factors do not affect IL-6 secretion by NK cells and 
that direct physical contact between NK cells and target cells is necessary for the 
triggering IL-6 production. 
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Figure 3.8: The effect of direct cell-cell interaction on the initiation of IL-6 
production by PBNK cells. Transwell inserts with 0.4 µm pore size were used. In the 
first well the PBNK cells in the upper compartment were separated from K562 cells in 
the lower compartment by Transwell membrane. In the second well, the PBNK cells 
were mixed with the K562 cells in the lower compartment and only culture medium 
was placed in upper compartment. In the third well, K562 cells were placed in lower 
compartment while only culture medium was placed in upper compartment. The assay 
was performed on purified PBNK cells from 3 healthy donors. A: Shows the results 
obtained with the individual donors. B: The mean ± SD for the 3 samples. The IL-6 
concentration significantly increased in the co-culture wells over that seen in the other 
two groups (P< 0.01). The error bars denote the SD; **, p<0.01.  
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Figure 3.9: The effect of direct cell-cell interaction on the initiation of IL-6 
production by PBNK cells. Same experimental setup as in Figure 3.8, but using HeLa 
as target cells. A: Individual results with purified PBNK cells from 3 healthy donors. 
B: The mean ± SD for the 3 sample groups was calculated. The IL-6 concentration 
significantly increased in the co-culture group than other two groups (P<0.01). 
Statistical analysis was performed using Wilcoxon signed rank test. The error bars 
denote the SD; **, p<0.01.  
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3.3 Discussion 
3.3.1  Cytokine and chemokine secretion by PBNK cells 
Natural Killer (NK) cells are an important element of innate immunity and 
have both regulatory and effector functions. Previous studies have demonstrated that 
NK cells are not a homogenous group of innate lymphocytes. Instead, at least two 
distinct subsets of NK cells are found based on the density of surface expression of 
CD56 and CD16 (FCγRIII) (Cooper et al, 2001a; Berahovich et al, 2006; Caligiuri, 
2008; Moretta, 2010). The CD56 
dim
 CD16 
bright
 cells express low levels of CD56 and 
high levels of CD16. They represent approximately 90% of NK cells in normal 
peripheral blood and function primarily as potent cytolytic effector cells (Cooper et al, 
2001a; Lünemann et al, 2009). In contrast CD56 
bright
 CD16 
dim/-
 cells constitute less 
than 10% of peripheral blood NK cells but are enriched in secondary lymphoid tissues 
(Cooper et al, 2001a; Lünemann et al, 2009; Poli et al, 2009). For many years, it was 
thought that CD56 
dim
 CD16 
bright
 cells are predominantly cytotoxic while CD56 
bright
 
CD16 
dim/-
 cells are mainly cytokine secretors. This based on the findings that upon 
exogenous monokine stimulation with IL-12, IL-15 and IL-18, CD56 
dim
 CD16 
bright
 
cells secrete only low levels of cytokines while CD56 
bright
 CD16 
dim/-
 NK cells 
produce large amounts of various cytokines including IFN-γ, TNF-α, GM-CSF, IL-10 
(Diefenbach et al, 2001 ; Béziat et al, 2010,) and chemokines such as macrophage 
inflammatory protein (MIP)-1 family members and RANTES (Diefenbach et al , 
2001). These cells become cytotoxic only after prolonged activation (Strowig et al, 
2008). However, in contrast to monokine stimulation, evidence accumulated during 
the past few years indicate that the CD56 
dim
 cells may be more important than CD56 
bright
 cells for cytokine and chemokine secretion following target cell recognition 
(Juelke et al, 2010; Fauriat et al, 2010). Fauriat et al (2010) demonstrated that in 
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response to target cell recognition (K562), CD56 
dim
 rather than CD56 
bright
 NK cells, 
were primarily responsible for the production of cytokines and chemokines, including 
MIP-1α, MIP-1β, RANTES, IFN-γ and TNF-α.  
 
3.3.2  IL-6 Secretion by PBNK cells 
This work was initiated after a number of observations about IL-6 
expression / secretion by NK cells in our laboratory. Firstly, in quantitative PCR array 
experiments IL-6 mRNA expression was seen both in NK cells isolated from the blood 
of healthy donors and the synovial fluid of RA patients. Secondly, using a multiple 
bead assay, significant IL-6 production was seen when the NK cells (isolated from the 
blood of the control individuals, or patients suffering from RA or systemic sclerosis) 
were co-cultured with the K562 cell line. However, the quality of the data in these 
experiments was only preliminary. Based on these findings it was decided to 
investigate the ability of PBNK cells to secrete IL-6 further.  
Production of IL-6 by NK cells is rather a novel concept. Intensive search in 
the literature revealed that this was only reported in one publication. Barakonyi et al 
(2004) studied cytokine production following the engagement of CD160, an Ig-like 
activating NK cell receptor whose expression is restricted to the CD56 
dim 
CD16 
bright
 
subset. Binding the ligand (HLA-C) or a mAb to this receptor induced PBNK cells to 
produce IFN-γ, TNF-γ, and IL-6. This CD160-mediated cytokine production was 
negatively controlled by the co-engagment of CD158b inhibitory receptor. However, 
the NK cells in this study were co-stimulated with both rhIL-2 and targets cells and 
therefore it is unclear which one was relevant for the IL-6 production.  Although the 
authors failed to demonstrate the significance of this IL-6 secretion by NK cells, they 
provided evidence that the NK cells have the potential to secrete this cytokine. 
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Moreover, this study supported the concept that that CD56 
dim
 CD16 
bright
 could be a 
major source of pro-inflammatory cytokines upon target cell recognition. 
Nevertheless, these results need to be confirmed by other groups independently. 
Together with TNF-α and IL-1, IL-6 is considered a major cytokine 
important in the protection from pathogens during an infection (Dienz and Rincon, 
2009). Since NK cells are involved in the early defence mechanisms against infection, 
therefore, the concept of IL-6 secretion by NK cells fit with the first line defence role 
of these cells. Furthermore, IL-6 has been shown to profoundly influence the adaptive 
immune response by determining CD4
+
 T cell differentiation (Rincón et al, 1997; 
Dienz and Rincon, 2009). Given that NK cells appear at the inflammation site at the 
early stages of the process where the number of other cells with a potential to secrete 
IL-6 is low, it is possible that NK cell-mediated IL-6 secretion is essential in 
orchestrating and potentiating the later stages of the adaptive immune response. 
Moreover, IL-6 is also known to play an important role in disease progression and 
tissue damage in some of CD4
+
 driven autoimmune diseases such as multiple sclerosis 
(Sfrent-Cornateanu et al , 2006 ; Barnes et al, 2011) and RA (Nishimoto N , 2006 ; 
Park and Pillinger , 2007 ; Srirangan, 2010). This fact, together with the preliminary 
findings in our laboratory that the NK cells isolated from the blood of patients with 
autoimmune diseases produce significantly more IL-6 after appropriate stimuli than 
the NK cells isolated from the blood of healthy donors (data not shown), raise the 
possibility that NK cells could regulate the T-cell response in these patients via IL-6 
secretion.  
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3.3.3  Secretion of IL-6 by PBNK cells upon target cell recognition 
To gain more insight into IL-6 production by NK cells, their ability to 
secrete this cytokine following the recognition of cellular targets was studied using 
two different cell lines. The widely used NK cell target cell line K562 was selected for 
these experiments because these cells lack the expression of MHC class I molecules, 
which normally inhibit NK cell activity (Powell et al, 1989; Nishimura et al, 1994)  
and therefore, in keeping with the “missing self hypothesis”, are killed by NK cells 
(Kärre et al, 1986; Ljunggren and Kärre, 1990). On the other hand, HeLa cells express 
MHC class I molecules, which could interact with various inhibitory KIRs (two and 
three domain, long cytoplasmic tailed forms of CD158 and others). However, due to 
the expression of ligands that interact with the dominant activating receptor, NKG2D, 
on the NK cells, these targets are still killed very efficiently (Pende et al, 2001).  
One confounding factor was that control experiments showed that IL-6 was 
constitutively secreted by both K562 and HeLa cells. This finding is not new for K562 
cells; a search in the literature showed that IL-6 secretion by these cells had previously 
been detected by others (Navarro et al, 1991). However, the observation with HeLa 
appears novel. Nonetheless, as shown here the secretion of IL-6 in the co-cultures of 
purified PBNK cells and K562 and HeLa cells was unquestionably raised compared to 
the K562 and HeLa control cultures. The signalling mechanisms activated in the NK 
cells in the presence of K562 cells, which lack the expression of MHC class I 
molecules and the class I positive HeLa cells may be completely non-overlapping. It is 
not just that K562 cells fail to engage the various inhibitory class I receptors resulting 
in the lack of the inhibitory signals provided by ITIM motifs of these receptors. In the 
absence of class I molecules stimulating receptors such as KIR2Ds and KIR3Ds (also 
recognise HLA-A,-B,-C locus proteins), and CD94/NKG2C, CD94/NKG2E and 
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CD94/NKG2H (recognise HLA-E locus proteins), will not be engaged either. On the 
other hand, with the class I positive HeLa cells one would predict KIR2DL and 
KIR3DL mediated inhibitory signalling events. However, HeLa cells express ligands 
for the dominant activating receptor, NKG2D. These include MICA (Groh et al, 1999; 
Zhang et al, 2001), weak expression of MICB proteins (Schrambach et al, 2007; Butler 
et al, 2009) and possibly weak expression of various forms of ULBPs as well (Butler 
et al, 2009). Binding of these proteins to NKG2D receptors on the surface of NK cells 
results in NK cell activation that cannot be overridden by the inhibitory signals elicited 
via the MHC class I binding KIRs and CD94/NKG2A (B) heterodimers. Comparing 
NK + K562 and NK + HeLa co-cultures is somewhat difficult since HeLa cells are 
physically much larger than K562. Thus, the number of NK cell interacting with a 
given target cell, and possibly the time the NK cells spend attached to the targets as 
well, is likely to be different. The work presented here tried to compensate for this 
difference in size by conducting the experiments with 5 times fewer HeLa cells, 
effectively increasing E: T ratios. 
 NK + HeLa co-cultures produced significantly higher IL-6 levels than NK 
+ K562 cultures at the same time points. Moreover, the IL-6 production was detectable 
sooner, as early as 1 hr in NK + HeLa co-cultures, compared to 6 hrs with NK + K562 
cells. Whether these differences were due to the physical characteristics of the two 
target cell lines or result from the engagement of distinct signalling pathways (or the 
combination of both) remains to be determined. Also, at this point it is unclear if IL-6 
production in the NK + K562 and the NK + HeLa cultures represents the convergence 
of two signalling pathways that are initiated at the cell surface via the engagement of 
two different receptors, or results from signalling via the same receptor irrespective of 
the target cells used, which will require further clarification.  
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3.3.4 IL-6 secretion by NK cells in response to IL-2 cytokine and non - 
specific chemical activators (PMA+ ionomycin) 
Since both target cells used in the co-culture experiments were able to 
produce IL-6 themselves, hypothetically it was possible that the increase seen in the 
co-cultures was due to elevated cytokine production by K562 or HeLa cells after the 
addition of NK cells. Since IL-6 secretion by NK cells is not a widely accepted 
concept, it was important to show that the NK cells themselves were able to produce 
this cytokine.  
 
3.3.4.1 The IL-2 response   
It is known that the stimuli able to increase the NK cell cytotoxicity are also 
up-regulate cytokine biosynthesis by these cells (Perussia, 1996). Therefore, purified 
NK cells were preincubated in the presence of IL-2, the cytokine that activates NK 
cells and markedly enhances their cytotoxic potential (Vivier et al, 2008). At first, 
activation of NK cell cytokine secretion was tried at a dose of 100 U/ml of IL-2. 
However, in a single preliminary experiment, negligible amounts of IL-6 similar to 
that secreted by resting PBNK cells, were expressed in the supernatants after 1, 3, 6 
and 18 hrs. Next, NK cells were activated with a high non-physiological dose of IL-2. 
500 U/ml of rhIL-2 was tested and the experiments were carried out on PBNK cells 
collected from 5 healthy donors. In all 5 samples IL-6 was significantly detected in the 
supernatants collected after 6 and 18 hrs with highest concentration at 18 hrs. This 
suggested that the 100U/ml dose of IL-2 used in the preliminary experiment may have 
been insufficient to induce IL-6 secretion by NK cells. The need for a rather high dose 
of IL-2 may be explained by the distribution of IL-2 receptor subunits on NK cells. 
Nagler et al (1990) and Baume et al (1992) have demonstrated that only CD56 
bright 
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subset, which constitute <10% of peripheral blood NK cells, carry the high affinity IL-
2Rαβγ (CD25) in addition to the free IL-2Rp75 chains. The vast majority of NK cells 
(CD56 
dim
)
 
express only the intermediate affinity IL-2βγ receptor on the cell surface. 
Thus, the need for a high IL-2 concentration in the IL-6 secretion experiments is 
consistent with the assumption that the process involves the CD56 
dim
, primarily 
cytotoxic, NK cell subset.  
 
3.3.4.2 The PMA + ionomycin response   
To investigate further the ability of NK cells to produce IL-6 non-specific 
chemical activation was also used. Our data revealed that stimulation with PMA + 
ionomycin was effective in inducing IL-6 production by NK cells. A significant 
increase of IL-6 concentration was observed as early as 6 hrs following stimulation. 
PMA acts as a direct agonist of protein kinase C (PKC) which plays a vital role in the 
cascade of events leading to cell activation. Treatment of a variety of cells with 
phorbol esters activates the expression of a range of early response genes through 
protein kinase C-dependent pathways (Blumberg, 1988). The protein kinase C (PKC) 
enzymes are known for their long-term activation. They remain activated after the 
original activation signal or the Ca
2+
 wave is gone (Klann et al, 1991; Sessoms et al, 
1992). This is presumably achieved by the production of diacylglycerol from 
phosphatidylinositol by a phospholipase; fatty acids may also play a role in long-term 
activation (Nishizuka, 1995). The relatively rapid expression of IL-6 cytokine 
following treatment of NK cells with PMA + ionomycin might be, at least in part, due 
to the presence of regulatory sequence elements in the corresponding IL-6 gene 
promoter through mechanisms that are protein kinase C-dependent. However, the 
amount of IL-6 in the tissue culture supernatants was noticeably less after PMA + 
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ionomycin exposure than that seen after co-cultures of NK cells and target cells, or 
that resulting from high dose IL-2. Thus, protein kinase C is unlikely to be the only 
pathway that is responsible for the secretion of this cytokine in NK cells following 
target cell recognition.  
 
3.3.5  The Transwell plates result 
Transwell plates were used to investigate whether IL-6 production by NK 
cells upon target cell activation was mediated by soluble mediators or cell–cell 
contact. Separating NK cells and target cells abolished increases in cytokine 
production proving that direct interaction between NK cells and target cells is 
necessary for triggering IL-6 production by NK cells, as the semi-permeable 
membrane of Transwell chambers allows for the free passage of soluble factors but 
prevents direct cell contact. 
 
In conclusion, the results presented in this chapter demonstrate that, 
although the IL-6 is secreted by K562 and HeLa cell lines, the concentration of IL-6 is 
significantly higher when these target cells are co-cultured with PBNK cells. These 
findings suggest that the NK cells can contribute to IL-6 secretion. This notion was 
confirmed by the observation that the NK cells secrete IL-6 when activated with PMA 
+ ionomycin or high doses of IL-2. The dose of IL-2 required for effective IL-6 
secretion suggests that the IL-6 is derived from NK cells that express receptors with 
only intermediate affinity for IL-2. The direct physical interaction between NK cells 
and target cells, probably via membrane bound receptor-ligand interaction, is 
necessary for triggering IL-6 production by NK cells, as it demonstrated by Transwell 
experiments. Given that NK cells appear at inflammation sites at the earliest stages of 
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the process, where the number of other cells with a potential to secrete IL-6 is low, it 
is possible that NK cell-mediated IL-6 secretion is essential in orchestrating and 
potentiating the later stages of the adaptive immune response. 
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4.1  Introduction 
The work presented in the previous chapter has shown that NK cells have 
the potential to secrete IL-6 following different stimuli. Although this secretion can be 
initiated with high doses of cytokine (IL-2) or with non specific chemical mediators 
(PMA+ ionomycin) these kinds of stimuli are unlikely to occur inside the body. In 
contrast, activation via target recognition is a common event under physiological 
conditions. The results of Transwell experiments clearly indicated that direct physical 
contact between NK cells and target cell (NK cell receptor-ligand interaction) was 
necessary for IL-6 secretion by these cells. 
 
4.1.1  Specific receptor engagement and the cytokine secretion by NK cells 
NK cells mediate protection against viruses and intracellular pathogens 
through direct lysis of infected cells and by secretion of cytokines that shape the 
subsequent adaptive immune response (Papazahariadou et al, 2007; Lanier, 2008). 
These NK cell functions are finely regulated by array of surface receptors inducing 
inhibitory and activating signals (Lanier, 1998; Long, 1999; Moretta et al, 2001; 
Vivier et al, 2004; Moretta et al, 2004; Lanier, 2005) as well as by the presence of 
soluble mediators (cytokines). The role of cytokines in the initiation of cytokine 
secretion by NK cells has been extensively studied. Many of these studies have shown 
that NK cells express a number of monokine receptors including IL-2R (Caligiuri et al, 
1990; Nagler et al, 1990; Baume et al, 1992), IL-1βR (Cooper et al, 2001b), IL-12R 
(Wang et al, 2000), and IL-18 R (Kunikata et al, 1998). In addition IL-15 can induce 
its effect on NK cells throught the common IL-2R βγ subunit (Carson et al, 1994). 
These receptors are distributed on both NK cell subsets but with different densities. 
Stimulation of these receptors by IL-2, IL-12, IL-15 and IL-18 alone or in 
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combination, results in expression / or secretion of cytokines including IFN-γ, TNF-α 
,GM-CSF, IL-4, IL-10 and IL-13  (Carson et al, 1997; Fehniger et al, 1999; Lauwerys 
et al, 2000) and chemokines such as MIP-1 family members (Bluman et al, 1996; 
Fehniger et al, 1999) by NK cells. 
On other hand, relatively less is known about cytokine production upon 
specific engagement of NK cell receptors (Fauriat et al, 2010). A number of 
structurally distinct receptors have been implicated in the activation of NK-cell 
effector functions despite the expression of MHC class I molecules. Depending on the 
way these receptors signal, they have been grouped into three categories (Bryceson et 
al, 2006): receptors that signal through immunoreceptor tyrosine-based activation 
motif (ITAM) containing subunits (e.g. CD16, NKp46, NKp44 and NKp30), the 
DAP10-associated receptor NKG2D, and several other receptors (e.g. 2B4, DNAM-1) 
that signal via other different pathways. Review on these recepotrs was described in 
Chapter 1. While  the role of NK cell receptors in the initiation of NK cell cytotoxicity 
is well known, minimal requirements for induction of cytokine secretion upon
engagement of these receptors with their monoclonal antibodies (mAbs) or ligands on 
target cells has still not been established clearly. Some studies have demonstrated that 
NK cells can release cytokines on recognition of targets (Bancroft et al, 1993; Tsutsui, 
et al, 1996) but the mechanism behind this remains unclear.  
CD16 is a 50-80 kDa glycoprotein that is expressed in two distinct (CD16a 
and CD16b) isoforms (Schumann et al, 1994). Cross-linking of CD16 or of the 
activating forms of CD94/NKG2 and activating KIR receptors on NK cells leads to 
production of GM-CSF, TNF-α, IFN-γ and IL-2 by NK cells (Mandelboim et al, 1998; 
Márquez et al, 2010).  
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Despite their major role in triggering NK-mediated killing of most tumour 
cell lines, evidence accumulated in recent years has suggested broader functions of 
natural cytotoxicity receptors (NCRs) that could involve cytokine secretion. Studies 
have shown that cross-linking human NKp46 or NKp30 can induce IFN-γ cytokine 
secretion by PBNK cells (Andre et al, 2004). This effect is synergized when these 
receptors are co-stimulated with NKG2D, 2B4, CD2 and, to a lesser extent, with 
DNAM-1 (Bryceson et al, 2006). The mAb-specific engagement of NKp30 was found 
to trigger the production of IFN-γ, TNF-α, MIP-1 α, MIP-1β, and GM-CSF cytokines 
by human decidual NK cells (dNK) cells  (El - Costa et al , 2008). Moreover, mouse 
splenic and intestinal NK cells can secrete IFN-γ and IL-22 in response to NKp46 
stimulation (Satoh-Takayama et al, 2009).  
NKG2D (CD314) is a lectin-like homodimeric receptor that recognizes a 
variety of stress-induced self-ligands, such as MICA, MICB and ULBP molecules in 
humans (Bauer et al, 1999; Steinle et al, 2001) as well as the H60, Rae1 and MULT 
molecules in mice (Cerwenka et al, 2000). Besides its expression on NK cells, 
NKG2D is also detected on CD8
+
 T cells and γδ T cells, and can be up-regulated by 
IL-15 (Bauer et al, 1999). NKG2D signalling is achieved through membrane 
association with signalling adaptor. The adaptor that associates with human NKG2D is 
the DAP10 transmembrane adaptor, which bears a YxxM motif and activates the 
phosphatidylinositol 3-kinase pathway (Wu et al, 1999). Cross-linking human NKG2D 
receptors with their specific ligands (but not with mAbs) is sufficient to induce IFN-γ 
secretion by human NK cells (Billadeau et al, 2003; Andre et al 2004). 
 
   
 
 
 
141 
 
4.1.2  Aims of this Chapter 
Here it was addressed how specific engagement of activating receptors 
recognizing non-MHC class I molecules, namely CD16, NKG2D (CD314), NKp46 
(NCR1), NKp44 (NCR2) and NKp30 (NCR3) regulated IL-6 mRNA expression and 
protein production by purified resting human PBNK cells. These aims were achieved 
by inducing NK cell activation with immobilized antibodies against these activating 
receptors and assessing the effect of the engagement of these receptors on PBNK IL-6 
gene expression at transcription level in different time points by quantitative real time 
PCR (qPCR). IL-6 secretion by NK cells was also measured in the supernatants at the 
same time points by ELISA. In addition the data obtained from these various receptors 
on the induction of IL-6 cytokine transcripts and protein production by PBNK cells 
were directly compared, thereby providing some insight into the IL-6 cytokine profile 
induced by these different receptors. 
 
4.2  In vitro stimulation of PBNK cells  
4.2.1 Preparation of plastic-immobilized antibodies 
100 µl (~10µg/ml) of anti CD16 monoclonal antibody (clone 3G8, gift from 
Inflammation Research Unit, University of Liverpool) were immobilized directly to 
96-well polystyrene tissue culture flat bottom plates. 3G8 is a mouse anti-human 
CD16 that specifically binds to the transmembrane form of the IgG Fc receptor 
(FcγRIIIa). Anti-NKG2D monoclonal antibody (clone 149810), anti-NKp46 (clone 
195314), anti-NKp44 (clone 253415) and  anti-NKp30 (clone 210845), (all from R & 
D Systems, UK)  were diluted in carbonate buffer (eBioscience) to approximately 10 
µg / ml  and immobilized directly to 96-well flat bottom polystyrene tissue culture 
plates (Loza et al, 2003). These antibodies were used in the activation of resting NK 
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cells and stimulation of IL-6 cytokine production by these cells. Following the 
addition of antibodies to the wells, the plates were incubated for 18 hrs at 4 °C. On the 
next day, the wells were washed two times with 1X PBS to remove unbound 
antibodies and filled with 200 µl of complete RPMI medium containing the effector 
NK cells.  
 
4.2.2  Preparation of effector cells 
Human NK cells from 10 healthy donors were isolated from fresh or short 
term PBMCs cultures by negative selection using an NK cell isolation kit (Miltenyi 
Biotec, Germany) as described in Chapter 2. For CD16, NKG2D, NKp46 and NKp30 
activation, NK cells from each healthy donor were added to the wells containing 
immobilized antibodies at a concentration of 1 x 10
5
 cells / well and the plate was 
incubated at 37° C for 1, 3, 6 and 24 hours in a humidified incubator. For NKp44 
activation, since this receptor is a marker for activated NK cells, and is not expressed 
by resting cells, the NK cells were pre-activated with recombinant human IL-2 (R & D 
Systems, UK) at a dose of 100 U / ml for 24 hrs prior to adding them to the wells 
containing the immobilized NKp44 antibody. This was followed by a further 1, 3, 6 
and 24 hours incubation at 37° C in a humidified incubator. Wells containing resting 
NK cells without antibody activation were used as negative control. Supernatant was 
collected from each well at 1, 3, 6 and 24 hrs and stored at -20 °C until tested for IL-6 
production using a human IL-6 ELISA kit (eBioscience). At the same time, the NK 
cells from each well were collected for RNA extraction, reverse transcription and 
quantitative PCR (qPCR). 
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4.2.3  RNA extraction from PBNK cells  
After activation with immobilized anti- CD16, anti-NKG2D, anti-NKp46, 
anti-NKp44 and anti-NKp30 antibodies, the NK cells (1 x 10
5
 cells / well) were 
collected from the tissue culture plates at 1, 3, 6 and 24 hrs. Resting NK cells from the 
same donors were also extracted at the same time points and used as negative controls. 
Total RNA was then extracted from both the activated and resting NK cells using the 
QIAamp RNA Blood Mini Kit (Chapter 2). Since the isolated RNA was then used in 
qPCR that are sensitive to very small amounts of DNA, so more RNA clean- up was 
necessary. Contaminants were removed by further washing with RWI and RPE 
buffers. High-quality RNA was then eluted in water. The concentration and purity of 
the RNA was determined by measuring the absorbance at 260 nm (A260) and 280 nm 
(A280) in a spectrophotometer as described in Chapter 2. Following extraction and 
quantification, the RNA was either stored at -80 °C or immediately reversed 
transcribed into complementary DNA (cDNA) as described in Chapter 2. However, in 
most cases the volume of the master mix was scaled up or down depending on the 
amount and volume of the extracted RNA. cDNAs from both the activated and resting 
NK cells were then used to assess IL-6 mRNA expression by real-time PCR.  
 
4.2.4  Real-time quantitative PCR (qPCR) 
A basic PCR reaction can be broken up into three phases (www.applied 
biosystems.com): exponential phase in which the accumulating products double at 
every cycle (assuming 100% reaction efficiency); linear phase in which the reaction 
components are becoming consumed and the reaction is slowing; and finally the 
plateau (end-point) phase in which the reaction is stopped and, if left long enough, the 
PCR products will begin to degrade (Figure 4.1 A). Real-time chemistries allow for 
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the detection of PCR amplification during the exponential phase of the reaction 
because this phase provides the most accurate and precise data for quantitation. Within 
the exponential phase, the real-time PCR instrument calculates two values (Figure 4.1 
B): The threshold line is the level of detection at which a PCR reaction reaches a 
fluorescent intensity above background; and the cycle threshold (Ct) which is the PCR 
cycle at which the sample reaches a fluorescent intensity above background. 
Measuring the kinetics of the reaction in the exponential phase of PCR provides a 
distinct advantage over traditional PCR detection. Traditional methods need post 
reaction analysis (e.g. use of agarose gels) for the detection of PCR amplification at 
the final phase or end-point of the PCR reaction. In addition, using real-time PCR the 
results can be tracked in “real-time” thus combining the amplification and the 
detection in one step. 
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Figure 4.1: A) The three different phases of PCR reaction. In the exponential phase 
the reaction components are in excess, there is an exact doubling of product each 
cycle, and the reaction is specific and precise. In the linear phase the reaction 
components are being consumed, amplification slows, and the reactions become 
highly variable. The final phase of PCR amplification is the plateau (end-point) phase. 
Here, the reaction is complete and no more products are being generated. The real time 
PCR takes its measurements during the exponential phase, while traditional PCR takes 
its measurements during the plateau phase. B) The real-time PCR reaction showing the 
threshold line and the cycle threshold (Ct). The Ct is the PCR cycle at which the 
fluorescence intensity of the sample increases above the background level. The 
threshold was calculated by the Rotor-Gene 5 software.   
Exponential 
Linear 
Plateau 
      Ct 
A 
B 
 
 
146 
 
4.2.4.1  Quantification assays in real-time PCR 
There are two methods used for quantification of gene expression in real-
time PCR. The first method is the absolute quantification assay which uses a standard 
curve of serially diluted standards of known quantities to determine the quantity of 
unknown samples (Wong et al, 2005). Absolute quantification results are reported as 
an absolute quantity (copies, ng, pg, etc.) extrapolated from the standard curve. The 
second method is the relative quantification (also known as comparative 
quantification) of gene expression which allows quantifying differences in the 
expression level of a specific gene between different samples (Cikos et al, 2007). The 
data output is expressed as a fold-change or a fold-difference of expression levels. 
Both absolute and relative quantification use the Ct values obtained during real-time 
PCR. In absolute quantification the Ct values of test samples are compared to those of 
the standards of known quantity plotted on a standard curve. Relative quantification 
involves comparing the Ct values of the test samples to those of control samples. This 
analysis yields a ratio rather than absolute quantity e.g. the relative amount (fold 
difference) of a target nucleic acid in target vs. control samples.  
 
4.2.4.2  Methods of monitoring PCR amplification in “real-time” 
1.  Fluorescent dyes 
Intercalating fluorescent dyes represent the simplest and cheapest way to 
monitor the real-time PCR reaction. The fluorescence of these reporter dyes increases 
as the PCR product accumulates with each successive cycle of amplification. By 
recording the amount of fluorescence emission at each cycle, it is possible to monitor 
the PCR reaction during the exponential phase.  
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SYBR-Green I is the most commonly used fluorescent dye in real-time PCR 
with excitation and emission maxima of 494 nm and 521 nm, respectively (Ponchel et 
al, 2003). It exhibits little fluorescence when it is free in solution, but its fluorescence 
increases up to 1000-fold when it binds double stranded DNA. As the number of 
copies of DNA increases during the reaction the fluorescence increases. Therefore, the 
overall fluorescent signal from a reaction is proportional to the amount of double 
stranded DNA present. Ethidium bromide can also be used for the detection of double 
starnaded DNA but its carcinogenic nature renders its use restrictive. Although these 
double stranded DNA-binding dyes provide the simplest and cheapest option for real 
time PCR, the principal drawback of DNA-binding dyes is their lack of specificity. As 
they bind to any double stranded DNA the presence of nonspecific products in a real-
time PCR reaction may contribute to the overall fluorescence and affect the accuracy 
of quantification.  
 
2.  TaqMAN hydrolysis probes 
In TaqMan® experiments, three oligonucleotides are used: forward and 
reverse primers specific to the target of interest and a fluorogenic probe. This probe is 
an oligonucleotide with a fluorescent reporter dye attached to the 5' end such as 6 -
carboxyfluorescein (FAM), and a quencher dye attached to the 3' end such as 6-
carboxy-tetramethyl-rhodamine (TAMRA). The oligonucleotide sequence of the probe 
is complementary to the target sequence. Initially the probe is not hydrolyzed and the 
quencher and the reporter fluorophore remain in proximity to each other. This 
proximity however, does not completely quench the fluorescence of the reporter dye 
and background fluorescence is observed (Leutenegger, 2001). During PCR the probe 
anneals specifically between the forward and reverse primer to an internal region of 
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the PCR product and has a melting temperature 10°C higher than that of the primers 
(Leutenegger, 2001). Binding of the TaqMan probe prior to the primers is crucial 
because without it PCR products would be formed without generation of fluorescence 
intensity and thus without being detected. The 3' phosphate group (P) prevents 
extension of the TaqMan probe. During extension the 5' exonuclease activity of the 
polymerase cleaves the probe, releasing the reporter molecule away from the close 
vicinity of the quencher. The fluorescence intensity of the reporter dye, as a result, 
increases. This process repeats in every cycle and does not interfere with the 
accumulation of PCR product. In real-time PCR, fluorescent primers and probes offer 
two main advantages over fluorescent dyes. First, they specifically detect the target 
sequence so nonspecific products do not affect the accuracy of quantification. Second, 
they allow multiplex reactions to be performed in a single tube. 
 
3.  Hybridisation probes (FRET probes) 
The hybridization probe system consists of four oligonucleotides: forward 
and reverse primers specific to the target of interest and two fluorophore - labelled 
hybridisation probes. The up-stream (donor) probe is labelled with a fluorophore at the 
3' end of olignucleotide sequence while the downstream (acceptor) probe is labelled 
with a fluorophore at the 5' end (Okamura et al, 2006). The two fluorophores are 
carefully chosen so that the emission spectrum of one overlaps significantly with the 
excitation spectrum of the other. Interactions between the excited states of these 
fluorophore molecules lead to the transfer of excitation energy from one (the donor) 
dye molecule to the other (acceptor molecule) (Juskowiak, 2011). This process is 
called Fluorescence Resonance Energy Transfer (FRET) and it is a distance - 
dependent (typically 10-80 nucleotides) (Lorenz et al, 2006). During PCR the two 
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different oligonucleotide probes hybridize to adjacent regions of the target DNA such 
that the fluorophores, which are coupled to the oligonucleotides, are in close proximity 
in the hybrid structure in a head-to tail arrangement. The donor fluorophore (F1) is 
excited by an external light source then passes part of its excitation energy to the 
adjacent acceptor fluorophore (F2). The excited acceptor fluorophore (F2) emits light 
at a different wavelength which can then be detected and measured (Howell, 2006). 
 
4.  Other primer- and probe- based methods 
Several other fluorescent primer- and probe-based chemistries have been 
devised for monitoring DNA/RNA amplification in real-time. These include molecular 
beacons, minor groove binder (MGB) - eclipse probes, amplifluor assays, scorpion 
primers, LUX primers, and ozyme primers. Molecular beacons are single-stranded bi-
labelled fluorescent probe held in a hairpin-loop conformation (around 20 to 25 
nucleotide) with complementary stem sequences (around 4 to 7 nucleotides) at the 5' 
and 3'ends of the probe (Li et al, 2008).  A fluorescent reporter molecule is attached to 
the 5' end of the molecular beacon, and a quencher is attached to the 3' end. Formation 
of the hairpin therefore brings the reporter and quencher together, so no fluorescence 
is emitted. During the annealing step of PCR, molecular beacons hybridize to their 
target sequence causing the hairpin-loop structure to open and the stem to denature. 
The reporter and quencher are thus separated. As the quencher is no longer close 
enough to absorb the emission from the reporter dye, the dye is allowed to fluoresce 
and the PCR instrument detects the increase of emitted energy. The measured 
fluorescent signal is directly proportional to the amount of target DNA. The MGB-
eclipse probe system consists of three oligonucleotides: forward and reverse gene-
specific primers and the eclipse probe. The eclipse probe has a complementary 
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sequence to the target DNA. The 5‟ end of the probe is attached to the quencher 
molecule and the MGB peptide moiety, while the reporter dye is attached to the 3‟ end 
of the probe (Cloud et al, 2005). The un-hybridized probe adopts a random three-
dimensional conformation that brings the reporter and quencher together, so 
quenching occurs. During PCR, the probe anneals to the target with the help of MGB, 
thus the probe becomes linearized. This leads to the separation of the reporter dye 
from the quencher to produce fluorescence. 
 
4.2.4.3  IL-6 real-time PCR primers 
Optimal design of the PCR primers is crucial for accurate and specific 
quantification using real-time PCR. For the assay described herein, detection is based 
on the binding of the SYBR Green I dye into double stranded IL-6 PCR products. As 
discussed above, while this assay is cheaper than probe-based methods, it loses the 
additional level of specificity introduced by the hybridisation of the PCR product to a 
specific fluorescent TaqMan probe. The sensitivity of detection with SYBR-Green I 
dye may therefore be compromised by the formation of primer-dimers, lack of 
specificity of the primers, primer concentration and the formation of secondary 
structures in the PCR product. All of these factors could potentially lead to the 
creation of unexpected double stranded DNA product, which would incorporate 
SYBR-Green I dye and register a fluorescent signal.  
Throughout this study IL-6 mRNA expression in CD16-, NKG2D-, NKp46-
, NKp44- and NKp30- activated PBNK cells was analyzed by real-time PCR from 10 
healthy donors using SYBR-Green I dye. The levels of IL-6 mRNA in un-stimulated 
(resting) NK cells were chosen as control. Gene expression levels in both activated 
and resting NK cells were normalized to GAPDH (glyceraldehyde-3-phosphate 
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dehydrogenase) mRNA and relative quantification was performed by a relative 
quantification method. Primer sequences used in this experiment for the real-time 
amplification of IL-6 and GAPDH were acquired from published papers (Chapter 2, 
Section 2.11). All IL-6 and GAPDH primers were tested to meet at least two critical 
criteria: single - amplicon specificity and consistently high amplification efficiencies. 
The single - amplicon specificity was experimentally validated with two quality 
control assays, a melt curve analysis and agarose gel electrophoresis. Both must verify 
that a single IL-6 or GAPDH gene specific product is produced. The second criterion 
to pass was an amplification efficiency > 90%.  
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4.3  Results 
4.3.1  Checking primers for single - amplicon specificity 
To test the performance and validity of IL-6 and GAPDH primers, a 
preliminary primer check was performed. Using 1 µl (~100-200 ng) of PBMCs cDNA 
as template and 2 X SensiMix
TM
 SYBR Green NO ROX kit (BioLine, UK), 20 µl real-
time PCR reactions (one for each IL-6 primer set and one for GAPDH with its 
negative contol) were prepared and run as described in Chapter 2. The PCRs were run 
in two independent experiments and at the end of the cycling programme the melting 
curves of the PCR reactions were checked. Ideally, melting curve should contain a 
single peak with no shoulders, and the agarose gels of the amplified product should 
reveal a single band corresponding to the predicted amplicon length. Figure 4.2 shows 
the melting curves and agarose gel electrophoresis for the IL-6 primers used for the 
optimisation steps. Apart from the pre-optimized primer from Qiagen, all other primer 
sets gave rise to melting curves with more than one peak and more than one band on 
agarose gel indicating either the production of primer dimers or nonspecific products. 
The primer dimers may be eliminated by optimizing primer concentration or changing 
thermocycling parameters. Many attempts were made to optimize primer 
concentrations and cyclic parameters but all these attempts failed. Since these were 
very time consuming procedures, all primers with more than one peak during melting 
curve analysis were excluded and the pre-optimized primer set (Qiagen) was selected 
for the final experiments. Regarding the specificity of the GAPDH primer set the 
melting curve clearly indicated a single peak and demonstrated that the GAPDH PCR 
product had a specific melting temperature at ~82 °C (Figure 4.3 A & B). 
Subsequently, the agarose gel electrophoresis showed that the band was specific with 
the expected length of 133 bp (Figure 4.3 C).  
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Figure 4.2: IL-6 primers test. Four IL-6 primer sets (selected from published papers) 
and one pre-optimized IL-6 primer set (purchased from Qiagen) were tested using 1µl 
(~100-200 ng) of PBMC cDNA and 2 X SensiMix
TM 
SYBR Green NO ROX kit. A) 
Real-time fluorescent detection of the IL-6 amplicon. B)  Dissociation (melting) 
curves of the different IL-6 PCR reactions. A single peak suggested the absence of 
non-specific amplification products. C) Agarose gel electrophoresis of real-time PCR 
products. Lane *: 100-10000 bp DNA Ladder; lane 1: IL-6 primer 1 (expected product 
size is 80 b.p); lane 2: IL-6 primer 2 (expected product size is 99 b.p); lane 3: IL-6 
primer 3 (expected product size is 143 b.p); lane 4: IL-6 primer 4 (expected product 
size is 193 b.p); lane 5: commercial pre-optimized IL-6 primer (expected product size 
is 107 b.p). Apart from the pre-optimized IL-6 primer set, all other primers gave rise to 
non specific PCR products. These primers were excluded from the final study. 
 
 
 
2 3 4 5    1 
100 bp 
* 
A B 
C 
 
 
154 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 4.3: Quality control of the GAPDH primer set. The GAPDH primer set was 
tested using 1 µl (~100-200 ng) of PBMC cDNA and the 2 X SensiMix
TM 
SYBR 
Green NO ROX kit. Real-time PCR was run in 20 μl volumes with 1 μl of forward and 
1 μl of reverse primers. PCR conditions were as follows: 95°C for 10 min, 40 cycles of 
[95°C for 15 seconds, 60°C for 15 seconds and 72°C for 20 seconds]. The melting of 
the PCR product was performed from 55°C to 95°C, rising in 0.5°C increments. A) 
Real-time fluorescent detection of GAPDH amplicon. B) Melting curve for GAPDH 
PCR reaction. The single peak suggests a single size product. C) Agarose gel 
electrophoresis of the GAPDH real-time PCR products.  The left lane shows the 100-
10000 bp molecular weight ladder. Lane 1 shows the amplicon (133 bp). No 
amplification was found in negative control (no template DNA sample, lane 2). 
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4.3.2  Testing the primers amplification efficiency 
The typical method to analyze real-time PCR data is the Livak method 
(Livak and Schmittgen, 2001). This is also referred to as the 2
-ΔΔCT
 method. It uses 
only Ct values and consists of three main steps:  
1) Normalization of the Ct value of gene of interest to that of reference 
gene, for both the test sample and the control sample. This is ΔCT: 
ΔCt (test) = Ct (Gene of interest, test) – Ct (reference gene, test) 
ΔCt (control) = Ct (Gene of interest, control) – Ct (reference gene, control) 
 
2) Calculation of the difference between the ΔCT of the test sample and the 
ΔCT of the control. This is called ΔΔCt: 
ΔΔCt = ΔCt (test) – ΔCt (control) 
 
3) Calculation of the expression ratio: 
Expression ratio (folds) = 2
–ΔΔCT
 
 
However, this method often assumes that both the gene of interest and the 
reference gene PCR assays have 100% amplification efficiency (a two-fold increase in 
the amount of the amplicon during each cycle). Since 100% efficiency is rarely seen in 
practice, therefore the error rate in the fold difference increases exponentially. PCR 
amplification efficiencies between 90-110% are generally considered acceptable and 
enable PCR assays to accurately analyze gene expression using the Livak method 
(Dorak, 2011). To determine the PCR amplification efficiency a calibration standard 
curve is required. The cDNA template of known concentration is serially diluted. After 
the end of the cycling, the dilution and Ct values are exported to Microsoft Excel and a 
standard curve is drawn by plotting the Ct values versus the log10 dilution values 
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(linear regression) and the slope is calculated from the standard curve. The efficiency 
of the reaction can be calculated by the following equation:  E = 10 (-1/slope) –1. 
Slopes of -3.1 to -3.6 in the Ct Vs. log-template amount standard curve correspond to a 
PCR efficiency of 90-110%. The closer the slope is to -3.33, the closer the 
amplification efficiency is to the theoretical 100% (Dorak, 2011). If the PCR 
efficiency is < 90%, the quantitative real-time PCR should be further optimized or 
alternative primers designed. If the efficiency is > 110%, running another standard 
curve experiment with a minimum of 3 replicates and a minimum of 5 logs of template 
concentration is recommended. Nowadays most of real-time PCR machines are 
provided with software that can generate the PCR efficiency calculations rapidly and 
automatically.  
The preliminary primer test experiment has indicated all the IL-6 primers 
gave rise to non specific bands apart from the pre-optimized primers from Qiagen. 
Since these primers are pre-optimized by the company for the IL-6, therefore no PCR 
amplification efficiency test was carried out on these primers. However, the GAPDH 
reference gene primers were evaluated for their amplification efficiency. Here 4 serial 
10 fold dilutions of PBMCs cDNA were made. Each dilution was prepared in 
triplicates and the PCR was run using the same parameters as in the previous 
experiment. As can be seen from Figure 4.4, the amplification efficiency of the 
GAPDH PCR reaction was 99%, R=0.99064, R2 = 0.98137. Therefore, these primers 
were used for the final experiments. 
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Figure 4.4 Amplification efficiency of the GAPDH primer set using SensiMix
TM 
SYBR Green NO ROX kit. A) Real-time amplification curve from a 10-fold dilution 
series of a GAPDH target amplified from PBMCs cDNA with starting amounts of 100 
ng. GAPDH was amplified in four triplicate reactions using the GAPDH experimental 
primer set. Real-time PCR was run in 20 μl of final volume with 1 μl of forward and 1 
μl of reverse primers. The PCR conditions were as follows: 95°C for 10 min, 40 cycles 
of [95°C for 15 seconds, 60°C for 15 seconds and 72°C for 20 seconds]. B) Melting 
curve analysis. Single peaks on the melting curve of all samples indicated that no 
contaminating DNA, primer dimers or non-specific products were present in the 
reaction. C) Log-transformation of the fluorescence measurements and the points of 
intersection of the amplification curves and the threshold. The threshold was 
determined by the Rotor Gene 5 software. D) Standard curve of the GAPDH 
amplification. The curve generated by the Rotor Gene 5 software provided with the 
Rotor Gene 2000 Thermocycler based on the log dilution (X-axis) and Ct values (Y-
axis). The efficiency of the PCR reaction was 99%. The correlation coefficient of the 
GAPDH standard was R = 0.99. 
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4.3.3 Involvement of different NK cell activating receptors in IL-6 mRNA 
expression and protein secretion   
4.3.3.1  Stimulation via CD16 
1.  Engagement of CD 16 induced IL-6 mRNA expression in PBNK cells 
First we tested whether the CD16 cross-linking on BPNK cells can stimulate 
IL-6 gene expression at a transcriptional level in these cells. PBNK cells were 
stimulated with anti-CD16 antibodies (clone 3G8) as described in Sections 4.2.1 and 
4.2.2, and mRNA expression was studied after 1, 3, 6 and 24 hours. Quantitative 
analysis was performed by comparing the IL-6 signal obtained from CD16-activated 
NK cells to that obtained from resting PBNK cells. Gene expression levels from both 
activated and non-activated PBNK cells were normalized to the house keeping gene 
(GAPDH signal) at same time points. Relative quantification was then performed 
using the ΔΔCT method. The results are shown in Figure 4.5 A and summarized in 
Figure 4.5 B. It is clear that 1 hour post stimulation, IL-6 mRNA expression was 
already more than 3-fold enhanced compared to the pre-stimulation levels (3.4 ± 2.3 
fold greater than resting). At 3 hours, the IL-6 mRNA expression significantly increase 
with more than 22 fold enhanced to pre-stimulation level (22.3 ± 17.65 fold greater 
than resting, p = 0.022). In most cases, the most prominent increase was found 6 hours 
after stimulation exceeding the pre-stimulation level more than 44-fold (44.6 ± 47.8 
fold greater than resting). However, this increase, when compared to that at 3 hours 
was not statistically significant (p = 0.064). IL-6 mRNA expression clearly peaked 
around this time as at 24 hours the levels were dropping compared to 6 hours, 
although, at least in some donors, they were still above background (7.01 ± 9.77 fold 
greater than resting, p = 0.013).   
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Figure 4.5: Effect of CD16 stimulation on IL-6 gene expression by PBNK cells at 
transcriptional level. Purified NK cells from 10 healthy donors were incubated with 
immobilized anti-CD16 antibodies (3G8) in a 96-well tissue culture plate. The NK 
cells were then collected at 1, 3, 6 and 24 hrs and analyzed in triplicates for IL-6 
mRNA expression. In all samples, gene expression levels were normalized to GAPDH 
mRNA and relative quantification was performed using the ΔΔCT method. A) In most 
cases, the most prominent increase in IL-6 mRNA expression was found at 6 hours 
(only two cases at 3 hours). B) The mean values and SD of the 10 independent 
experiments. IL-6 mRNA started to increase significantly at 3 hours (p < 0.05) 
following stimulation. The most prominent increase was noticed at 6 hrs while a 
significant reduction of IL-6 mRNA expression was observed at 24 hours post 
stimulation (p <0.05). Statistical analysis was performed using Wilcoxon signed rank 
test. The error bars denote the SD; *, p<0.05  
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2.  Engagement of CD16 induced IL-6 protein secretion by PBNK cells  
The IL-6 protein secretion by PBNK cells from the same donors used in the 
above experiment was also studied after exposure of these cells to immobilized CD16 
mAb as described above. The quantity of IL-6 released by these cells into the medium 
was then determined by enzyme-linked immunosorbent assay at 1, 3, 6 and 24 hours 
(Figure 4.6A). It was found that the engagement of CD16 receptors on the surface of 
NK cells by their mAb significantly enhanced IL-6 synthesis in a time-dependent 
fashion. By 1 hour after exposure CD16 stimulated cultures synthesized almost 4 
times more IL-6 (7.28 ± 4.34) than was produced by identical cultures of non-
stimulated NK cells (2.11 ± 0.70), p = 0.010 (Figure 4.6 B). At 3 hours post 
stimulation, the amount of synthesized IL-6 was increased up to 22 pg/ml (22.04 ± 
11.79) in comparison to less than 4 pg/ml (3.62 ± 1.45) seen without stimulation (p < 
0.001). The secretion of IL-6 by CD16 activated NK cells continued to increase 
thereafter and reached about 48 % of maximum at 6 hours. However, in contrast to IL-
6 mRNA expression which inhibited at 24 hours, the IL-6 protein secretion showed a 
maximum at 24 hours post stimulation (92.48 ± 25.80). 
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Figure 4.6: IL-6 protein secretion by CD16 activated PBNK cells. A) The PBNK 
cells from 10 healthy donors (same donors as in real-time PCR experiment) were 
purified by negative magnetic selection and then stimulated with immobilized anti-
CD16 mAb in a 96-well plate. IL-6 accumulation in the medium was measured by 
ELISA at 1, 3, 6 and 48 hours after stimulation. B) The mean values and S.D. of 10 
determinations from 10 independent experiments are shown and compared to mean 
values obtained from resting NK cells from same donors. Statistical analysis was 
performed using Wilcoxon signed rank test. The error bars denote the SD; **, p < 
0.01; ***, p < 0.001. Significant difference at p < 0.05.   
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4.3.3.2  Stimulation via NKG2D 
1.  Engagement of NKG2D receptors induced a greater increase in IL-6 
transcript level in PBNK cells compared to CD16  
We then assessed the effect of the engagement of another NK receptor, 
NKG2D, on IL-6 mRNA expression (Figure 4.7 A). Purified PBNK cells from 10 
healthy donors were cultured in 96-well tissue culture plate in the presence of 
immobilized anti-NKG2D mAbs as described in Section 4.2.1 and 4.2.2. The IL-6 
transcripts synthesized by these cells were determined by real-time PCR at 1, 3, 6 and 
24 hours using the same experimental approach as with CD16. Despite some inter-
individual variations, activation of NK cells through NKG2D receptors produced more 
IL-6 transcripts than CD16 at all 4 time points. In all cases, the IL-6 transcripts were 
up-regulated as early as 1 hour (13.46 ± 13.08 fold greater than resting), increased 
further at 3 hours (29.20 ± 23.95 fold greater than resting ) and reached a maximal 
level at 6 hours (89.46 ± 84.24 fold greater than resting ) (Figure 4.7 B) . Although 
NKG2D engagement resulted in the production of more IL-6 transcripts (29.20 ± 
23.95 fold greater than resting) than CD16 engagement (22.3 ± 17.65 fold greater than 
resting) at 3 hours, no significant statistical difference was found between 1 and 3 
hours (p = 0.085). This was due to the fact that NKG2D induce more IL-6 transcripts 
at 1 hour compared to CD16. However, IL-6 gene expression significantly increased at 
6 hours (p= 0.043). Again, the expression of the transcript appeared to be transient as 
the mRNA expression was profoundly lower by 24 hours (10.76 ± 17.7 fold greater 
than resting, p < 0.001).  
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Figure 4.7: The effect of NKG2D stimulation on IL-6 gene expression by PBNK 
cells. After purification NK cells from each donor (n=10) were incubated in the 
presence of an immobilized anti-NKG2D mAb in a 96-well tissue culture plate. The 
NK cells were then collected at 1, 3, 6 and 24 h and analyzed for IL-6 mRNA 
expression in triplicates.  Results represent the relative fold increase over resting (non-
stimulated) PBNK cells in the 10 individuals. Gene expression levels were normalized 
to GAPDH and relative quantification was performed. A) Results of real-time PCR. 
The most prominent increase in IL-6 mRNA expression was found at 6 hours. B) The 
mean values and SD of the 10 experiments. IL-6 mRNA increased significantly by 6 
hours (p < 0.05) but started to return to baseline at 24 hours post stimulation (p 
<0.001). Statistical analysis was performed using Wilcoxon signed rank test. The error 
bars denote the SD; *, p < 0.05 ; ***, p < 0.001  
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2.  NKG2D engagement markedly stimulated IL-6 protein secretion by 
PBNK cells 
Conditioned media of cultured PBNK cells from same 10 healthy donors as 
in the real time experiment stimulated with immobilized anti-NKG2D mAb were also 
assayed for the production of IL-6 protein at 1, 3, 6 and 24 hours by ELISA (Fig 4.8A 
& B). PBNK cells cultured in medium alone produced negligible amount of IL-6 after 
1 hour of incubation (2.11 ± 0.70). Cross-linking of NKG2D significantly increased 
IL-6 production to 9.89 ± 8.09 pg/ml (p= 0.0173). A continuous significant response 
was observed after incubation for 3 hours, in which IL-6 production increased to 28.04 
pg /ml ± 17.12 compared to resting NK cells (3.62 ± 1.45, p < 0.001). At 6 hours 
conditioned medium from PBNK cells stimulated with anti-NKG2D mAb possessed 
significantly greater IL-6 activity (76.77 ± 38.95) than that of un-stimulated PBNK 
cells (4.97 ± 1.84, p < 0.001). In contrast to IL-6 mRNA expression, 24 hours of 
stimulation with antibodies elicited maximum levels of IL-6 protein (181.47 ± 97.33), 
which was highly significantly different from non-stimulated cells (6.589 ± 2.30, p < 
0.001). The amount of IL-6 induced by anti-NKG2D antibodies, however, was 
substantially more than that elicited by anti-CD16 at all four time points.   
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Figure 4.8: The effect of NKG2D engagement on IL-6 secretion by PBNK cells. 
A) NKG2D-stimulated IL-6 secretion by purified PBNK cells (n = 10).The tissue 
culture plate was pre-treated with 10 µg/ml of anti-NKG2D mAb for 24 hours. 
Supernatants were collected from a 96 well tissue culture plate at 1, 3, 6 and 24 hours 
after the addition of the PBNK cells and IL-6 levels were determined by ELISA. B) 
Results from the 10 samples expressed as the mean ± SD compared to mean ± SD 
values obtained from resting NK cells from same donors. Statistical analysis was 
performed using Wilcoxon signed rank test. The error bars denote the SD; **, p < 
0.01; ***,p < 0.001. Significant difference at p < 0.05.   
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4.3.3.3   Stimulation via NKp46 
1.   NKp46 stimulation induced IL-6 expression comparable to that seen 
with NKG2D   
Purified PBNK cells from 10 healthy donors were stimulated with 
immobilized anti-NKp46 mAb and the IL-6 mRNA expression was assessed by real-
time PCR as described previously (Figure 4.9 A). Similar to the results of the anti-
CD16 and anti-NKG2D stimulation experiments, the induction of IL-6 mRNA was 
very rapid, reaching 18% of maximum at 1 hour post-stimulation (6.56 ± 5.55 fold 
greater than resting) and peaking between 3 (20.12 ± 42..03 fold greater than resting) 
and 6 hours (115.58 ± 267.42 fold greater than resting) (Figure 4.9 B).  IL-6 mRNA 
levels by 24 hours were lower, comparable to those seen at 1 hour (15.42 ± 33.68) 
(Figure 4.9 B). No statistically significant difference was found in IL-6 mRNA 
expression between 1 and 3 hours (p = 0.33), 3 and 6 hours (p = 0.28), and 6 and 24 
hours (p = 0.26) respectively. However, it should be noted that production by donor 1 
was much higher than anyone else in all experiments and this sample was clearly an 
outlier.  
 
2.  NKp46 cross-linking also induced IL-6 protein production  
After stimulation with immobilized anti-NKp46 mAb, the supernatants from 
the cultured PBNK cells were harvested at 1, 3, 6 and 24 hours and analyzed for IL-6 
protein secretion (Figure 4.10 A). A significant detectable level of IL-6 protein was 
detected at 1 hours post stimulation (12.34 ± 5.76) in comparison to (2.11 ± 0.70) in 
non-stimulated cultures, p < 0.01 (Figure 4.10 B). With increasing exposure IL-6 
cytokine-secretion progressively increased toward (29.49 ± 26.11) at 3 hours and 
(73.16 ± 40.03) at 6 hours in comparison to (3.62 ± 1.45) and (4.97 ± 1.84) in non-
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stimulated cells respectively (p <0.001). Similar to the observations  with CD16 and 
NKG2D stimulation, the IL-6 protein secretion reached a peak after 24 h of culture 
with 170.09 pg/ml ± 54.24 in comparison to 6.59 ± 2.30 by non-stimulated cells (p < 
0.001) (Figure 4.10 B). 
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Figure 4.9: IL-6 mRNA expression in PBNK cells after NKp46 stimulation. 
Purified PBNK cells established from 10 healthy donors were incubated in 96-well 
tissue culture plate in the presence of an immobilized anti-NKp46 mAb (10µg/ml). IL-
6 and GAPDH mRNA expression levels were determined (in triplicates) by real-time 
PCR and compared to those obtained from non-stimulated (resting) NK cells. A) 
Results of real-time PCR quantitation in individual donors. Maximum level of induced 
cytokine mRNA was seen at 6 hours. B) The mean and SD values of the maximum 
levels of 10 healthy donors. A return towards baseline IL-6 mRNA expression was 
observed at 24 hours post stimulation.    
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Figure 4.10: Kinetics of IL-6 protein production by PBNK cells after NKp46 
stimulation. Purified PBNK cells from 10 healthy donors were cultured in a 96-well 
plate pre-treated with anti-NKp46 mAb at a concentration of 10µg/ml. The anti-
NKp46 mAb was allowed to immobilize on the surface of plate for 18 hrs prior to 
addition of purified PBNK cells. Supernatants were collected at 1, 3, 6 and 24 after the 
stimulation. Supernatants from non-stimulated PBNK cells from same donors were 
taken at the same time points and used as negative control. A) IL-6 production by 
PBNK cells was detectable after 1 hr stimulation with mAb and peaked at 24 hrs. B) 
Mean and SD from all 10 tested individuals compared to non-stimulated samples at 
the times indicated. IL-6 production by NKp46 stimulated PBNK cells significantly 
increased as early as 1 hr compared to non-stimulated cells. Error bars denote the SD; 
**, p < 0.01; ***, p < 0.001. Significant difference at p < 0.05 
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4.3.3.4  Stimulation via NKp30 
1.  NKp30 was less efficient than CD16, NKG2D or NKp46 in stimulating 
IL-6 mRNA expression 
The effect of the engagement of NKp30 receptors on PBNK cells is shown 
in Figure 4.11 A and B. Crosslinking NKp30 induced detectable levels of IL-6 mRNA 
about 4-fold higher than resting at 1 hour (4.37 ± 7.19). However, there was no 
significant further increase at 3 hours (4.35 ± 5.87 fold greater than resting, p > 0.05) 
or 6 hours in IL-6 transcript levels (5.74 ± 5.91 fold change over resting, p > 0.05). As 
with other receptors, IL-6 mRNA expression started to return to baseline levels at 24 
hours (2.60 ± 2.38 fold greater than resting); a feature that seems to be consistent with 
observations made with all other receptors tested.  
 
2.  A smaller increase in IL-6 transcript levels following NKp30-activation 
resulted in a limited increase in IL-6 protein secretion  
To analyze whether the considerably reduced IL-6 mRNA response elicited 
by anti-NKp30 activation affected the cytokine protein secretion profile of these cells, 
supernatants were collected at the same 4 time intervals and analyzed for IL-6 protein 
by ELISA (Figure 4.12 A). Although the general pattern of protein secretion was still 
maintained and increased over time, the lower level of IL-6 transcripts resulted in 
reduction in the secreted IL-6 protein in NKp30-activated PBNK cell cultures (Figure 
4.12 B). Nevertheless, these reduced levels of IL-6 proteins were still higher than 
those obtained from resting cells at all 4 time points. One hour post stimulation, the 
mean IL-6 concentration (4.98 ± 3.61) was higher, although not statistically different, 
than without stimulation (2.11 ± 0.70, p > 0.05). Activation for 3 hours with mAb 
resulted in significantly increased IL-6 concentration (9.11 ± 2.93) as compared to the 
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control samples (p < 0.05). PBNK cells stimulated with mAb for 6 hours showed a 
greater increase in IL-6 secretion (16.12 ± 8.06) than untreated PBNK cells (4.97 ± 
1.8, p < 0.01). A peak in IL-6 levels was observed in anti-NKp30- stimulated NK cells 
at 24 hours (41.75 ± 20.92); a level which was highly significantly different from the 
non-activated control samples (6.59 ± 2.30, p < 0.001). 
 
 
 
.  
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Figure 4.11: Effect of NKp30 stimulation on IL-6 mRNA expression by PBNK 
cells. Purified PBNK cells from 10 healthy donors were cultured in the presence of 
immobilized anti-NKp30 mAb (10µg/ml) for the indicated time periods. A) Real-time 
PCR results from 10 individual donors. B) The combined mean and SD values from 
all 10 samples. Compared to anti-CD16, NKG2D and NKp46, anti-NKp30 induced 
markedly lower increase in IL-6 transcripts. No significant change was found in IL-6 
mRNA expression at any of the 4 time points tested. 
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Figure 4.12: IL-6 secretion by NKp30-activated PBNK cells. The PBNK cells 
(n=10) were cultured for 24 hours in 96-well plate in the presence of immobilized anti-
NKp30 mAb (10µg/ml). Cell supernatants were collected at the indicated time points 
to measure the IL-6 concentration by ELISA. Supernatants from resting PBNK cells 
from the same donors at the same time points were taken as controls. A) Results of 
ELISA experiments from the 10 individual donors. B) Mean and SD of the 10 
determinations compared to mean and SD obtained from controls. Statistical analysis 
was performed using Wilcoxon signed rank test. The error bars denote the SD;* p < 
0.05 **, p < 0.01; ***,p < 0.001. Significant difference at p < 0.05.   
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4.3.3.5  Stimulation via NKp44 
1.  Cross-linking of NKp44 induced different IL-6 mRNA profiles by NK 
cells 
The NKp44 receptor is a marker of IL-2 activated NK cells and its 
expression is confined to these pre-stimulated cells (Vitale et al, 1998). In order to 
study the effect of the engagement of this receptor on the expression of IL-6 mRNA 
by PBNK cells, purified PBNK cells from 3 donors were pre-activated for 24 hours 
with human recombinant IL-2 (hrIL-2) at a dose of 100 U /ml.  Following this 
activation, PBNK cells were washed with 1X PBS and cultured in 96-well plates in the 
presence of an immobilized anti-NKp44 mAb. Thereafter, the cells were collected at 
1, 3, 6 and 24 hours and investigated for IL-6 mRNA expression by real-time PCR. 
The profile of the accumulation of mRNA encoding the IL-6 was different from that 
seen in the experiments studying the effects of the other receptors. mAb- mediated 
cross-linking of NKp44 resulted in a down-regulation of IL-6 mRNA levels rather 
than increased expression in two of the three volunteers studied (Figure 4.13 A). After 
1 hour stimulation, the mean IL-6 transcripts in NKp44-stimulated NK cells showed 
only two-fold increase over non-stimulated NK cells (1.07 ± 0.86) (Figure 4.13 B). At 
3 hours post stimulation, there was no significant further increase (1.44 ± 0.39 fold 
greater than resting, p =0.53) while cultures at 6 hours after mAb stimulation clearly 
demonstrated a decrease in IL-6 mRNA levels (-3.10 ± 8.78) followed by a further 
decrease at 24 hours (-12.55 ± 20.74 fold less than control values). However, it is 
important to mention that these experiments were carried out on cells from only three 
volunteers and these results may need to be confirmed further.   
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Figure 4.13: Analysis of IL-6 mRNA expression in NKp44-activated PBNK cells.  
PBNK cells from 3 health donors were purified by negative magnetic selection and 
activated for 24 hours with rhIL-2 at a dose of 100 U/ml. After activation NK cells 
were washed with 1X PBS and added to 96-well plate at a concentration of 1 x 10
5
 
cells / well in the presence of immobilized anti-NKp44 mAb (10 µg / ml). Thereafter 
the cells were collected at 1, 3, 6 and 24 hours and assayed for IL-6 mRNA expression 
by real-time PCR. A) Fold change of NKp44 mRNA levels over control conditions 
(standardized using the internal reference GAPDH gene) in 3 healthy donors. Two out 
of the three donors showed down-regulation of IL-6 transcripts over time. B) Bars 
represent mean and SD of the changes from the above three donors at the specific time 
points indicated. Results demonstrated down-regulation rather than an increased 
expression with maximum inhibition seen at 24 hours. 
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 2.  IL-6 protein levels in NKp44- activated NK cells did not run in parallel 
with IL-6 mRNA measurements 
To verify whether the IL-6  down-regulation at the mRNA level in NKp44-
activated PBNK cells was associated with similar alteration of IL-6 bioactivity, the 
protein concentrations of IL-6 in the supernatant from the same 3 healthy donors were 
measured at 1, 3, 6 and 24 hours  (Figure 4.14 A & B). The results showed that the 
PBNK cells still secreted high amounts of IL-6 following NKp44 stimulation. One 
hour post stimulation (when the IL-6 transcription level was only two fold greater than 
control), IL-6 concentration was about 9 times higher in activated NK cells (18.65 ± 
7.90) than in the resting group (2.2 ± 2.23), p = 0.022. At 3 hours (when the IL-6 
mRNA expression in NKp44 activated NK cells was not significantly changed), a 
consistent significant increase in IL-6 was observed (42.72 ± 26.21) compared to the 
control resting PBNK cells cultures (2.56 ± 3.12512), p = 0.015. In contrast to the 
expression profile of IL-6 mRNA which was down-regulated at 6 hours, the IL-6 
protein level continued to increase reaching 77.03 ± 29.29. This level was prominently 
higher than the resting level (3.44 ± 4.55), p < 0.01. The highest level of induction for 
IL-6 protein was observed at the late stage of stimulation i.e. 24 hours with 288.05 ± 
74.88 pg/ml (significantly higher than non-stimulated NK cells, p < 0.001). Thus, our 
results indicated that the cytokine protein levels did not run in parallel with the 
corresponding mRNA transcription levels throughout the time course examined. This 
discrepancy was particularly pronounced at 6 and 24 hours. 
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Figure 4.14: IL-6 production by PBNK cells after stimulation with immobilized 
anti-NKp44 mAb. Human PBNK cells were isolated from PBMCs of 3 healthy 
donors by negative selection and activated for 24 hours in the presence of 100 U / ml 
of recombinant IL-2 human (rhIL-2) followed by incubation in the presence of anti-
human NKp44 immobilized mAbs at a concentration of 10 µg / ml in a 96 well plate. 
A) Results of the ELISA experiments from the 3 individual donors. B) Mean and SD 
values compared to the mean and SD obtained using control cells. Statistical analysis 
was performed using Wilcoxon signed rank test. The error bars denote the SD.*, p < 
0.05; **, p < 0.01; ***, p < 0.001. Significant difference at p < 0.05.   
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4.3.4 Direct comparison of IL-6 mRNA expression and protein secretion 
following activation of PBNK cells via the CD16, NKG2D, NKp46, NKp44 and 
NKp30 receptor pathways 
In the previous experiments IL-6 gene expression and protein production 
were measured in cultured PBNK cells (from healthy donors) following in vitro mAb 
cross-linking of CD16, NKG2D, NKp46, NKp44 and NKp30 receptors. Here we 
summarised the results from direct comparison of our data. When comparing the 
different receptors with each other, four features were evaluated: the time of induction, 
the time and the level of maximal accumulation, and the time of inhibition. The time 
of induction is the first measurable response to stimulation and is defined here by the 
earliest point in time (within the time frame utilized in this study) with a statistically 
significant increase in the levels of IL-6 mRNA or protein compared to non-stimulated 
cells at the same time point. With all receptors studied IL-6 transcripts were detected 
as early as 1 hour following stimulation (Figure 4.15 A). At this time point anti-
NKG2D was the strongest inducer of IL-6 mRNA expression with a more than 13 fold 
increase (13.46 ± 13.08) followed by anti-NKp46 with more than 6 fold increase (6.56 
± 5.55). Stimulation via CD16 and NKp30 resulted in only a moderate induction of IL-
6 mRNA expression with 3.4 ± 2.3 and 4.37 ± 7.19 fold increase respectively. NKp44 
cross-linking had only a two fold increase at this time point (1.07 ± 0.86 fold of 
control levels).  
 Maximum expression was observed at 6 hours in all receptors except 
NKp44. Here anti-NKp46 showed the highest mean levels of IL-6 mRNA (115.58 ± 
267.42 fold increase) followed by anti-NKG2D (89.46 ± 84.24 fold). CD16 
stimulation resulted in a less pronounced increase with 44.58 ± 47.80 fold greater than 
resting cells. NKp30 binding resulted in only a very small increase (5.74 ± 5.91) while 
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anti-NKp44 induced a different expression profile as it down-regulated IL6 transcripts 
at 6 hours (-3.10 ± 8.78). With the exception of NKp44 where only 3 donors were 
examined, the data presented above were derived from the mean ± SD of the 10 
different donors. When the 10 individuals were compared, there were some differences 
in maximum production of IL-6 mRNA between NKG2D and NKp46 at 6 hours. 
While anti-NKp46 stimulated maximum mRNA expression in only 3 individuals, anti-
NKG2D stimulated maximum mRNA expression by NK cells in 7 donors (Table 4.1). 
 
Table 4.1: Maximum IL-6 mRNA expression (fold change) by NKp46 and 
NKG2D at 6 hours 
 
 NKG2D NKp46 
Donor 1 283.38 873.09 
Donor 2 4.44 1.22 
Donor 3 45.25 57.81 
Donor 4 11.92 28.70 
Donor 5 133.43 21.45 
Donor 6 74.88 14.25 
Donor 7 70.19 27.28 
Donor 8 144.66 86.22 
Donor 9 108.63 43.41 
Donor 10 17.75 2.31 
Average 89.45 
 
115.57 
 
 
24 hours post stimulation IL-6 mRNA expression showed a tendency to 
return towards baseline values irrespective of the receptor stimulated. The most 
pronounced drop (compared to values at 6 hours) was observed with anti-NKp46 
antibody followed by anti-NKG2D, anti-CD16 anti-NKp44 and NKp30 antibodies 
respectively.   
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Regarding protein secretion (Figure 4.15 B), detectable levels of IL-6 were 
observed as early as 1 hour post stimulation with all receptors studied. In these 
experiments anti-NKp44 was the strongest inducer of IL-6 secretion (18.65 ± 7.90) 
followed by anti-NKp46 (12.34 ± 5.76) and anti-NKG2D (9.89 ± 8.10) respectively. 
Anti-CD16 induced a smaller increase (7.26 ± 4.34), while anti-NKp30 only caused a 
small increase (4.98 ± 3.61). A similar consistent increase in IL-6 production was also 
observed with all receptors at 3 hours. At 6 hours following activation, anti-NKp44 
still elicited the highest IL-6 concentration (77.03 ± 29.29). However, this was only 
marginally different from that observed with anti-NKG2D (76.77 ± 38.95) and anti-
NKp46 (73.16 ± 40.03). In comparison anti-CD16 (45.09 ± 18.20) and anti-NKp30 
(16.12 ± 8.07) were less potent stimulators. The most prominent increase of IL-6 
production was observed at 24 hours in all receptors. Thus, anti-NKp44 stimulated the 
maximum IL-6 production by PBNK cells at all 4 time points. However, it should be 
pointed out that this receptor is a marker of IL-2 activated NK cells and the PBNK 
cells for testing the effect of this pathway were co-cultured with IL-2 for 24 hours 
before their activation with immobilized anti-NKp44 mAb. 
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.  
 
Figure 4.15: A) Comparison of IL-6 mRNA expression after stimulation via 
CD16, NKG2D, NKp46, NKp44 and NKp30 receptors. At 1 hour anti-NKG2D was 
the strongest inducer of IL-6 mRNA expression followed by anti-NKp46. Maximum 
expression was observed at 6 hours in all receptors studied except NKp44.  IL-6 
transcripts were returning towards baseline levels at 24 hours except NKp44 where 
diminishing levels of IL-6 mRNA were observed much earlier, at 6 hours. B) 
Comparison of IL-6 protein secretion by PBNK cells after stimulation via the 
different activating receptors at 1, 3, 6 and 24 hours. Anti-NKp44 stimulated 
maximum IL-6 protein secretion at all 4 time points. 
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4.4  Discussion  
4.4.1  Receptor engagement and cytokine secretion 
NK cells recognize and destroy malignant and virally infected cells and 
respond to signals generated by activating and inhibitory receptors on their surfaces to 
constrain killing to appropriate target cells (Reefman et al, 2010). Such responses are 
not confined to cytotoxic effector mechanisms but also involve the secretion of 
cytokines and chemokines as immuno-defensive agents that additionally serve to 
activate resident inflammatory cells and recruit other cells to the site of inflammation. 
These NK cell-sourced cytokines can also regulate dendritic cells (Zhang et al, 2006), 
T cells (Scharton et al, 1993; Vankayalapati et al, 2004), and B cells (Zhang et al, 
2006). Thus, cytokine production by NK cells influences the innate and shapes the 
subsequent adaptive immune responses. Although cytokine secretion in response to 
soluble mediators has been extensively studied, little is known about how cytokines 
are secreted by NK cells in response to specific engagement of NK cell receptors and 
what are the minimal requirements for cytokine secretion upon engagement of these 
receptors (Fauriat et al, 2010).  
It was earlier shown that resting PBNK cells are induced to produce IL-6 
upon target cell recognition (Chapter ), although such production could also be 
induced with high doses of IL-2 or stimulation with phorbol diesters. The major goal 
of this chapter was to provide an experimental assessment of how specific 
involvement of different activating receptors, namely CD16, NKG2D, NKp46, NKp44 
and NKp30 can regulate IL-6 mRNA expression and protein secretion by resting NK 
cells. To achieve this, NK cells were purified from fresh or short-term cultured 
PBMCs by immunomagnetic negative selection. As mentioned before, the purity of 
these cells was more than 95%. The purified NK cells were cultured in 96 tissue 
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culture plates in the presence of immobilized mAb to CD16, NKG2D, NKp46, NKp44 
and NKp30. The cells and supernatants were collected at 1, 3, 6 and 24 hours and 
analysed for the IL-6 transcripts by real-time PCR and protein production by ELISA. 
This allowed identification of multiple pathways that modulate the release of IL-6 
cytokine stimulated by these different receptors. The role of activating KIRs was not 
investigated mainly because of the unavailability of specific agonist KIR receptor 
antibodies. The data presented here show that cytokine secretion by resting NK cells 
(in the absence of exogenous cytokines) can be induced by activating receptors.  
 
4.4.2  Real-time PCR considerations: The choice of housekeeping gene  
Relative quantification with real-time PCR has been widely used to estimate 
the expression level of genes of interest. In this experimental approach the expression 
of a target gene is measured with respect to an internal reference gene (so-called 
housekeeping gene). The critical issue that defines the reliability of the obtained data 
is the choice of the housekeeping gene. The housekeeping gene must meet certain 
criteria before it can be used as an effective reference gene. Relative gene expression 
comparisons work best when the gene expression of the chosen endogenous / internal 
control is more abundant and remain constant in proportion to total RNA among the 
samples (Dorak, 2011). The most common, but not necessarily the most suitable, 
choices are housekeeping genes which code for components of ribosomal subunits 
(18S rRNA), components of the cytoskeleton (β-actin), components of the major 
histocompatibility complex (β2-microglobulin), and enzymes of the glycolytic 
pathway (GAPDH) (Bas et al, 2004). 
18S rRNA is a structural RNA for the small component of eukaryotic 
cytoplasmic ribosomes (Nazar, 2004), one of the basic components of all eukaryotic 
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cells. Although this gene was considered the most stable housekeeping gene used for 
normalization in comparative analyses of mRNA expression in some human blood 
cells such as T lymphocytes (Bas et al, 2004), several factors limit its use in this study. 
Firstly, because the 18S rRNA samples lack poly-A tails, so they are not reversed 
transcribed by the oligo dT method (Zhu and Altmann, 2005) that was used for cDNA 
synthesis in this study. Secondly, as the 18S rRNA is a ribosomal RNA (not mRNA), 
therefore it may not always represent the overall cellular mRNA population. Thirdly, 
since it is abundantly expressed, 18S rRNA yields very small (<15) Ct values which is 
not desirable, especially when the target gene has a low expression level (Dorak, 
2011). Lastly, because of the absence of introns in the 18S rRNA molecule, this gene 
is also susceptible to false results from contaminating genomic DNA. 
The β-actin is one of the two non-muscle cytoskeletal actins that are 
involved in cell motility, structure and integrity (Ng et al, 1985). The β-actin gene is 
frequently used for determination of the mRNA content and the efficiency of reverse 
transcription in analysed samples. However, it has been shown that the human genome 
contains processed β-actin pseudogenes (Ng et al, 1985; Ullmannová and Haskovec, 
2003), which can result in the amplification of fragments from genomic DNA 
displaying the same size as those generated from the cDNA template. Therefore, β-
actin is not a suitable control gene for reverse-transcription polymerase chain reaction 
(RT-PCR) (Selvey et al, 2001). Additionally, similarly to 18S rRNA, β-actin is a 
highly expressed gene and yields a strong amplification signal even from very small 
template amounts (Ullmannová and Haskovec, 2003). Therefore, the use of such a 
control may lead to a wrong interpretation of PCR assays if the investigated gene is 
expressed at a markedly lower level (Ullmannová and Haskovec, 2003).  
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β2-microglobulin is commonly used as a housekeeping gene for quantitative 
RT-PCR. However, its expression level varies considerably between tissues. For 
example, it has been found that the expression of β2-microglobulin was 112-fold 
higher in leukocytes compared with fetal brain indicating large tissue specific 
variations (Oselin et al, 2003). Although it was suggested that β2-microglobulin was a 
good target for normalization of leukocyte mRNA expression (Vandesompele et al, 
2002), this study did not take into consideration the differential expression of β2-
microglobulin in leukocyte subtypes. Oselin et al (2003) have demonstrated that the 
mean β2-microglobulin expression in CD19+ cells was significantly lower than in 
CD4
+
, CD8
+
, and CD56
+
 cells. They concluded that the use of β2-microglobulin for 
normalization of the target mRNA expression in different subsets of PBMCs could 
lead to misinterpretation of the data.  
The GAPDH (glyceraldehyde-3-phosphate dehydrogenase) catalyzes the 
oxidative phosphorylation of glyceraldehyde 3-phosphate to 1,3-bisphosphoglycerate 
during glycolysis as well as the reverse reaction in tissues involved in gluconeogenesis 
(Zainuddin et al, 2010). Its RNA is universally expressed and therefore it is one of the 
most commonly housekeeping genes used in comparisons of gene expression data 
(Barber et al, 2005). However, as with β2-microglobulin, the expression of GAPDH 
varies considerably between tissues (Vandesompele et al, 2002; Barber et al, 2005). 
Moreover, Suzuki et al (2000) have shown that its expression may be up-regulated in 
proliferating cells and therefore its use in cancer studies could be criticized. 
In addition to the variability in the level of expression of housekeeping 
genes among different tissues, it is also known that experimental treatment can also 
affect the expression of these genes. For example, the expression of β-actin increased 
up to nine-fold under all conditions of reverse transcription (Schmittgen and 
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Zakrajsek, 2000). β-actin expression also increased following treatment with insulin 
(Messina, 1992) but reduced after treatment with thyroid hormones (Savonet et al, 
1997). Similarly, GAPDH expression is also influenced by treatment with insulin 
(Alexander et al, 1988), thyroid hormones and mitogenic agents such as epidermal 
growth factor (EGF) (Savonet et al, 1997). Moreover, the expression of 18S rRNA 
increased with serum-stimulation when the cDNA synthesized from non-normalized 
total RNA was assayed (Schmittgen and Zakrajsek, 2000).  
There are no published papers about the validity of different housekeeping 
genes in NK cells. However, a search in the literature has shown that GAPDH was the 
most common housekeeping gene used to normalize real-time PCR data in NK cells. 
At least ten (but not all) recent publications used GAPDH as the housekeeping gene to 
normalize the real-time PCR data in PBNK cells  (Takahashi et al ,2007 ; Duluc et al, 
2009 ; Della Chiesa et al, 2010 ; Yamaguchi et al, 2010 ; De Maria et al, 2011; Textor 
et al, 2011 ; Negrini et al; 2011 ; Monaco-Shawver et al, 2011 ; Miah et al, 2011 ; 
Munk et al; 2011 , Vairo et al, 2011 ; Narni-Mancinelli et al, 2012 ; Durrenberger et 
al, 2012). Based on these publications it was decided to use GAPDH as internal 
reference gene (housekeeping gene) in this study. Furthermore, IL-6 mRNA 
expression by PBNK cells was studied at different time points and it has been found 
that GAPDH is the least affected housekeeping gene over time in comparison to other 
genes such as β-actin which shows a diurnal rhythm and its expression may increase 
up to five-fold after 12 hours (Bakkar and Timmer, 2004). 
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4.4.3  IL-6 mRNA expression upon single receptor engagement 
The results presented in this chapter showed that mAbs cross-linking of 
CD16, NKG2D, NKp46 and NKp30 receptors in isolation was sufficient for the 
induction of IL-6 mRNA expression by PBNK cells. This can be explained on the 
basis of IL-6 promoter activation. The human IL-6 promoter contains at least four 
regulatory elements (transcription factor binding sites) such as those binding the 
transcription factors belonging to activation protein-1 (AP-1), cAMP response element 
(CRE)-binding protein (CREB), nuclear factor for IL-6 expression (NF-IL6), and 
nuclear factor-κB (NF-κB) (Figure 4.16).  
 
 
Figure 4.16: IL-6 promoter showing the transcription factor binding sites (Keller 
et al, 1996). 
 
The transcription factor AP-1 is a heterodimer constituting the oncoproteins 
resulting from c-fos and c-jun gene translation (Natoli et al, 1994). AP-1 may be 
activated by various cytokines including TNF-α, and via different types of protein 
tyrosine kinases and mitogen-activated protein (MAP) kinases (Karin et al, 1997) 
which subsequently activate a cascade of intracellular kinases, leading to the up-
regulation of the IL-6 gene.  
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CREB regulates diverse cellular responses, including proliferation, survival 
and differentiation. It is induced by a variety of growth factors and inflammatory 
signals and subsequently mediates the transcription of genes containing a cAMP-
responsive element (Wen et al, 2010). Several immune-related genes possess this 
cAMP-response element including IL-2, IL-6, IL-10, and TNF-α (Wen et al, 2010). In 
NK cells, it has been found that CREB activation has a prominent regulatory role in 
the IL-2-induced expression of functional c-fos and AP-1 (Ponti et al, 2002). 
The nuclear factor-κB (NF-κB) family of transcription factors includes RelA 
(p65), c-Rel, RelB, NF-κB1 (p50 and p105) and NF-κB2 (p52 and p100) 
(Oeckinghaus and Ghosh, 2009). RelA, c-Rel, and RelB contain transcriptionally 
active domains in their C-terminal halves and mediate the majority of NF-κB–
mediated gene transcription, whereas p50 and p52 do not contain transactivation 
domains but can modulate NF-κB activity by forming heterodimers with RelA, c-Rel, 
and RelB (Verma, 2004). Typical activators of NF-κB are Toll Like receptors (TLRs), 
which initiate a signalling cascade beginning with TLR adapter molecules MyD88 and 
TRIF, resulting in NF-κB pathway activation and the triggering of other important 
signalling cascades (Zhang et al, 2001). In addition to TLRs, the NF-κB pathway can 
also be activated by pro-inflammatory cytokines such as IL-1β and TNF-α (Lawrence 
et al, 2009). Activation of the NF-κB pathway promotes the transcription of genes 
involved in pro-inflammatory immune responses including IL-6.  
Triggering of any of these regulatory elements via their transcription factors 
is sufficient for the activation of a cascade of intracellular kinases leading to the up-
regulation of the IL-6 gene. Increasing DNA binding activity of IL-6 transcription 
factors via cross-linking of some of the activating NK cells receptors has been linked 
to the activation of IFN-γ and TNF-α expression/or secretion and increase in the NK 
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cell cytotoxicity (Trotta et al, 1996; Chuang et al, 2001). Since the activation of these 
transcription factors also results in the up-regulation of IL-6 itself, therefore, it is not 
surprising that cross-linking of activating NK cells receptors leads to an increase in IL-
6 transcripts as well. Thus a single regulatory element is functionally sufficient to 
confer responsiveness to a variety of inducers and hence functions as a multiple 
response element. This might explain why cross-linking of individual NK cell 
receptors was sufficient to induce IL-6 transcripts. 
 
4.4.4  IL-6 protein secretion upon single receptor engagement 
In contrast to IFN-γ, which reportedly requires engagement of multiple 
different receptors, we demonstrated that the engagement of the activating receptors 
CD16, NKG2D, NKp46, NKp44 and NKp30 alone were sufficient for the rapid 
secretion of IL-6. The finding that NK cells are capable of IL-6 secretion upon single 
receptor engagement may be attributed to the relatively low expression of the SH2-
containing 5' inositol phosphatase 1 (SHIP-1) enzyme (Ritz, 2005) and the high 
expression of the protein phosphatase inhibitor SET (Trotta et al, 2007) in NK cells, 
facilitating a lower activation threshold for IL-6 secretion. The engagement of multiple 
different receptors required for IFN-γ induction suggests a tighter control and a higher 
activation threshold. Taken together these results may reveal different activation 
thresholds for distinct cytokine secretion by NK cells.  
The SHIP-1 enzyme is a protein with an N-terminal SH2 domain, an inositol 
phosphatase domain, and two C-terminal protein interaction domains and the 
expression of this protein is restricted to haematopoietic cells (Giuriato et al, 2003) . 
Recruitment of SHIP-1 from the cytosol to plasma membrane is responsible for the 
inhibitory signals that modulate phosphatidylinositol 3-kinase (PI3K)-dependent 
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signalling pathways (Gloire et al, 2007). Overall, the protein functions as a negative 
regulator of cell proliferation and survival (Brooks et al, 2010). This adaptor protein 
was described to play an important role in the suppression of cytokine secretion by 
CD56 
bright 
NK cells (Ritz, 2005).  
The SET (I2PP2A, IGAAD, and TAF1b) proteins are localized to the 
nucleus and cytoplasm and have a critical role in the regulation of normal and cancer 
signal transduction (Trotta et al, 2007). In fact, SET are potent inhibitors of protein 
phosphatase type 2A (PP2A) activity (a major cellular serine threonine phosphatase 
involved in the negative regulation of a variety of cellular processes and signal 
transduction pathways). The SET are highly expressed in human CD56 
bright
 cells and 
they are up-regulated upon monokine (IL-12, IL-15 and IL-18) stimulation of primary 
human NK cells (Trotta et al, 2007). Over-expression of SET significantly enhanced 
the IFN-γ gene expression in these cells (Trotta et al, 2007). On other hand, RNAi-
mediated suppression of SET expression renders NK cells inefficient in producing 
high levels of IFN-γ in response to monokine co-stimulation (Trotta et al, 2007).  
 
4.4.5  Time course for IL-6 mRNA expression and protein secretion 
Despite some variation between receptors regarding the level of IL-6 protein 
production, cross-linking of PBNK cells with immobilized mAbs against CD16, 
NKG2D, NKp46, NKp44 and NKp30 resulted in increased IL-6 protein levels at all 
four time points studied. Compared to non-stimulated resting cells, IL-6 secretion in 
activated PBNK cells started to increase as early as 1 hour, increased further at 3 and 6 
hours and reached its peak at 24 hours. This seems to be consistent in all donors with 
all receptors examined. The fact that IL-6 secretion became significantly detectable as 
early as 1 hour after incubation with immobilized mAbs is an important finding. It fits 
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with the role of NK cells as cells of innate immunity that appear at the inflammatory 
site at the early stages of an immune response. It also fits with the role of IL-6 as a 
cytokine that plays an important role in the induction of the acute phase response. 
Overall, these results support the concept that NK cells may promote resistance to 
infections and shape adaptive immune responses, at least in part through the secretion 
of IL-6. However, the observation that various receptors can induce IL-6 secretion 
suggests the involvement of different signalling pathways. As various signals can 
result in the activation of NK-cell function redundancy is apparent between receptors. 
For example, CD16 that signals through an ITAM containing subunit is sufficient to 
activate, but other NK cell receptors signalling through the same ITAM subunit  
(NKP46 for example) or through a different subunit (DAP10 associated) such as 
NKG2D can also activate (Bryceson et al, 2006). It appears that NK cells do not have 
a dominant activation receptor, unlike T-lymphocytes for example, where the TCRs 
are central for the activation process. This kind of redundancy forms the basis for the 
natural cytotoxicity observed with NK cells from mice with a double Syk/ZAP70 
deficiency (signalling kinases for CD16) (Bryceson et al, 2006). These cells can still 
be activated and react with their targets using the NKG2D receptor signalling 
pathways. Moreover, apart from ITAM- and DAP10-based signals, additional 
combinations of signals are available and can result in the activation of cytotoxicity. 
Thus it is not unexpected to see a similar redundancy in the receptors that initiate 
cytokine secretion.  
The detection of IL-6 protein within a relatively short time period  following 
the initial signal may suggest that there is constitutive expression of the mRNA coding 
for this cytokine in NK cells and, therefore, IL-6 release happens almost without 
delay. However, our results with quantitating IL-6 transcripts clearly indicated that 
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this cytokine was also regulated at the transcriptional level. Apart from NKp44, 
stimulation via any receptor increased mRNA levels as early as 1 hour, and increased 
it further at 3 hours and caused a peak at 6 hours, in parallel with protein secretion. 
Whether NK cells regulate the IL-6 secretion at transcriptional or both transcriptional 
and translational levels needs to be further clarified by using earlier time points. 
Moreover, our study demonstrated that the IL-6 transcripts were declining at 24 hours 
in contrast to IL-6 protein which continued to increase. This means that IL-6 mRNA 
expression is not sustained for a long time even in presence of a continuous stimulus. 
This is probably due to the transient nature of AP-1, NF-κB and CREB (Adcock, 
1997; Paludan, 2001; Mann et al, 2002). In addition, the stability of IL-6 mRNA could 
be affected via modulation of cytoplasmic factors binding the AU-rich sequences of 
the 3„untranslated region of IL-6 mRNA that control mRNA stability (Musso et al, 
1992). Taking these facts into consideration, it is likely that the decline in IL-6 mRNA 
expression begins even earlier than 24 hours. In LPS stimulated human peripheral 
blood it has been shown that IL-6 mRNA levels showed rapid kinetics of induction, 
reaching a peak at 4 hours and returning to control levels at 8 hours (DeForge et al, 
1991).  
 
4.4.6  The involvement of CD16 
CD16 (Fcγ RIII) has been described as a receptor expressed on NK cells 
that facilitate lysis of virus-infected cells and tumour cells through antibody-dependent 
cellular cytotoxicity (Mandelboim et al, 1999). However, many studies have shown 
that CD16 has a broader function and is directly involved (alone or in-combination 
with other receptors) in cytokine and chemokine gene expression and protein 
secretion. One of the earliest studies on the role of CD16 in the induction of cytokine 
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gene expression and protein secretion by NK cells was published by Anegon et al in 
1988. In this study the authors showed that cross-linking of CD16 by anti-CD16 
antibodies induced the transcription of interleukin 2 receptor (CD25) and cytokines 
(IFN-γ and TNF-α) and the accumulation of their protein products in human natural 
killer cells. These findings were confirmed later by other studies (Aste-Amezaga et al, 
1994; Mandelboim et al, 1998; Bryceson et al, 2006; Márquez et al, 2010). Moreover, 
CD16 stimulation is also known to stimulate cytokine secretion (IL-1 and TNF-α) in 
other cells such as monocytes and monocyte-derived macrophages (Kramer et al, 
2004). The present results extend these findings, showing that cross-linking of CD16 
on the surface of PBNK cells is sufficient to stimulate IL-6 secretion as well. Thus, 
NK cells respond with IL-6 mRNA expression and protein production to activation 
through FcγRIII, as it occurs upon recognition and killing of antibody sensitized target 
cells.  
The CD16 receptor signals through immunoreceptor tyrosine-based 
activation motif (ITAM)–containing subunits (Lanier, 2003; Bryceson et al, 2006). In 
humans, NK cells express CD16 in association with homodimers or heterodimers of 
membrane-bound signalling adaptor CD3δ or FcεRIγ molecules (Lanier, 2003). The 
preferred ligands for CD16 on NK cells are IgG1 and IgG3 (Wu et al, 1997). Cross-
linking of CD16 on the surface of NK cells results in Ca2+ flux followed by the 
phosphorylation of CD3δ or FcεRIγ by Lymphocyte-specific protein tyrosine kinase 
(Lck) and the recruitment of SYK family kinases-tyrosine kinase ( Syk ) and Zeta-
chain associated protein kinase 70kDa ( ZAP70 ) (Lanier, 2003) . The activation of 
these signalling cascades stimulates a series of downstream events including activation 
of nuclear factor of activated T cells (NFAT). NFAT activation results in transcription 
and expression of many cytokines including IFN-γ, TNF-α, GM-CSF (Aramburu et al, 
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1995) and FasL (Furuke et al, 1999). This suggests that FcγRIII (CD16)-dependent 
NK cell expression/or secretion of IL-6 can occur through molecular mechanisms in 
which Ca2+ plays an important role.  
The anti-FcR antibody used for the activation of NK cells in these 
experiments was clone 3G8. It is documented that the F(ab')2 fragments of 3G8 are as 
active as the intact IgG in the induction of NK cell activation (Cassatella et al, 1989). 
The antibody molecules can mimic the effect of natural ligands on FcγRIII (CD16) 
and this interaction is sufficient to transduce signals intracellularly. However, this 
effect might not be seen with other anti- FcR antibodies, for example anti-CDw32 
antibody reportedly induces a [Ca2+] rise in granulocytes after cross-linking at the cell 
surface, but does not exert this effect on NK cells (Cassatella et al, 1989). This is 
obviously due to the fact that NK cells, unlike polymorphonuclear cells and 
monocytes, bear only one FcγR type that is CD16, through which the NK cell 
activation is induced.  
 
4.4.7  The involvement of NKG2D 
The NKG2D is expressed as a disulphide-bonded homodimer on the surface 
of NK cells, γδ T cells and CD8+ T cells (Ogasawara and Lanier, 2005). In the mouse, 
NKG2D is associated with both DAP10 and KARAP/DAP12 signalling subunits. The 
latter is an ITAM motif bearing subunit that activates Syk and ZAP70 kinases. In 
association with DAP12, the mouse NKG2D receptor has been shown to function as a 
primary recognition structure that can lead to the full activation of mouse NK cells, 
including NK cell cytotoxicity and cytokine secretion (Gilfillan et al, 2002; 
Diefenbach et al, 2002; André et al, 2004). In humans NKG2D is only associated with 
the DAP10 transmembrane adaptor that lacks any ITAM motif (Wu et al, 1999). 
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Instead, DAP10 bears an intracytoplasmic YxxM motif that upon ligand binding or 
antibodies cross-linking couples to and activates the phosphatidylinositol 3-kinase 
(PI3K) pathway (André et al, 2004). While the role of NKG2D in initiation of human 
NK cell cytotoxicity is well known, its role in stimulating cytokine secretion is less 
understood. Some studies argued that NKG2D in humans acts as a co-receptor rather 
than a primary receptor (Wu et al, 2000; Billadeau et al, 2003; André et al, 2004). This 
conclusion was reached based on their finding that cross-linking NKGD receptors with 
immobilized mAbs did not stimulate cytokine secretion (IFN-γ, TNF-α and GM-CSF) 
and the observation that NKG2D can function as a co-stimulatory receptor for antigen-
specific responses of CD8
+
 T cells (Groh et al, 2001). This view was further supported 
by the fact that the PI3K-dependent pathway, the main signalling pathway for the 
NKG2D/DAP10 complexes, also mediates signalling of other co-stimulatory 
molecules, such as CD28, ICOS and CD19 (André et al, 2004). Nevertheless, other 
studies including that conducted by André et al clearly demonstrated that stimulation 
of human NK cells with soluble recombinant NKG2D ligands (i.e. ULBP-1 and 
MICA) induces GM-CSF and IFNγ production by activated NK cells (Sutherland et al, 
2001, Sutherland et al,2002; André et al, 2004). In contrast to the above studies, the 
present results clearly demonstrated that cross-linking of NKG2D with an immobilized 
mAb was sufficient to induce IL-6 secretion at all four time points investigated. 
Moreover, the finding that NKG2D cross-linking produced more IL-6 transcripts and 
protein than CD16 cross-linking may suggest the relevant importance of DAP10 
associated pathways in the initiation and triggering of IL-6 secretion by human NK 
cells. Considering the fact that IL-6 could be detected upon cross-linking of the 
NKG2D receptors with an immobilized mAb while other investigators failed to find  
this with the other cytokines they were studying, one can argue that the signalling 
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pathways which lead to IL-6 secretion upon NKG2D activation are distinct from those 
necessary for IFN-γ, TNF-α and GM-CSF production.  
It is known that the CD16 is the most important receptor that induces IFN-γ, 
TNF-α and GM-CSF secretion by NK cells (Fauriat et al, 2010). No other activating 
receptor can induce such a response alone (although stimulating a combination other 
receptors can). CD16 cross linking on the surface of NK cells initiates a cascade of 
signalling events via Syk and ZAP70 kinases (Lanier, 2003). Thus, it is logical to 
assume that these kinases are the main signalling kinases that regulate the IFN-γ, TNF-
α and GM-CSF secretion by NK cells. Since NKG2D cross-linking activates totally 
different kinases, so it not surprising that activation of NKG2D is unable to stimulate 
IFN-γ, TNF-α and GM-CSF secretion by NK cells. The situation might be different for 
IL-6. As described before, the activation of the NKG2D/DAP 10 complexes, whether 
by natural ligands or anti-NKG2D mAbs, leads to the activation of the 
phosphatidylinositol 3-kinase (PI3K) pathway. The activation of this pathway has 
been described to regulate IL-6 secretion in several other cells including B-cells 
(Venkataraman et al, 1999), Kupfer cells (Dahle et al, 2004) osteoblasts (Hanai et al, 
2006), normal myeloid cells and cells that arose in myeloid leukaemia (Birkenkamp et 
al, 2000; Vesely et al, 2007) as well as cancer cells (Jee et al, 2000). Activation of the 
PI3K pathway was also reported to increase IL-6 mRNA expression in some cells 
lines (Dommisch et al, 2008). Moreover, it was found that the LPS dependent 
activation of IL-6 secretion in B-cells and the IL-1 dependent IL-6 mRNA expression 
and secretion by the Caco-2 cell line is mediated by PI3K pathway (Venkataraman et 
al, 1999; Cahill et al, 2008). However, the PI3K pathway might not be the only one 
activated upon NKG2D engagement in NK cells. Some studies also suggest the 
involvement of other activation pathways such as phospholipase-C γ and VAV 
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(Billadeau et al, 2003; Bryceson et al, 2006). Activation of these signalling pathways 
has been linked to IL-6 production in mast cells (Song et al, 1999). All these studies 
support the idea that the mechanism of IL-6 secretion and expression in NK cells is 
likely to be different from that involved in IFN-γ, TNF-α and GM-CSF secretion.  
 
4.4.8 The involvement of NCR receptors (NKp46, NKp44 and NKp30) 
Natural cytotoxicity receptors (NCRS) play a crucial role in MHC class I- 
independent recognition and killing of target cells by NK cells (Bottino et al, 2000). In 
humans NKp46 and NKp30 are expressed by both resting and activated NK cells 
(Sivori et al, 1997; Sivori et al, 1999; Pende et al, 1999), while the expression of 
NKp44 is restricted to IL-2 activated NK cells (Vitale et al, 1998). Cross-linking 
NKp46 on the surface of human or mouse NK cells with their specific mAbs elicit 
cytokine release as well as the de-granulation of cytotoxic effector molecules (Andre 
et al, 2004; Satoh-Takayama et al, 2009). Similar results have been obtained using 
anti-NKp30 antibodies, suggesting that the engagement of NCRs by their respective 
ligands or mAb can modulate both cytotoxicity and cytokine secretion (Andre et al, 
2004; El - Costa et al, 2008; Satoh-Takayama et al, 2009). 
Our results have shown that cross-linking NKp46 by immobilized mAb 
stimulated IL-6 cytokine secretion by PBNK cells. The pattern of secretion was 
similar to that found with CD16 and NKG2D and the amount of IL-6 produced was 
similar to that seen with NKG2D. NKp46 receptors are characterized by two 
immunoglobulin-type C2 domains in the extracellular portion (Figure 4.17). Their 
short intra-cytoplasmic portion lacks typical tyrosine-based activating motifs, while 
positively charged amino acids are present in the transmembrane region and allow 
association with ITAM-bearing polypeptides (Moretta et al, 2000). The latter for 
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NKp46 includes CD3δ and FcεRIγ. As with CD16, the engagement of ITAM-
dependent receptors initiates a signal transduction cascade that is Ca2+ dependent. 
First, the members of src protein tyrosine kinase (PTK) family induce the 
phosphorylation of both ITAM tyrosine residues, allowing the consequent recruitment 
and activation of Syk and/or ZAP70. The finding that NK cells produce more IL-6 
transcript and protein in response to NKp46 compared to CD16 is difficult to explain 
since both of these receptors use the same signalling pathways. One possible 
explanation might be a difference in the strength of signalling via the ITAM chains 
associated with NKp46 compared to those associated with CD16. Augugliaro et al 
(2003) has shown that mAb-mediated cross-linking of NKp46 resulted not only in 
tyrosine phosphorylation of the NKp46-associated CD3δ and FcεRIγ, but also resulted 
in tyrosine phosphorylation of the NKp30-associated CD3δ and NKp44-associated 
DAP12 polypeptides at the same time. This “cross-phosphorylation” effect was strictly 
confined to NCR complexes, since cross-linking NKp46 never resulted in tyrosine 
phosphorylation on the CD3δ or DAP12 chains associated with CD16 and p50.3. 
Thus, the engagement of NKp46 appears to be able to activate the signalling cascades 
associated with the other NCRs, possibly resulting in the amplification of the 
activating signals. This suggests the existence of a functional cross-talk among NCR 
(Augugliaro et al, 2003) while a similar event does not happen with other CD3δ or 
DAP12-associated receptor molecules i.e. the engagement of CD16 or p50.3 receptors 
will not result in co-stimulation of other ITAM-bearing subunit receptors such us 
NKp46 and NKp30 or NKp44 respectively. This observation is supported by our 
finding that co-stimulation of CD16 and NKp46 together did not stimulate further IL-6 
mRNA expression or protein production (data not shown). Moreover, other 
researchers have shown that IFN-γ cytokine secretion by CD16-activated NK cells is 
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synergized by co-stimulation of other NK cell receptors (NKG2D, 2B4, CD2, or 
DNAM-1) but not with NKp46 (Bryceson et al, 2006), suggesting that CD16 is 
excluded from this interplay between NCRs despite the usage of similar signal 
transducing polypeptides. 
 
 
Figure 4.17: Structure of natural cytotoxicity receptors (NCRs) and their 
association with distinct signal-transducing molecules. Reproduced from Moretta et 
al (2000) 
 
The induction of IL-6 transcripts and protein secretion was also more 
prominent with NKp46 compared to that induced by NKp30. This observation gives 
rise to an important question whether this activity difference could be due to their 
downstream signalling through different adaptors. Biochemical analysis has revealed 
that NKp46 is associated with both CD3δ and FcεRIγ adaptor proteins, which contain 
ITAMs, whereas NKp30 uses only CD3δ (Figure 4.17). Does the association of 
NKp46 receptors with two different adaptor molecules further amplify their activating 
signals? siRNA silencing of CD3δ and FcεRIγ in PBNK may help to further clarify 
this issue in the future. 
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IL-6 production by NKp44-activated PBNK cells was different from that 
seen with cells stimulated via the other receptors tested. After 1 and 3 hours of 
stimulation there was no significant increase in IL-6 transcripts levels compared to 
resting NK cells while cultures at 6 hours after mAb stimulation clearly demonstrated 
a decrease in IL-6 mRNA levels, followed by a further decrease at 24 hours. 
Surprisingly, in sharp contrast to mRNA expression, IL-6 protein secretion continued 
to increase at all 4 time points to levels even higher than those seen with the other 
receptors. It is essential to point out that the PBNK cells used in these experiments 
were pre-stimulated with IL-2 at a dose of 100 U/ml for 24 hours before NKp44 cross-
linking with the immobilized mAb. As described in the previous chapter this dose of 
IL-2 in itself was insufficient for the induction of IL-6 production by NK cells.  
Similar observations were made in other cells such as monocytes in which the IL-2 
induction of IL-6 protein secretion is a dose-dependent requiring a minimum of 250 U 
/ ml of IL-2 for effective stimulation (Musso et al, 1992). We concluded that the 
down-regulation of IL-6 mRNA transcription was due to the transient nature of IL-6 
transcription factors and to mRNA degradation as a result of prolonged NK cell 
activation. Nevertheless, how can continuous IL-6 protein secretion despite the down-
regulation of IL-6 mRNA expression be explained? One could suggest that IL-2 
induces the production of IL-6 mRNA and possibly even its translation into protein. 
However, in itself it may not be able to induce the secretion of the cytokine. If NKp44 
cross-linking induced this secretory pathway this could explain the increased IL-6 
protein secretion at all 4 times studied potentially even in the absence of IL-6 mRNA 
during the NKp44 stimulation phase of these experiments. However, given the 
constraints of time and resources we decided not to investigate this issue further. 
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5.1  Introduction 
Experiments described in the previous chapter clearly demonstrated that 
cross-linking NKG2D and NKp46 with their corresponding antibodies on the surface 
of resting PBNK cells stimulated the highest IL-6 mRNA expression and protein 
production. Some investigators, however, argue that the mechanisms by which an anti-
NKG2D mAb and the physiological NKG2D ligands activate NK cell proliferation 
and cytokine production are different (André et al, 2004).  In these experiments human 
NK cells failed to produce IFN-γ and GM-CSF in the presence of anti-NKG2D mAb 
whereas  soluble recombinant NKG2D ligands such as MICA-Fc and ULBPs-Fc 
fusion proteins were able to elicit such responses (Sutherland et al, 2001; Sutherland et 
al, 2002, André et al, 2004). Moreover, NK cells did not undergo cell proliferation or
increased expression of IL-2Rα (CD25) in the presence of anti-NKG2D mAb, while 
stimulation with soluble recombinant NKG2D ligands induced both of these (André et 
al, 2004). Considering the highly heterogeneous structure of NKG2D ligands (Raulet, 
2003), these observations suggest that NKG2D epitopes targeted by mAbs and the 
various natural ligands might be distinct and their stimulation could, therefore, lead to 
different signalling events (André et al, 2004). However, the finding that NKG2D 
cross-linking using a monoclonal antibody was sufficient to induce IL-6 mRNA 
expression and protein production contradicts this argument, at least as far as IL-6 
production is concerned. Nevertheless, to test the hypothesis of specific epitope-
dependent receptor triggering, it was decided to express the ligands of NKG2D, 
namely MICA, MICB, ULBP1, ULBP2 and ULBP3, as Fc fusion proteins to see if IL-
6 production is affected by the nature of the NKG2D stimulation. Such experiments 
may also show if there was a preference for certain NKG2D ligands in inducing IL-6 
secretion.   
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5.1.1  Aims of the chapter 
The aim of this chapter was to demonstrate the role of NKG2D signalling in 
the initiation of IL-6 by PBNK cells through the expression of hNKG2D ligands, 
namely MICA, MICB, ULBP1, ULBP2 and ULBP3 as Fc- fusion proteins. The 
production of these fusion proteins was planned to be achieved by fusing the sequence 
encoding for the extracellular portion of these ligands with the Fc sequence of mouse 
IgG (mIgG) either by overlap-extension PCR or by simple ligation. The plasmids 
containing these recombinant genes were then attempted to be expressed as fusion 
proteins via transfection into CHO or HEK-293 cells.  
 
5.2  Approach 1 For Expression of hNKG2D Ligand - mFc Fusion Proteins 
by Overlap-Extension PCR Using the pFUSE-mIgG2A-Fc1 Vector 
 
5.2.1  Strategy used for cloning of hNKG2D ligand - mFc recombinant genes 
The C-terminal ends of the extracellular region of hNKG2D ligands, namely 
MICA, MICB, ULBP1, ULBP2 and ULBP3 proteins were planned to be fused to the 
N-terminus of the Fc-region of mouse IgG2a. To combine the two proteins, fragments 
of their genes were generated in separate PCRs using specific primers designed to 
create products which contain complementary sequences at their 3‟ ends. These 
intermediate PCR products overlapped partially and an extension of the matching 
sequence produced a recombinant gene in which the original sequences were „fused‟ 
together using overlap-extension PCR. The resulting recombinant hNKG2D ligand - 
mFc gene was then double digested with restriction enzymes and orientationally 
cloned into the pFUSE mIgG2A-Fc1 expression vector digested using the same 
restriction enzymes (Figure. 5.1).  
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Figure 5.1: Overall strategy used for the cloning of hNKG2D ligand -mFc 
recombinant gene into pFUSE-mIgG2A-Fc1 expression vector. The hNKG2D 
ligand - mFc recombinant gene was generated by three-round PCRs. The PCR1 
amplified the gene sequence encoding for extracellular portions of hNKG2D ligands 
started from the start codon (ATG). The EcoRI restriction site was incorporated 
upstream of forward primer of PCR1. The PCR2 amplified a relatively short 
nucleotide sequence (169 bp) started from position 1 to 169 of the Fc portion of 
mIgG2a (from beginning of mIgG2a sequence to downstream of the BspHI restriction 
site). The primers were designed so that the end of PCR1 overlaps the beginning of 
PCR 2. The two genes were fused together through a third-round PCR (PCR3) and the 
hNKG2D ligand-mFc recombinant gene was generated. Both the recombinant gene 
and the vector were then double digested via EcoRI and BspHI restriction 
endonucleases. The fused gene was then introduced in frame into the digested pFUSE-
mIgG2A-Fc1 vector. 
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5.2.2  pFUSE-mIgG2A-Fc1 vector 
pFUSE - Fc vectors (Invivogen, USA) are a family of plasmid vectors 
developed to facilitate the construction of Fc-fusion proteins by fusing the 
extracellular region of a protein to the Fc fragment of an immunoglobulin G (IgG). 
Given that the pFUSE-mIgG2A-Fc1 vector used for the cloning of hNKG2D ligand- 
mFc genes is an unusual commercial design its details are summarised here (Figure 
5.2). The plasmid has two composite promoters: the hEF1-HTLV promoter and the 
CMV enh/hFerL promoter. The hEF1-HTLV promoter drives the expression of the Fc 
fusion protein. It is comprised of the Elongation Factor-1α (EF-1α) core promoter 
(www.invivogen.com; Kim et al, 1990) and the R segment and part of the U5 
sequence (R-U5‟) of the Human T-Cell Leukaemia Virus (HTLV) Type 1 Long 
Terminal Repeat (www.invivogen.com; Takebe et al, 1988). The EF-1α promoter 
exhibits a strong activity and yields lasting expression of the gene of interest in vivo 
(www.invivogen.com). The R-U5‟ has been coupled to the EF-1α core promoter to 
enhance the stability of the resulting mRNA. The CMV enh/hFerL promoter combines 
the human cytomegalovirus immediate-early gene 1 enhancer and the core promoter of 
the human ferritin light chain gene. This ubiquitous promoter drives the expression of 
the Zeocin resistance gene in mammalian cells. The pFUSE vector has also the Simian 
Virus 40 late polyadenylation (SV40 pAn) signal which enables efficient cleavage and 
polyadenylation reactions resulting in high levels of steady-state mRNA. Unique 
restriction enzyme sites within the multi- cloning segment (MCS) are shown in red 
bold print while the unique restriction enzyme sites within the whole plasmid are 
shown in black bold print. The EcoRI site within the MCS and a unique BspHI site 
within the mIgG2A-Fc sequence were utilised for the orientational cloning of the 
inserts. 
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Figure 5.2: pFUSE-mIg2A-Fc1 vector map (4150 bp) showing the MCS (multiple 
cloning site), hEF1-HTLV promoter driving the Fc fusion and CMV enh / hFerL 
promoter driving the Zeocin resistance in mammalian cells. Reproduced from 
www.Invivogen.com/cloning and expression/Fc fusion/pFUSE-mIgG2A-Fc1. 
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5.2.3  NKG2D ligands- mFc1 sequences 
The MICA, MICB, ULBP1, ULBP2 and ULBP3 nucleotide and protein 
sequences together with their recombinant Fc sequences and their homology to 
published NKG2D sequences were presented in Chapter 9 (Appendix chapter). The 
gene sequences encoding for the extracellular portion of NKG2D ligands were 
amplified and fused to the gene encoding for Fc portion of mIgG2a.    
 
5.2.4  Details of primer design  
1.  Forward or sense primer for PCR 1 (primer a) 
The open reading frame of the MICA gene starts with the sequence 5‟ATG 
GGG CTG GGC CCG GTC 3‟ (Chapter 9). Since it was planned to insert the MICA-
Fc1 recombinant gene into the pFUSE-mIgG2A-Fc1 vector at the EcoRI and BspHI 
restriction sites, therefore an EcoRI restriction site (5‟GAA TTC3‟) was introduced 
upstream of the 5‟ end of the primer: 
 
Forward primer with restriction site: 5‟GAA TTC ATG GGG CTG GGC CCG GTC 3‟. 
 
 
To ensure that the restriction site at the end of the amplified segment is 
optimally cleaved by the enzyme three additional nucleotides were placed upstream of 
the restriction site: 
 
 
Complete MICA forward primer: 5‟TCT GAA TTC ATG GGG CTG GGC CCG GTC 3‟. 
 
 
 
EcoRI restriction site 
EcoRI restriction site 
 
Start codon  
 
Additional nucleotides 
Start codon 
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The total length of this oligonucleotide is 27 bp. The forward primers for 
MICB, ULBP1, ULBP2 and ULBP3 were designed using the same principles. The 
sequences are as follows: 
Complete MICB forward primer: 5‟ TCT GAA TTC ATG GGG CTG GGC CGG GTC 3‟. 
Complete ULBP1 forward primer: 5‟ TCT GAA TTC ATG GCA GCG GCC GCC AGC 3‟. 
Complete ULBP2 forward primer: 5‟ TCT GAA TTC ATG GCA GCA GCC GCC GCT 3‟. 
Complete ULBP3 forward primer: 5‟ TCT GAA TTC ATG GCA GCG GCC AGC CCC 3‟. 
 
2.  Reverse or anti-sense primer for PCR 1 (primer b) 
The reverse primer was designed so that it would anneal to the end of the 
extracellular portion of the MICA gene followed by an overlap extension to the 
beginning of the mIgG2A-Fc sequence. The 3‟ end of the MICA sequence encoding 
for the extracellular portion of MICA protein is 5‟ CAC CCT GTG CCC TCT 3‟ 
(Bahram et al, 1996) and the beginning of Fc sequence of mIgG2a is 5‟ CCC AGA 
GGG CCC ACA 3‟: 
 
 
5’ ATG                                  CAC CCT GTG CCC TCT - CCC AGA GGG CCC ACA 3’ 
 
 
Since all primers should be in 5‟ to 3‟ orientation (for purchasing purposes), 
so the final reverse primer for PCR1 is as follows (reverse complement): 
 
 MICA reverse (pFUSE overlap) primer for PCR1: 5‟ TGT GGG CCC TCT GGG AGA GGG 
CAC AGG GTG 3‟. 
Downstream of hMICA 
sequence 
Upstream of Fc sequence of 
mIgG2a 
5’ 3’ 
     gtg  gga  cac  ggg   aga -  ggg  tct   ccc   ggg   tgt 
Sense strand: 
Reverse primer 
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In the same manner, the reverse primers for MICB, MICB, ULBP1, ULBP2 
and ULBP3 were: 
MICB reverse (pFUSE overlap) primer: 5‟ TGT GGG CCC TCT GGG – AGG GTG AGT 
GCC GTG 3‟ 
ULBP1 reverse (pFUSE overlap) primer: 5‟ TGT GGG CCC TCT GGG – TTG TTC CCA 
GTA CAT 3‟ 
ULBP2 reverse (pFUSE overlap) primer: 5‟ TGT GGG CCC TCT GGG – GCT GTC CAT 
GCC CAT 3‟ 
ULBP3 reverse (pFUSE overlap) primer: 5‟ TGT GGG CCC TCT GGG – CTT CTT CCT 
GTG CAT 3 ‟ 
 
3.  Forward primer for PCR 2 (primer c)  
The forward primer for PCR2, encoding the Fc portion of the fusion protein, 
is the beginning of Fc sequence of mIgG2a (5‟ CCC AGA GGG CCC ACA 3‟) with 
an overlap extension to the 3‟ end of MICA sequence (5‟ CAC CCT GTG CCC TCT 
3‟). Thus, the final forward primer for PCR2 is:  
 
                                                   5’ CAC CCT GTG CCC TCT CCC AGA GGG CCC ACA 3’                                                                      
 
 
Using the same principle, the following forward primers were used for 
PCR2: 
pFUSE forward (MICB overlap) primer:   5‟  CAC GGC ACT CAC CCT- CCC AGA GGG 
CCC ACA 3‟ 
pFUSE forward (ULBP1 overlap) primer: 5‟ ATG TAC TGG GAA CAA - CCC AGA GGG 
CCC ACA 3‟ 
Upstream of Fc sequence of 
mIgG2a 
 
Downstream of hMICA 
sequence 
 
pFUSE forward (MICA 
overlap) primer for PCR2 
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pFUSE forward (ULBP2 overlap) primer: 5‟ ATG GGC ATG GAC AGC – CCC AGA GGG 
CCC ACA 3‟ 
pFUSE forward (ULBP3 overlap) primer: 5‟ ATG CAC AGG AAG AAG - CCC AGA GGG 
CCC ACA 3‟ 
 
4.  Reverse primer for PCR2 (primer d) 
This reverse primer should ideally anneal to the 3‟ end of the mIgG2a-Fc 
sequence. However, since this end of the PCR product was planned to be incorporated 
in to the pFUSE-mIgG2A vector using the BspHI restriction site, therefore this primer 
could be placed anywhere in the mIgG2a-Fc sequence downstream of the BspHI 
restriction site: 
  
 
  
 
 
 
 
 
The final reverse primer for PCR2 was as follows (5‟ to 3‟ orientation):  
 
PFUSE reverse primer for PCR2: 5‟ CTG GGT CAT CCT CGC TCA CAT CCA CCA 3‟.  
 
As the amplified mFc fragment is the same for all the constructs, only a 
single primer was necessary for all the reactions. 
TGGTGG ATGTGA GCGAGG ATG ACCCAG 5’ CCC TGG 3’ 
Beginning of 
Fc sequence of 
mIgG2a 
Stop codon  
Sense strand  
BspHI 
3’ 5’ 
Position of reverse primer for PCR2 
acc acc tac act cgc tcc tac tgg gtc 
Reverse primer 
Fc sequence of mIgG2a 
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5.2.5  Checking the recombinant MICA-, MICB-, ULBP1-, ULBP2- and 
ULBP3-mFc1 gene sequences for EcoRI and BspHI restriction sites 
Since the recombinant hMICA-, hMICB-, hULBP1-, hULBP2- and 
hULBP3-mFc1 genes were to be cloned into the pFUSE-mIgG2A-Fc1 vector at the 
EcoRI and BspHI restriction sites, it was necessary to check both the vector and the 
recombinant gene sequences for these restriction sites. This was done using an online 
tool called NEB cutter V.2.0 that produces a comprehensive report of the restriction 
sites within the input sequence (Vincze et al, 2003). Sequences for all the designed 
molecules only contained a single EcoRI and a single BspHI site, so the planned 
cloning strategy was feasible (Figure 5.3). 
 
 
 
 
Figure 5.3: Restriction map of the hMICA-mFc1 sequence. Enzymes with a single 
cutting site are shown. Note that the EcoRI restriction site was added to the beginning 
of the sequences by the primers while the BspHI restriction site was part of the mFc 
sequence. The # symbol indicated that these enzymes are methylation sensitive and 
their cutting here is blocked by DNA methylation. 
 
hMICA – mFc1 sequence 
Single cutter enzymes 
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5.2.6  Results 1 
5.2.6.1  Overlap - extension PCR 
As several studies have shown that HeLa cells express MICA (Groh et al, 
1999; Zhang et al, 2001; Butler et al, 2009) cDNA derived from these cells was used 
for amplification of the extracellular portion of MICA. Caco-2 cDNA was used to 
amplify the extracellular regions of MICB, ULBP2 and ULBP3 as these cells are 
known to express these transcripts (Butler et al, 2009). ULBP1 proved difficult to 
amplify; amplification of this molecule from HeLa, Caco-2 and Jurkat cDNAs failed. 
Therefore, the extracellular fragment of ULBP1 was amplified from cDNA derived 
from ULBP1 transfected CHO Cells (Gift from Dr. Hugh Reyburn, Spain). In brief, 
the total RNA was first extracted from these cell lines using QiaAmp
 
RNA Blood Mini 
Kit. Total RNA concentration and integrity were checked by spectrophotometer and 
agarose gel respectively (Figure 5.4) and then converted into cDNA using AMV 
reverse transcription system. The cDNAs were stored at -20 °C until use. The overlap-
extension PCR reactions were carried out as described in Chapter 2. The amplicons 
generated during the various stages of the overlap-extension PCR process together 
with their approximate sizes are shown in Figure 5.5. The recombinant (fused) PCR 
products were gel purified using PureLink
TM
 Gel Purification Kit and then digested 
with EcoRI and BspHI. The sizes of the digested inserts were 1003, 994, 721, 721 and 
724 bp for MICA-, MICB-, ULBP1-, ULBP2- and ULBP3-Fc1 respectively (Figure 
5.6 A). However, the double digest of the pFUSE-mIgG2A-Fc1 vector proved 
problematic. 0.5-1µg of empty pFUSE-mIgG2A-Fc1 vector obtained from minipreps 
of the plasmid propagated in DH-5 α E.coli was checked for single EcoRI and BspHI 
digests. While the EcoRI digest was complete after two hours, digestion with BspHI 
resulted in the formation of two bands (Figure 5.6 B). This was unlikely due to cutting 
 
 
217 
 
at two different sites since there is only one documented BspHI restriction site in the 
entire plasmid sequence. It was also unlikely due to star activity (the enzyme cutting at 
non-specific sites during extended digests) as, according to the manufacturer, the 
enzyme shows no star activity and it is suitable for extended or overnight digest (NEB 
website). Overnight digestion did not improve results (Figure 5.6 B) and subsequent 
ligation and transformation failed. The problem with BspHI digestion was that this 
restriction enzyme is methylation sensitive; i.e. the digestive activity of this enzyme is 
blocked by overlapping dam methylation. For this enzyme to work the BspHI 
restriction site should be non-methylated. This was achieved by propagating the 
pFUSE-mIgG2A-Fc1 vector in the dam 
- 
strain of E. coli such as C2925I strain. As 
illustrated in Figure 5.6 C using this bacterial strain resolved the problem. The 
digested plasmid was then gel purified before proceeding to ligation to ensure that the 
vector would not re-ligate to its digested fragment during the ligation step.  
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Figure 5.4: A) RNA agarose-formaldehyde gel stained with ethidium bromide 
showing 18 S and 28 S ribosomal RNA bands. The total RNA was extracted from 1x 
10 
6
 HeLa cells using the Qiagen QIAamp RNA Blood Mini Kit. 1 µl was loaded on 
the gel. B) Regular agarose gel. 5μl of DNA marker and 1 μl of HeLa RNA were 
loaded on 1% molecular biology grade agarose in 1X TAE buffer stained with 
ethidium bromide. The left lane shows the 200-10000 bp HyperLadder (BioLine, UK) 
while the right lane shoes the RNA bands. Note the position of the 28S and 18S 
ribosomal RNA bands appear at approximately 2000 and 1000 bp and respectively.  
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Figure 5.5: Generation of recombinant hMICA-, hMICB-, hULBP1-, hULBP2- 
and hULBP3 – mFc1 genes by overlap – extension PCR. In PCR1 (column 1) the 
genes encoding for extracellular portions of hMICA, hMICB and hULBPs (including 
the leading sequences) were amplified. In PCR (column 2) the genes encoding for part 
of the Fc sequence of mIgG2a were amplified. In PCR3 (column 3) the PCR1 and 
PCR2 products were fused together to generate the recombinant (chimeric) genes. All 
PCR products were run on 1% agarose gels. Lane 1 contained a 300-10000 bp DNA 
ladder.  
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Figure 5.6: Digestion of pFUSE-mIgG2A-Fc1 vector and recombinant PCR 
products with EcoRI and BspHI. A) Double digest of hMICA-mFc1 and hMICB-
mFc1 overlap PCR products. B) Incomplete digestion of the pFUSE-mIgG2A-Fc1 
vector (obtained from minipreps after transformation into DH-5 α E.coli) by BspHI 
enzyme at 2 and 16 hrs due to overlapping dam methylation. C) Complete digestion of 
the pFUSE-mIgG2A-Fc1 vector (obtained from minipreps after transformation into 
dam
– 
E.coli) by BspHI enzyme at 2 hrs. Note that there was no visible difference 
between the single (EcoRI or BspHI) and double (EcoRI + BspHI digest) on the 
agarose gel. However the presence of another band (~159 bp) in lane 5 confirmed the 
double digest. Lane 1 is the 100-10000 bp DNA ladder. 
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5.2.6.2  Ligation of the digested overlap PCR products into the digested 
pFUSE-mIgG2A vector, and transformation into competent E.coli  
The digested purified vector and recombinant overlap PCR products were 
then ligated together using T4 Ligase enzyme according to manufacturer‟s 
instructions. The ligation mix was left overnight at 4 
o
C. The next day all the ligation 
mixture was transformed into competent dam 
-  
E.coli using the method described by 
Chung et al (1989). The E.coli were then plated onto LB agar with Zeocin and allowed 
to grow overnight at 37°C with vigorous shaking. The next day bacterial colonies were 
screened by colony PCR using the forward primer of PCR1 and the reverse primer of 
PCR2 (Chapter 2). The resulting PCR products were then visualized on 1% agarose 
gel/ 1X TAE buffer stained with 1 µl ethidium bromide (Figure 5.7).  
Positive colonies on colony PCR were allowed to grow in 6 ml LB broth + 
Zeocin over night at 37°C with vigorous shaking. Plasmid DNA was purified using 
Qiagen Plasmid Miniprep Kit and digested with EcoRI and BspHI. The resulting DNA 
fragments were separated on a 1 % agarose gel/ 1X TAE buffer stained with 1 µl 
ethidium bromide (Figure 5.8) to confirm that the cloning of hNKG2D ligands-mFc1 
recombinant genes into pFUSE-mIgG2A-Fc1 vector was successful. The insert 
sequences of the plasmid clones were confirmed by DNA sequencing that was carried 
out by Source BioScience LifeSciences (Cambridge, UK). Figure 5.9 shows an 
example chromatogram of the ULBP 2-mIgGaFc1 plasmid. Translating the obtained 
DNA sequences resulted in the expected protein sequences, although occasional single 
nucleotide differences from the published sequences were observed. Cultures 
containing the correct inserts were used for the preparation of DNA plasmids for 
transfection using Qiagen Plasmid Maxiprep Kit. 
 
 
 
223 
 
                    
 
                               
 
 
 
 
 
 
 
 
Figure 5.7: Results of Colony-PCR. The colonies of dam 
–
 E.coli were picked from 
the Zeocin LB plates after transformation with recombinant plasmid constructs. The 
PCR reaction was carried out using the forward primer of PCR1 and the reverse 
primer of PCR2 as described in Chapter 2. Thereafter, 5 µl of resulting PCR products 
were loaded and visualized on 1% agarose gel/ 1X TAE buffer stained with 1 µl 
ethidium bromide. In most cases, more than one colony needed to be checked for the 
recombinant inserts.      
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Figure 5.8: Double digest of NKG2D ligands-mIgG2A-Fc1 minpreps. The positive 
colonies on colony PCR were grown in LB broth + Zeocin
 
over night. Plasmid DNA 
was purified using Qiagen Miniprep Kit and digested with EcoRI and BspHI enzymes. 
The resulting DNA fragments were separated on a 1 % agarose gel/ 1X TAE buffer 
stained with 1 µl ethidium bromide. Note the presence of two bands on double digest, 
one corresponding to the size of digested plasmid and the other corresponding to the 
size of the recombinant insert.  
  
 
 700 bp 
1000 bp 
4000 bp 
Double 
digested 
pFUSE-
mIgG2A-Fc1 
plasmid 
(3991 bp) 
hULBP2-mFc1 
fragment 
(~720bp) 
 
1000 bp 
700 bp 
4000 bp 
Double 
digested 
pFUSE-
mIgG2A-Fc1 
plasmid 
(3991 bp) 
hULBP1-mFc1 
fragment 
(~720bp) 
700 bp 
1000 bp 
Double 
digested 
pFUSE-
mIgG2A-Fc1 
plasmid 
(3991 bp) 
hULBP3-mFc1 
fragment (~720 
bp) 
ULBP1 ULBP2 
ULBP3 
4000 bp 
Double 
digested 
pFUSE-
mIgG2A-Fc1 
plasmid 
(3991 bp) 
hMICA-mFc1 
fragment 
(~1000 bp) 
1000 bp 
MICA MICB 
Double 
digested 
pFUSE-
mIgG2A-Fc1 
plasmid 
(3991 bp) hMICB-mFc1 
fragment 
(~1000  bp) 
00 bp 
100 bp 
00 bp 
 bp 
 
 
225 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
226 
 
 
 
 
 
 
 
 
 
GAATTCATGGCAGCAGCCGCCGCTACCAAGATCCTTCTGTGCCTCCCGCTTCTGCTCCTGCTGTCCGGCTGGTCCCGG
GCTGGGCGAGCCGACCCTCACTCTCTTTGCTATGACATCACCGTCATCCCTAAGTTCAGACCTGGACCACGGTGGTGT
GCGGTTCAAGGCCAGGTGGATGAAAAGACTTTTCTTCACTATGACTGTGGCAGCAAGACAGTCACACCTGTCAGTCCC
CTGGGGAAGAAACTAAATGTCACAACGGCCTGGAAAGCACAGAACCCAGTACTGAGAGAGGTGGTGGACATACTTACA
GAGCAACTGCGTGACATTCAGCTGGAGAATTACACACCCAAGGAACCCCTCACCCTGCAGGCCAGGATGTCTTGTGAG
CAGAAAGCTGAAGGACACAGCAGTGGATCTTGGCAGTTCAGTTTCGATGGGCAGATCTTCCCCCTCTTTGACTCAGAG
AAGAGAATGTGGACAACGGTTCATCCTGGAGCCAGAAAGATGAAAGAAAAGTGGGAGAATGACAAGGTTGTGGCCATG
TCCTTCCATTACTTCTCAATGGGAGACTGTATAGGATGGCTTGAGGACTTCTTGATGGGCATGGACAGCCCCAGAGGG
CCCACAATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCT
CCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAGGATGAC
CCAGATGTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACAGCTCAGACACAAACCCATAGAGAGGATTAC
AACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCACCAGGACTGGATGAGTGGCAAGGAGTTCAAATGCAAG
GTCAACAACAAAGACCTCCCAGCGCCCATCGAGAGAACCATCTCAAAACCCAAAGGGTCAGTAAGAGCTCC (1007 
bp) 
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Figure 5.9: A representative example of the NKG2D ligand-mIgG2A-Fc1 
sequencing chromatogram. The ULBP2- mIgG2AFc1 vector construct was purified 
by Qiagen miniprep kit, quantified by spectrophotometry and sent to Source 
BioScience LifeSciences (Cambridge, UK) for DNA sequencing. The hULBP2 
sequence is highlighted in black and the mFc1 sequence highlighted in blue. The 
hULBP2-mFc1 insert (727 bp) is underlined.  5‟GAATTC3‟ is the EcoRI restriction 
site while 5‟ TCATGA3‟is the BspHI restriction site. The total length of the sequenced 
segment is 1007 bp. Chromas 2.33 software (Technelysium Pty Ltd, Australia) was 
used to draw the chromatogram, copy the nucleotide sequence and analyse the protein 
translation.   
 
 
5.2.6.3  Transfection 
After confirming the results of DNA sequencing and preparation of 
recombinant plasmid constructs, the expression of the recombinant hMICA-, hMICB-, 
hUBP1-, hULBP2- and hULBP3-mFc1 clones was attempted by transient transfection 
into Chinese Hamster Ovary (CHO) cells. To insert the recombinant plasmids into 
these cells, jetPRIME transfection reagent was used. jetPRIME is a non liposomal 
transfection reagent with claimed transfection efficiencies between 70-90% on a wide 
variety of adherent cell lines (www.polyplus.com). Transient transfection was used 
before proceeding with the generation of stable cell lines to permit preliminary 
assessment of the recombinant products. As described in Chapter 2, 20 ml of 
supernatants were harvested 27-96 hours after the transfection, stored at -20°C until 
purified by affinity chromatography using protein A/G cartridges. The purified 
supernatants together with the purified supernatants from un-transfected CHO cells 
(negative controls) were reduced and run on denaturing 10% SDS-PAGE acrylamide 
gels followed by Coomassie Blue staining. The expected sizes of the recombinant 
proteins were around 60 kDa for MICA/B and 50 kDa for ULBPs although the 
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predicted and actual molecular weights might not be identical due to post-translational 
modifications. Search in the literature revealed that the actual molecular weight of 
recombinant MICA/B- Fc fusion proteins in reducing conditions is between 90-100 
kDa and that for ULBPs-Fc fusions proteins is between 55-60 kDa. Unfortunately, in 
these experiments, the production of the fusion proteins was unsuccessful in the 
supernatants collected from all transiently transfected CHO cells (Figure 5.10). Since 
the choice of transfection technology can influence transfection efficiency therefore 
other methods, including electroporation and combination of both cell-type specific 
solutions (nucleofactor
®
 Solution) and eletroporation were also attempted (Chapter 2). 
However, the expected Fc fusion proteins remained undetectable. Using another cell 
lines such as HEK-293 was also tried but without any improvement of results.    
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Figure 5.10: SDS-PAGE analysis of recombinant hNKG2D ligands – mFc1 
proteins. CHO cells were transiently transfected with the recombinant pFUSE-
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mIgG2A-Fc1 constructs containing the recombinant MICA-, MICB-, ULBP1-, 
ULBP2- and ULBP3-mFc1 genes using the jetPRIME transfection reagent. 20 ml of 
supernatants from the transfected as well as from un-transfected CHO cells were 
collected, purified by affinity chromatography using protein A/G cartridges and 
analyzed on 10% SDS-PAGE gels stained with Coomassie Blue. Lanes: 1, protein 
standards; 2, transfected CHO cells; 3 un-transfected CHO cells. Note that the heavy 
chain (~55 kDa) and light chain (~25kDa) of IgG were purified from the fetal calf 
serum present in the tissue culture medium. 
 
 
5.2.6.4  Western blot 
Failure of detection of recombinant fusion proteins by Coomassie Blue 
staining did not necessarily mean that the fusion proteins were not produced and 
secreted. This could be due to the relatively low sensitivity of Coomassie Blue 
staining. The approximate sensitivity of this dye is ~ 100-150 ng protein / spot (Dunn, 
1999) and it depends largely on the visual inspection of the gel. Therefore, to verify 
the secretion of NKG2D ligands fusion proteins, Western blot analysis was employed. 
This method has the additional advantage of not detecting the heavy and light chains 
of IgG and other contaminating proteins present in the tissue culture medium. Using 
an anti-MICA/B mAbs (Clone F6, Santa Cruz biotechnology, USA), a preliminary 
experiment was carried out first on HeLa and Caco-2 cell lysates to check for the 
antibody and to optimize the Western blot protocol. This preliminary experiment 
detected a MICA band around 62 kDa (Figure 5.11). After this experiment, the 
secretion of recombinant MICA fusion proteins by transfected CHO cells was tested. 
Unfortunately, no protein was detected in the supernatant. This was also confirmed in 
the supernatants collected from the hMICA- mFc1 transfected CHO cells by 
electroporation, and the nucleofactor
®
 Solution and electroporation.  Based on the 
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results of both Coomassie Blue staining and Western blotting, it was concluded that no 
fusion proteins were secreted by the transfected cells.  
 
 
 
 
                     
                                         
Figure 5.11: Western blot analysis of MICA expression in HeLa and CHO cell 
lysates. The cells were cultured for 4-5 days in complete DMEM medium (for HeLa 
cells) or Ham F-12 medium (for CHO cells) without changing the media. Thereafter, 
the cells were trypsinized, centrifuged and re-suspended in 1X SDS sample buffer at a 
concentration of ~1x10
6
 cells / 100 µl. The cell suspensions were then boiled for 5-10 
minutes and sonicated 3-4 times. 10 µl (100,000 cells) of total cell lysate were loaded 
on 10% SDS-PAGE under reducing conditions and analyzed for MICA expression by 
Western blot, using anti-MICA antibody as a primary antibody and biotinylated goat 
anti-mouse HRP-labelled monoclonal antibody as a secondary antibody. A & B are 
HeLa cell lysate while C is CHO cell lysate. Positions of molecular weight markers 
(kDa) are indicated.  
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5.2.6.5  Stable transfection 
Although the secretion of recombinant fusion proteins by transient 
transfection failed, it was decided to try stable transfection for the following reasons: 
1) Stable transfection often involves the integration of the gene of interest into the 
target cell chromosome and hence the gene of interest can be analyzed in a more 
natural chromatin configuration and at more natural copy number than when analyzed 
by transient transfection (Carey and Smale, 2001). These features allows the gene of 
interest to mimic its normal function more accurately than in transient transfection and 
therefore stable transfection is useful for studying a control region that is inactive or 
does not exhibit its expected activity in transient transfection (Carey and Smale, 2001). 
2) The expansion of antibiotic resistant cell clones gives an idea about the efficiency 
of the transfection protocol.  
Before using Zeocin for selection purposes, the sensitivity of the un- 
transfected CHO was determined using Zeocin concentrations of 100, 250, 400,800 
and 1000 µg/ml for up to 3 weeks. Fresh medium and antibiotic were added every 2-3 
days. 400 µg/ml Zeocin killed most cells by days 14-15 (Figure 5.12). No 
spontaneously resistant colonies appeared at this concentration after 3 weeks. After 
establishing the Zeocin kill curve, the pFUSE-mIgG2A-Fc1 vectors containing the 
recombinant MICA-, MICB-, ULBP1-, ULBP2- and ULBP3-mFc1 genes were 
linearized by digestion at the NotI restriction site and purified by phenol extraction 
and ethanol precipitation. Thereafter, CHO cells were transfected in 12-well tissue 
culture plate using jetPRIME, electroporation or a combination of electroporation and 
nucleofactor
®
 Solution according to standard protocols described in Chapter 2. Twenty 
four hours later the cells were exposed to Zeocin at a dose of 400 µg / ml to establish 
the recombinant CHO- Zeo
R
 cells. Fresh medium and antibiotic were added to the 
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cells every 2-3 days as described previously. Resistant clones started to appear 2-3 
weeks later. They were isolated, expanded in 25 cm
2
 then in 75 cm
2
 tissue culture 
flasks while maintaining continuous antibiotic selection. The supernatants were 
collected, purified using protein A/G cartridges and analysed for the secretion of 
fusion proteins by SDS-PAGE gel. While colonies resistant to the selective medium 
were generated with all 3 methods, the production of the fusion protein was still 
undetectable during all these experiments. 
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Figure 5.12: Zeocin kill curve for CHO cells. The CHO cells were allowed to grow 
in complete Ham-F12 culture medium in 12-well plate until reached ~ 60-80% 
confluency. Thereafter Zeocin were added to the cells at concentrations of 100, 250, 
400,800 and 1000µg / ml for up to three weeks. Fresh medium and antibiotic were 
added every 2-3 days. The minimum concentration needed to kill most of CHO cells 
by 2 weeks was 400 µg / ml. 
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5.3  Approach 2 For Expression of hNKG2D Ligand - mFc Fusion Proteins 
by Overlap-Extension PCR Using pFUSE-mIgG2A-Fc2 Vector 
 
5.3.1  Introduction 
Despite significant amount of time and effort spent at cloning the 
recombinant genes into pFUSE-mIgG2A-Fc1 fusion vector, the production of soluble 
NKG2D ligands – mFc fusion proteins was unsuccessful. Following this, another 
pFUSE vector called pFUSE-mIgG2A-Fc2 was used in the hope of producing the 
desired fusion proteins. The main difference between pFUSE-mIgG2A-Fc1 and Fc2 
vectors is that the Fc2 series vectors contain the human interleukin-2 signal sequence 
(hIL-2ss) that facilitates the secretion of Fc-fusion proteins by mammalian cells. Since 
the hNKG2D ligands are not naturally secreted proteins (MICA/B are transmembrane 
proteins while the ULBPs are GPI anchor proteins), therefore there was a possibility 
that their natural internal signal peptides directed translocation into the secretory 
pathways, but they were not cleaved when the proteins passed through the ER and 
hence the proteins were not processed as expected. To test this hypothesis, the 
sequences encoding for these signal peptides were removed from the NKG2D ligands 
and replaced with the hIL-2ss using the pFUSE-mIgG2A-Fc2 vector. Moreover, the 
Fc2 series of pFUSE vectors also contain a Kozak sequence immediately upstream of 
the IL-2ss. These structural differences in the vector backbone should, at least 
theoretically, improve the expression and secretion of the recombinant proteins that 
are not physiologically secreted by eukaryotic cells. Figure 5.13 shows the map of the 
pFUSE-mIgG2A-Fc2 vector used in these experiments.  
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Figure 5.13: The pFUSE-mIgG2A-Fc2 vector map (4212 bp) showing the hEF1-
HTLV promoter driving the Fc fusion, hIL-2ss, MCS (multiple cloning site), mIgG2a-
Fc region and CMV enh / hFerL promoter driving the Zeocin resistance in mammalian 
cells. Reproduced from www.Invivogen.com/cloning and expression / Fc 
fusion/pFUSE-mIgG2A-Fc2.  
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5.3.2  The recombinant hNKG2D ligand- mFc2 sequences  
The recombinant hMICA-, MICB-, ULBP1-, ULBP2- and ULBP3- mFc2 
sequences together with their homology to published NKG2D sequences were 
presented in Chapter 9 (Appendix chapter). As with Fc1 sequences, only the gene 
sequences encoding for the extracellular portion of hNKG2D ligands were amplified 
and fused to the gene encoding for Fc portion of mIgG2a. Natural leader sequences of 
NKG2D ligands were removed and replaced with hIL-2ss from pFUSE-mIgG2A-Fc2 
vector.      
 
5.3.3  Primers used for the amplification of hNKG2D ligand-mFc2 
recombinant genes 
The hNKG2D ligand-mFc2 recombinant genes were inserted into the 
pFUSE-mIgG2A-Fc2 vector at EcoRI and BspHI restriction sites. To do this the 
forward primer specific for the individual NKG2D ligands had to be redesigned as 
follows:  
 
The sequence encoding for the hIL-2ss and MCS of pFUSE-mIgG2A-Fc2 is 
presented below: 
 
.........AGGAGGGCCACCATGTACAGGATGCAACTCCTGTCTTGCATTGCACTA 
 
AGTCTTGCACTTGTCACGAATTCGATATCGGCCATGGTTAGATCTCCCAGA...
...................  
 
 
The end of the IL-2ss sequence is ....GTCACGAATTCG. Cutting of this 
sequence at the EcoRI (GAATTC) restriction site results in GTCACG................ 
 
Kozak sequence IL-2ss  
MCS 
EcoRI 
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Designing a primer starting with EcoRI restriction site and annealing at the 
beginning of the MICA nucleotide sequence (without internal leader sequence) results 
in:  
 
5‟GAA TTC GAG CCC CAC AGT CTT CGT TA 3‟ 
 
 
 
Digestion of the EcoRI restriction site in 5‟ to 3‟ orientation leads to: 
 
5‟...........AA TTC GAG CCC CAC AGT CTT CGT TA...............3‟ 
 
Ligation of the two sequences after digestion with EcoRI enzyme results in: 
 
 
5‟...GTCACGAATTC GAGCCC CAC AGT CTT CGT TA...................................3‟ 
  
 
 
However, this would lead to the loss of a G nucleotide at the end of the IL-
2ss sequence and so if the above primer was used, this would result in a frame shift. 
To keep the sequence in frame a G nucleotide needs to be added after the C nucleotide 
at the end of the IL-2 sequence. Therefore the forward primer (primer a) for PCR1 
should be as follows:  
Forward MICA primer: 5‟GAA TTC G GAG CCC CAC AGT CTT CGT TA3‟  
 
Finally 2-4 nucleotides are needed to be added to the beginning of this 
primer to facilitate digestion of the amplified gene segment.  Therefore the complete 
forward primer for PCR1 (primer a) will be as follows: 
 
EcoRI  Beginning of MICA sequence  
End of IL-2           
sequence 
Beginning of MICA sequence 
EcoRI Beginning of MICA sequence 
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Complete MICA forward primer: 5‟ TCT GAA TTC GGA GCC CCA CAG TCT TCG 
TTA3‟  
Similarly, the final forward primers for MICB, ULBP1, ULBP2 and 
ULBP3 are as follows: 
Complete MICB forward primer: 5‟ TCT GAA TTC GGA GCC CCA CAG TCT TCG 
TTA3‟  
Complete ULBP1 forward primer: 5‟ TCT GAA TTC G TG TGA AGT TCA AGG CCT GGT 
3‟ 
Complete ULBP2 forward primer:  5‟ TCT GAA TTC GTG TGC GGT TCA AGG CCA 
GGT 3‟                                                          
Complete ULBP3 forward primer: 5‟ TCT GAA TTC G TG TGA GGT CCA GAG CCA 
GGT 3‟ 
 
5.3.4  Cloning strategy 
The strategy used for the cloning of the recombinant hMICA-, hMICB-, 
hULBP1-, hULBP2- and ULBP3-mFc2 genes into pFUSE-mIgG2A-Fc2 vector was 
similar to that used for the cloning of Fc1 recombinant genes into pFUSE-mIgG2A-
Fc1 vector (Figure 5.1). This involved the generation of the chimeric genes by overlap 
extension PCR and then inserting these genes in frame into pFUSE-mIgG2A-Fc2 
vector at the EcoRI and BspHI restriction sites. 
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5.3.5  Results 2 
5.3.5.1  Generation of hMICA-, hMICB-, hULBP1-, hULBP2- and hULBP3 - 
mFc2 genes by overlap - extension PCR 
The recombinant hNKG2D ligand- mFc2 genes were constructed by overlap 
extension PCR using the gene specific forward primers described above (Section 
5.3.3)  in combination with the gene specific reverse primers for PCR1 and the 
forward and reverse primers used in the first cloning attempt (primers b, c and d, 
section 5.2.4). The resulting amplified PCR fragments were 846 bp for MICA, 834 bp 
for MICB, 487 bp for ULBP1, ULBP2 and ULBP3 respectively, while the Fc 
sequence of mIgG2a including the overlap area is 184 bp (Figure 5.14). The sizes of 
the recombinant (fused) PCR products were ~ 1000 bp for MICA/B-mFc2 and ~ 640 
bp for ULBP1-, ULBP2- and ULBP3-mFc2 (Figure 5.14).  
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Figure 5.14: Generation of the recombinant MICA-, MICB-, ULBP1-, ULBP2-, 
and ULBP3-mFc2 genes by overlap-extension PCR. Lane 1 is the 100-10000 bp 
DNA ladder; Lane 2 is the PCR1 in which the genes encoding for extracellular region 
of MICA, MICB, ULBP1, ULBP2, and ULBP3 (without internal leading sequence) 
were amplified; Lane 3 is the PCR2 in which part of the sequence encoding for Fc 
sequence mIgG2A was amplified; Lane 4 is the overlap PCR products (fusion of 
PCR1 and PCR2).   
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5.3.5.2  Cloning of hNKG2D ligands – mFc2 recombinant genes  
Double digestion of the pFUSE-mIgG2A-Fc2 vector with the EcoRI and 
BspHI enzymes lead to release of two linear fragments, one large fragment of ~ 4078 
bp and one small fragment of ~ 134 bp. Similarly, the MICA-, MICB-, ULBP1-, 
ULBP2- and ULBP3 - mFc2 recombinant genes were double digested by these two 
enzymes. The rest of the cloning process was identical to that described earlier for the 
pFUSE-mIg2A-Fc1 constructs. In brief   the digested purified recombinant genes were 
ligated to purified pFUSE-mIgG2A-Fc2 vector using T4 ligase and the plasmid 
constructs were then transformed into competent dam 
-
 E. coli cells. DNA from Zeocin 
resistant colonies was purified using standard DNA minipreps before the plasmid was 
tested for the presence of inserts by colony PCR (Figure 5.15), confirmed by 
endonuclease digestion of minipreps (Figure 5.16) and sequencing. When the 
sequencing of the pFUSE-mIgG2A vector confirmed the presence of the recombinant 
genes, maxiprep freezing stocks were made and stored at –80 °C to be used for 
transfection. Transient expression of the generated plasmids was carried out as 
described above (Section 5.2.6.3) and detailed in Chapter 2. Again, no resolution of a 
single band that approximates the predicted or glycosylated molecular weight was 
detected in the supernatant collected from all transfected CHO cells or HEK293 as 
determined by SDS-PAGE gel followed by Coomassie Blue staining. This was 
confirmed by Western blotting for MICA.  
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Figure 5.15: Results of colony – PCR. The hMICA-, hMICB-, hULBP1-, hULBP2- 
and hULBP3- mFc2 plasmid constructs were transformed into dam 
– 
E.coli. Some of 
the Zeocin resistant colonies were picked up and tested for the presence of the 
recombinant DNA inserts by colony- PCR using the forward primer for PCR1 and 
reverse primer for PCR2. The resulting DNA fragments were separated on a 1 % 
agarose gel/ 1X TAE buffer stained with 1 µl ethidium bromide.  
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Figure 5.16: Endonuclease double digestion of hMICA-, hMICB-, hULBP1-, 
hULBP2-, hULBP3 - mFc2 plasmid constructs. The recombinant plasmids 
containing the recombinant NKG2D ligands were double digested by EcoRI and 
BspHI. This resulted in release of two fragments as shown on 1% agarose gel/TAE 
buffer stained with ethidium bromide. Upper bands corresponded to the size of the 
digested plasmid while the lower bands corresponded to the size of the recombinant 
DNA insert. 
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5.3.5.3  Analysis of transfected CHO lysate for the recombinant protein 
production 
Failure of detection of the recombinant NKG2D ligands in the supernatant 
collected from the transfected CHO cells raised the possibility that these proteins were 
produced but not cleaved and secreted by the cells. To check for this possibility, cell 
lysates from the hMICA-mFc1, hMICA-mFc2 and un- transfected CHO cells 
respectively were prepared using the method described in section 5.2.6.4. These cell 
lysates were then run on 10% acrylamide SDS- PAGE gel followed by Coomassie 
Blue staining and analysed for recombinant MICA proteins (Figure 5.17). No 
differences were found between the cell lysates collected from the MICA-Fc1, MICA-
Fc2 and un-transfected CHO cells indicating that no recombinant proteins were 
produced. 
 
Figure 5.17: Whole CHO Cell Lysate - Coomassie Blue staining.  10 µl (100,000 
cells) of total cell lysate were loaded on 10% SDS-PAGE under reducing conditions 
and analyzed for MICA expression by Coomassie Blue stain. Lane 1 is the protein 
ladder; lane 2 is the MICA-mFc1 transfected CHO cells; lane 3 is the MICA-mFc2 
transfected CHO cells; lane 4 is the un-transfected CHO cells; lane 5 is supernatant 
collected from un-transfected CHO cells and purified by affinity chromatography. No 
visible differences were found between the transfected and un-transfected cell lysates. 
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5.4  Approach 3 For the Production of hNKG2D Ligand - mFc Fusion 
Proteins by Simple Ligation Using pFUSE-mIgG2A-Fc2 Vector 
 
5.4.1  Introduction 
As the overlap - extension PCR based cloning strategies failed, a simpler 
approach for the construction of the Fc-fusion proteins was tried. This is based on a 
simple ligation of the genes encoding for extracellular regions of hNKG2D ligands 
into the MCS of the pFUSE – mIgG2A-Fc2 vector. This approach, which was 
described by Flanagan et al (2007), leaves a few extra nucleotides between hNKG2D 
gene sequence and Fc-fragment, thus extending the hinge segment between the gene of 
interest and the immunoglobulin fusion partner. This strategy was carried out on 
MICA only as a prototype hNKG2D ligand.   
 
5.4.2  Cloning strategy  
The multiple cloning site of the pFUSE-mIgG2A-Fc2 vector is a short 
nucleotide sequence (21 bp in length) containing only three restriction sites for 
EcoRV, NcoI and BglII (Figure 5.13). Since the hMICA sequence contains restriction 
sites for both EcoRV and NcoI (analysed by NEB cutter), these restriction sites could 
not be used for inserting the hMICA genes into the pFUSE-mIgG2A-Fc2 vector. 
Instead the genes encoding for the extracellular region of hMICA was planned to be 
inserted between the EcoRI restriction site at the end of the IL-2ss and BglII restriction 
site in 5‟ to 3‟ orientation respectively. Here, unlike the overlap-extension PCR, the 
BglII restriction site separates the hMICA sequence from the mFc sequence (for 
complete sequence see Chapter 9). 
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5.4.3  Primer design 
The forward primer is the same as that used for the cloning of hMICA-mFc2 
into pFUSE-mIgG2A-Fc2 vector by overlap-extension PCR. The reverse primer 
should contain the end of the sequence encoding for the extracellular portion of MICA 
gene followed by a BglII site at its 3‟ end.  
 
The end of MICA sequence:    5‟ AGC ACT CAC CCT GTG CCC TCT 3‟ 
 
Reverse sequence:                   3‟ TCG TGA GTG GGA CAC GGG AGA TCT AGA 5‟ 
 
5’ to 3’ orientation:                5‟ AGA TCT AGA GGG CAC AGG GTG AGT GCT 3‟ 
 
Adding few nucleotides to 5‟end of the primer results in: 
Final reverse primer for MICA: 5‟GTTAGATCTAGAGGGCACAGGGTGAGTGCT 3‟ 
 
5.4.4  Results 3 
5.4.4.1  Cloning of hMICA into pFUSE-mIgG2A-Fc2 vector by simple ligation 
HeLa cDNA was used as a template to amplify the gene encoding for the 
extracellular portion of MICA protein without natural leader sequence by PCR using 
the primer set described above. The amplified PCR fragment (835 bp) containing the 
EcoRI and BglII restriction sites at its flanking 5‟ and 3‟ ends respectively was 
resolved on 1% agarose gel (Figure 5.18). The hMICA target gene was gel purified 
and double digested with EcoRI and BglII. Similarly, aliquots of empty pFUSE-
mIgG2A-Fc2 vector (0.5-1 µg) were double digested with the same enzymes and the 
large fragment of 4191 bp containing the vector backbone was gel purified, ligated 
with the insert and then transformed into dam
-
 E. coli cells. Zeocin resistant colonies 
BglII restriction site 
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were tested for the presence of the hMICA by colony-PCR (Figure 5.19 A). Plasmid 
DNA was purified from positive colonies using a Qiagen Miniprep Kit and confirmed 
positive by endonuclease digestion (Figure 5.19 B).  When the sequencing of the 
pFUSE-mIgG2A vector confirmed the presence of the hMICA gene, freezing stocks 
from maxipreps were made and stored –80 °C for transfection. CHO cells were then 
transfected with the pFUSE-mIgG2A vector containing the recombinant hMICA gene. 
Transient transfection with the jetPRIME transfection reagent was used  and the 
supernatant collected after 72 hours. After collection, supernatants were purified by 
protein A/G catridges and  tested for the secretion of hMICA by running on SDS-
PAGE gel stained with Coomassie Blue staining. Unfortunately, no secretion of 
protein was detected. This failure of secretion was confirmed by Western blotting 
using anti human MICA antibody.  
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Figure 5.18: Agarose gel electrophoresis of amplified hMICA gene. The HeLa 
cDNA was used a template for amplification of the genes encoding for the 
extracellular portion of hMICA. The size of the amplified segment including the 
flanking EcoRI and BglII restriction sites is 835 bp. 
 
 
 
 
                                                                                                                                    
 
   
               
 
 
Figure 5.19: A) Colony – PCR of the hMICA. All the 4 colonies were positive for 
hMIICA. B) Results of EcoRI and BglII digestion of hMICA-mFc2 plasmid 
minipreps. 
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5.5 Discussion 
5.5.1  Expression of NKG2D ligands as Fc fusion proteins  
Results presented in the previous chapter did not support the idea that 
signals initiated from cross-linking of NKG2D receptors by their mAbs are different 
from that initiated by NKG2D ligands since it was found that cross-linking NKG2D 
with an antibody on the surface of NK cells was sufficient to induce IL-6 mRNA 
expression and protein production. However, it was decided to express NKG2D 
ligands as soluble Fc fusion proteins for the following reasons: 1) To see if the 
stimulation of NKG2D receptors via their soluble ligands induces IL-6 mRNA 
expression and protein secretion profiles distinct from those produced by antibody 
cross-linking. 2) To see if there was a preference between various NKG2D ligands in 
the induction of IL-6 secretion. 3) To test the hypothesis of epitope – dependent 
receptor triggering. André et al (2004) suggest that NKG2D epitopes targeted by mAb 
and ligands might be distinct. Since the structure of the NKG2D ligands is highly 
heterogeneous, therefore NKG2D engagement may lead to the initiation of distinct 
signalling events (André et al, 2004). As no documented ligands are still known for the 
other activating receptors (NKp46, NKp44 and NKp30) these cannot be utilised for 
similar studies. 
 
5.5.2  Failure of Fc- protein production: possible implications  
The results presented in this chapter showed that the  MICA-, MICB-, 
ULBP1-, ULBP2- and ULBP3- mFc genes were successfully cloned into pFUSE-
mIgG2A-Fc1 and Fc2 vectors whether by overlap extension PCR or by simple 
ligation. This was demonstrated by colony-PCR, restriction digestion of the 
recombinant plasmids and by DNA sequencing of the plasmids. However, in all these 
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experiments the production and secretion of the recombinant hNKG2D ligand- mFc 
fusion proteins failed irrespective of the methods used. The reason for this is difficult 
to ascertain, but there are a number of possible factors that can be involved. When 
considering these results, it is logical to find an explanation for the expression 
problems at the levels of gene, vector, host, protein and induction conditions (see 
below).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.20: Possible explanations for the failure of recombinant MICA-, MICB-, 
ULBP1-, ULBP2- and ULBP3 - mFc fusion protein production and secretion. 
Different parameters which might affect the protein expression were considered at 
levels of gene, vector, host, protein and induction conditions. 
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5.5.2.1  Sequence parameters that can affect protein expression 
1.  Sequence translation and open reading frame  
The most critical process in construction of an immunoglobulin fusion gene 
is the actual joining of the sequence encoding the target protein and the 
immunoglobulin sequence (Hollenbaugh and Aruffo, 2002). Any mistakes that result 
in an out-of-frame fusion, which sometimes arise inadvertently during PCR 
amplification of the target gene, will result in no fusion protein being produced 
(Hollenbaugh and Aruffo, 2002). Moreover, mutations during PCR amplification of 
the target gene can result in the creation of stop codons and result in severely truncated 
and rapidly degraded proteins. Although this might be the most important explanation 
for failure of protein production and secretion by the host cells, it was unlikely to be 
the case in this study for several reasons. First, all the primers used throughout this 
study were designed to ensure the accurate amplification of the target genes and the 
proper overlap of the of the hNKG2D ligand sequences to mFc sequence. Second, all 
the recombinant fusion sequences were checked to ensure that they run in open 
reading frame and hence they do not contain premature stop codons. Third, all the 
PCR experiments were carried out using the high fidelity Phusion® DNA polymerase 
that has a low reported error rate (approximately 50-fold lower than that of Thermus 
aquaticus DNA polymerase, and 6-fold lower than that of Pyrococcus furiosus DNA 
polymerase). Finally, all recombinant plasmid constructs containing the recombinant 
MICA-, MICB-, ULBP1-, ULBP2- and ULBP3-mFc inserts were sent for plasmid 
DNA sequencing and the presence of the expected sequence was confirmed before 
transfection into the mammalian cells was done.  
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2.  Initiation of translation: role of Kozak sequence 
Gene expression is regulated at multiple levels; including the transcriptional 
level in which the gene is copied to produce mRNA (a primary transcript) with 
essentially the same sequence as the gene; and the translational level where the mRNA 
is translated into protein (Day and Tuite, 1998). Compared to transcriptional 
regulation, translational control of mRNAs allows for more rapid changes in cellular 
concentration of the encoded proteins (Sonenberg and Hinnebusch, 2009). The process 
of translation can be divided into initiation, elongation, termination, and ribosome 
recycling (Merrick, 2009). Most regulation is exerted at the first stage, where the AUG 
start codon is identified and decoded by the methionyl tRNA (Met-tRNAi) (Sonenberg 
and Hinnebusch, 2009). Initiation of translation proceeds via recognition of the m
7
G 
cap at the 5 terminus of the mRNA followed by scanning of the ribosome to the 
initiation codon, which is identified by proximity to the 5 -end and sequence context 
(Kozak, 1986a; Kozak, 1999; Welch et al, 2011). Kozak (1986b) found that the 
presence of an A/GCCACC sequence upstream of the start codon (AUG) followed by 
another G plays a major role in the initiation of the translation process.   
Eukaryotic (Kozak sequence) 
5‟ – A/GCCACCAUGG – 3‟ 
The absence of the Kozak sequence might, at least partially, explain the failure of the 
recombinant NKG2D ligand-mFc1 protein production in the experiments detailed in 
Section 5.3 of this chapter. However, it is unlikely to explain the failure of 
recombinant protein production in the experiments described in Sections 5.3 and 5.4. 
In these experiments a pFUSE-mIgG2A-Fc2 vector was used that has an internal 
Kozak sequence just upstream of the IL-2ss as shown below. 
                                      
5‟....GAGGGCCACCATGTACA..........3‟ 
+1 
Initiator 
IL-2 ss Kozak sequence 
Initiator 
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3.  mRNA instability and mRNA secondary structures: Role of poly (A) 
tail and cis – elements  
Studies have demonstrated that the modulation of mRNA stability plays an 
important role in regulating gene expression (Guhaniyogi and Brewer 2001; Hollams 
et al, 2002). The stability of eukaryotic mRNA transcripts is determined by multiple 
factors including the presence of the m
7G cap at the 5‟ end and the poly (A) tail at the 
3‟ end of mRNA molecule (Hollams et al, 2002). Both the cap and poly (A) tail 
function to prevent mRNA degradation and improve translation efficiency 
(Shimotohno et al, 1977; Preiss and Hentze, 1998). The presence of a poly (A) tail at 
the 3‟ end of the cloned sequences was not a problem since all the pFUSE vectors used 
have the Simian Virus 40 late polyadenylation (SV40 pAn) signal directly downstream 
of the Fc sequence (Figures. 5.2 & 5.13). The presence of this sequence enables 
efficient cleavage and polyadenylation reactions resulting in high levels of steady-state 
mRNA (Carswell and Alwine, 1989). Similarly the presence of the UR5‟ segment of 
HTLV1 virus (part of the vector promoter) at the 5‟ end of the fusion sequence further 
increases the stability of mRNA (Attal et al, 2000).  
Among the other factors that determine the stability of a given mRNA 
transcript is the presence of sequences within the mRNA known as cis-elements 
(Hollams et al, 2002; Cheneval et al, 2010). Cis elements are RNA (or DNA) 
sequence-specific regions which can be bound by trans-acting RNA (or DNA)-binding 
proteins to inhibit or enhance mRNA decay (or gene expression) (Strachan and Read, 
2004). The presence of negative cis- elements within the mRNA transcripts may 
shorten their half- life and enhance their degradation. In addition, some sequences in 
the mRNA molecule might be complementary with the ribosome binding site and/or 
translation start site. This leads to the formation of RNA secondary structures which 
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further inhibit protein translation. Research was attempted to determine the mRNA 
structure and to predict the cis-elements and mRNA secondary structures. Approaches 
include both experimental  and computational methods (Welch et al, 2011).  
 
4.  Codon bias and GC content of the gene  
Each amino acid is encoded from one (methionine and tryptophan) to as 
many as six different codons (arginine, leucine, and serine) in the canonical genetic 
code (Welch et al, 2011). Different organisms use synonymous codons with different
apparent preferences (Welch et al, 2011). Several studies have proven the immense 
impact of codon choice on gene expression in mammalian cells (Graf et al, 2004; 
Gustafsson et al, 2004; Fath et al, 2011). These studies concluded that proteins which 
are difficult to express outside their original context might contain codons that are 
rarely used in the desired host. This is particularly true when expression of a non-
mammalian gene is attempted in a mammalian host (Fath et al, 2011). However, 
besides inter-species variations, evidence accumulated in the last decade suggesting 
codon usage even differs among different tissues of the same host (Plotkin et al, 2004; 
Fath et al, 2011). Recently, differences in tissue-specific expression of individual 
tRNA species and the relative abundance of tRNA- isoacceptors were described to 
strongly correlate with the codon usage of genes highly expressed in specific tissues 
(Fath et al, 2011). Studies on the more commonly expressed mammalian housekeeping 
genes indicate that they are usually associated with higher GC-content than low-
expressing genes (Kudla et al, 2006; Fath et al, 2011).  
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5.5.2.1.1  Suggested solution for the sequence problems 
Obviously some of these sequence parameters which negatively affect the 
expression of proteins such as mRNA instability, negative cis elements and codon bias 
are internally inherited and cannot be controlled experimentally. However, the above 
findings strongly necessitate a comprehensive optimization strategy that involves a 
simultaneous modulation of multiple sequence parameters to enhance an optimal 
performance of human genes in autologous expression systems. This can be achieved 
by using a gene optimization technology that can alter both the naturally occurring and 
recombinant gene sequences to achieve the highest possible levels of productivity in 
any given expression system. This technology (OptimumGene™ from GeneScript or 
GeneOptimizer® from Life Technologies) takes into consideration a variety of critical 
factors involved in different stages of protein expression, such as codon adaptability, 
mRNA structure, and various cis-elements in transcription and translation. Using 
codon optimization tools, the chances of recombinant NKG2D ligand - mFc proteins 
to be expressed in CHO or HEK-293 cells were not very high and the gene sequences 
needed to be optimized (see below). 
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Figure 5.21: The histograms show the percentage of distribution of hMICA-mFc2 
codons which fall into a certain quality class. The value of 100 is set for the codon 
with the highest usage frequency for a given amino acid in the CHO mammalian 
expression organism. Codons with values lower than 30 are likely to hamper the 
expression efficiency. A) Original hMICA-mFc2 sequence before optimization. This 
non-optimized gene can reduce the efficiency of translation or even disengage the 
translational machinery. B) hMICA-mFc2 after optimization using geneOptimizer® 
from Life Technologies. The codon usage was adapted to the codon bias of Cricetulus 
griseus (CHO) genes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.22: The plots show the quality of the used codon at the indicated codon 
position to be expressed in CHO cells. The possibility of high protein expression 
level correlates with the value of Codon Adaptation Index (CAI). A  CAI of 1.0 is 
considered to be ideal while a CAI of > 0.9 is rated as high chance for expression in 
the desired expression organism. The lower the number, the higher the chance the gene 
would be expressed poorly. A) Original hMICA-mFc2 sequence before optimization. 
CAI: 0.82. B) hMICA-mFc2 after optimization using geneOptimizer® from Life 
Technologies. CAI after optimization: 0.96. 
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Figure 5.23: The average GC content. The ideal percentage range of GC content is 
between 30 to 70%. Any peaks outside of this range will adversely affect 
transcriptional and translational efficiency. A) Original hMICA-mFc2 sequence before 
optimization. Average GC content: 52.98%. B) hMICA-mFc2 after optimization using 
geneOptimizer® from Life Technologies. Average GC content: 61%.  
 
 
The advantages of this optimization process were that it automatically 
allowed the following cis-acting sequence motifs, which negatively inhibit protein 
secretion, to be avoided (where applicable in the hNKG2D ligand- mFc sequences): 1) 
internal TATA-boxes, chi-sites and ribosomal entry sites. 2) AT-rich or GC-rich 
sequence stretches 3) RNA instability motifs 4) repeat sequences and RNA secondary 
structures. 5) Cryptic splice donor and acceptor sites in higher eukaryotes. In addition, 
regions of very high (> 80 %) or very low (< 30 %) GC content have been avoided 
where possible.  
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This optimized hMICA-mFc2 sequence generated by the software was 
highlighted in yellow and aligned to the non-optimized sequence below.    
 
Query  1     ATGTACCGGATGCAGCTGCTGTCCTGTATCGCCCTGTCTCTGGCCCTCGTGACCAACTCC  60 
             |||||| ||||||| || ||||| || || || ||   ||| || || || || || ||  
Sbjct  1     ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCG  60 
 
Query  61    GAGCCTCACTCCCTGCGGTACAACCTGACCGTGCTGTCTTGGGACGGCTCCGTGCAGTCT  120 
             ||||| |||   || || || ||||| || |||||||| ||||| || || ||||||||  
Sbjct  61    GAGCCCCACAGTCTTCGTTATAACCTCACGGTGCTGTCCTGGGATGGATCTGTGCAGTCA  120 
 
Query  121   GGCTTTCTGGCCGAAGTGCACCTGGACGGCCAGCCCTTCCTGAGATACGACCGGCAGAAG  180 
             || ||||| || || || || ||||| || |||||||||||| | || ||| |||||||  
Sbjct  121   GGGTTTCTTGCTGAGGTACATCTGGATGGTCAGCCCTTCCTGCGCTATGACAGGCAGAAA  180 
 
Query  181   TGCCGGGCCAAGCCTCAGGGACAGTGGGCTGAAGATGTGCTGGGCAACAAGACCTGGGAC  240 
             ||| |||| ||||| |||||||||||||| |||||||| ||||| || ||||| |||||| 
Sbjct  181   TGCAGGGCAAAGCCCCAGGGACAGTGGGCAGAAGATGTCCTGGGAAATAAGACATGGGAC  240 
 
Query  241   AGAGAGACACGGGACCTGACCGGCAACGGCAAGGACCTGAGAATGACCCTGGCCCACATC  300 
             ||||||||  ||||| |||| || ||||| |||||||| || ||||||||||| || ||| 
Sbjct  241   AGAGAGACCAGGGACTTGACAGGGAACGGAAAGGACCTCAGGATGACCCTGGCTCATATC  300 
 
Query  301   AAGGACCAGAAAGAGGGCCTGCACAGCCTGCAGGAAATCAGAGTGTGCGAGATCCACGAG  360 
             |||||||||||||| ||| ||||   ||| ||||| || || || || |||||||| ||  
Sbjct  301   AAGGACCAGAAAGAAGGCTTGCATTCCCTCCAGGAGATTAGGGTCTGTGAGATCCATGAA  360 
 
Query  361   GACAACTCCACCCGGTCCTCCCAGCACTTCTACTACGACGGCGAGCTGTTCCTGAGCCAG  420 
             ||||||  |||| ||  ||||||||| ||||||||||| || ||||| |||||   |||  
Sbjct  361   GACAACAGCACCAGGAGCTCCCAGCATTTCTACTACGATGGGGAGCTCTTCCTCTCCCAA  420 
 
Query  421   AACCTGGAAACCGAGGAATGGACCGTGCCCCAGTCCTCCAGAGCCCAGACCCTGGCTATG  480 
             |||||||| || ||||||||||| |||||||||||||||||||| |||||| |||| ||| 
Sbjct  421   AACCTGGAGACTGAGGAATGGACAGTGCCCCAGTCCTCCAGAGCTCAGACCTTGGCCATG  480 
 
Query  481   AACGTGCGGAACTTCCTGAAAGAGGACGCCATGAAGACCAAGACCCACTACCACGCCATG  540 
             |||||  |||| ||| |||| || || ||||||||||||||||| ||||| ||||| ||| 
Sbjct  481   AACGTCAGGAATTTCTTGAAGGAAGATGCCATGAAGACCAAGACACACTATCACGCTATG  540 
 
Query  541   CACGCCGACTGTCTGCAGGAACTGCGGAGATACCTGGAATCCGGCGTGGTGCTGCGGAGA  600 
             || || ||||| ||||||||||| ||| |||| || ||||||||||| || ||| ||||| 
Sbjct  541   CATGCAGACTGCCTGCAGGAACTACGGCGATATCTAGAATCCGGCGTAGTCCTGAGGAGA  600 
 
Query  601   ACCGTGCCTCCTATGGTCAACGTGACCAGATCCGAGGCCAGCGAGGGCAACATCACCGTG  660 
             || ||||| || ||||| || || ||| |   |||||||   |||||||||||||||||| 
Sbjct  601   ACAGTGCCCCCCATGGTGAATGTCACCCGCAGCGAGGCCTCAGAGGGCAACATCACCGTG  660 
 
Query  661   ACCTGCAGAGCCTCCTCCTTCTACCCCCGGAACATCATCCTGACATGGCGGCAGGATGGC  720 
             || ||||| || |||  |||||| |||||||| ||||| ||||| ||||| ||||||||  
Sbjct  661   ACATGCAGGGCTTCCAGCTTCTATCCCCGGAATATCATACTGACCTGGCGTCAGGATGGG  720 
 
Query  721   GTGTCCCTGTCTCACGATACACAGCAGTGGGGCGACGTGCTGCCTGACGGCAATGGCACC  780 
             || ||  ||   ||||| || ||||||||||| || || |||||||| || ||||| ||| 
Sbjct  721   GTATCTTTGAGCCACGACACCCAGCAGTGGGGGGATGTCCTGCCTGATGGGAATGGAACC  780 
 
Query  781   TATCAGACCTGGGTGGCCACACGGATCTGCAGAGGCGAGGAACAGCGGTTCACCTGTTAC  840 
             || |||||||||||||||||  |||| ||| |||| ||||| ||| |||||||||| ||| 
Sbjct  781   TACCAGACCTGGGTGGCCACCAGGATTTGCCGAGGAGAGGAGCAGAGGTTCACCTGCTAC  840 
 
Query  841   ATGGAACACTCCGGCAACCACTCCACCCACCCTGTGCCTTCTCCACGGGGCCCTACCATC  900 
             |||||||||  ||| || |||  ||| ||||||||||| |||||  | || || || ||| 
Sbjct  841   ATGGAACACAGCGGGAATCACAGCACTCACCCTGTGCCCTCTCCCAGAGGGCCCACAATC  900 
 
Query  901   AAGCCTTGCCCCCCTTGCAAGTGCCCTGCCCCTAATCTGCTGGGCGGACCCTCCGTGTTC  960 
             ||||| || || || ||||| ||||| || ||||| ||  |||| ||||| ||||| ||| 
Sbjct  901   AAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTC  960 
 
Query  961   ATCTTCCCACCCAAGATCAAGGACGTGCTGATGATCTCCCTGTCCCCCATCGTGACCTGT  1020 
             |||||||| || ||||||||||| || || ||||||||||||  |||||| || || ||| 
Sbjct  961   ATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGT  1020 
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Query  1021  GTGGTGGTGGACGTGTCCGAGGACGACCCCGATGTGCAGATCAGTTGGTTCGTGAACAAC  1080 
             ||||||||||| |||  |||||| ||||| ||||| |||||||| ||||| ||||||||| 
Sbjct  1021  GTGGTGGTGGATGTGAGCGAGGATGACCCAGATGTCCAGATCAGCTGGTTTGTGAACAAC  1080 
 
Query  1081  GTGGAAGTGCACACCGCTCAGACCCAGACACACAGAGAGGACTACAACAGCACCCTGCGG  1140 
             |||||||| ||||| |||||||| || || || |||||||| |||||||| || || ||| 
Sbjct  1081  GTGGAAGTACACACAGCTCAGACACAAACCCATAGAGAGGATTACAACAGTACTCTCCGG  1140 
 
Query  1141  GTGGTGTCCGCCCTGCCTATCCAGCACCAGGACTGGATGTCCGGCAAAGAATTCAAGTGC  1200 
             |||||    ||||| || |||||||||||||||||||||   ||||| || ||||| ||| 
Sbjct  1141  GTGGTCAGTGCCCTCCCCATCCAGCACCAGGACTGGATGAGTGGCAAGGAGTTCAAATGC  1200 
 
Query  1201  AAAGTGAACAACAAGGATCTGCCAGCCCCCATCGAGCGGACCATCTCCAAGCCTAAAGGC  1260 
             || || |||||||| || || ||||| ||||||||| | |||||||| || || |||||  
Sbjct  1201  AAGGTCAACAACAAAGACCTCCCAGCGCCCATCGAGAGAACCATCTCAAAACCCAAAGGG  1260 
 
Query  1261  AGCGTGCGGGCTCCCCAGGTGTACGTGCTGCCACCTCCTGAGGAAGAGATGACCAAGAAA  1320 
                ||  | ||||| ||||| || ||  |||| || || || ||||||||||| |||||| 
Sbjct  1261  TCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGAAGAAGAGATGACTAAGAAA  1320 
 
Query  1321  CAAGTGACCCTGACCTGCATGGTCACCGACTTCATGCCCGAGGACATCTACGTGGAATGG  1380 
             || || || ||||||||||||||||| ||||||||||| || ||||| |||||||| ||| 
Sbjct  1321  CAGGTCACTCTGACCTGCATGGTCACAGACTTCATGCCTGAAGACATTTACGTGGAGTGG  1380 
 
Query  1381  ACAAACAATGGCAAGACCGAGCTGAACTACAAGAACACCGAGCCCGTGCTGGACTCCGAC  1440 
             || ||||| || || || ||||| |||||||||||||| || || || |||||||| ||  
Sbjct  1381  ACCAACAACGGGAAAACAGAGCTAAACTACAAGAACACTGAACCAGTCCTGGACTCTGAT  1440 
 
Query  1441  GGCTCCTACTTCATGTACTCCAAGCTGCGCGTGGAAAAGAAAAACTGGGTGGAACGGAAC  1500 
             || || ||||||||||||  ||||||| | ||||||||||| |||||||||||| | ||  
Sbjct  1441  GGTTCTTACTTCATGTACAGCAAGCTGAGAGTGGAAAAGAAGAACTGGGTGGAAAGAAAT  1500 
 
Query  1501  TCCTACTCCTGCTCCGTGGTGCACGAGGGACTGCACAATCACCACACCACCAAGTCCTTC  1560 
               ||||||||| || ||||| |||||||| ||||||||||||||||| || |||  |||| 
Sbjct  1501  AGCTACTCCTGTTCAGTGGTCCACGAGGGTCTGCACAATCACCACACGACTAAGAGCTTC  1560 
 
Query  1561  TCCCGGACCCCCGGCAAGTGA  1581 
             |||||||| || || || ||| 
Sbjct  1561  TCCCGGACTCCGGGTAAATGA  1581 
 
 
 
Figure 5.24: Alignment of optimized hMICA-mFc2 sequence with non optimized 
sequence. Although there were many nucleotide differences between the two 
sequences, both of them encode for the same hMICA-mFc2 fusion protein. The 
optimized gene, which can be made synthetically, should therefore allow high and 
stable expression rates in CHO cells. 
 
 
5.5.2.2  Leader sequence (Signal sequence) 
Successful protein secretion requires effective translocation of the protein 
across the endoplasmic reticulum (ER) before being transport into Golgi complex (Tan 
et al, 2002; Stern et al, 2007). A signal peptide at the N-terminal end of the nascent 
polypeptide directs the molecule into the ER lumen. This is cleaved off by signal 
peptidase once it has served its purpose of targeting the protein to, and importing it 
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into the ER (Stern et al, 2007). Thus the signal peptide serves as a “stamp” that direct 
the protein towards its destination pathway. In the experiments presented in Section 
5.2, the native signal peptide sequences of hMICA, hMICB, hULBP1, hULBP2 and 
hULBP3 were used. The use of these signal peptide sequences was based on the 
assumption that many secreted eukaryotic proteins are efficiently processed in 
mammalian expression host via their native signal sequences (Tan et al, 2002). Since 
both membrane and secreted proteins are synthesized on ER membrane bound 
ribosomes and enter the ER to be moved and matured through the same secretory 
pathway (Lodish et al, 2000), it was decided to keep these signal sequences without 
change despite the fact that these proteins are not naturally secreted. However, failure 
of secretion of the fusion proteins with these native signal sequences led to a change of 
strategy. It was hoped that removing the native leader sequences of hMICA, hMICB, 
hULBP1, hULBP2 and hULBP3 and replacing them with the leader sequence of the 
secreted IL-2 protein (hIL-2ss) may improve the secretion. Nevertheless, the new 
strategy also failed, and whether this was due to the low efficiency of the hIL-2ss as a 
secretion signal needs further clarification. Stern et al (2007) found that the IL-2 signal 
peptide is inferior to other signal peptides in secreting the Gaussia luciferase (Gluc) 
recombinant protein in CHO cells. They concluded that the choice of the signal 
peptide may have a major impact on the synthesis/secretion of the recombinant 
proteins in mammalian expression system. The different efficiencies of signal peptides 
with which a nascent polypeptide enters the secretory pathway may be attributed to the 
diversity of their primary sequences. Although all the commonly available leader 
sequences possess a positively charged N-terminal region, a central hydrophobic 
region and a C-terminal cleavage region (Nothwehr and Gordon, 1990), they are rarely 
conserved in their primary structures (Tan et al, 2002). Moreover, alterations or 
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modifications in the basic N-terminal and/or the central hydrophobic domains of the 
same signal peptide can alter the secretion of mature protein. Zhang et al (2005) found 
that by increasing the basicity of the N-terminal and hydrophobicity of the classic IL-2 
signal peptide increased the secretion of two different proteins by 3 fold.   
 
5.5.2.3  Vector considerations 
The most important vector parameter to be considered is the vector 
promoter driving the expression of the recombinant fusion proteins. A promoter is a 
specific DNA sequence usually located upstream of the gene (towards the 5' region) 
and facilitate its transcription (DuBois, 1990). In the experiments presented in this 
chapter, the pFUSE-mIgG2A-Fc1 and pFUSE-mIgG2A-Fc2 vectors were used. Both 
of them have the same hybrid promoter known as hEF1-HTLV. This promoter 
consists of two parts: 1) The human Elongation Factor 1α (EF-1α) core promoter 
which exhibits a strong activity and long lasting expression of a transgene in vivo 
(Kim et al, 1990). 2) The RU5‟ segment of human T-Cell Leukemia Virus (HTLV) -1 
Long Terminal Repeat which enhances the stability of mRNA (Attal et al, 2000). This 
is thought to be the strongest promoter ever found because it combines the unique 
properties of both the EF-1α promoter and the RU5‟ segment of HTLV-1. Several 
studies have shown that EF-1α is a stronger and more efficient promoter than the more 
commonly used cytomegalovirus (CMV) promoter for the generation of both transient 
and stable cell clones in different cell lines. Chung et al (2002) found that the EF-1α 
promoter robustly drove reporter gene expression in transiently transfected mouse 
embryonic stem cell lines, while the CMV promoter was inactive. Moreover, they also 
demonstrated that the EF-1α promoter effectively drove gene expression at different 
stages of cell development while the CMV promoter had only significant activity at 
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the later stage of cell differentiation. Tokushige et al (1997) found that the generation 
of stable human hepatocellular carcinoma (HCC) and murine myeloma cell lines 
expressing the Hepatitis C virus (HCV) core protein were only established using 
constructs driven by the EF-1 α promoter and not by constructs driven by the CMV 
promoter. Similarly, Teschendorf et al (2002) compared the efficacy of the EF-1 α 
promoter to the promoter of CMV for the generation of stable colon carcinoma cell 
(HT-29) transfectants using green fluorescent protein (GFP) expression cassettes both 
in vitro by FACS analysis and in vivo after HT-29 clones were grown as xenografts in 
nude mice. They found that >97% of all cells homogeneously expressing GFP were 
generated with the EF-1 α promoter compared to only up to 60% of the cells were 
GFP-positive using the CMV promoter. In vivo tumours carrying the EF-1 α promoter 
were homogeneously GFP-positive, whereas the CMV promoter gave rise to a 
scattered pattern of GFP expression. Based on the results of these studies, it was 
concluded that the failure of fusion protein production and/or secretion was unlikely to 
be due to vector issues. This conclusion was supported by two other observations from 
these experiments. Firstly, the hMICA-mFc2 fusion protein failed to be expressed in 
the pcDNA3 vector which is a CMV driven vector (data not shown). Secondly, stable 
CHO cell lines expressing the Zeocin resistant marker with all recombinant hMICA-, 
hMICB-, hULBP1-, hULBP2- and hULBP3-mFc plasmid constructs were successfully 
generated, suggesting that the failure of expression of these genes could not be 
attributed to other vector causes such as vector loss or instability.            
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5.5.2.4  Host considerations 
1.  Prokaryotic vs. eukaryotic expression systems 
To achieve the goal of this chapter, it was necessary not only to be 
successful in secreting these fusion proteins, but also to produce biologically and 
functionally active proteins. Although the prokaryotic expression system is the easiest 
system to express the recombinant Fc-fusion proteins, the use of this system didn‟t 
fulfil the aim of this study since several factors limited its use in these experiments. 
When eukaryotic proteins are produced in prokaryotes they usually lack 
posttranslational modifications (PTMs) including phosphorylation, glycosylation and 
acetylation that are often necessary for their function (Stern et al, 2007). In addition, 
recombinant protein expression is usually under the control of strong inducible 
promoters from plasmids which results in unusually high transcription rates (Gasser et 
al, 2008). Such over-production of recombinant proteins is stressful for the bacterial 
host and has a profound negative impact on protein quality (Gasser et al, 2008). 
Finally, recombinant proteins produced by prokaryotic cells very often fail to fold and 
reach their native conformation due to diverse events such as improper codon usage 
and lack of disulfide-bond formation (Gasser et al, 2008; Stern et al, 2007). Mis-folded 
protein species usually deposit as amorphous masses of insoluble material called 
inclusion bodies. Refolding recombinant proteins from inclusion bodies can be 
challenging, taking a lot of time, and the yields of correctly folded proteins can be very 
low (Tao et al, 2010). Obviously the most effective system to express a recombinant 
protein with full biological functions that are comparable to those of their natural 
counterparts is the use of eukaryotic mammalian cells. Taking all these factors in 
considerations, it was decided to use the eukaryotic expression system because this 
system provides the best chances of obtaining fully functional proteins.     
 
 
265 
 
2.  The use of CHO cells: Advantages and disadvantages 
CHO cells were used in this study because they are the most commonly 
used cells for recombinant protein production (Andersen and Krummen, 2002). 
Despite the availability of many cell lines, nearly 70% of all therapeutic recombinant 
proteins produced today are made in CHO cells (Jayapal et al, 2007). Beside this, 
CHO cells have a lot of other advantages that make them a logical first choice to 
express recombinant fusion proteins. First, although these cells are not of human 
origin, they have been proven to produce proteins with glycoforms that are both 
compatible and bioactive in humans (Jayapal et al, 2007). Second, these cells have 
been demonstrated to be the safest host for synthesis of biologic therapeutic agents 
(Jayapal et al, 2007). Third, purified CHO cell products have been proven to contain 
no more than picogram levels of contaminating CHO DNA per dose of the product 
(Wurm, 2005). Lastly, CHO cells are very easy to transfect using different transfection 
methods. However, the use of CHO cells may not be without problems. A quality 
issue that was observed with recombinant Fc- molecules is the fragmentation of the Fc 
moiety after purification by affinity chromatography (Robert et al, 2009). This 
degradation was first attributed to many causes that can be related to the protein 
sequence and its conformations, or to physico-chemical environment such as storage, 
temperature, pH and buffers (Liu et al., 2006; Cohen et al, 2007; Gaza-Bulseco and 
Liu, 2008). However, accumulating evidence suggests that the cause for this 
degradation may be biological rather than a physico- chemcial action and was 
attributed to the activity of proteases released by cultured cells (Robert et al, 2009). 
Many cell lines are known to produce and release such proteases such as NS0 
myeloma cells (Spens  and Häggström, 2005), hybridoma cells (Karl et al, 1990), and 
CHO cells (Satoh et al,1990;  Elliott et al, 2003; Robert et al, 2009). Although the 
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extracellular proteolytic degradation of recombinant Fc-fusion proteins could be an 
explanation for the experienced expression problems, two factors make this possibility 
less likely. 1) In all experiments complete culture medium supplemented with serum 
was used for the expression of Fc-fusion proteins. It is known that serum consists of 
up to 10% protease inhibitors (Cook and Chen, 1988), particularly of serine proteases 
(McGilligan and Thomas, 1991). The protein components of this supplemented 
medium are also substrates for extracellular proteases and may compete with the 
recombinant proteins for degradation by these proteolytic enzymes, thus decreasing 
the overall proteolysis of recombinant proteins. 2) Because the expression of the 
recombinant NKG2D ligand - mFc fusion proteins in CHO cells failed, so it was worth 
testing another cell line (HEK-293) which are not known to produce extracellular 
proteases. However, similarly to CHO cells, production and secretion of the 
recombinant proteins in HEK-293 also failed.   
 
5.5.2.5  Transfection considerations: The choice of transfection method  
Several methods for transfection of nucleic acids have been developed over 
the years. These include chemical reagents such as DEAE-dextran and calcium 
phosphate, physical methods such as electroporation, viral carriers such as adenoviral 
vectors, and lipid methods such as liposomal and non-liposomal lipids. The choice of 
the most appropriate transfection technology among these different methods may be 
difficult. Ideally, the transfection method should be fast and easy to perform, give high 
efficiencies and reproducible results, cause minimal cytotoxicity and preferably be 
compatible with serum and antibiotics. A non-liposomal lipid transfection reagent, 
jetPRIME, was used to perform transfections. It is a fast and easy to perform and 
extremely efficient on a wide variety of cell lines even in the presence of serum and 
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antibiotics, with reported transfection efficiencies between 70-90%. It also requires 
only low amounts of nucleic acid per transfection; hence resulting in very low 
cytotoxicity. However, since the choice of transfection technology can strongly 
influence the transfection efficiency, therefore two additional methods based on 
electroporation and a combination of both cell-type specific solutions (nucleofactor
®
 
Solution) and electroporation were also introduced. The failure to detect Fc fusion 
proteins was unlikely to be due to transfection since it was able to generate stable 
CHO clones that were resistant to Zeocin in all experiments indicating that the 
transfection process itself was working, ensuring the entry of the plasmid into the host 
cells. 
 
5.5.2.6  Protein considerations  
1.  Protein mis-folding  
Quite often the target protein itself, due to properties of its structure or its 
activity, is a strong determinant of expression yield (Welch et al, 2011). In fact protein 
stability has been identified as an important determinant of the probability that a 
protein will be retained in the ER (Ellgaard and Helenius, 2003; Hegde and Ploegh, 
2010). The protein may be particularly unstable in the host, especially if it is poorly 
folded due to inherent instability (Privalov, 1996), mistranslation (Lee et al, 2006; 
Welch et al, 2011), or improper post-translational modifications (Dobson, 2003) 
resulting in diverse non-native conformations. Mis-folded proteins formed in the ER 
are transported back to the cytosol where they are degraded by cytosolic proteasomes 
(Tsai et al, 2002). Protein folding problems are one of the major challenges in large 
scale protein production. Although it is known that a given sequence of amino acids 
almost always folds into a 3D structure with certain functions, it is impossible to 
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predict, with high precision, the exact folding pattern. A computational approach has 
been introduced to help scientists to predict the 3 D structure of the protein depending 
on the amino acid sequence (Dill et al, 2007). This approach greatly improved the 
prediction of 3D structure of simple proteins consisting of a single polypeptide chain 
(Dill et al, 2007). However, for complex proteins containing multiple structural 
domains or for proteins consisting of multiple subunits, prediction of their 3D 
structures can be challenging (Dill et al, 2007). Since the Fc-fusion proteins are 
complex proteins consisting of multiple subunits therefore, prediction of their folding 
and their 3 D structure is impossible. Protein mis-folding could be one of the most 
likely explanations for the failure of NKG2D ligand-mFc protein expression. Indeed 
the theory of Fc-fusion proteins mis-folding in these experiments is supported by the 
following facts 1) Searching the web for the commercially available recombinant 
MICA proteins revealed that the manufacturers used sequences with 9 amino acids 
longer than the used MICA sequence. These 9 amino acids (GKVLVLQSH) are 
actually stalk amino acids and not part of the extracellular portion of the MICA protein 
according to the sequence described by Bahram et al (1996a). This is also observed 
with other proteins namely, MICB, ULBP1, ULBP2 and ULBP3 where there were 
also additional amino acids at the C-terminal ends of their extracellular portions. 
These observations give rise to an important question whether these additional amino 
acids are essential for proper folding and hence proper expression of these proteins. 2) 
We could not detect any of the recombinant NKG2D ligand-mFc fusion proteins 
neither in the supernatant nor in the cell lysate of transfected CHO cells. This 
indicated that these proteins are either not produced or being degraded inside the cells.  
Degradation of the proteins inside the cells favours the possibility that these proteins 
are mis-folded since the mis-folded proteins are rapidly removed by the cells (Tsai et 
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al, 2002; Ellgaard and Helenius, 2003). 3) Protein mis-folding in Fc-fusion proteins 
was observed by others who suggested that the Fc-fusion proteins are in fact artificial 
constructs that do not appear in nature, and some constructs may therefore be 
susceptible to problems with folding and/or secretion (Lee et al, 2007).     
 
2.  Protein toxicity 
Protein toxicity is another possibility for the failure of Fc-fusion expression 
and secretion. Although MICA, MICB and ULBPs proteins are naturally occurring 
proteins, it is not known whether their fusion with mFc protein renders them toxic to 
host cells. Protein toxicity often leads to host suppression of protein synthesis and 
expression (Welch et al, 2011). 
 
5.5.2.7  Growth and induction parameters 
Several factors related to the expression environments have been observed 
to influence the expression level. Among these factors is the cell culture temperature. 
Some studies suggested that shifting of the cell culture temperature from 37 °C to a 
lower temperature (28 to 33 °C) may improve the expression of recombinant proteins 
in mammalian cells. The effect ranged from moderate improvement (Kaufmann et al, 
1999; Yoon et al, 2003) to significant improvement (Lee et al, 2007).  The principle is 
to allow an initial phase of rapid and maximum cell growth at 37 °C followed by a 
stationary phase (growth arrest phase) at a lower temperature where cell viability is 
extended and the cellular energies are conserved towards the production of 
recombinant proteins (Kumar et al, 2008). Indeed, this parameter was not tested since 
all these studies presumed at least some degree of protein production and they are 
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aimed to improve this production; while in experiments presented in this chapter there 
was no detectable expression at all.    
The failure to produce the desired NKG2D ligand-Fc fusion proteins was a 
major disappointment. Many of the above considerations could have been tried. 
However, due to the time intensive nature of any further troubleshooting of the protein 
expression process meant that work on the production of these proteins was not 
feasible. 
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6.1  Introduction 
As discussed in the previous chapter a significant amount of time and effort 
was spent at cloning NKG2D ligands into Fc fusion vectors and expressing these 
constructs. The aim was to provide further evidence of the role of NKG2D signalling 
pathways in the initiation of IL-6 production by NK cells. Since this approach was 
unsuccessful an alternative strategy to study the role of NKG2D ligands in inducing 
IL-6 secretion was pursued. Here stably transfected CHO cell lines expressing the full 
length human MICA, MICB, ULBP1, ULBP2 and ULBP3 ligands on the cell surface 
were co-cultured with human PBNK cells. These cells were a gift from Dr. Hugh 
Reyburn (Spain). The work could provide valuable data on the affinity of the various 
ligands for this receptor for the following reasons: 1) The CHO cells are non-human, 
therefore any detection of human IL-6 in the supernatant after their co-culture with 
human NK cells can be attributed directly to the NKG2D ligand-NKG2D receptor 
interaction since no other factors such as adhesion molecules or NCR ligands are 
present. 2) In contrast to other human cell lines that express NKG2D ligands and 
secrete human IL-6 at the same time (such as HeLa cells), these cells are non human 
and therefore their secretion of IL-6 (if any) cannot be detected using a human IL-6 
ELISA kits.  
 
6.2  Approach used for the detection of human IL-6 from co-cultures   
Human NK cells were purified from short term- frozen PBMCs by 
immunomagnetic negative selection using the method described in Chapter 2. The 
purity of the cells was confirmed to be more than 95% by flow cytometry. After 
isolation, aliquots of 1 x 10
5
 NK cells were co-cultured with similar concentrations of 
MICA-, MICB-, ULBP1-, ULBP2- and ULBP3- transfected CHO cells in 96-well 
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round bottom tissue culture plate in the presence of equal volumes of complete RPMI 
and Ham-F12 media. The cells were incubated in a humidified incubator at 37 °C with 
5% CO2. Supernatants were collected from wells at 1, 3, 6, 18 and 24 hours and stored 
at -20 °C until analysed for IL-6 secretion using the human IL-6 Ready Set – Go® 
ELISA kit. Supernatants from the purified NK cells and un-transfected CHO cells in 
same concentrations as co-cultures were also collected and used as negative controls.    
 
6.3  Results  
6.3.1  MICA (and to lesser extent MICB) were involved in the NKG2D-
induced secretion of IL-6 by NK cells 
All the co-culture experiments were carried out in duplicates. The results of 
these experiments are shown in Figure 6.1. These results are representative of 4 
independent experiments and are presented as mean ± SD. In MICA co-cultures IL-6 
started to increase as early as 1 hr (7.25 pg/ml ± 5.66) in comparison to (2.44 pg/ml 
±1.67) in resting NK cells. Continuous steady increase in the IL-6 concentration was 
observed at 3 hours (9.89 ± 4.74), 6 hours (12.98 ± 2.5) and 18 hours (17.19 ± 6.05) 
respectively. The maximum concentration was found at 24 hours where the IL-6 in the 
supernatant was 25.49 pg/ml ± 11.55. No significant difference in the IL-6 
concentration was found between 1 and 24 hours (p=0.068). The supernatants 
collected from the co-cultures of NK cells with MICB-transfected CHO cells produced 
less IL-6 at all time points in comparison to MICA. At 1 hour, the IL-6 concentration 
was 2.3 ± 1.20. It increased slightly thereafter at 3 hours (3.77 ± 2.9); 6 hours (5.07 ± 
4.07); 18 hours (5.52 ± and 24 hours (7.75 ± 7.4). However, these concentration were 
higher (although not statistically significant) than those obtained from NK + ULBP co-
cultures.     
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Figure 6.1: IL-6 production by NK cells following activation with NKG2D 
ligands. Aliquots of 1x10
5
 purified NK cells isolated from 4 healthy donors were 
cultured with the same number of MICA-, MICB-, ULBP1-, and ULBP2- and 
ULBP3-transfected CHO cells in 96 well plates. Supernatants were harvested at 1, 3, 
6, 18 and 24 hrs and analyzed for IL-6 production by ELISA. Co-cultures of PBNK + 
MICA-transfected CHO cells produced the highest IL-6 concentration at all time 
points in comparison to MICB, ULBPs co-cultures and negative controls. Supernatants 
collected from co-cultures of PBNK + ULBP –transfected CHO cells did not stimulate 
further IL-6 production over those obtained from NK cells alone. All measurements 
were performed in duplicates and presented as the mean of 4 independent experiments. 
Statistical analysis was performed using a Wilcoxon signed rank test. The error bars 
denote the SD. 
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6.3.2  MICA involvement induced significant amounts of IL-6 in comparison 
to other NKG2D ligands at 6, 18 and 24 hours post activation  
For the next analysis IL-6 concentrations were compared in the supernatants 
taken from co-cultures of purified PBNK and MICA-transfected CHO cells with those 
obtained from co-cultures of purified PBNK cells and MICB-, ULBP1-, ULBP2- and 
ULBP3-transfected CHO cells at each time point. The results are presented in Figure 
6.2. 1 hr post activation, the IL-6 concentration in the PBNK+ MICA co-cultures (7.25 
pg/ml ± 5.66) was higher, but not significantly different, from those obtained from 
PBNK + MICB (2.3 ± 1.2, p > 0.05) , PBNK + ULBP1 (2.7 ± 1.2, p > 0.05), PBNK + 
ULBP2 ( 2.3 ± 1.3, p > 0.05), and PBNK + ULBP3 ( 2.96 ± 0.7, p > 0.05) co-cultures 
respectively. The concentration of IL-6 continued to increase insignificantly in BPNK 
+ MICA co-cultures at 3 hours (9.89 ± 4.7) in comparison to those obtained from  
PBNK + MICB (3.8 ± 2.9), PBNK + ULBP1 (2.23 ± 1.7), PBNK + ULBP2 (2.6 ± 1.4) 
and PBNK + ULBP3 (2.7 ± 1.3) co-cultures respectively. The significant increase in 
the IL-6 concentrations in PBNK + MICA co-cultures over ULBP co-cultures became 
apparent at 6 hrs (p = 0.029). However, this concentration was still not significantly 
different from that obtained from MICB co-culture (p = 0.057). At 24 hrs following 
activation the IL-6 production in PBNK+ MICA co-cultures was 25.5 pg/ml ± 11.6. 
This concentration was significantly higher than that observed with PBNK+ MICB 
(7.7 ± 7.3, p < 0.05), PBNK + ULBP1 (4.55 ± 4.4, p < 0.05), PBNK + ULBP2 (3.5 ± 
2.06, p < 0.05) and BPNK + ULBP3 (3.99 ± 2.11, p < 0.05) co-cultures respectively.      
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Figure 6.2: Comparison of IL-6 secretion by NK cells in different NKG2D ligand- 
CHO co-cultures. At all time points, the concentrations of IL-6 were higher in the 
supernatant collected from NK cells + MICA- transfected CHO cells. Significant 
difference in IL-6 production in NK + MICA co-cultures over NK+ULBPs co-cultures 
were noted as early as 6 hours post stimulation. However, a longer time period (24 
hours) was needed for the secretion to be significantly different over NK+ MICB co-
cultures. Statistical analysis was performed using Wilcoxon signed rank test. The error 
bars denote the SD; *, p<0.05.  
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6.4  Discussion 
6.4.1  The advantages of using non-human cell lines transfected with human 
NKG2D ligands. 
To clarify the role of NKG2D ligand- receptor interaction in the initiation of 
IL-6 secretion by NK cells, NKG2D ligand-Fc fusion proteins were first proposed as 
an experimental model (Chapter 5). However, failure to produce these fusion proteins 
made the use of alternative approaches necessary. One of the possible alternatives was 
to transfect human cell lines (known to be NKG2D ligand negative) with full length 
NKG2D ligands. These cell lines would then be co-cultured with NK cells to test how 
the IL-6 secretion would be affected. Another approach was to transfect non-human 
cell lines with the human NKG2D ligands and then to test if these induce IL-6 
secretion by NK cells. The latter approach was more valuable since any detection of 
IL-6 in the supernatant is a strong indication of direct involvement of the NKG2D 
signalling pathway without interference from other signalling pathways. It also 
allowed indirect study of the role of other factors such as co-stimulation or adhesion 
molecules that contributed to this secretion. Another major advantage of using non-
human cell lines was that any secretion of IL-6 by these cell lines would not be 
detectable using a human ELISA kit. 
 
6.4.2  NKG2D-transfected CHO co-cultures produced less IL-6 than HeLa 
cell co-cultures    
In the experiments presented in this chapter, purified PBNK cells were co-
cultured with CHO cells transfected with full length MICA, MICB, ULBP1, ULBP2 
and ULBP3. The supernatants were collected over 1, 3, 6, 18 and 24 hours and 
analysed for IL-6 by ELISA. In general, the level of IL-6 detected in these co-culture 
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experiments was very low in comparison to that obtained when NK cells were co-
cultured with NKG2D expressing human cell lines such as HeLa cells (Chapter 3) at 
all time points studied (Table 6.1). 
 
Table 6.1: Comparison of IL-6 levels in the supernatants collected from PBNK 
cells + HeLa with those obtained from PBNK cells + MICA- transfected CHO 
cells 
  PBNK + HeLa 
(pg/ml ± SD) 
PBNK + MICA-transfected 
CHO cells 
(pg/ml ± SD) 
1 hr 79.8 ± 12.26 7.25 ± 5.66 
3 hrs 139.78 ± 13.29 9. 89 ± 4.7 
6 hrs 189.27 ±  13.7 12.98 ± 2.51 
18 hrs 270 ± 14.8 17.19   ± 6.04 
24 hrs 390 ± 22.77 25.49 ± 11.55 
  
These results might point to the significance of other factors such as co-
stimulation or the adhesion molecules in the secretion of IL-6 by PBNK cells when co-
cultured with target cells. Some studies demonstrated that HeLa cells are not only 
NKG2D ligand positive, but they are also NCR ligand positive (Moretta et al, 2001). 
These studies showed that lysis of HeLa cells when co-cultured with NCR 
bright 
NK 
cells was completely inhibited by masking both NCR and NKG2D receptors, while 
only partial inhibition was noted when the NCR or NKG2D receptors were blocked 
individually. Does co-engagement of both the NKG2D and NCR receptors further 
amplified the IL-6 secretion by NK cells when co-cultured with HeLa cells? 
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Unfortunately, NCR receptor ligands remain poorly characterized, so they could not be 
used to answer this question directly. 
Adhesion molecules play a central role in NK cell-target cell interactions 
that are critical in the generation of effective immune responses (Robertson et al, 
1990; Stewart et al, 2006). Resting NK cells are known to express a number of 
adhesion molecules. These include lymphocyte function-associated antigen (LFA-1 or 
CD11a/CD18), LFA-3 (CD58) and neural cell adhesion molecule (NCAM or CD56) 
(Robertson et al, 1990). Surface expression of these adhesion molecules increases four 
to six fold after treatment with IL-2 (Robertson et al, 1990). Increases in the 
expression of these molecules have been linked to enhanced NK cell-mediated killing 
of sensitive targets and the induction of cytotoxicity against cells that are otherwise 
resistant to NK cell-mediated lysis (Robertson et al, 1990). Recent evidence indicated 
that some of these adhesion molecules were not only involved in the regulation of NK 
cell cytotoxicity but also in the regulation of cytokine secretion by these cells. Fauriat 
et al (2010) demonstrated that the co-engagement of LFA-1 augmented the secretion 
of cytokines and chemokines by NKG2D and 2B4 receptors in Drosophila cells. While 
the role of LFA-1 is only synergistic for NKG2D and 2B4 in the secretion of TNF-α, 
MIP-1 α, MIP-1 β and RANTES, the secretion of IFN-γ by NKG2D and 2B4 is 
particularly LFA-1 dependent (Fauriat et al, 2010). Overall these findings addressed 
not only the significance of LFA-1–mediated adhesion, but also indicate the signalling 
pathways involved. Since HeLa cells express high level of ICAM-1 (Jakiela et al, 
2008) which is  a ligand for the LFA-1 receptor, therefore, one explanation for high 
IL-6 secretion in HeLa co-cultures could be the involvement of different signalling 
pathways including different NK cell receptors (NKG2D and NCRs) and adhesion 
molecules like LFA-1. On other hand, the low levels of IL-6 concentration secreted by 
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NK cells when co-cultured with NKG2D-transfected CHO cells might reflect the 
absence of human NK cell co-simulation and adhesion molecule co-expression. 
Nevertheless, the fact that IL-6 was detected in the supernatants collected from co-
cultures with these NKG2D ligand transfected cells provided strong evidence for the 
direct involvement of the NKG2D pathway.   
NK cells also express a family of receptors including DNAM-1, Tactile and 
CRTAM (class I-restricted T cell-associated molecule) (Stewart et al, 2006). Tactile 
and CRTAM are only expressed on the surface of activated NK cells. They mediate 
adhesion and stimulate cytotoxicity (Fuchs et al, 2004; Boles et al, 2005). CRTAM 
also promotes in vitro secretion of IFN-γ by CD8+ T-cells. DNAM-1 is associated with 
LFA-1 in NK cells and is phosphorylated by protein kinase C (Shibuya et al, 1999). 
The role of DNAM-1 in the secretion of cytokines by NK cells was investigated by 
Bryceson et al (2006). They found that DNAM -1 synergised strongly with 2B4 and, 
to a lesser extent, with NKG2D, NKp46 and CD2 in the secretion of IFN-γ and TNF-α 
by NK cells. The ligands for DNAM-1 are Nectin-2 (CD112) and the poliovirus 
receptor (PVR) (Pende et al, 2005). These ligands are also expressed on HeLa cells 
(El-Sherbiny et al, 2005; Akhtar et al, 2008) giving another potential explanation for 
higher IL-6 secretion in HeLa co-cultures compared to NKG2D ligand-transfected 
CHO co-cultures.  
 
6.4.3  MICA involvement in the NKG2D-induced secretion of IL-6 could 
reflect either differences in surface expression or differences in the affinities of 
NKG2D ligands for their receptor 
The findings also indicated that the MICA and MICB (to lesser extent) were 
involved in the NKG2D-mediated IL-6 secretion pathway in NK cells. ULBPs induced 
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no significant IL-6 secretion over resting NK cells while no IL-6 was detected in the 
supernatant collected from un-transfected CHO cells. These observations reflected 
either differences in the surface expression of these ligands by CHO cells or different 
affinities of the NKG2D ligands for NKG2D receptor. All the MICA-, MICB-, 
ULBP1-, ULBP2- and ULBP3-transfected CHO cells were checked and confirmed 
positive for the expression of these ligands by RT-PCR. Since MICA and MICB were 
the two ligands mostly involved in the NKG2D-induced secretion of IL-6, therefore 
the surface expression of these ligands was also tested by flow cytometry. Our 
observations indicated differences in the surface expression of these ligands as shown 
in Figure 6.3. Unfortunately, these experiments cannot establish whether the observed 
differences in IL-6 secretion were due to the different affinities of these ligands for the 
NKG2D or simply attributable to differences in surface expression levels on the 
transfected cells.  
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Figure 6.3: Expression of MICA/B proteins by transfected CHO cells as 
determined by flow cytometry. MICA- and MICB- transfected CHO cells were 
cultured for 3 days in Ham‟s F-12 medium at 37°C and 5% CO2. Thereafter, 1 x 105 
cells were stained with 0.25 µg of mIgG2a k isotype control (Clone: MOPC-173, 
Biolegend) (red histogram) or 0.25 μg of mouse anti‐human MICA/B Purified (Clone: 
6D4, ebioscience) (green histogram) followed by anti‐mouse IgG FITC (ebioscience). 
Total viable cells were used for analysis. Gate was set by forward and side scatter to 
exclude dead cells, debris, and cell aggregates. The percentage of positive cells was 
79.1% for MICA and 12.3 % for MICB as determined by DAKO Summit software 
(blue histogram). 
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Differences in the affinity of human and mouse NKG2D ligands for the 
NKG2D receptor have been demonstrated in many studies (O'Callaghan et al, 2001; 
Sutherland et al, 2002; Takada et al, 2008; Eagle et al, 2009). The affinities of the 
different human NKG2D ligands for NKG2D receptors range between 6 nM for 
MICA to 1.1 µM for ULBP1 as determined by surface plasmon resonance studies 
(Mistry and O'Callaghan, 2007; Nausch and Cerwenka, 2008). The reported affinity of 
ligands to NKG2D receptor is MICA > MICB > ULBP1 (Figure 6.4).  
 
 
 
 
 
Figure 6.4: Affinities of different NKG2D ligands for NKG2D receptor as 
determined by surface plasmon resonance (SPR). The equilibrium dissociation 
constant (KD) was used to describe the affinity between NKG2D ligands and receptors. 
The smaller the dissociation constant, the higher the affinity.  ND = not determined. 
Reproduced from Mistry and O'Callaghan (2007). 
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It is still largely unknown whether the differences in the NKG2D ligand 
affinities for the NKG2D receptor have an impact on NK cell activation and function. 
Do these differences in the ligand affinity translate into functional differences in NK 
cell stimulation? In fact this is supported by the findings of others who observed that 
the differences in the binding affinity of different alleles for NKG2D within the same 
ligand itself (different MICA alleles) could have profound effect on NK cell activation 
and in the modulation of T-cell responses (Steinle et al, 2001). The results presented 
here may also suggest that this is the case. However, a definitive answer would require 
the standardisation of NKG2D ligand density. This, in the context of transfected cell 
lines is practically impossible.   
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7.1  Introduction 
IL-6 is a pleiotropic cytokine with multiple functions that plays many roles 
in inflammation and immune responses (Kishimoto, 2006). Since IL-6 is secreted 
rather ubiquitously by many cells types (Naka et al, 2002), therefore it was necessary 
to show that IL-6 secreted from NK cells is biologically relevant in influencing the 
immune response. Although not defined as a chemokine, one of the reported functions 
of IL-6 is T cell recruitment both in vitro (Weissenbach et al, 2004) and in vivo 
(McLoughlin et al, 2005). This function of IL-6 seems at first to be secondary by 
regulation of chemokine secretion and/or chemokine receptor expression on target 
cells (Romano et al, 1997; McLoughlin et al, 2005). However, Weissenbach et al 
(2004) provided evidence that IL-6 could be a direct mediator of CD4
+
 T cell 
migration. In this chapter the direct effect of IL-6 secreted by NK cells on in vitro 
migration of CD4
+
 T cells was studied. It was hypothesized that IL-6 secreted by NK 
cells could contribute, at least partially, to the migration of other inflammatory and 
immune cells to the site of inflammation. This hypothesis was based on the 
observations that IL-6 could induce direct CD4
+
 T cell migration. Given the findings 
that NK cells can secrete IL-6 one can speculate that NK cells could be responsible for 
the migration of lymphocytes that occurs after initial NK cell activation. This 
mechanism could facilitate the transition between innate and acquired immunity.  
 
7.2  Approach used for in vitro trans-migration assay  
A modified Boyden chamber trans-migration assay was used to assess the 
migration of CD4
+
 T cells in response to NK cell activation. Details of the protocol 
used were described in Chapter 2. NK cells were purified by negative selection. The 
purity of NK cells was more than 95% as shown by flow cytometry. At the time of NK 
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cell purification, the non-NK cell fraction from each donor was saved and CD4
+
 T 
cells were purified by positive selection using a CD4
+
 T cell isolation kit. After 
selection, the NK cells were activated overnight by co-culture with HeLa cells at a 
ratio of 5:1 and IL-2 at a dose of 100 U / ml. The next day lymphocyte migration in 
response to IL-6 secreted by NK cells was assessed in 24-well Transwell plates with 
two different pore size inserts (8 and 3 µm). Transwell inserts were pre-coated with 
fibronectin (5µg/cm
2
) since lymphocyte migration in response to IL-6 was shown to be 
fibronectin dependent (Weissenbach et al, 2004). Four wells were prepared for each 
sample. In the first well, 2 x 10
5
 CD4
+
 T cells were suspended in 100 µl RPMI culture 
medium and placed in the upper compartment. The same number of NK cells from the 
same donor was suspended in 600 µl of culture medium and placed in the lower 
compartment. In a second well CD4
+
 T cells were seeded in the upper compartment 
and NK cells in the lower compartment but in the presence of a neutralizing anti-IL-6 
antibody (0.15 μg / ml for each 2.5 ng / ml of human IL 6 as recommended by the 
manufacturer). Lymphocyte migration in response to activated NK cells was compared 
to migration in response to 20 ng/ml of recombinant human IL-6 (rhIL-6) contained in 
600 µl of culture medium  in a third well (positive control) and culture medium alone 
in the fourth well (negative control). After 4 hours incubation the cells in the lower 
compartment were mixed with a known number of counting beads before harvesting. 
Thereafter the cells and the beads were removed from the lower compartment, washed 
with 1X PBS and stained with a mouse anti-CD4
+
FITC antibody. The absolute number 
of migrating CD4
+
 T cells was counted by flow cytometry and the level of migration 
was expressed as a migration percentage calculated in relation to the total number 
CD4
+
 T cells used in the upper compartment. 
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7.3  Results 
7.3.1  Trans-migration assay using 8 µm pore size Transwell inserts 
To start with, it was decided to use inserts with 8 µm pore size since these 
inserts are commonly used in the literature for trans-migration assay for lymphocytes. 
Before proceeding with the actual experiments it was necessary to check these inserts 
for the spontaneous migration of lymphocytes and compare this to that of test samples 
and positive control. Therefore, a preliminary experiment with only one donor was 
carried out as outlined in section 7.2. After 4 hours incubation the percentage of 
migration of CD4
+
 T cells to the lower compartment was calculated as follows: 
 
Absolute number of migrating CD4
+
 cells/ 1 µl: 
 
 
 
 
Total number of migrating CD4
+
 T cells in the lower compartment: 
 
 
 
 
The percentage of migrating CD4
+
 T cells: 
  
 
 
 
Number of CD4
+
 cell events            Assigned bead count of the lot (25000 beads/25 μl) 
Number of beads events                     Volume of sample (μl) used in flow analysis 
 
x 
Absolute number of CD4
+
 T cells in lower compartment / μl x volume of sample 
in lower compartment  
 
Total number of migrating CD4
+
 T cells 
Total number of CD4
+
 T cells 
 
x  100 
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When no anti- IL-6 antibody was used, the percentage of migrating CD4
+
 T 
cells elicited by activated NK cells was 37.8 % (Figure 7.1). However, in the presence 
of an anti- IL-6 antibody in the lower compartment the migration was inhibited to 
around 3.9 % (Figure 7.2). In the positive control well when only rhIL-6 was used, the 
migration percentage of CD4
+ 
T cells was 95.94% (Figure 7.3) compared to 11.4% in 
the negative control well, where only culture medium was used in the lower 
compartment (Figure 7.4). These preliminary results were very promising suggesting 
that IL-6 secreted by NK cells might, at least partially, participate in the migration of 
CD4
+
T lymphocytes. However, since the size of the insert pores was large (8 µ) there 
is a possibility that some of these lymphocytes might diffuse through the insert pores 
by gravity and not by transmigration. For this reason it was decided not to continue 
with 8 µm inserts and replace them with smaller pore size (3 µm) inserts.  
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 21080               25000 
 4173                 1000 
 
126 x 600 = 75600 cells. This represents the total number of CD4
+
 lymphocytes in the 
lower compartment 
 
The migration percentage of CD4
+
 T cells = 75600/200000 x 100 = 37.8 %. 
 
Figure 7.1: CD4
+
 T cell migration elicited by activated NK cells. Transwell inserts 
(8 µm pore size) were pre-coated with fibronectin 45 -60 minutes before the 
experiment. 2 x 10
5
 CD4 
+
 T cells were placed in the upper compartment. The same 
number of activated NK cells was seeded in the lower compartment. After 4 hours of 
incubation, a known number of fluorescent counting beads were added to the lower 
compartment before collection. These beads were present during all following stages 
of processing, washing and staining with an anti- CD4
+
FITC antibody, allowing for 
correction for losses during these steps. A) Forward and sideward scatter. R1 refers to 
the gated cells (NK cells + migrating CD4
+
 T cells) while R2 is the beads gate. B) 
Flow cytometry histogram showing the CD4
- 
cells (R3) and the CD4
+
 T cells (R4).  
 
  
Region Count % Hist % All 
Total 100000 100.00 100.00 
R1 55878 55.88 55.88 
R2 4173 4.17 4.17 
 
Region Count % Hist % All 
Total 55878 100.00 55.88 
R3 34797 62.27 34.80 
R4 21080 37.73 21.08 
   
 
 
 
A B 
x = 126 cells / µl   
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  3813               25000 
  7207               1000 
The total number of CD4
+
 lymphocytes in the lower compartment is: 13 x 600 = 
7800 cells. 
The percentage of migration of CD4
+
 T cells = 7800/200000 x 100 = 3.9 %. 
 
Figure 7.2: CD4
+
 T cell migration in response to NK cells in the presence of anti-
IL-6 antibody. 2 x 10
5
 CD4
+
 T cells were placed in upper compartment. The same 
number of activated NK cells was seeded in lower compartment.  IL-6 secreted by NK 
cells was neutralized by adding a monoclonal anti-IL-6 antibody to a final 
concentration of   0.15 μg / ml for each  2.5 ng / mL of human IL 6. The absolute 
number and the percentage of migrating CD4
+
 T cells were calculated after 4 hours. A) 
Forward and side scatter. R1 represents the gated lymphocytes and NK cells, R2 is the 
beads gate. B) Flow cytometry histogram showing CD4
- 
(R3) and CD4
+
 cells (R4).  
 
Region Count % Hist % All 
Total 100000 100.00 100.00 
R1  40.71 40.71 
R2  7.21 7.21 
 
Region Count % Hist % All 
Total 40711 100.00 40.71 
R3 36898 90.63 36.90 
R4 3813 9.37 3.81 
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41781               25000 
3266                 1000 
 
The total number of CD4
+
 lymphocytes in the lower compartment is: 320 x 600 = 
192000 cells. 
 
The percentage of migrating CD4
+
 T cells = 192000/200000 x 100 = 96.0 %. 
 
 
Figure 7. : CD4
+
 T cell migration in response to recombinant human IL-6 (rhIL-
6). 2 x 10
5
 purified CD4
+
 T cells were placed in the upper compartment of 8 µm pore 
size Transwell wells. Migration was induced by addition of 20 ng/ ml of rh IL-6 into 
the lower compartment. The number of migrating CD4+ T cells and the migration 
percentage were calculated after 4 hours using flow cytometry. A) FACS analysis of 
the cells in the lower compartment showing the forward and side scatter. R1 represents 
lymphocytes and R2 is the beads gate. B) Flow cytometry histogram showing CD4
- 
(R3) and CD4
+
 T cells (R4). 
  
 
Region Count % Hist % All 
Total 100000 100.00 100.00 
R1 64616 64.62 64.62 
R2 3266  3.27 3.27 
 
Region Count % Hist % All 
Total 64616 100.00 64.62 
R3 22835 35.34 22.84 
R4 41781 64.66 41.78 
   
 
 
 
  
x = 320 cells / µl   
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  21806              25000 
  14330              1000 
 
The total number of CD4
+
 lymphocytes in the lower compartment is: 38 x 600 = 
22800 cells. 
 
The percentage of migration of CD4
+
 T cells = 192000/200000 x 100 = 11.4 %. 
 
Figure 7.4: Spontaneous CD4
+
 T cell migration in 8 µm pore size Transwell wells. 
2 x 10
5
 of purified CD4
+
 T cells were applied to the upper compartment. Only culture 
medium (RPMI) was placed in the bottom chamber. Migration of CD4
+
 T cells was 
assessed at 4 hours as described above. A) FACS analysis of the cells in the lower 
compartment showing the forward and side scatter. R1 contains migrating CD4
+
 T 
cells. R2 is the beads gate. B) Flow cytometry histogram showing the CD4
- 
cells (R3) 
and the CD4
+
 T cells (R4). Approximately 11 % of the CD4
+ 
T cells migrated 
spontaneously.  
Region Count % Hist % All 
Total 100000 100.00 100.00 
R1 33501 33.50 33.50 
R2 14330  14.33 14.33 
 
Region Count % Hist % All 
Total 33501 100.00 33.50 
R3 11695 34.91 11.70 
R4 21806 65.09 21.81 
   
 
 
 
  
x = 38 cells / µl   
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7.3.2  Trans-migration assay using 3 µm pore size inserts 
The trans-migration assay was repeated using 3 micron pore size Transwell 
inserts using cells from 4 additional healthy donors. As described previously, 
Transwell inserts were first coated with human fibronectin (5µg/cm
2
) suspended in 
100 µl PBS and left for 45-60 minutes for sedimentation. The placement of the cells 
and controls was the same as for the preliminary experiment using the larger pore 
inserts. The results are expressed as percentage migration of CD4
+
 T cells. In sample 1 
the migration of the CD4
+
 T cells in response to activated NK cells was 38.3%. 
However, this migration was inhibited by more than half in the presence of a 
neutralising anti-IL-6 antibody (15.8%). In sample 2, the migration of CD4
+
 T cells in 
response to NK cells was inhibited from 48.8% to only 12.1% in the presence of IL-6 
antibody. A prominent inhibition was also seen in sample 3 where the migration of 
CD4+ T cells was inhibited from 61.5% to 18.8% in the presence of IL-6 antibody. 
Although the CD4
+
 T cell migration in sample 4 was as low as 9.6%, but the migration 
to the lower chamber was still inhibited by more than half in the presence of the anti 
IL-6 antibody (4.3%).   
Regarding the positive control where the migration of CD4
+
 T cells was 
assessed in response to 20 ng/ml of recombinant IL-6 in the lower compartment, the 
migration percentage of T cells was 95.4%, 99.8%, 111.0% and 19.6% in samples 1, 2, 
3 and 4 respectively. Spontaneous migration of CD4
+
 T cells in the absence of any 
external stimuli was also recorded. However, this migration did not exceed 8.8%. in 
all samples. Overall, these results supported the preliminary findings and further 
suggested the involvement of IL-6 secreted by NK cells in the migration of CD4
+ 
T 
cells.         
 
 
 
297 
 
 
 
 
                                                         
     
 
 
B 
 
 
 
 
                          
 
C 
 
 
      
 
 
                
D 
 
 
 
   
  
Region Count % Hist % All 
Total 20000 100.00 100.00 
R1 13631 68.16 68.16 
R2 414  2.07  2.07 
 
 
CD4+Tcells (upper 
compartment). 
NK cells (lower 
compartment). 
No anti- IL-6 antibody 
 
  
Region Count % Hist % All 
Total 10147 100.00 50.73 
R1 8336 82.15 41.68 
R2 1811  17.85  9.05 
 
Region Count % Hist % All 
Total 20000 100.00 100.00 
R1 13397 66.98 66.98 
R2 584  2.92  2.92 
 
Region Count % Hist % All 
Total 13397 100.00 66.98 
R1 10414 77.73 52.07 
R2 2983 22.27  14.92 
 
Region Count % Hist % All 
Total 20000 100.00 100.00 
R1 10147 50.73 50.73 
R2 861  4.30  4.30 
 
Region Count % Hist % All 
Total 13631 100.00 68.16 
R1 8361 61.34 41.81 
R2 5268 38.65  26.34 
 
Region Count % Hist % All 
Total 20000 100.00 100.00 
R1 7071 35.35 35.35 
R2 2533 12.67 12.67 
 
Region Count % Hist % All 
Total 7071 100.00 35.35 
R1 4086 57.79 20.43 
R2 2985 42.21  14.92 
 
CD4+Tcells (upper 
compartment.) 
NK cells (lower 
compartment.) 
Anti- IL-6 antibody. 
CD4+Tcells (upper 
compartment). 
Human IL-6 (lower 
compartment). 
CD4+Tcells (upper 
compartment). 
Culture medium (lower 
compartment). 
38.3% 
15.8% 
95.4% 
8.8% 
A 
 
 
298 
 
Figure 7.5: Migration of CD4
+
 T cells in sample 1 across the 3 µm pore size 
Transwell filters. 2 x 10
5
 purified CD4
+
 T cells were placed in the upper chamber of 
Transwell wells and assessed for migration across the membranes in response to 
different stimuli in the lower chamber by flow cytometry. A) CD4
+
 T cell migration 
across the membrane in response to 2 x 10
5 
pre-stimulated NK cells from the same 
donor.
 
The percentage of migration was 38.3%. B) CD4
+
 T cell migration across the 
membrane in response to same concentration of pre-activated NK cells from same 
donor in the presence of mouse anti-human anti-IL-6 antibody in the lower chamber. 
C) CD4
+
 T cell migration to the lower compartment in response to 20 ng/ml 
recombinant human IL-6 (positive control). D) Spontaneous CD4
+
 T cell migration 
(negative control). 
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Region Count % Hist % All 
Total 20000 100.00 100.00 
R1 12119 60.59 60.59 
R2 466  2.33  2.33 
 
 
CD4+Tcells (upper 
compartment). 
NK cells (lower 
compartment). 
No anti- IL-6 antibody. 
 
 
Region Count % Hist % All 
Total 3873 100.00 19.36 
R1 3399 87.76 16.99 
R2 474 12.24 2.37 
 
Region Count % Hist % All 
Total 20000 100.00 100.00 
R1 4924 24.62 24.62 
R2 219  1.10  1.10 
 
Region Count % Hist % All 
Total 4924 100.00 24.62 
R1 3500 71.08 17.50 
R2 1424 28.92 7.12 
 
Region Count % Hist % All 
Total 20000 100.00 100.00 
R1 3873 19.36 19.36 
R2 295 1.47  1.47 
 
Region Count % Hist % All 
Total 12119 100.00 60.59 
R1 5913 48.79 29.57 
R2 6206 51.21  31.03 
 
Region Count % Hist % All 
Total 20000 100.00 100.00 
R1 7071 35.35 35.35 
R2 2533 12.67 12.67 
 
Region Count % Hist % All 
Total 7071 100.00 35.35 
R1 4086 57.79 20.43 
R2 2985 42.21  14.92 
 
CD4+Tcells (upper 
compartment). 
NK cells (lower 
compartment). 
Anti- IL-6 antibody 
CD4+Tcells (upper 
compartment). 
Human IL-6 (lower 
compartment). 
CD4+Tcells (upper 
compartment.) 
Culture medium  (lower 
compartment). 
48.8% 
12.1% 
99.8% 
7.0% 
A 
B 
C 
D 
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Figure 7.6: Migration of CD4
+
 T cells in sample 2 across the 3 µm pore size 
Transwell filters. Isolated human CD4
+ 
T cells were seeded into the upper reservoir 
of the chamber. The number of migrated cells was determined 4 hrs after stimulation 
by counting the cells that found in the lower compartment of Transwell wells by flow 
cytometry. A) CD4
+
 T cell migration across the membrane in response to pre-activated 
NK cells from the same donor.
 
B) CD4
+
 T cell migration across the membrane in 
response to pre- activated NK cells from same donor in the presence of mouse anti-
human anti-IL-6 antibody in the lower chamber. C) CD4
+
 T cell migration to the lower 
compartment in response to recombinant human IL-6 (positive control). D) 
Spontaneous CD4
+
 T cell migration (negative control).The percentage of migration of 
CD4
+
 T cells were given in relation to total number of CD4
+
 T cells used.  
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Region Count % Hist % All 
Total 20000 100.00 100.00 
R1 13747 68.73 68.73 
R2 506  2.53  2.53 
 
CD4+Tcells (upper 
compartment). 
NK cells (lower 
compartment). 
No anti- IL-6 antibody. 
 
 
Region Count % Hist % All 
Total 10878 100.00 54.39 
R1 8528 78.40 42.64 
R2 2349 21.59 11.74 
 
Region Count % Hist % All 
Total 20000 100.00 100.00 
R1 12819 64.09 64.09 
R2 589  2.94 2.94 
 
Region Count % Hist % All 
Total 12819 100.00 64.09 
R1 7984 62.28 39.92 
R2 4833 37.70 24.16 
 
Region Count % Hist % All 
Total 20000 100.00 100.00 
R1 10878 54.39 54.39 
R2 937 4.69  4.69 
 
Region Count % Hist % All 
Total 13747 100.00 68.73 
R1 6209 45.17 31.05 
R2 7538 54.83  37.69 
 
Region Count % Hist % All 
Total 20000 100.00 100.00 
R1 2883 14.41 14.41 
R2 3396 16.98 16.98 
 
Region Count % Hist % All 
Total 2883 100.00 14.41 
R1 1235 42.84 6.17 
R2 1648 57.16 8.24 
 
CD4+Tcells (upper 
compartment). 
NK cells (lower 
compartment). 
Anti- IL-6 antibody. 
CD4+Tcells (upper 
compartment). 
Human IL-6 (lower 
compartment). 
CD4+Tcells (upper 
compartment). 
Culture medium  (lower 
compartment). 
61.5% 
18.8% 
111.0% 
3.6% 
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Figure 7.7: Migration of CD4
+
 T cells from sample 3 across the 3µm pore size 
Transwell inserts. As described for sample 1 and 2, the migration of CD4
+
 T cells 
across the membrane was assessed in response to different stimuli. A) 61.5% of the 
total CD4+ T cells in the upper compartment migrated in response to pre-activated NK 
cells in the lower compartment from the same donor. B) The migration of T cells was 
inhibited to 18.8% when anti-IL-6 antibody was added to pre-activated NK cells in the 
lower compartment. C) All the cells in the upper compartment migrated across the 
membrane in response to recombinant human IL-6 in the lower compartment. D) Only 
3.6% of the total T cell in the upper compartment migrated spontaneously to lower 
chamber in the absence of any external stimuli (negative control).    
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Region Count % Hist % All 
Total 20000 100.00 100.00 
R1 8240 41.20 68.73 
R2 1850 9.25  2.53 
 
CD4+Tcells (upper 
compartment.) 
NK cells (lower 
compartment.) 
No anti- IL-6 antibody. 
 
 
Region Count % Hist % All 
Total 7980 100.00 39.90 
R1 7497 93.95 37.48 
R2 483 6.05 2.42 
 
Region Count % Hist % All 
Total 20000 100.00 100.00 
R1 7857 39.28 39.28 
R2 794  3.97 3.97 
 
Region Count % Hist % All 
Total 7857 100.00 39.28 
R1 6838 87.03 34.19 
R2 1019 12.97 5.10 
 
Region Count % Hist % All 
Total 20000 100.00 100.00 
R1 7980 39.90 39.90 
R2 834 4.17  4.17 
 
Region Count % Hist % All 
Total 8240 100.00 41.20 
R1 33.98 41.24 16.99 
R2 4842 58.76 24.21 
 
Region Count % Hist % All 
Total 20000 100.00 100.00 
R1 3236 16.18 16.18 
R2 3549 17.75 17.75 
 
Region Count % Hist % All 
Total 3236 100.00 16.18 
R1 1408 43.51 7.04 
R2 1827 56.46 9.13 
 
CD4+Tcells (upper 
compartment). 
NK cells (lower 
compartment.) 
Anti- IL-6 antibody. 
CD4+Tcells (upper 
compartment). 
Human IL-6 (lower 
compartment). 
CD4+Tcells (upper 
compartment.) 
Culture medium  (lower 
compartment). 
9.6% 
4.3% 
19.6% 
3.9% 
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Figure 7.8: CD4+ T cell migration profiles in sample 4 in response to pre-
activated NK cells, IL-6 and anti IL-6 antibody. Although the CD4
+
 T cell 
migration profiles were lower than those observed with the other 3 samples, the 
migration was still inhibited by more than half when the effect of IL-6 secreted by NK 
cells was neutralized with anti-IL-6 antibody.     
 
 
 
 
7.3.3  CD4
+
 T cell recruitment in response to activated NK cells was inhibited 
by more than 30% in the presence of neutralizing concentration of anti-IL-6 
antibody 
Next the data obtained from the transmigration assay from all 4 samples 
were compared and the results were presented as means ± SD. In response to pre-
activated NK cells, the average CD4
+
 T cell migration from the upper to lower 
chambers of 3µm Transwell wells was ~ 40 % (39.45 ± 19.1).This migration was 
inhibited by ~ 30% (12.75 ± 5.4) when the medium in the NK cell chamber contained 
a neutralizing anti-IL-6 antibody. In positive control wells where CD4
+
 T cell 
migration was induced by rIL-6, the average migration was 81% ± 36.2 compared to 
only 5.8 ± 2.2 in negative controls where the migration of CD4
+
 T cells was assessed 
only in response to culture medium alone. The data obtained from the all 4 samples are 
summarized in Figure 7.9.  
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Figure 7.9 Effect of IL-6 neutralization on CD4
+
 T cell migration across 3 µm 
Transwell membrane in response to activated NK cells.  Results comparing data 
obtained from all 4 samples. From the bottom, the 1
st
 bar is the percentage of 
migration of CD4
+
 T cells in response to activated NK cells; the 2
nd
 bar represents the 
migration of CD4
+ 
T cells when the NK cells were incubated with neutralizing anti-IL-
6 antibody; the 3
rd
 bar is the positive control where the migration of T cells was 
induced by IL-6; the 4
th
 bar is the percentage migration of CD4
+
 T cells in response to 
culture medium (negative control). All data are presented as means ± SD.  
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7.4  Discussion 
7.4.1  The role of NK cells in T cells recruitment 
NK cells represent a component of the innate immunity known for their 
cytotoxic activity against intracellular pathogens and transformed cells (Trinchieri et 
al, 1989). In addition to their cytotoxic activity NK cells can also regulate the 
development of subsequent adaptive immune response via direct cell-to cell 
interaction (Gerosa et al, 2002; Piccioli et al, 2002; Lünemann et al, 2009) or via the 
secretion of immunoregulatory cytokines and chemokines (Kos, 1998; Biron et al, 
1999; French and Yokoyama, 2004). These immunoregulatory functions include DC 
maturation, CD4
+
 T cell polarization, selective editing of antigen presenting cells 
(APC), B cell activation and immunoglobulin isotype switching (Lünemann et al, 
2009).  
The recruitment of lymphocytes to the site of inflammation is a critical step 
in the generation of an effective adaptive immune response. NK cells dominate among 
the early invading cells in allografts and virus infected tissues (Somersalo et al, 1994) 
and their appearance precedes the influx of T cells. T cell recruitment to the site of 
inflammation is a complex process during which chemotactic cytokines and 
chemokines play a pivotal role (Roda et al, 2006). Many studies have shown that NK 
cells could participate in the initiation of a specific immune response by facilitating 
the recruitment of T cells to the site of inflammation through the secretion of cytokines 
and chemokines. Somersalo et al (1994) showed that NK cells activated in vitro with 
histamine and IL-2, or with a combination of IL-2 and an anti-CD16 monoclonal 
antibody increased both CD4
+
 and CD8
+
 T cell migration through fibronectin coated 
filters by 30-70%. This migration was inhibited by ~ 60% when the NK cells 
supernatant were pre-incubated with neutralizing antibodies to IL-8. Moreover, MIP-
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1α (CCL3) and RANTES (CCL5), two additional chemokines known to be secreted by 
NK cells in response to FcR/cytokine receptor co-stimulation, were documented in 
mediating T-cell chemotaxis (Roda et al, 2006). Hedrick et al (1997) found that 
lymphotactin (XCL1), a member of the XC chemokine family, is produced by NK 
cells and is responsible for the in vivo recruitment of both NK and T cells to the site of 
inflammation. NK cell depletion also has been shown to result in inhibition of T cell 
recruitment to the brain of Plasmodium berghei -infected animals (Hansen et al, 2007). 
Overall, these observations confirm that NK cells have the potential to recruit T 
lymphocytes, a function that fits with their unique role in bridging innate and adaptive 
immunity. 
 
7.4.2  IL-6 involvement in the migration of inflammatory and immune cells: 
Evidence from in vitro and in vivo studies  
Although IL-6 is not a classical chemokine, there is strong evidence that it 
alone or in combination with other cytokines, has a role in both in vitro and in vivo 
migration of other inflammatory and immune cells. Initially the ability of IL-6 to 
stimulate cell migration was attributed to IL-6 induced expression of other chemokines 
such as MCP-1 (CCL2) and IL-8 (CXCL8) (Romano et al, 1997). However, it has 
been found that IL-6 itself has the potential to act as a chemotactic factor by direct 
stimulation of cell migration. In dissecting the role of IL-6 in the migration of 
lymphocytes, Weissenbach et al (2004) found that, in the presence of extracellular 
matrix, IL-6 induced migration of human CD4
+
/CD45RO
+ 
T cells and human Karpas-
299 CD4
+
 T cell line. Moreover, they showed that this activity was not due to release 
of secondary chemotactic factors but was a direct response to IL-6. These findings are 
of great significance since the recruitment of CD4
+
 T cells to the site of inflammation 
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is a crucial step in inflammation as well as in many autoimmune diseases. The role of 
IL-6 in stimulating the migration of lymphocytes was also investigated by others. 
Bacon et al (1990) found that IL-6 together with IL-3 and IL-4 directly induced 
peripheral lymphocyte migration in vitro. Lawlor et al (1990) demonstrated that IL- 6 
was not only capable of inducing human CD4
+
 lymphocyte migration but also CD8
+ 
migration in vitro. 
The finding that IL-6 is involved in T-lymphocyte trafficking is also 
supported by observations from in vivo studies in both inflammation and 
autoimmunity. Through analysis of mononuclear cell infiltration in wild type (WT) 
and IL-6-deficient mice during peritoneal inflammation, McLoughlin et al (2005) 
reported that IL-6-deficient mice exhibited impaired T cell recruitment. They showed 
that IL-6 selectively governs T cell infiltration by regulating chemokine secretion 
(CXCL10, CCL4, CCL5, CCL11, and CCL17) and chemokine receptor (CCR3, 
CCR4, CCR5, and CXCR3) expression within the CD3
+
 infiltrate. Moreover, CD4
+
 T-
cells were unable to enter the infected lung in the absence of IL-6 during the course of 
an infection (Longhi et al, 2008; Dienz and Rincon, 2009). Using a mouse model of 
multiple sclerosis (experimental autoimmune encephalomyelitis), Arima et al (2012)  
showed that auto-reactive CD4
+ 
T cells access the central nervous system via the 
lumbar spinal cord. This access into the central nervous system was IL-6 dependent 
through up-regulation of the chemokine CCL20 in associated dorsal blood vessels. 
Interestingly, IL-6 trans-signalling events in an animal model of arthritis not only 
increase the severity of the disease through maintaining lymphocytes within the 
inflamed joint, but also through increasing lymphocyte recruitment an infiltration into 
the joint (Nowell et al, 2003). 
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In addition to lymphocytes, IL-6 was also reported to induce migration of 
other cells. IL-6 has been shown to be involved in the migration of monocytic cells 
(Clahsen and Schaper, 2008), and in the switching of the immune response from 
innate to acquired response (Kaplanski et al, 2003). Vasse et al (1999) demonstrated 
that IL-6 was a direct chemo-attractant for human dermal microvasculature endothelial 
cells (HMEC-1s) in vitro. Dominguez et al (2008) found that IL-6 in association with 
CXCL10 is a potent chemoattractive factor for trophoblast cells in a human model.  
 
7.4.3  In vitro trans-migration assay: Important considerations 
To test the specificity of CD4
+
 T cell migration in response to IL-6 secreted 
by NK cells a modified Boyden chamber assay was used. CD4
+
 lymphocytes were 
placed in the upper compartment of a Transwell chamber and were separated from the 
NK cells, IL-6 or culture medium in the lower compartment by the membrane of the 
insert. Cells were allowed to migrate through the pores of the membrane into the lower 
compartment. After 4 hours of incubation time the cells in the lower compartment 
were mixed with a known amount of beads to facilitate accurate quantitation, stained 
with an anti- CD4
+ 
FITC antibody and analysed by flow cytometry. 
Cell migration is an active process that requires the cells to change their 
shape in a process similar to diapedesis that occurs in vivo (Colantonio, 2004). For this 
reason the selection of the appropriate Transwell plate with suitable pore size inserts is 
important as part of the optimization process for trans-migration assay. If the pore size 
is too small, there will be no cells migrating through the membrane. On the other hand 
if the pore size is large, there would be cells diffusing across the membrane by gravity 
and not by true trans-migration (Sherman and Rothenberg, 2012). There is some 
controversy regarding the most suitable insert‟s pore size used for studying the 
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migration of lymphocytes. In some studies 3 µm pore size was used (Marelli-Berg et 
al, 1999; Edelbauer et al, 2010; O'Boyle et, 2012).  In other studies 5 µm (Taub et al, 
1995; Zang et al, 2000; Roda et al, 2006; Damsker et al, 2007; Knieke et al, 2009) and 
8 µm (Graeler and Goetzl , 2002; Graeler et al, 2002; Weissenbach et al, 2004; Qin et 
al,2009; Kim et al, 2010) pore sizes were utilised. Inserts with 8 µm pore size are 
usually recommended for migration of large cells like endothelial and epithelial cells, 
while 3 µm pore size inserts are recommended for small cells like leukocytes 
(Transwell manufacturers‟ recommendations). In the preliminary experiment using 8 
µm pore size inserts the non specific (spontaneous) migration of the CD4
+
 T cells was 
around 11 %. Because of the large pore size there was a possibility that some of the 
CD4
+
 cells collected from the lower compartment diffused through the Transwell 
membranes by gravity and not by migration. In an attempt to keep the spontaneous 
migration as low as possible and to obtain maximal signal compared to background 
the 8 µm inserts were replaced with 3 µm inserts.   
Another important point to be considered in trans-migration assay is the 
method used to calculate the number of cells that migrated into the lower 
compartment. In general, there are two methods used when counting the migrating 
cells by flow cytometry: “time-dependent acquisition of events” and “bead-dependent 
acquisition of events” (Colantonio, 2004). The first method depends on running all the 
samples at same event acquisition rate and the same period of time. Although this 
method is simple and inexpensive, it is not always accurate. The second method 
depends on using known number of microsphere particles that are brightly fluorescent 
across a wide range of excitation and emission wave lengths. These particles should be 
added to a known volume of sample and the absolute number of the cells can then be 
calculated using an equation.      
 
 
311 
 
7.4.4  NK cell - secreted IL-6 stimulates CD4
+
 T cell migration   
The current study examined the ability of activated PBNK cells to stimulate 
CD4
+
 T cell migration in vitro through fibronectin coated Transwell inserts. The 
results demonstrated that in the presence of NK cells that were pre-activated by 
culturing them in the presence of target cells and IL-2, about 40% of all CD4
+
 T cells 
in the upper compartment migrated into the lower compartment during the 4 hrs of the 
assay period. This migration was inhibited to ~ 13% (~ 30% inhibition) in the presence 
of an anti-IL-6 antibody. IL-8 (CXCL8), MIP-1α (CCL3), and RANTES (CCL5) are 
among the chemokines secreted by NK cells that are known to stimulate T cell 
migration or recruitment. However, this is apparently the first study shows that IL-6 
from NK cells could cause this migration. This adds IL-6 to the growing list of 
cytokines and chemokines that are secreted by NK cells and have been found to 
stimulate in vitro T cell migration. 
The ability of human NK cells to recruit T lymphocytes cells was 
investigated by others (section 7.4.1) and found to be dependent on the method used 
for activating NK cells and the state of T lymphocytes (naïve or activated). Somersalo 
et al (1994) showed that NK cells which were purified in the presence of 10% foetal 
calf serum (FCS), or which were activated in the absence of FCS but with histamine, 
IL-2, or with a combination of IL-2 and anti-CD16 mAbs increased both CD4
+
 and 
CD8
+
 T cell migration through fibronectin coated inserts by 30-70%.  This migration 
was inhibited by ~ 60% in the presence of neutralizing antibodies to IL-8. Roda et al 
(2006) found that naïve T cells exhibit reduced migration (less than 10%) in response 
to NK cells stimulated with antibody-coated tumour cells and IL-2. In contrast, they 
found that NK cells co-stimulated with antibody-coated tumour cells and IL-12 
induced significant levels of chemotaxis (∼36% of T cells migrated) as compared with 
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those derived from NK cells stimulated with single stimulation conditions. When 
activated T cells were used, ~ 20% of the total cells migrated when the NK cells were 
activated with IL-12 alone compared to more than 50% migration when the NK cells 
were activated with antibody-coated tumour cells and IL-12. In the current study NK 
cells were activated overnight with HeLa cells + IL-2 before using in the trans-
migration assay. This activation recruited ~ 40% of CD4
+
 T lymphocytes in the upper 
compartment. Therefore, our results extend the findings obtained by the above two 
groups and showed that activation of NK cells with targets + IL-2 was also sufficient 
to induce T cell migration. 
The main aim of this chapter was to examine the functional significance of 
IL-6 secreted by NK cells. Having shown that activated NK cells could stimulate 
CD4
+
 T cell migration did not necessarily indicate that IL-6 was causing this 
migration.  As stated before, IL-8 (CXCL8), MIP-1α (CCL3) and RANTES (CCL5) 
are secreted by NK cells and these chemokines have been shown to stimulate T cell 
migration. To confirm that IL-6 secreted by NK cells could also cause migration it was 
very necessary to neutralize the effect of IL-6 by an anti-IL-6 antibody. The results 
showed that the migration of CD4
+
 T cells in response to NK cells was inhibited by ~ 
30% when the NK cells were maintained in the presence of a neutralizing 
concentration of anti-IL-6 antibody. These results confirmed that IL-6 secreted by NK 
cells could, at least partially, contribute to T cell migration. Comparing these results 
with other chemokines, it has been found that the migration of T lymphocytes was 
inhibited by about 50-60% when the NK were pre-incubated with neutralizing 
antibodies to IL-8 (Somersalo et al, 1994; Roda et al, 2006). Neutralizing of MIP-1α 
or RANTES had only a slight (~10%) effect on the migration of both naïve and 
 
 
313 
 
activated T lymphocytes (Roda et al, 2006). Therefore, IL-6 comes only second to IL-
8 as a single cytokine secreted by NK cells that contributes to T cell migration.     
One can argue about the significance of IL-6 secreted by NK cells in 
stimulating T lymphocyte migration since many other cytokines and chemokines 
secreted by NK cells can recruit T cells. Indeed, there are many possible answers to 
this question. 1) Neither these results nor the results of other investigators confirm that 
a single cytokine or chemokine secreted by NK cells could stimulate 100% migration 
by T cells. Even with the positive control when the percentage T cell migration was > 
95%, very high doses of IL-6 were used (20 ng/ ml) in comparison to picogram 
concentrations secreted by NK cells (Chapter 3). Such artificially high doses of IL-6 
are unlikely to persist in an inflammatory milieu.  Therefore, it is highly likely that IL-
6 acts in combination with other cytokines and chemokines (IL-8, MIP-1α and 
RANTES) to stimulate maximal T cell migration by NK cells. In support of this view, 
Roda et al (2006) found that neutralization of IL-8 + MIP-1α + RANTES together had 
a dramatic effect on the migration of activated T cells in response to NK cells, 
reducing chemotaxis to ∼20% of the original level. It still remains a possibility that 
NK cell-derived IL-6 can induce autocrine or paracrine production of chemokines 
which then mediate the chemotactic effect. 2) The significance of CD4
+
 T cell 
migration in response to IL-6 secreted by NK cells derives from the significance of IL-
6 itself in both inflammation and autoimmunity. IL-6 is not only known to induce T 
cell recruitment, but also T cell proliferation, activation and differentiation. Lotz et al 
(1988) found that IL-6 acts as a co-stimulatory molecule for T cell proliferation 
independently of IL-2 gene expression. IL-6 was also found to prolong the survival of 
CD4
+
 T cells both in vitro (Teague et al, 1997; Dienz and Rincon, 2009) and in vivo 
(Takeda et al, 1998) due to its anti-apoptotic properties. Antigen specific CD4
+
 T cells 
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also expand more vigorously in vivo when IL-6 is present during immunization, due to 
reduced apoptosis, suggesting that IL-6 may increase the effector/memory T cell 
population (Dienz and Rincon, 2009). IL-6 was also shown to act synergistically with 
IL-1 in promoting T cell activation (Mizutani et al, 1988). In the light of these findings 
it is likely that NK cells, through the secretion of IL-6, may enhance the defensive 
immune response by coupling the induction of trafficking with stimulation of 
proliferation, activation and differentiation of CD4
+ 
T cells. 3) NK cells suggested to 
have an important role in several CD4
+
 T cell- driven autoimmune diseases such as 
rheumatoid arthritis (RA) in which IL-6 has a major impact. In this disease NK cells 
were found in abundance in the synovial fluid as well as in the serum of RA patients 
(Pridgeon, 2002; Langley, 2005). Since NK cells are found at inflammatory sites at 
very early stages where the concentration of CD4
+
 T cells is still very low, the 
abundance of the NK cells in the synovium of these patients further raises the 
possibility that NK cells could play a role in the initiation and progression of the 
disease by enhancing the CD4
+
 T cell recruitment through IL-6 secretion.    
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 NK cells have been shown to be important in defence against viral 
infections such as lymphocytic choriomeningitis virus (LCMV), murine 
cytomegalovirus (MCMV), herpes simplex virus (HSV), vaccinia virus and influenza 
virus (Rager-Zisman et al, 1987; Biron et al, 1999). They are able to kill virally 
infected cells through direct lysis of the infected cells via the secretion of cytolytic 
granules or interaction via death receptors (Fas-FasL interaction). However, in most of 
these infections, secretion of anti-viral cytokines was observed and demonstrated to 
have an important protective role.  
INF-γ and TNF-α are the two major cytokines secreted by NK cells and are 
known to have antiviral activity. However, in some of these infections where the NK 
cells have an important role in the defence mechanism, IL-6 appears to play a 
significant anti-viral role. For example, studies using IL-6 deficient mice have shown 
that IL-6 is involved in protection against HSV (LeBlanc et al, 1999; Murphy et al, 
2008). It also increases the rate of HSV clearance following infection (Murphy et al, 
2008). Similarly, in vaccinia virus infections IL-6 has a significant antiviral role as 
demonstrated by widespread infection in IL-6 deficient mice (Kopf et al, 1994). In 
addition to viral infections, NK cells were also reported to play an important defence 
role against some bacterial, fungal and parasitic infections. These include, but are not 
limited to, Mycobacterium tuberculosis (Brill et al, 2001), Staphylococcus aureus 
(Small et al, 2008), Listeria monocytogenes (Naper et al, 2011) and Aspergillus 
fumigatus (Bouzani et al, 2011). In these infections NK cells directly mediate the 
defence functions by the release of cytokines (Small et al, 2008, Bouzani et al, 2011). 
Interestingly, in separate in vivo studies on IL-6 deficient mice for all of the infections 
listed above IL-6 was found to have a specific protective role (Dalrymple et al, 1995; 
Ladel et al, 1997; Cenci et al, 2001; Hume et al, 2006). Considering the role of both 
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IL-6 and NK cells in these infections raises the possibility that IL-6 secretion by NK 
cells could be a main defence mechanism against them.    
During acute inflammation IL-6, together with IL-1 and TNF-α, is required 
for induction of the acute phase response. This response is composed of fever, 
corticosterone release, and hepatic production of acute phase proteins such as C 
reactive protein (CRP). The induction of the acute phase reaction by IL-6 has been 
regarded as part of an attempt to maintain homeostasis (Xing et al, 1998). In addition 
to the acute phase response, IL-6 was found to play a critical role in controlling the 
extent of local and systemic acute inflammatory responses by suppressing the level of 
pro-inflammatory cytokines without compromising the level of anti-inflammatory 
cytokines (Xing et al, 1998; Gabay, 2006). Its role is also crucial in the successful 
resolution of acute inflammation by facilitating the transition of initial neutrophil 
infiltrates into a more sustained mononuclear cell population such as monocytes and 
lymphocytes (Kaplanski et al, 2003; Fielding et al, 2008). Impaired IL-6 secretion may 
lead to impaired neutrophil clearance and increased tissue damage from the 
accumulation of neutrophil-secreted proteases at the site of inflammation (Fielding et 
al, 2008). Indeed, this situation has been implicated in the pathogenesis of many 
inflammatory diseases such as peritonitis, sepsis, inflammatory bowel diseases, 
obstructive pulmonary diseases and renal injury (Fielding et al, 2008). Overall, these 
studies demonstrate the protective role of IL-6 in acute inflammation. Therefore, the 
concept of IL-6 secretion by NK cells could fit with the latter protective role as a first 
line defence mechanism appearing very early at inflammation sites. It also fits with 
their role as cells of innate immunity that have the potential of influencing the later 
stages of the immune response. 
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During chronic inflammation IL-6 may exhibit a contrasting feature. IL-6 
has been found to be responsible for the persistent mononuclear cell infiltrates at the 
site of inflammation in a number of chronic inflammatory and autoimmune diseases 
such as rheumatoid arthritis (RA). In these diseases IL-6 acts as a pro-inflammatory 
rather than anti-inflammatory cytokine. Recent findings clearly indicate that IL-6 is a 
key factor involved in the regulation of T cell differentiation, activation and survival 
(Dienz and Rincon, 2009). Memory CD4
+ 
T lymphocytes have been shown to expand 
more vigorously in vivo when IL-6 is present due to the anti-apoptotic properties of 
this cytokine (Rochman et al, 2005). In addition, IL-6 stimulation has been linked to 
increased migration of activated CD4
+ 
T cells both in vitro and in vivo, which could 
explain their inability to enter the infected tissues in the absence of IL-6 during an 
infection (Weissenbach et al, 2004; Dienz and Rincon, 2009). NK cells have been 
shown to constitute a significant fraction of the infiltrating cells in RA and these cells 
are predominantly of the CD56 
bright
 phenotype (Pridgeon et al, 2003; Poli et al, 2009; 
Conigliaro et al, 2011). Interestingly, in concordance with the pro-inflammatory role 
of IL-6, NK cells were also found to play a significant pathogenic role in these 
diseases. Taking into consideration that cells with the CD56 
bright
 phenotype are mainly 
cytokine secretors (Cooper  et al, 2001) together with that fact that IL-6 is a powerful 
regulator of CD4
+
 T cell response (Dienz and  Rincon, 2009) one can speculate that 
NK cells could be a major source of IL-6 secretion in these patients. Furthermore, the 
preliminary findings in this laboratory that NK cells isolated from the blood of patients 
with RA produce significantly more IL-6 after in vitro stimulation than NK cells 
isolated from the blood of healthy donors supports the hypothesis that NK cells could 
augment the T-cell response in these patients via IL-6 secretion.  
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In addition to RA, surprising evidence has arisen regarding the co-
involvement of both NK cells and IL-6 in the pathogenesis of several other CD4
+
 T 
cell driven autoimmune diseases and therefore it is plausible that these cells might be 
the source of IL-6 secretion in these diseases. For example, disorders characterised by 
increasing number of NK cells such as NK cell lymphocytosis and leukaemia are often 
associated with autoimmune diseases such as vasculitis (Tefferi et al, 1994; French 
and Yokoyama, 2004). Interestingly, IL-6 is often found to play an important 
pathogenic role in vasculitis as demonstrated by increasing serum concentration of IL-
6 in these diseases (Roche et al, 1993; Emilie et al, 1994) as well as by the induction 
of disease remission using anti-IL-6 therapy (Seitz et al, 2011; Salvarani et al, 2012). 
Similarly, in animal models of autoimmunity, such as experimental autoimmune 
uveoretinitis (EAU), depletion of NK cells before immunization resulted in 
significantly less severe EAU demonstrating that NK cells participate in the 
development of EAU either by directly mediating cellular damage or by supporting 
rather than suppressing autoreactive T cells (Kitaichi et al, 2002; French and 
Yokoyama, 2004). A murine model of autoimmune-mediated diabetes after viral 
infection with Coxsackie B4 virus (CVB4) provides another example of NK cell-
mediated damage (Flodström et al, 2002; French and Yokoyama, 2004). In this model, 
depletion of NK cells before infection with CVB4 prevented the development of 
diabetes, implying that NK cells contributed to the destruction of the infected 
pancreatic beta cells. Surprisingly, separate studies on the role of IL-6 in these 
diseases have shown IL-6 to play an important role in pathogenesis of these diseases 
and IL-6 blockade is often observed to be beneficial (Hohki et al, 2010). Based on 
these observations from both human and animal models of autoimmunity, it may be 
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useful to look at NK cell-induced IL-6 secretion in these disorders to see how this 
secretion could contribute to the abnormalities seen in these diseases.   
The work presented in this thesis demonstrated that IL-6 concentration was 
significantly increased following exposure of NK cells to target cells against which 
these cells are known to exhibit direct cytotoxicity (either K562 or HeLa cells). The 
described secretory response was rapid with IL-6 being significantly higher as early as 
1 hr in HeLa co-cultures compared to 6 hors in the case of K562 co-cultures. Since 
both the K562 and HeLa cells are able to secrete IL-6 endogenously, a question arose 
whether the increase in IL-6 secretion following co-culture of NK cells with the target 
cells was coming from these cells rather than from NK cells. This issue was addressed 
when NK cells were activated alone with high doses of IL-2 or with non specific 
chemical activators (PMA+ ionomycin). The result of these experiments clearly 
showed that NK cells alone have the potential to secrete IL-6 in the absence of the 
target cells. The finding that NK cells secrete this multifaceted cytokine within a short 
period of time has its impact on the subsequent immune response. Taking into 
consideration the effect of IL-6 on the cells of specific (adaptive) immunity together 
with the fact that NK cells appear at inflammatory sites during the very early stages 
when the number of other cells such as T cells is negligible, NK cell-mediated IL-6 
secretion has the potential to influence the later stages of the immune response. Thus 
this mechanism may provide a critical link between the innate and adaptive immune 
response of the host. Furthermore, as described above, NK cell-induced IL-6 secretion 
in various autoimmune diseases, for example RA, may be relevant to the pathogenesis 
of these disorders.  
Investigating the activation pathway which triggers the secretion of IL-6 by 
NK cells was the next step. This is an important point to clarify from both a biological 
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and a clinical perspective in order to fully understand the role of NK cells in regulating 
adaptive immune response. It was known from the Transwell experiments presented in 
Chapter 3 that when NK cells come in contact with target cells, direct cell–cell contact 
is required for IL-6 production. For many years it was thought that the NK cells 
recognize the target cells as “friends or enemies” depending on the surface expression 
of MHC class I molecules on these cells; the “missing self hypothesis”. However, this 
concept represents an oversimplification of the way that NK cells recognize their 
targets. In the last decade it has been demonstrated that NK cells could attack some 
targets despite the expression of MHC class I molecules. On the other hand, some 
other cells are not sensitive to NK cell-lysis despite low or absent class I MHC 
expression. These observations necessitated the presence of other mechanisms, in 
addition to the “missing self hypothesis” by which NK cell target recognition is 
mediated. It is now clear that NK cells are controlled by complex combinations of 
activating and inhibitory receptors and the integration of signals derived from these 
receptors can determine whether the NK cell would become activated or not. The fact 
that HeLa, an MHC class I positive target cell line, provides a stimulus for IL-6 
production by NK cells indicates that KIR receptors recognising MHC class I proteins 
as an inhibitory molecule, play no role in the initiation of IL-6. This observation also 
indicates that the pathway involved provides an activating signal not “switched off” by 
inhibitory KIR signalling. On other hand, the finding that NK cells exposed to HeLa 
cells secrete more IL-6 than those exposed to K562 suggesting the involvement of 
different NK cell activating receptors in this secretion. Some studies using K562 cells 
as targets have demonstrated that NKG2C is involved in the NK cell induced lysis of 
these cells (Düchler et al, 1995). Despite this study, because K562 cells lack the 
surface expression of MHC-class I molecules, therefore the involvement of NKG2C 
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(recognise HLA-E alleles) in K562 lysis is less likely. The involvement of this 
receptor in NK cell induced lysis and cytokine secretion in case of HeLa cells seems to 
be unlikely also. Moretta et al (2001) suggested that in the case of MHC class I 
+
 cells, 
NKG2C (and activated KIRs) could only initiate NK cell triggering if the target cells 
do not express ligands for NKG2D and the NK cells are of NCR 
dull
 phenotype i.e. 
when the involvement of NKG2D and NCR pathways is lacking. Since HeLa cells are 
NKG2D ligand and NCR ligand positive (Moretta et al, 2001), therefore NKG2D and 
NCRs receptors are the most likely cell surface receptors satisfying this criterion, 
although some of the other natural killer receptors such as CD16, as well as other, less 
widely studied pathways, may also be theoretically responsible. One of the easiest 
ways to identify the molecular pathways involved in IL-6 secretion by NK cells would 
be the use of blocking monoclonal antibodies (antagonist mAbs) against different 
activating NK cell receptors to see if blocking of these receptors resulted in 
significantly reduced levels of IL-6 production by NK cells. Blocking some of these 
receptors such as NKG2D was indeed attempted (data not shown). The experiment 
was carried out on four healthy donors and the NK cells were co-cultured with HeLa 
cells in the presence and absence of an anti-NKG2D antibody (clone 1D11) at a 
concentration of 10 µg/ml. This antibody clone was used by others to block NKG2D 
receptors in NK and CD8
+
 T cells (Carbone et al, 2005; Mincheva - Nilsson et al, 
2006; Crane et al, 2010). In these experiments the results were inconsistent. Only one 
sample showed a prominent inhibition of IL-6 secretion by NK cells in the presence of 
blocking antibody while two samples showed only mild inhibition and one sample 
showed no inhibition at all. These findings, together with the fact that monoclonal 
antibodies with blocking properties are not commercially available against all NK 
receptors, made it necessary to consider other ways to study the differential 
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involvement of NK cell receptors in IL-6 secretion. An alternative approach to 
receptor blocking experiments was to stimulate NK cells in the presence of stimulating 
(agonist) antibodies. Immobilized agonist mAbs against a wide range of NK receptors, 
namely anti-CD16 (clone 3G8), anti-NKG2D (clone 149810), anti-NKp46 (clone 
195314), anti-NKp44 (clone 253415) and anti-NKp30 (clone 210845) are widely 
available and were used to activate NK cells (Chapter 4). In concordance with the 
HeLa co-culture experiments, the results demonstrated that NKG2D and NKp46 (in 
addition to CD16 to lesser extent) were the main receptors involved in inducing IL-6 
expression / or secretion. This response was detectable as early as 1 hour following 
stimulation, increased further at 3 and 6 hours and reached a peak at 24 hours. The 
finding that different receptors can induce IL-6 secretion suggests the involvement of 
different activating pathways in this secretion. Although structurally different, both 
NKp46 and CD16 NK cell activating receptors signalling through the same ITAM 
containing subunits (CD3δ or FcεRIγ). Activation of these  receptors on the surface of 
NK cells results in Ca
2+ flux followed by the phosphorylation of CD3δ or FcεRIγ by 
Lymphocyte-specific protein tyrosine kinase (Lck) and the recruitment of SYK family 
kinases-tyrosine kinase (Syk) and Zeta-chain associated protein kinase 70kDa 
(ZAP70). NKG2D receptors are not associated with CD3δ or FcεRIγ and instead they 
are associated with another ITAM bearing subunit (DAP10). Activation of NKG2D 
receptors on the surface of NK or CD8
+
 T cells stimulates another signalling cascade 
characterised by recruitment of phosphatidylinositol 3-kinase (PI3K). Therefore 
different NK cell receptors activate different signalling pathways. However, in 
contrast to other cytokines secreted by NK cells such as IFN-γ and TNF-α, the 
observation that the engagement of a single receptor was sufficient for the secretion of 
IL-6 by NK cells may reflect a lower threshold for IL-6 secretion by these cells. In fact 
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this lower threshold for IL-6 secretion by NK cells fits with the pivotal role of IL-6 in 
inflammation. 
In the relative real time experiments fold change differences in IL-6 mRNA 
expression was detected as early as 1 hour, increased further at 3 and 6 hours but was 
then inhibited at 24 hours regardless of whether the NK cells were stimulated with 
immobilized antibodies to NKG2D, NKp46 or CD16. The fact that IL-6 mRNA 
expression was detected as early as 1 hour post activation is an important finding into 
the activation mechanism. It may indicate that IL-6 message is constitutively 
expressed by NK cells. However, the subsequent findings that IL-6 mRNA increased 
further at later stages also indicate that IL-6 expression is regulated at transcription 
level. Therefore, the assumption is that IL-6 expression by NK cells following 
appropriate activation is regulated both at transcriptional and translational levels. 
However, transcriptional regulation seemed to be transient since there was a decline at 
24 hours to a level comparable to base line background.  
It is known that activating mouse NK cells with anti-NKG2D mAbs can 
lead to a potent NKG2D - dependent stimulation of cytokine release (Diefenbach and 
Raulet, 2001; Jamieson et al, 2002). However, the role of NKG2D in cytokine 
production by human NK cells upon mAbs triggering remains unclear. In contrast to 
mouse studies, cross linking human NKG2D receptors by mAbs failed to stimulate 
IFN-γ secretion by NK cells (Billadeau et al, 2003; André et al, 2004). These 
contradictory findings were attributed to structural differences in the NKG2D 
receptors between these two species. In the mouse two alternative splice products of 
the NKG2D gene co-exist on the surface of the activated NK cells (mNKG2D-L and 
mNKG2D-S) whereas there is only one human NKG2D product (Rosen et al, 2004). 
Since NKG2D receptors in both mouse and human lack intrinsic signalling capability, 
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therefore they need to be associated with adaptor molecules within their 
transmembrane (TM) region. The mNKG2D-L and hNKG2D are selectively 
associated with DAP10; while the mNKG2D-S can be associated with either DAP10 
or DAP12 molecules. In other words, mouse NKG2D receptors can be associated with 
both DAP10 and DAP12 while human NKG2D can only be associated with DAP10. It 
has been reported that mAbs activation of DAP10 associated NKG2D receptors 
stimulates NK cell cytotoxicity but not cytokine secretion, while activation of 
receptors in association with DAP12 can stimulate both cytotoxicity and cytokine 
secretion (André et al, 2004). These findings led to the assumption that while NKG2D 
can act as a primary activating receptor on mouse NK cells, it functions only as a co-
receptor in humans (Diefenbach et al, 2002). In contrast, we found that triggering of 
hNKG2D receptors with immobilized mAbs can stimulate both mRNA expression and 
secretion of IL-6. This is apparently the first work demonstrating that human NK cells 
can be induced to secrete a cytokine upon NKG2D triggering via a monoclonal 
antibody. This discrepancy can, however, be easily explained. All other studies 
focused on the secretion of IFN-γ, a cytokine that is regulated by different signalling 
elements than IL-6. As discussed in Chapter 4, Syk and ZAP70 kinases are the main 
signalling element involved in the secretion of IFN-γ by human NK cells. Since 
triggering of hNKG2D receptors by a mAbs activates totally different kinases, 
therefore it is not surprising that cross-linking of these receptors cannot activate IFN-γ 
secretion. As explained above, the activation of DAP10 associated NKG2D stimulates 
another signalling pathway, PI3K. Moreover, NKG2D activation in association with 
DAP10 has also shown to activate other activating pathways namely phospholipase-C 
γ and VAV (Billadeau et al, 2003; Bryceson et al, 2006). Stimulation of PI3K, 
phospholipase-C γ and VAV signalling elements has been linked to increased IL-6 
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secretion in a variety of normal as well as malignant human cells. Taken together these 
results may reveal distinct activation mechanisms for different cytokines by NK cells. 
As stated before, these results demonstrated that NKG2D and NKp46 were 
the main receptors involved in inducing IL-6 expression. To assess which NKG2D 
ligands were involved in this process, the expression of the NKG2D ligands as fusion 
proteins was attempted. Unfortunately, the expression of these fusion proteins was 
unsuccessful. As an alternative strategy target cells transfected with the individual 
ligands were used. Results showed that MICA and, and to a lesser extent, MICB were 
involved in NKG2D induced secretion of IL-6 by NK cells. Although this might 
indicate variation in the affinity of different ligands to NKG2D (which is supported in 
the literature), differences in the surface expression of these ligands on the target cells 
cannot be excluded as a potential explanation.    
It is known that the recruitment of leukocytes to the site of inflammation is a 
crucial step in the immune response. Chemokines play a central role in this process. 
Initially neutrophils are recruited first to the site of inflammation followed by 
mononuclear cells such as monocytes and lymphocytes. Although not a classical 
chemokine, IL-6 has been found to play an important role in recruitment of 
lymphocytes to the site of inflammation and therefore facilitating the switching of the 
immune response from the innate to the more specific adaptive response. The potential 
of IL-6 to induce cell migration was attributed to 1) induction of expression of 
chemokines such as monocyte chemoattractant protein-1 (MCP-1) and IL-8. 2) a direct 
effect of IL-6 on T cell migration. Given the role of NK cells as cells of innate 
immunity with immunoregulatory functions, it is possible that NK cells recruit these 
cells to the site of inflammation via IL-6 secretion. To test this hypothesis, an in vitro 
transmigration assay using a modified Boyden chamber was used. The results 
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demonstrated that CD4
+
 T cell migration in response to NK cells was inhibited by 
about 30% in the presence of neutralizing antibody to IL-6. These results signify the 
relative biological importance of IL-6 induced secretion by NK cells.    
 After this research, more questions are raised and needed to be explored in 
the future. It is known that NK cells are not a homologous group of cells and are 
divided into two phenotypic subsets according to their surface expression of CD56. 
These are CD56 
dim
 cells which constitute ~ 90% of PBNK cells and CD56 
bright 
cells 
which constitute ~10% of PBNK cells but are enriched in secondary lymphoid tissues 
(SLTs). For many years it was generally accepted that CD56 
dim 
cells are mainly 
responsible for cytotoxicity and target cell killing, while CD56 
bright
 cells are mainly 
cytokine secretors and acquire cytotoxicity only after prolonged activation. However, 
this concept is now challenged by the recent findings that CD56 
dim 
cells are also a 
potent source of cytokine and chemokines that are secreted within relatively short times 
(hours) after target cell recognition (Fauriat et al,2010 ; Juelke et al, 2010 ; Moretta, 
2010). Since CD56 
bright
 cells express more monokine receptors (IL-2, IL-12, IL-15 and 
IL-18) than CD56 
dim 
cells (Cooper et al, 2001), therefore it may be possible that this 
NK subtype are the main subset responsible for cytokine secretion upon monokine 
activation. However, CD56 
dim
 cells seem to be the main cytokine secretors upon target 
cell recognition. Based on these observations, it would be interesting in the future to see 
which of these differential subsets contributes to IL-6 secretion by NK cells. 
Identification of the phenotype of the NK cell subset responsible for IL-6 secretion 
would facilitate a better understanding of the biology of NK cell subsets. Moreover, it 
may also have an important clinical implication in monitoring the role of NK cells in 
pathologic conditions in which these effectors may contribute to defence or, possibly, 
to tissue damage.  
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There is some preliminary evidence in this laboratory that NK cells isolated 
from patients with autoimmune diseases such as RA persistently produce more IL-6 
than control groups (unpublished data). Whether this reflects differences in the 
activation state of NK cells between the patients and controls or represents an inherent 
genetic feature of the disease needs to be further clarified in the future.    
Another important direction for future study will be an in vivo evaluation of 
the biological significance of IL-6 secretion by NK cells. IL-6 is secreted rather 
ubiquitously by many cell types. To see if IL-6 production by NK cells is biologically 
relevant in influencing antiviral and antibacterial defence mechanisms, the use of 
animal models with selective NK cell deficiency are planned. Here two animal models 
are suggested. In the first model IL-6 knockout mice will be subjected to viral 
infection such as LCMV, HSV or vaccinia virus. The susceptibility of mice to these 
infections would be assessed later by measuring viral load in the blood and local 
tissues by PCR. IL-6 knockout mice will then be divided into three groups. The first 
group will be left untreated (negative control), the second group will be injected with 
NK cells derived from wild type (WT)-IL-6 secreting congeneic animals and the third 
group will be injected with PBMCs from WT donors, which have been depleted of NK 
cells. The mice will then be monitored over an appropriate period of time to see if the 
function of any of the three groups will be re-constituted. If giving WT NK cells 
improves the outcome then the argument can be made that IL-6 secretion by NK cells 
is a critical step in protecting the animals against the infection. On the other hand, if 
the giving WT NK cells afford little or no benefit, while injecting other mononuclear 
cells from animals that can produce IL-6 proves beneficial, this would indicate that IL-
6 secretion by cells other than NK cells is the critical step in generating a protective 
immune response. The second model is a more direct evaluation of the importance of 
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NK cell-secreted IL-6. During the course of the in vivo experiments three groups of 
mice will be subjected to NK cell depletion by injecting them with rabbit antiserum to 
asialo GM1, a neutral glycosphingolipid present in high concentration on the surface 
of mouse NK cells. The first group of animals will then be left untreated – negative 
control – while the second group of mice will be reconstituted with NK cells that can 
produce IL-6 while the third group will be injected with NK cells derived from IL-6 
knockout animals. A few hours later these three groups will be challenged with a 
virus. Over a period of days post infection the animals will be evaluated for viral load 
in the blood. If the IL-6 produced by NK cells is biologically relevant and contributes 
to the defence mechanisms of the body against infection, one would expect that the 
first and the third groups of mice will develop a more serious infection while the 
second group will be at least partially protected. 
One of the future aims would be to expand this work to see if IL-6 
production by NK cells can affect the activity of B cells and DCs in a variety of 
experimental models as well as in autoimmune diseases. For example, it is known that 
IL-6 plays a central role in B cell activation, survival and differentiation. Thus it is a 
critical component of the regulation of both protective and autoreactive B cells 
(Hirano et al, 1985; Kishimoto, 1989). At the same time, activated PBNK cells have 
been shown to directly stimulate resting B cells to produce IgM and IgG (Yuan et al, 
1992; Gray and Horwitz, 1995). Combining these findings together, it is possible that 
NK cells stimulate resting B cells through IL-6 secretion. Moreover, it has been  
demonstrated that both NK cells and IL-6 play a crucial role in the pathogenesis of 
some of B cell autoimmune diseases such as experimental autoimmune myasthenia 
gravis (French and Yokoyama, 2004; Arecha et al, 2011). Therefore, it would be 
interesting to assess role of NK cell-induced IL-6 in this disease.  
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9.1  Human MICA sequence  
Human MICA sequence, transcript variant 1 (allele MICA*00801) (NCBI Reference 
Sequence: NM_001177519) is presented below. Basically, it consists of a leader peptide (L), alpha-1 
(α1), alpha-2 (α2), alpha-3 (α3), transmembrane portion (TM) and cytoplasmic tail (Bahram et al, 
1996a). The sequence encoding for extracellular region includes L, α1, α2, α3 and it is 891 bp in length 
(Bahram et al, 1996a). It starts at position 40 and ends at position 930.  
 
CACTGCTTGA GCCGCTGAGA GGGTGGCGAC GTCGGGGCCA TGGGGCTGGG CCCGGTCTTT 
CTGCTTCTGG CTGGCATCTT CCCTTTTGCA CCTCCGGGAG CTGCTGCTGA GCCCCACAGT 
CTTCGTTATA ACCTCACGGT GCTGTCCTGG GATGGATCTG TGCAGTCAGG GTTTCTTGCT 
GAGGTACATC TGGATGGTCA GCCCTTCCTG CGCTATGACA GGCAGAAATG CAGGGCAAAG 
CCCCAGGGAC AGTGGGCAGA AGATGTCCTG GGAAATAAGA CATGGGACAG AGAGACCAGG 
GACTTGACAG GGAACGGAAA GGACCTCAGG ATGACCCTGG CTCATATCAA GGACCAGAAA 
GAAGGCTTGC ATTCCCTCCA GGAGATTAGG GTCTGTGAGA TCCATGAAGA CAACAGCACC 
AGGAGCTCCC AGCATTTCTA CTACGATGGG GAGCTCTTCC TCTCCCAAAA CCTGGAGACT 
GAGGAATGGA CAGTGCCCCA GTCCTCCAGA GCTCAGACCT TGGCCATGAA CGTCAGGAAT 
TTCTTGAAGG AAGATGCCAT GAAGACCAAG ACACACTATC ACGCTATGCA TGCAGACTGC 
CTGCAGGAAC TACGGCGATA TCTAGAATCC GGCGTAGTCC TGAGGAGAAC AGTGCCCCCC 
ATGGTGAATG TCACCCGCAG CGAGGCCTCA GAGGGCAACA TCACCGTGAC ATGCAGGGCT 
TCCAGCTTCT ATCCCCGGAA TATCATACTG ACCTGGCGTC AGGATGGGGT ATCTTTGAGC 
CACGACACCC AGCAGTGGGG GGATGTCCTG CCTGATGGGA ATGGAACCTA CCAGACCTGG 
GTGGCCACCA GGATTTGCCG AGGAGAGGAG CAGAGGTTCA CCTGCTACAT GGAACACAGC 
GGGAATCACA GCACTCACCC TGTGCCCTCT GGGAAAGTGC TGGTGCTTCA GAGTCATTGG 
CAGACATTCC ATGTTTCTGC TGTTGCTGCT GGCTGCTGCT ATTTTTGTTA TTATTATTTT 
CTATGTCCGT TGTTGTAAGA AGAAAACATC AGCTGCAGAG GGTCCAGAGC TCGTGAGCCT 
GCAGGTCCTG GATCAACACC CAGTTGGGAC GAGTGACCAC AGGGATGCCA CACAGCTCGG 
ATTTCAGCCT CTGATGTCAG CTCTTGGGTC CACTGGCTCC ACTGAGGGCA CCTAGACTCT 
ACAGCCAGGC GGCTGGAATT GAATTCCCTG CCTGGATCTC ACAAGCACTT TCCCTCTTGG 
TGCCTCAGTT TCCTGACCTA TGAAACAGAG AAAATAAAAG CACTTATTTA TTGTTGTTGG 
AGGCTGCAAA ATGTTAGTAG ATATGAGGCA TTTGCAGCTG TGCCATATT (1369 bp) 
  
 
Red:      Leader sequence = 69 nucleotides 
Blue:    Alpha 1 domain = 256 nucleotides  
Green:  Alpha 2 domain = 286 nucleotides 
Purple: Alpha 3 domain = 280 nucleotides 
 
 
9.1.1  Recombinant (Chimeric) hMICA-mFc1 sequence  
Recombinant hMICA-mFc1 sequence cloned (1590 bp) is presented below (5‟ to 3‟ 
orientation). The cloned sequence started with the start codon ATG and end with the stop codon TGA. 
No other stop codons (TAG, TAA, and TGA) were found through the entire sequence.  
                                                 
ATGGGGCTGGGCCCGGTCTTCCTGCTTCTGGCTGGCATCTTCCCTTTTGCACCTCCGGGAGCTGCTGCTG
AGCCCCACAGTCTTCGTTATAACCTCACGGTGCTGTCCTGGGATGGATCTGTGCAGTCAGGGTTTCTCAC
TGAGGTACATCTGGATGGTCAGCCCTTCCTGCGCTGTGACAGGCAGAAATGCAGGGCAAAGCCCCAGGGA
CAGTGGGCAGAAGATGTCCTGGGAAATAAGACATGGGACAGAGAGACCAGAGACTTGACAGGGAACGGAA
AGGACCTCAGGATGACCCTGGCTCATATCAAGGACCAGAAAGAAGGCTTGCATTCCCTCCAGGAGATTAG
GGTCTGTGAGATCCATGAAGACAACAGCACCAGGAGCTCCCAGCATTTCTACTACGATGGGGAGCTCTTC
CTCTCCCAAAACCTGGAGACTAAGGAATGGACAATGCCCCAGTCCTCCAGAGCTCAGACCTTGGCCATGA
ACGTCAGGAATTTCTTGAAGGAAGATGCCATGAAGACCAAGACACACTATCACGCTATGCATGCAGACTG
CCTGCAGGAACTACGGCGATATCTAAAATCCGGCGTAGTCCTGAGGAGAACAGTGCCCCCCATGGTGAAT
GTCACCCGCAGCGAGGCCTCAGAGGGCAACATTACCGTGACATGCAGGGCTTCTGGCTTCTATCCCTGGA
ATATCACACTGAGCTGGCGTCAGGATGGGGTATCTTTGAGCCACGACACCCAGCAGTGGGGGGATGTCCT
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GCCTGATGGGAATGGAACCTACCAGACCTGGGTGGCCACCAGGATTTGCCAAGGAGAGGAGCAGAGGTTC
ACCTGCTACATGGAACACAGCGGGAATCACAGCACTCACCCTGTGCCCTCTCCCAGAGGGCCCACAATCA
AGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCC
AAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAG
GATGACCCAGATGTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACAGCTCAGACACAAACCC
ATAGAGAGGATTACAACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCACCAGGACTGGATGAG
TGGCAAGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATCGAGAGAACCATCTCAAAA
CCCAAAGGGTCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGAAGAAGAGATGACTAAGAAAC
AGGTCACTCTGACCTGCATGGTCACAGACTTCATGCCTGAAGACATTTACGTGGAGTGGACCAACAACGG
GAAAACAGAGCTAAACTACAAGAACACTGAACCAGTCCTGGACTCTGATGGTTCTTACTTCATGTACAGC
AAGCTGAGAGTGGAAAAGAAGAACTGGGTGGAAAGAAATAGCTACTCCTGTTCAGTGGTCCACGAGGGTC
TGCACAATCACCACACGACTAAGAGCTTCTCCCGGACTCCGGGTAAATGA (1590 bp) 
 
Black: Leader sequence = 69 nucleotides 
Red:  Sequence encodes for extracellular portion of MICA protein = 822 bp 
Blue:  Sequence encodes for Fc region of mIgG2A = 699 bp 
TCATGA: BspHI restriction site 
 
Translation (5’ to 3’ frame of the above nucleotides sequence) 
MGLGPVFLLLAGIFPFAPPGAAAEPHSLRYNLTVLSWDGSVQSGFLTEVHLDGQPFLRCDRQKCRAKPQ
GQWAEDVLGNKTWDRETRDLTGNGKDLRMTLAHIKDQKEGLHSLQEIRVCEIHEDNSTRSSQHFYYDGE
LFLSQNLETKEWTMPQSSRAQTLAMNVRNFLKEDAMKTKTHYHAMHADCLQELRRYLKSGVVLRRTVPP
MVNVTRSEASEGNITVTCRASGFYPWNITLSWRQDGVSLSHDTQQWGDVLPDGNGTYQTWVATRICQGE
EQRFTCYMEHSGNHSTHPVPSPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVV
VDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPI
ERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSD
GSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK 
 
Black: Leader protein sequence 
Red:    Extracellular portion of MICA protein  
Blue:  Fc portion of mIgG2A 
Molecular weight = 60011. 35 Daltons 
 
9.1.1.1  Alignment of the cloned nucleotide sequence to hMICA-mFc1 sequence 
The result of hMICA - mFc1 sequencing was aligned to the sequence described in section 
9.1.1 using BLAST tool from NCBI website. Note that the Query sequence is the sequencing result, 
while the Sbjct sequence is the sequence described in section 9.1.1 
  
Sequencing result  
 
CGCCTACCTTGAAGATCCACCCGATAGAATTCATGGGGCTGGGCCCGGTCTTCCTGCTTCTGGCTGGCATCTTCCC
TTTTGCACCTCCGGGAGCTGCTGCTGAGCCCCACAGTCTTCGTTATAACCTCACGGTGCTGTCCTGGGATGGATCT
GTGCAGTCAGGGTTTCTCACTGAGGTACATCTGGATGGTCAGCCCTTCCTGCGCTGTGACAGGCAGAAATGCAGGG
CAAAGCCCCAGGGACAGTGGGCAGAAGATGTCCTGGGAAATAAGACATGGGACAGAGAGACCAGAGACTTGACAGG
GAACGGAAAGGACCTCAGGATGACCCTGGCTCATATCAAGGACCAGAAAGAAGGCTTGCATTCCCTCCAGGAGATT
AGGGTCTGTGAGATCCATGAAGACAACAGCACCAGGAGCTCCCAGCATTTCTACTACGATGGGGAGCTCTTCCTCT
CCCAAAACCTGGAGACTAAGGAATGGACAATGCCCCAGTCCTCCAGAGCTCAGACCTTGGCCATGAACGTCAGGAA
TTTCTTGAAGGAAGATGCCATGAAGACCAAGACACACTATCACGCTATGCATGCAGACTGCCTGCAGGAACTACGG
CGATATCTAGAATCCGGCGTAGTCCTGAGGAGAACAGTGCCCCCCATGGTGAATGTCACCCGCAGCGAGGCCTCAG
AGGGCAACATCACCGTGACATGCAGGGCTTCTGGCTTCTATCCCTGGAATATCACACTGAGCTGGCGTCAGGATGG
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GGTATCTTTGAGCCACGACACCCAGCAGTGGGGGGATGTCCTGCCTGATGGGAATGGAACCTACCAGACCTGGGTG
GCCACCAGGATTTGCCAAGGAGAGGAGCAGAGGTTCACCTGCTACATGGAACACAGCGGGAATCACAGCACTCACC
CTGTGCCCTCTCCCAGAGGGCCCACAATCAAGCCCTGTCCTCCATGCAANNNNNCNNNNCCTN 
AATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGG
ACCATCCGTCTTCATCTTCGCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTG
GTGGTGGATGTGAGCGAGGATGACCCAGATGTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACAGCTC
AGACACAAACCCATAGAGAGGATTACAACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCACCAGGACTG
GATGAGTGGCAAGGAGNNNNTNNNNNGN 
 
GAATTC: EcoRI restriction site 
 
TCATGA: BspHI restriction site 
 
 
Alignment 
 
Query  33    ATGGGGCTGGGCCCGGTCTTCCTGCTTCTGGCTGGCATCTTCCCTTTTGCACCTCCGGGA  92 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1     ATGGGGCTGGGCCCGGTCTTCCTGCTTCTGGCTGGCATCTTCCCTTTTGCACCTCCGGGA  60 
 
Query  93    GCTGCTGCTGAGCCCCACAGTCTTCGTTATAACCTCACGGTGCTGTCCTGGGATGGATCT  152 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61    GCTGCTGCTGAGCCCCACAGTCTTCGTTATAACCTCACGGTGCTGTCCTGGGATGGATCT  120 
 
Query  153   GTGCAGTCAGGGTTTCTCACTGAGGTACATCTGGATGGTCAGCCCTTCCTGCGCTGTGAC  212 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121   GTGCAGTCAGGGTTTCTCACTGAGGTACATCTGGATGGTCAGCCCTTCCTGCGCTGTGAC  180 
 
Query  213   AGGCAGAAATGCAGGGCAAAGCCCCAGGGACAGTGGGCAGAAGATGTCCTGGGAAATAAG  272 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181   AGGCAGAAATGCAGGGCAAAGCCCCAGGGACAGTGGGCAGAAGATGTCCTGGGAAATAAG  240 
 
Query  273   ACATGGGACAGAGAGACCAGAGACTTGACAGGGAACGGAAAGGACCTCAGGATGACCCTG  332 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241   ACATGGGACAGAGAGACCAGAGACTTGACAGGGAACGGAAAGGACCTCAGGATGACCCTG  300 
 
Query  333   GCTCATATCAAGGACCAGAAAGAAGGCTTGCATTCCCTCCAGGAGATTAGGGTCTGTGAG  392 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301   GCTCATATCAAGGACCAGAAAGAAGGCTTGCATTCCCTCCAGGAGATTAGGGTCTGTGAG  360 
 
Query  393   ATCCATGAAGACAACAGCACCAGGAGCTCCCAGCATTTCTACTACGATGGGGAGCTCTTC  452 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361   ATCCATGAAGACAACAGCACCAGGAGCTCCCAGCATTTCTACTACGATGGGGAGCTCTTC  420 
 
Query  453   CTCTCCCAAAACCTGGAGACTAAGGAATGGACAATGCCCCAGTCCTCCAGAGCTCAGACC  512 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421   CTCTCCCAAAACCTGGAGACTAAGGAATGGACAATGCCCCAGTCCTCCAGAGCTCAGACC  480 
 
Query  513   TTGGCCATGAACGTCAGGAATTTCTTGAAGGAAGATGCCATGAAGACCAAGACACACTAT  572 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  481   TTGGCCATGAACGTCAGGAATTTCTTGAAGGAAGATGCCATGAAGACCAAGACACACTAT  540 
 
Query  573   CACGCTATGCATGCAGACTGCCTGCAGGAACTACGGCGATATCTAGAATCCGGCGTAGTC  632 
             ||||||||||||||||||||||||||||||||||||||||||||| |||||||||||||| 
Sbjct  541   CACGCTATGCATGCAGACTGCCTGCAGGAACTACGGCGATATCTAAAATCCGGCGTAGTC  600 
 
Query  633   CTGAGGAGAACAGTGCCCCCCATGGTGAATGTCACCCGCAGCGAGGCCTCAGAGGGCAAC  692 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  601   CTGAGGAGAACAGTGCCCCCCATGGTGAATGTCACCCGCAGCGAGGCCTCAGAGGGCAAC  660 
 
Query  693   ATCACCGTGACATGCAGGGCTTCTGGCTTCTATCCCTGGAATATCACACTGAGCTGGCGT  752 
             || ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  661   ATTACCGTGACATGCAGGGCTTCTGGCTTCTATCCCTGGAATATCACACTGAGCTGGCGT  720 
 
Query  753   CAGGATGGGGTATCTTTGAGCCACGACACCCAGCAGTGGGGGGATGTCCTGCCTGATGGG  812 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  721   CAGGATGGGGTATCTTTGAGCCACGACACCCAGCAGTGGGGGGATGTCCTGCCTGATGGG  780 
 
Query  813   AATGGAACCTACCAGACCTGGGTGGCCACCAGGATTTGCCAAGGAGAGGAGCAGAGGTTC  872 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  781   AATGGAACCTACCAGACCTGGGTGGCCACCAGGATTTGCCAAGGAGAGGAGCAGAGGTTC  840 
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Query  873   ACCTGCTACATGGAACACAGCGGGAATCACAGCACTCACCCTGTGCCCTCTCCCAGAGGG  932 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  841   ACCTGCTACATGGAACACAGCGGGAATCACAGCACTCACCCTGTGCCCTCTCCCAGAGGG  900 
 
Query  933   CCCACAATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCA  992 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  901   CCCACAATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCA  960 
 
Query  993   TCCGTCTTCATCTTCGCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATA  1052 
             ||||||||||||||| |||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  961   TCCGTCTTCATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATA  1020 
 
Query  1053  GTCACATGTGTGGTGGTGGATGTGAGCGAGGATGACCCAGATGTCCAGATCAGCTGGTTT  1112 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1021  GTCACATGTGTGGTGGTGGATGTGAGCGAGGATGACCCAGATGTCCAGATCAGCTGGTTT  1080 
 
Query  1113  GTGAACAACGTGGAAGTACACACAGCTCAGACACAAACCCATAGAGAGGATTACAACAGT  1172 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1081  GTGAACAACGTGGAAGTACACACAGCTCAGACACAAACCCATAGAGAGGATTACAACAGT  1140 
 
Query  1173  ACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCACCAGGACTGGATGAGTGGCAAGGAG  1232 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1141  ACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCACCAGGACTGGATGAGTGGCAAGGAG  1200 
 
 
9.1.2 Recombinant hMICA-mFc2 sequence  
The cloned sequence of recombinant hMICA-mFc2 (1581 bp) is presented below (5‟ to 3‟ 
orientation). Natural leading sequence for MICA protein were removed and replaced by the leader 
sequence of IL-2 protein. Start codon ATG and stop codon TGA were highlighted in colours.  
       
ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCGGAGCCCCAC
AGTCTTCGTTATAACCTCACGGTGCTGTCCTGGGATGGATCTGTGCAGTCAGGGTTTCTTGCTGAGGTA
CATCTGGATGGTCAGCCCTTCCTGCGCTATGACAGGCAGAAATGCAGGGCAAAGCCCCAGGGACAGTGG
GCAGAAGATGTCCTGGGAAATAAGACATGGGACAGAGAGACCAGGGACTTGACAGGGAACGGAAAGGAC
CTCAGGATGACCCTGGCTCATATCAAGGACCAGAAAGAAGGCTTGCATTCCCTCCAGGAGATTAGGGTC
TGTGAGATCCATGAAGACAACAGCACCAGGAGCTCCCAGCATTTCTACTACGATGGGGAGCTCTTCCTC
TCCCAAAACCTGGAGACTGAGGAATGGACAGTGCCCCAGTCCTCCAGAGCTCAGACCTTGGCCATGAAC
GTCAGGAATTTCTTGAAGGAAGATGCCATGAAGACCAAGACACACTATCACGCTATGCATGCAGACTGC
CTGCAGGAACTACGGCGATATCTAGAATCCGGCGTAGTCCTGAGGAGAACAGTGCCCCCCATGGTGAAT
GTCACCCGCAGCGAGGCCTCAGAGGGCAACATCACCGTGACATGCAGGGCTTCCAGCTTCTATCCCCGG
AATATCATACTGACCTGGCGTCAGGATGGGGTATCTTTGAGCCACGACACCCAGCAGTGGGGGGATGTC
CTGCCTGATGGGAATGGAACCTACCAGACCTGGGTGGCCACCAGGATTTGCCGAGGAGAGGAGCAGAGG
TTCACCTGCTACATGGAACACAGCGGGAATCACAGCACTCACCCTGTGCCCTCTCCCAGAGGGCCCACA
ATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTC
CCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTGGATGTG
AGCGAGGATGACCCAGATGTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACAGCTCAGACA
CAAACCCATAGAGAGGATTACAACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCACCAGGAC
TGGATGAGTGGCAAGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATCGAGAGAACC
ATCTCAAAACCCAAAGGGTCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGAAGAAGAGATG
ACTAAGAAACAGGTCACTCTGACCTGCATGGTCACAGACTTCATGCCTGAAGACATTTACGTGGAGTGG
ACCAACAACGGGAAAACAGAGCTAAACTACAAGAACACTGAACCAGTCCTGGACTCTGATGGTTCTTAC
TTCATGTACAGCAAGCTGAGAGTGGAAAAGAAGAACTGGGTGGAAAGAAATAGCTACTCCTGTTCAGTG
GTCCACGAGGGTCTGCACAATCACCACACGACTAAGAGCTTCTCCCGGACTCCGGGTAAATGA (1581 
bp) 
 
  
Green: Leader sequence for human IL-2 secreting protein (hIL-2 signal sequence) = 60 nucleotides 
Red:    Sequence encoding for the extracellular region of hMICA = 822 nucleotides 
Blue:   Sequence encoding for Fc region of mIgG2A = 699 nucleotides 
 
BspHI 
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Translation (5’ to 3’ orientation) 
 
MYRMQLLSCIALSLALVTNSEPHSLRYNLTVLSWDGSVQSGFLAEVHLDGQPFLRYDRQKCRAKPQGQW
AEDVLGNKTWDRETRDLTGNGKDLRMTLAHIKDQKEGLHSLQEIRVCEIHEDNSTRSSQHFYYDGELFL
SQNLETEEWTVPQSSRAQTLAMNVRNFLKEDAMKTKTHYHAMHADCLQELRRYLESGVVLRRTVPPMVN
VTRSEASEGNITVTCRASSFYPRNIILTWRQDGVSLSHDTQQWGDVLPDGNGTYQTWVATRICRGEEQR
FTCYMEHSGNHSTHPVPSPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDV
SEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERT
ISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEVLDSDGSYF
MYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK 
 
Green: Leader sequence for IL-2 protein 
Red:    Extracellular region of hMICA protein   
Blue:    Fc region of mIgG2A  
Molecular weight = 60308.58 
 
 
9.1.2.1 Alignment of the cloned nucleotide sequence to hMICA-mFc2 sequence 
The result of hMICA-mFc2 sequencing was aligned to the sequence described in section 
9.1.2 using BLAST tool from NCBI website. Query sequence is the sequencing result, while Sbjct 
sequence is the sequence described in section 9.1.2 
 
 
 
Sequencing result  
 
ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCGGAGCCCCACAGTCTTCG
TTATAACCTCACGGTGCTGTCCTGGGATN 
NNNNNNNNNCNNNGTNNNGTCCTGGGATGNATCTGTGCAGTCAGGGTTTCTTGCTGAGGTACATCTGGATGGTCAGC
CCTTCCTGCGCTATGACAGGCAGAAATGCAGGGCAAAGCCCCAGGGACAGTGGGCAGAAGATGTCCTGGGAAATAAG
ACATGGGACAGAGAGACCAGGGACTTGACAGGGAACGGAAAGGACCTCAGGATGACCCTGGCTCATATCAAGGACCA
GAAAGAAGGCTTGCATTCCCTCCAGGAGATTAGGGTCTGTGAGATCCATGAAGACAACAGCACCAGGAGCTCCCAGC
ATTTCTACTACGATGGGGAGCTCTTCCTCTCCCAAAACCTGGAGACTGAGGAATGGACAGTGCCCCAGTCCTCCAGA
GCTCAGACCTTGGCCATGAACGTCAGGAATTTCTTGAAGGAAGATGCCATGAAGACCAAGACACACTATCACGCTAT
GCATGCAGACTGCCTGCAGGAACTACGGCGATATCTAGAATCCGGCGTAGTCCTGAGGAGAACAGTGCCCCCCATGG
TGAATGTCACCCGCAGCGAGGCCTCAGAGGGCAACATCACCGTGACATGCAGGGCTTCCAGCTTCTATCCCCGGAAT
ATCATACTGACCTGGCGTCAGGATGGGGTATCTTTGAGCCACGACACCCAGCAGTGGGGGGATGTCCTGCCTGATGG
GAATGGAACCTACCAGACCTGGGTGGCCACCAGGATTTGCCGAGGAGAGGAGCAGAGGTTCACCTGCTACATGGAAC
ACAGCGGGAATCACAGCACTCACCCTGTGCCCTCTCCCAGAGGGCCCACAATCAAGCCCTGTCCTCCATGCAAATGC
CCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCT
GAGCCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAGGATGACCCANATGTCCAGATCAGCTGGTTTGTGAACA
ACGTNNNNTACACACAGCTCANANNCANANCCNATANANNNG 
 
 
 
GAATTC: EcoRI restriction site 
 
TCATGA: BspHI restriction site 
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Alignment  
 
 
Query  1     ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCG  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1     ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCG  60 
 
Query  61    GAGCCCCACAGTCTTCGTTATAACCTCACGGTGCTGTCCTGGGATGNATCTGTGCAGTCA  120 
             |||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||| 
Sbjct  61    GAGCCCCACAGTCTTCGTTATAACCTCACGGTGCTGTCCTGGGATGGATCTGTGCAGTCA  120 
 
Query  121   GGGTTTCTTGCTGAGGTACATCTGGATGGTCAGCCCTTCCTGCGCTATGACAGGCAGAAA  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121   GGGTTTCTTGCTGAGGTACATCTGGATGGTCAGCCCTTCCTGCGCTATGACAGGCAGAAA  180 
 
Query  181   TGCAGGGCAAAGCCCCAGGGACAGTGGGCAGAAGATGTCCTGGGAAATAAGACATGGGAC  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181   TGCAGGGCAAAGCCCCAGGGACAGTGGGCAGAAGATGTCCTGGGAAATAAGACATGGGAC  240 
 
Query  241   AGAGAGACCAGGGACTTGACAGGGAACGGAAAGGACCTCAGGATGACCCTGGCTCATATC  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241   AGAGAGACCAGGGACTTGACAGGGAACGGAAAGGACCTCAGGATGACCCTGGCTCATATC  300 
 
Query  301   AAGGACCAGAAAGAAGGCTTGCATTCCCTCCAGGAGATTAGGGTCTGTGAGATCCATGAA  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301   AAGGACCAGAAAGAAGGCTTGCATTCCCTCCAGGAGATTAGGGTCTGTGAGATCCATGAA  360 
 
Query  361   GACAACAGCACCAGGAGCTCCCAGCATTTCTACTACGATGGGGAGCTCTTCCTCTCCCAA  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361   GACAACAGCACCAGGAGCTCCCAGCATTTCTACTACGATGGGGAGCTCTTCCTCTCCCAA  420 
 
Query  421   AACCTGGAGACTGAGGAATGGACAGTGCCCCAGTCCTCCAGAGCTCAGACCTTGGCCATG  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421   AACCTGGAGACTGAGGAATGGACAGTGCCCCAGTCCTCCAGAGCTCAGACCTTGGCCATG  480 
 
Query  481   AACGTCAGGAATTTCTTGAAGGAAGATGCCATGAAGACCAAGACACACTATCACGCTATG  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  481   AACGTCAGGAATTTCTTGAAGGAAGATGCCATGAAGACCAAGACACACTATCACGCTATG  540 
 
Query  541   CATGCAGACTGCCTGCAGGAACTACGGCGATATCTAGAATCCGGCGTAGTCCTGAGGAGA  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  541   CATGCAGACTGCCTGCAGGAACTACGGCGATATCTAGAATCCGGCGTAGTCCTGAGGAGA  600 
 
Query  601   ACAGTGCCCCCCATGGTGAATGTCACCCGCAGCGAGGCCTCAGAGGGCAACATCACCGTG  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  601   ACAGTGCCCCCCATGGTGAATGTCACCCGCAGCGAGGCCTCAGAGGGCAACATCACCGTG  660 
 
Query  661   ACATGCAGGGCTTCCAGCTTCTATCCCCGGAATATCATACTGACCTGGCGTCAGGATGGG  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  661   ACATGCAGGGCTTCCAGCTTCTATCCCCGGAATATCATACTGACCTGGCGTCAGGATGGG  720 
 
Query  721   GTATCTTTGAGCCACGACACCCAGCAGTGGGGGGATGTCCTGCCTGATGGGAATGGAACC  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  721   GTATCTTTGAGCCACGACACCCAGCAGTGGGGGGATGTCCTGCCTGATGGGAATGGAACC  780 
 
Query  781   TACCAGACCTGGGTGGCCACCAGGATTTGCCGAGGAGAGGAGCAGAGGTTCACCTGCTAC  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  781   TACCAGACCTGGGTGGCCACCAGGATTTGCCGAGGAGAGGAGCAGAGGTTCACCTGCTAC  840 
 
Query  841   ATGGAACACAGCGGGAATCACAGCACTCACCCTGTGCCCTCTCCCAGAGGGCCCACAATC  900 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  841   ATGGAACACAGCGGGAATCACAGCACTCACCCTGTGCCCTCTCCCAGAGGGCCCACAATC  900 
 
Query  901   AAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTC  960 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  901   AAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTC  960 
 
Query  961   ATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGT  1020 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  961   ATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGT  1020 
 
Query  1021  GTGGTGGTGGATGTGAGCGAGGATGACCCANATGTCCAGATCAGCTGGTTTGTGAACAAC  1080 
             |||||||||||||||||||||||||||||| ||||||||||||||||||||||||||||| 
Sbjct  1021  GTGGTGGTGGATGTGAGCGAGGATGACCCAGATGTCCAGATCAGCTGGTTTGTGAACAAC  1080 
 
 
 
BspHI 
 
EcoRI 
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9.1.3  hMICA-mFc2 sequence with EcoRI and BglII restriction sites  
When MICA sequence was planned to be inserted between the EcoRI (5‟GAATTC3‟) and 
BglII (5‟ AGATCT 3‟) restriction sites of pFUSE-mIgG2A-Fc2 vector by simple ligation, the BglII 
restriction site separated the hMICA sequence from the mFc sequence. 
ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCGGAGCCCCAC
AGTCTTCGTTATAACCTCACGGTGCTGTCCTGGGATGGATCTGTGCAGTCAGGGTTTCTTGCTGAGGTA
CATCTGGATGGTCAGCCCTTCCTGCGCTATGACAGGCAGAAATGCAGGGCAAAGCCCCAGGGACAGTGG
GCAGAAGATGTCCTGGGAAATAAGACATGGGACAGAGAGACCAGGGACTTGACAGGGAACGGAAAGGAC
CTCAGGATGACCCTGGCTCATATCAAGGACCAGAAAGAAGGCTTGCATTCCCTCCAGGAGATTAGGGTC
TGTGAGATCCATGAAGACAACAGCACCAGGAGCTCCCAGCATTTCTACTACGATGGGGAGCTCTTCCTC
TCCCAAAACCTGGAGACTGAGGAATGGACAGTGCCCCAGTCCTCCAGAGCTCAGACCTTGGCCATGAAC
GTCAGGAATTTCTTGAAGGAAGATGCCATGAAGACCAAGACACACTATCACGCTATGCATGCAGACTGC
CTGCAGGAACTACGGCGATATCTAGAATCCGGCGTAGTCCTGAGGAGAACAGTGCCCCCCATGGTGAAT
GTCACCCGCAGCGAGGCCTCAGAGGGCAACATCACCGTGACATGCAGGGCTTCCAGCTTCTATCCCCGG
AATATCATACTGACCTGGCGTCAGGATGGGGTATCTTTGAGCCACGACACCCAGCAGTGGGGGGATGTC
CTGCCTGATGGGAATGGAACCTACCAGACCTGGGTGGCCACCAGGATTTGCCGAGGAGAGGAGCAGAGG
TTCACCTGCTACATGGAACACAGCGGGAATCACAGCACTCACCCTGTGCCCTCTAGATCTCCCAGAGGG
CCCACAATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTC
ATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTG
GATGTGAGCGAGGATGACCCAGATGTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACAGCT
CAGACACAAACCCATAGAGAGGATTACAACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCAC
CAGGACTGGATGAGTGGCAAGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATCGAG
AGAACCATCTCAAAACCCAAAGGGTCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGAAGAA
GAGATGACTAAGAAACAGGTCACTCTGACCTGCATGGTCACAGACTTCATGCCTGAAGACATTTACGTG
GAGTGGACCAACAACGGGAAAACAGAGCTAAACTACAAGAACACTGAACCAGTCCTGGACTCTGATGGT
TCTTACTTCATGTACAGCAAGCTGAGAGTGGAAAAGAAGAACTGGGTGGAAAGAAATAGCTACTCCTGT
TCAGTGGTCCACGAGGGTCTGCACAATCACCACACGACTAAGAGCTTCTCCCGGACTCCGGGTAAATGA 
(1587 bp) 
 
 
9.1.3.1  Alignment of the cloned nucleotide sequence to hMICA-mFc2 sequence (with EcoRI 
and BglII restriction sites)  
 
Results of sequencing  
 
ATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCGGAGCCCCACAGTCTTCGTTATAACCT
CACGGTGCTGTCCTGGGATGGATCTGTGCAGTCAGGGTTTCTTGCTGAGGTACATCTGGATGGTCAGCCCTTCCTGC
GCTATGACAGGCAGAAATGCAGGGCAAAGCCCCAGGGACAGTGGGCAGAAGATGTCCTGGGAAATAAGACATGGGAC
AGAGAGACCAGGGACTTGACAGGGAACGGAAAGGACCTCAGGATGACCCTGGCTCATATCAAGGACCAGAAAGAAGG
CTTGCATTCCCTCCAGGAGATTAGGGTCTGTGAGATCCATGAAGACAACAGCACCAGGAGCTCCCAGCATTTCTACT
ACGATGGGGAGCTCTTCCTCTCCCAAAACCTGGAGACTGAGGAATGGACAGTGCCCCAGTCCTCCAGAGCTCAGACC
TTGGCCATGAACGTCAGGAATTTCTTGAAGGAAGATGCCATGAAGACCAAGACACACTATCACGCTATGCATGCAGA
CTGCCTGCAGGAACTACGGCGATATCTAGAATCCGGCGTAGTCCTGAGGAGAACAGTGCCCCCCATGGTGAATGTCA
CCCGCAGCGAGGCCTCAGAGGGCAACATCACCGTGACATGCAGGGCTTCCAGCTTCTATCCCCGGAATATCATACTG
ACCTGGCGTCAGGATGGGGTATCTTTGAGCCACGACACCCAGCAGTGGGGGGATGTCCTGCCTGATGGGAATGGAAC
CTACCAGACCTGGGTGGCCACCAGGATTTGCCGAGGAGAGGAGCAGANNANNNNGNNNNNNNN 
TGCCGAGGAGAGGAGCAGAGGTTCACCTGCTACATGGAACACAGCGGGA
ATCACAGCACTCACCCTGTGCCCTCTAGATCTCCCAGANGGCCCACAATCAAGCCCTGTCCTCCATGCAAATGCCCA
GCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAG
CCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAGGATGACCCANATGTCCAGATCAGCTGGTTTGTGAACAACG
TNNNNTACACACAGCTCANANNCANANCCNATANANNNGATTACANNNANTNNNNGGGNNGNCANTGCCCTCCCATC
NGCACAGGACTGGATNANTGCAAGGAGTTCAATGCAAGNNACANANNACNNCCNNCNCCATCNANAGAANCNTCTNA
ANCNAAAGGNCANTANNN 
 
GAATTC: EcoRI restriction site 
 
AGATCT: BglII restriction site 
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Alignment 
Query  1     ATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCGGAGCCCCAC  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  10    ATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCGGAGCCCCAC  69 
 
Query  61    AGTCTTCGTTATAACCTCACGGTGCTGTCCTGGGATGGATCTGTGCAGTCAGGGTTTCTT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  70    AGTCTTCGTTATAACCTCACGGTGCTGTCCTGGGATGGATCTGTGCAGTCAGGGTTTCTT  129 
 
Query  121   GCTGAGGTACATCTGGATGGTCAGCCCTTCCTGCGCTATGACAGGCAGAAATGCAGGGCA  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  130   GCTGAGGTACATCTGGATGGTCAGCCCTTCCTGCGCTATGACAGGCAGAAATGCAGGGCA  189 
 
Query  181   AAGCCCCAGGGACAGTGGGCAGAAGATGTCCTGGGAAATAAGACATGGGACAGAGAGACC  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  190   AAGCCCCAGGGACAGTGGGCAGAAGATGTCCTGGGAAATAAGACATGGGACAGAGAGACC  249 
 
Query  241   AGGGACTTGACAGGGAACGGAAAGGACCTCAGGATGACCCTGGCTCATATCAAGGACCAG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  250   AGGGACTTGACAGGGAACGGAAAGGACCTCAGGATGACCCTGGCTCATATCAAGGACCAG  309 
 
Query  301   AAAGAAGGCTTGCATTCCCTCCAGGAGATTAGGGTCTGTGAGATCCATGAAGACAACAGC  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  310   AAAGAAGGCTTGCATTCCCTCCAGGAGATTAGGGTCTGTGAGATCCATGAAGACAACAGC  369 
 
Query  361   ACCAGGAGCTCCCAGCATTTCTACTACGATGGGGAGCTCTTCCTCTCCCAAAACCTGGAG  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  370   ACCAGGAGCTCCCAGCATTTCTACTACGATGGGGAGCTCTTCCTCTCCCAAAACCTGGAG  429 
 
Query  421   ACTGAGGAATGGACAGTGCCCCAGTCCTCCAGAGCTCAGACCTTGGCCATGAACGTCAGG  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  430   ACTGAGGAATGGACAGTGCCCCAGTCCTCCAGAGCTCAGACCTTGGCCATGAACGTCAGG  489 
 
Query  481   AATTTCTTGAAGGAAGATGCCATGAAGACCAAGACACACTATCACGCTATGCATGCAGAC  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  490   AATTTCTTGAAGGAAGATGCCATGAAGACCAAGACACACTATCACGCTATGCATGCAGAC  549 
 
Query  541   TGCCTGCAGGAACTACGGCGATATCTAGAATCCGGCGTAGTCCTGAGGAGAACAGTGCCC  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  550   TGCCTGCAGGAACTACGGCGATATCTAGAATCCGGCGTAGTCCTGAGGAGAACAGTGCCC  609 
 
Query  601   CCCATGGTGAATGTCACCCGCAGCGAGGCCTCAGAGGGCAACATCACCGTGACATGCAGG  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  610   CCCATGGTGAATGTCACCCGCAGCGAGGCCTCAGAGGGCAACATCACCGTGACATGCAGG  669 
 
Query  661   GCTTCCAGCTTCTATCCCCGGAATATCATACTGACCTGGCGTCAGGATGGGGTATCTTTG  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  670   GCTTCCAGCTTCTATCCCCGGAATATCATACTGACCTGGCGTCAGGATGGGGTATCTTTG  729 
 
Query  721   AGCCACGACACCCAGCAGTGGGGGGATGTCCTGCCTGATGGGAATGGAACCTACCAGACC  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  730   AGCCACGACACCCAGCAGTGGGGGGATGTCCTGCCTGATGGGAATGGAACCTACCAGACC  789 
 
Query  781   TGGGTGGCCACCAGGATTTGCCGAGGAGAGGAGCAGAGGTTCACCTGCTACATGGAACAC  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  790   TGGGTGGCCACCAGGATTTGCCGAGGAGAGGAGCAGAGGTTCACCTGCTACATGGAACAC  849 
 
Query  841   AGCGGGAATCACAGCACTCACCCTGTGCCCTCTAGATCTCCCAGANGGCCCACAATCAAG  900 
             ||||||||||||||||||||||||||||||||||||||||||||| |||||||||||||| 
Sbjct  850   AGCGGGAATCACAGCACTCACCCTGTGCCCTCTAGATCTCCCAGAGGGCCCACAATCAAG  909 
 
Query  901   CCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATC  960 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  910   CCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATC  969 
 
Query  961   TTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTG  1020 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  970   TTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTG  1029 
 
 
 
 
 
EcoRI 
 
Bglll 
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9.2 Human MICB sequence  
The MICB mRNA nucleotide sequence was submitted to NCBI (Reference Sequence: 
NM_005931.3) and presented below. Like MICA, MICB consists of a leader peptide (L), α1, α2, α3, 
transmembrane portion (TM) and cytoplasmic tail (Bahram et al, 1996b). The sequence encoding for 
extracellular portion includes L, α1, α2, α3 and it is 882 bp in length (Bahram et al, 1996b). It starts at 
position 117 and ends at position 998.  
 
ACTGGATAAG CGGTCGCTGA GCGGGGCGCA GGTGACTAAA TTTCGACGGG GTCTTCTCAC 
GGGTTTCATT CAGTTGGCCA CTGCTGAGCA GCTGAGAAGG TGGCGACGTA GGGGCCATGG 
GGCTGGGCCG GGTCCTGCTG TTTCTGGCCG TCGCCTTCCC TTTTGCACCC CCGGCAGCCG 
CCGCTGAGCC CCACAGTCTT CGTTACAACC TCATGGTGCT GTCCCAGGAT GGATCTGTGC 
AGTCAGGGTT TCTCGCTGAG GGACATCTGG ATGGTCAGCC CTTCCTGCGC TATGACAGGC 
AGAAACGCAG GGCAAAGCCC CAGGGACAGT GGGCAGAAAA TGTCCTGGGA GCTAAGACCT 
GGGACACAGA GACCGAGGAC TTGACAGAGA ATGGGCAAGA CCTCAGGAGG ACCCTGACTC 
ATATCAAGGA CCAGAAAGGA GGCTTGCATT CCCTCCAGGA GATTAGGGTC TGTGAGATCC 
ATGAAGACAG CAGCACCAGG GGCTCCCGGC ATTTCTACTA CGATGGGGAG CTCTTCCTCT 
CCCAAAACCT GGAGACTCAA GAATCGACAG TGCCCCAGTC CTCCAGAGCT CAGACCTTGG 
CTATGAACGT CACAAATTTC TGGAAGGAAG ATGCCATGAA GACCAAGACA CACTATCGCG 
CTATGCAGGC AGACTGCCTG CAGAAACTAC AGCGATATCT GAAATCCGGG GTGGCCATCA 
GGAGAACAGT GCCCCCCATG GTGAATGTCA CCTGCAGCGA GGTCTCAGAG GGCAACATCA 
CCGTGACATG CAGGGCTTCC AGCTTCTATC CCCGGAATAT CACACTGACC TGGCGTCAGG 
ATGGGGTATC TTTGAGCCAC AACACCCAGC AGTGGGGGGA TGTCCTGCCT GATGGGAATG 
GAACCTACCA GACCTGGGTG GCCACCAGGA TTCGCCAAGG AGAGGAGCAG AGGTTCACCT 
GCTACATGGA ACACAGCGGG AATCACGGCA CTCACCCTGT GCCCTCTGGG AAGGCGCTGG 
TGCTTCAGAG TCAACGGACA GACTTTCCAT ATGTTTCTGC TGCTATGCCA TGTTTTGTTA 
TTATTATTAT TCTCTGTGTC CCTTGTTGCA AGAAGAAAAC ATCAGCGGCA GAGGGTCCAG 
AGCTTGTGAG CCTGCAGGTC CTGGATCAAC ACCCAGTTGG GACAGGAGAC CACAGGGATG 
...................................................... 
TAAATGTTTA CTCTTTAAAT AGAAAAAAAA AAAAAAA (2497 bp)  
 
Red:       Leader sequence = 69 nucleotides 
Blue:      Alpha 1 domain = 256 nucleotides 
Green:    Alpha 2 domain = 288 nucleotides 
Purple:   Alpha 3 domain = 270 nucleotides 
 
 
9.2.1 Recombinant (Chimeric) hMICB-mFc1 sequence (1581 bp) 
ATGGGGCTGGGCCGGGTCCTGCTGTTTCTGGCCGTCGCCTTCCCTTTTGCACCCCCGGCAGCCGCCGCT
GAGCCCCACAGTCTTCGTTACAACCTCATGGTGCTGTCCCAGGATGGATCTGTGCAGTCAGGGTTTCTC
GCTGAGGGACATCTGGATGGTCAGCCCTTCCTGCGCTATGACAGGCAGAAACGCAGGGCAAAGCCCCAG
GGACAGTGGGCAGAAAATGTCCTGGGAGCTAAGACCTGGGACACAGAGACCGAGGACTTGACAGAGAAT
GGGCAAGACCTCAGGAGGACCCTGACTCATATCAAGGACCAGAAAGGAGGCTTGCATTCCCTCCAGGAG
ATTAGGGTCTGTGAGATCCATGAAGACAGCAGCACCAGGGGCTCCCGGCATTTCTACTACGATGGGGAG
CTCTTCCTCTCCCAAAACCTGGAGACTCAAGAATCGACAGTGCCCCAGTCCTCCAGAGCTCAGACCTTG
GCTATGAACGTCACAAATTTCTGGAAGGAAGATGCCATGAAGACCAAGACACACTATCGCGCTATGCAG
GCAGACTGCCTGCAGAAACTACAGCGATATCTGAAATCCGGGGTGGCCATCAGGAGAACAGTGCCCCCC
ATGGTGAATGTCACCTGCAGCGAGGTCTCAGAGGGCAACATCACCGTGACATGCAGGGCTTCCAGCTTC
TATCCCCGGAATATCACACTGACCTGGCGTCAGGATGGGGTATCTTTGAGCCACAACACCCAGCAGTGG
GGGGATGTCCTGCCTGATGGGAATGGAACCTACCAGACCTGGGTGGCCACCAGGATTCGCCAAGGAGAG
GAGCAGAGGTTCACCTGCTACATGGAACACAGCGGGAATCACGGCACTCACCCTCCCAGAGGGCCCACA
ATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTC
CCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTGGATGTG
AGCGAGGATGACCCAGATGTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACAGCTCAGACA
CAAACCCATAGAGAGGATTACAACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCACCAGGAC
TGGATGAGTGGCAAGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATCGAGAGAACC
ATCTCAAAACCCAAAGGGTCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGAAGAAGAGATG
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ACTAAGAAACAGGTCACTCTGACCTGCATGGTCACAGACTTCATGCCTGAAGACATTTACGTGGAGTGG
ACCAACAACGGGAAAACAGAGCTAAACTACAAGAACACTGAACCAGTCCTGGACTCTGATGGTTCTTAC
TTCATGTACAGCAAGCTGAGAGTGGAAAAGAAGAACTGGGTGGAAAGAAATAGCTACTCCTGTTCAGTG
GTCCACGAGGGTCTGCACAATCACCACACGACTAAGAGCTTCTCCCGGACTCCGGGTAAATGA  
(1581 bp) 
 
Black:  Leader sequence = 69 bp 
Red:   Sequence encodes for extracellular portion of MICB protein = 813 bp 
Blue:  Sequence encoding for Fc region of mIgG2A = 699 bp. 
TCATGA: BspHI restriction site 
 
Translation (5’ to 3’ orientation) 
 
MGLGRVLLFLAVAFPFAPPAAAAEPHSLRYNLMVLSQDGSVQSGFLAEGHLDGQPFLRYDRQKRRAKPQG
QWAENVLGAKTWDTETEDLTENGQDLRRTLTHIKDQKGGLHSLQEIRVCEIHEDSSTRGSRHFYYDGELF
LSQNLETQESTVPQSSRAQTLAMNVTNFWKEDAMKTKTHYRAMQADCLQKLQRYLKSGVAIRRTVPPMVN
VTCSEVSEGNITVTCRASSFYPRNITLTWRQDGVSLSHNTQQWGDVLPDGNGTYQTWVATRIRQGEEQRF
TCYMEHSGNHGTHPPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDP
DVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKG
SVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLR
VEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK 
 
Black: Leader protein sequence 
Red:    Extracellular portion of MICB protein  
Blue:  Fc portion of mIgG2A 
Molecular weight = 59566.72 Daltons 
 
9.2.1.1 Alignment of the cloned nucleotide sequence to hMICB-mFc1 sequence 
 
Result of sequencing 
 
NNNAANTGGNNNTNNNCNGNNNNANGGTAANGTTTAAANNNNNAGNTNGAAGACCGAGGNCNTTNTCCGNNCGNTCC
CNTGNAGGCCTACNTAGNTCANNNGNNNNNACGCTTTGCCTGACCNGCTTGNTCAANNNTANGTNTTGTTTCGTTTT
CTGTTNTGCGCCGTTACAGANNNAAGCTGTGACCGGGCGCNTACCTGAGATCACCGGTGAATTCATGGGGCTGGGCC
GGGTCCTGCTGTTTCTGGCCGTCGCCTTCCCTTTTGCACCCCCGGCAGCCGCCGCTGAGCCCCACAGTCTTCGTTAC
AACCTCATGGTGCTGTCCCGGGATGGATCTGTGCAGTCAGGGTTTCTCGCTGAGGGACATCTGGATGGTCAGCCCTT
CCTGCGCTATGACAGGCAGAAACGCAGGGCAAAGCCCCAGGGACAGTGGGCAGAAAATGTCCTGGGAGCTAAGACCT
GGGACACAGAGACCGAGGACTTGACAGAGAATGGGCAAGACCTCAGGAGGACCCTGACTCATATCAAGGACCAGAAA
GGAGGCTTGCATTCCCTCCAGGAGATTAGGGTCTGTGAGATCCATGAAGACAGCAGCACCAGGGGCTCCCGGCATTT
CTACTACGATGGGGAGCTCTTCCTCTCCCAAAACCTGGAGACTCAGGAATCGACAGTGCCCCAGTCCTCCAGAGCTC
AGACCTTGGCTATGAACGTCACAAATTTCTGGAAGGAAGATGCCATGAAGACCAAGACACACTATCACGCTATGCAG
GCAGACTGCCTGCAGAAACTACAGCGATATCTGAAATCCGGGGTGGCCATGAGGAGAACAGTGCCCCCCATGGTGAA
TGTCACCTGCAGCGAGGTCTCAGANNNNNNNNNNNNNNNNN 
TGTCACCTGCAGCGAGGTCTCAGAGGGCAACATCACCGTGACATGCAGGGCTTCCAGCTTCTATCCCCGGAATATCA
CACTGACCTGGCGTCAGGATGGGGTATCTTTGAGCCACAACACCCAGCAGTGGGGGGATGTCCTGCCTGATGGGAAT
GGAACCTACCAGACCTGGGTGGCCACCAGGATTCGCCAAGGAGAGGAGCAGAGGTTCACCTGCTACATGGAACACAG
CGGGAATCACGGCACTCACCCTCCCAGAGGGCCCACAATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACC
TCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTC
ACATGTGTGGTGGTGGATGTGAGCGAGGATGACCCAGATGTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACA
CACAGCTCAGACACAAACCCATAGAGAGGATTACAACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCACC
AGGACTGGATGAGTGGCAAGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATCGAGAGAACCATC
TCAAAACCCAAAGGGTCAGTAAGAGCTCCACAGNNNNNNNNNNNN  
 
GAATTC: EcoRI restriction site 
 
TCATGA: BspHI restriction site 
 
 
 
342 
 
Alignment 
 
Query  219   ATGGGGCTGGGCCGGGTCCTGCTGTTTCTGGCCGTCGCCTTCCCTTTTGCACCCCCGGCA  278 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1     ATGGGGCTGGGCCGGGTCCTGCTGTTTCTGGCCGTCGCCTTCCCTTTTGCACCCCCGGCA  60 
 
Query  279   GCCGCCGCTGAGCCCCACAGTCTTCGTTACAACCTCATGGTGCTGTCCCGGGATGGATCT  338 
             ||||||||||||||||||||||||||||||||||||||||||||||||| |||||||||| 
Sbjct  61    GCCGCCGCTGAGCCCCACAGTCTTCGTTACAACCTCATGGTGCTGTCCCAGGATGGATCT  120 
 
Query  339   GTGCAGTCAGGGTTTCTCGCTGAGGGACATCTGGATGGTCAGCCCTTCCTGCGCTATGAC  398 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121   GTGCAGTCAGGGTTTCTCGCTGAGGGACATCTGGATGGTCAGCCCTTCCTGCGCTATGAC  180 
 
Query  399   AGGCAGAAACGCAGGGCAAAGCCCCAGGGACAGTGGGCAGAAAATGTCCTGGGAGCTAAG  458 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181   AGGCAGAAACGCAGGGCAAAGCCCCAGGGACAGTGGGCAGAAAATGTCCTGGGAGCTAAG  240 
 
Query  459   ACCTGGGACACAGAGACCGAGGACTTGACAGAGAATGGGCAAGACCTCAGGAGGACCCTG  518 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241   ACCTGGGACACAGAGACCGAGGACTTGACAGAGAATGGGCAAGACCTCAGGAGGACCCTG  300 
 
Query  519   ACTCATATCAAGGACCAGAAAGGAGGCTTGCATTCCCTCCAGGAGATTAGGGTCTGTGAG  578 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301   ACTCATATCAAGGACCAGAAAGGAGGCTTGCATTCCCTCCAGGAGATTAGGGTCTGTGAG  360 
 
Query  579   ATCCATGAAGACAGCAGCACCAGGGGCTCCCGGCATTTCTACTACGATGGGGAGCTCTTC  638 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361   ATCCATGAAGACAGCAGCACCAGGGGCTCCCGGCATTTCTACTACGATGGGGAGCTCTTC  420 
 
Query  639   CTCTCCCAAAACCTGGAGACTCAGGAATCGACAGTGCCCCAGTCCTCCAGAGCTCAGACC  698 
             ||||||||||||||||||||||| |||||||||||||||||||||||||||||||||||| 
Sbjct  421   CTCTCCCAAAACCTGGAGACTCAAGAATCGACAGTGCCCCAGTCCTCCAGAGCTCAGACC  480 
 
Query  699   TTGGCTATGAACGTCACAAATTTCTGGAAGGAAGATGCCATGAAGACCAAGACACACTAT  758 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  481   TTGGCTATGAACGTCACAAATTTCTGGAAGGAAGATGCCATGAAGACCAAGACACACTAT  540 
 
Query  759   CACGCTATGCAGGCAGACTGCCTGCAGAAACTACAGCGATATCTGAAATCCGGGGTGGCC  818 
             | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  541   CGCGCTATGCAGGCAGACTGCCTGCAGAAACTACAGCGATATCTGAAATCCGGGGTGGCC  600 
 
Query  819   ATCAGGAGAACAGTGCCCCCCATGGTGAATGTCACCTGCAGCGAGGTCTCAGAGGGCAAC  878 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  601   ATCAGGAGAACAGTGCCCCCCATGGTGAATGTCACCTGCAGCGAGGTCTCAGAGGGCAAC  660 
 
Query  879   ATCACCGTGACATGCAGGGCTTCCAGCTTCTATCCCCGGAATATCACACTGACCTGGCGT  938 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  661   ATCACCGTGACATGCAGGGCTTCCAGCTTCTATCCCCGGAATATCACACTGACCTGGCGT  720 
 
Query  939   CAGGATGGGGTATCTTTGAGCCACAACACCCAGCAGTGGGGGGATGTCCTGCCTGATGGG  998 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  721   CAGGATGGGGTATCTTTGAGCCACAACACCCAGCAGTGGGGGGATGTCCTGCCTGATGGG  780 
 
Query  999   AATGGAACCTACCAGACCTGGGTGGCCACCAGGATTCGCCAAGGAGAGGAGCAGAGGTTC  1058 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  781   AATGGAACCTACCAGACCTGGGTGGCCACCAGGATTCGCCAAGGAGAGGAGCAGAGGTTC  840 
 
Query  1059  ACCTGCTACATGGAACACAGCGGGAATCACGGCACTCACCCTCCCAGAGGGCCCACAATC  1118 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  841   ACCTGCTACATGGAACACAGCGGGAATCACGGCACTCACCCTCCCAGAGGGCCCACAATC  900 
 
Query  1119  AAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTC  1178 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  901   AAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTC  960 
 
Query  1179  ATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGT  1238 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  961   ATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGT  1020 
 
Query  1239  GTGGTGGTGGATGTGAGCGAGGATGACCCAGATGTCCAGATCAGCTGGTTTGTGAACAAC  1298 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1021  GTGGTGGTGGATGTGAGCGAGGATGACCCAGATGTCCAGATCAGCTGGTTTGTGAACAAC  1080 
 
 
 
 
BspHI 
 
 
343 
 
Query  1299  GTGGAAGTACACACAGCTCAGACACAAACCCATAGAGAGGATTACAACAGTACTCTCCGG  1358 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1081  GTGGAAGTACACACAGCTCAGACACAAACCCATAGAGAGGATTACAACAGTACTCTCCGG  1140 
 
Query  1359  GTGGTCAGTGCCCTCCCCATCCAGCACCAGGACTGGATGAGTGGCAAGGAGTTCAAATGC  1418 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1141  GTGGTCAGTGCCCTCCCCATCCAGCACCAGGACTGGATGAGTGGCAAGGAGTTCAAATGC  1200 
 
Query  1419  AAGGTCAACAACAAAGACCTCCCAGCGCCCATCGAGAGAACCATCTCAAAACCCAAAGGG  1478 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1201  AAGGTCAACAACAAAGACCTCCCAGCGCCCATCGAGAGAACCATCTCAAAACCCAAAGGG  1260 
 
Query  1479  TCAGTAAGAGCTCCACAG  1496 
             |||||||||||||||||| 
Sbjct  1261  TCAGTAAGAGCTCCACAG  1278 
 
 
9.2.2  Recombinant hMICB-mFc2 sequence 
ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCGGAGCCCCAC
AGTCTTCGTTACAACCTCATGGTGCTGTCCCAGGATGGATCTGTGCAGTCAGGGTTTCTCGCTGAGGGA
CATCTGGATGGTCAGCCCTTCCTGCGCTATGACAGGCAGAAACGCAGGGCAAAGCCCCAGGGACAGTGG
GCAGAAAATGTCCTGGGAGCTAAGACCTGGGACACAGAGACCGAGGACTTGACAGAGAATGGGCAAGAC
CTCAGGAGGACCCTGACTCATATCAAGGACCAGAAAGGAGGCTTGCATTCCCTCCAGGAGATTAGGGTC
TGTGAGATCCATGAAGACAGCAGCACCAGGGGCTCCCGGCATTTCTACTACGATGGGGAGCTCTTCCTC
TCCCAAAACCTGGAGACTCAAGAATCGACAGTGCCCCAGTCCTCCAGAGCTCAGACCTTGGCTATGAAC
GTCACAAATTTCTGGAAGGAAGATGCCATGAAGACCAAGACACACTATCGCGCTATGCAGGCAGACTGC
CTGCAGAAACTACAGCGATATCTGAAATCCGGGGTGGCCATCAGGAGAACAGTGCCCCCCATGGTGAAT
GTCACCTGCAGCGAGGTCTCAGAGGGCAACATCACCGTGACATGCAGGGCTTCCAGCTTCTATCCCCGG
AATATCACACTGACCTGGCGTCAGGATGGGGTATCTTTGAGCCACAACACCCAGCAGTGGGGGGATGTC
CTGCCTGATGGGAATGGAACCTACCAGACCTGGGTGGCCACCAGGATTCGCCAAGGAGAGGAGCAGAGG
TTCACCTGCTACATGGAACACAGCGGGAATCACGGCACTCACCCTCCCAGAGGGCCCACAATCAAGCCC
TGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAG
ATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAGGAT
GACCCAGATGTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACAGCTCAGACACAAACCCAT
AGAGAGGATTACAACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCACCAGGACTGGATGAGT
GGCAAGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATCGAGAGAACCATCTCAAAA
CCCAAAGGGTCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGAAGAAGAGATGACTAAGAAA
CAGGTCACTCTGACCTGCATGGTCACAGACTTCATGCCTGAAGACATTTACGTGGAGTGGACCAACAAC
GGGAAAACAGAGCTAAACTACAAGAACACTGAACCAGTCCTGGACTCTGATGGTTCTTACTTCATGTAC
AGCAAGCTGAGAGTGGAAAAGAAGAACTGGGTGGAAAGAAATAGCTACTCCTGTTCAGTGGTCCACGAG
GGTCTGCACAATCACCACACGACTAAGAGCTTCTCCCGGACTCCGGGTAAATGA  (1572 bp) 
 
Green: Leader sequence for IL-2 secreting protein (hIL-2 signal sequence) = 60 nucleotides. 
Red:    Sequence encoding for the extracellular region of hMICB = 822 nucleotides 
Blue:   Sequence encoding for Fc region of mIgG2A = 699 nucleotides. 
 
 
Translation 
 
MYRMQLLSCIALSLALVTNSEPHSLRYNLMVLSQDGSVQSGFLAEGHLDGQPFLRYDRQKRRAKPQGQWA
ENVLGAKTWDTETEDLTENGQDLRRTLTHIKDQKGGLHSLQEIRVCEIHEDSSTRGSRHFYYDGELFLSQ
NLETQESTVPQSSRAQTLAMNVTNFWKEDAMKTKTHYRAMQADCLQKLQRYLKSGVAIRRTVPPMVNVTC
SEVSEGNITVTCRASSFYPRNITLTWRQDGVSLSHNTQQWGDVLPDGNGTYQTWVATRIRQGEEQRFTCY
MEHSGNHGTHPPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQ
ISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVR 
APQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSY 
FMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK 
 
Green: Leader sequence for IL-2 protein 
Red:    Extracellular region of hMICA protein   
Blue:    Fc region of mIgG2A  
Molecular weight = 59493.63 
 
 
 
344 
 
9.2.2.1  Alignment of the cloned nucleotide sequence to hMICB-mFc2 sequence  
 
Results of sequencing  
 
GTGACCGGCGCCTACCTGAGATCACCGGCGAAGGAGGGCCACCATGTACAGGATGCAACTCCTGTCTTG
CATTGCACTAAGTCTTGCACTTGTCACGAATTCGGAGCCCCACAGTCTTCGTTACAACCTCATGGTGCT
GTCCCAGGATGGATCTGTGCAGTCAGGGTTTCTCGCTGAGGGACATCTGGATGGTCAGCCCTTCCTGCG
CTATGACAGGCAGAAACGCAGGGCAAAGCCCCAGGGACAGTGG 
NNNNNNCNNGNNNNNNNNNNNNGCNAAGCCCCAGGGACAGTGGGCAGAAAATGTCCTGGGAGCTAAGAC
CTGGGACACAGAGACCGAGGACTTGACAGAGAATGGGCAAGACCTCAGGAGGACCCTGACTCATATCAA
GGACCAGAAAGGAGGCTTGCATTCCCTCCAGGAGATTAGGGTCTGTGAGATCCATGAAGACAGCAGCAC
CAGGGGCTCCCGGCATTTCTACTACGATGGGGAGCTCTTCCTCTCCCAAAACCTGGAGACTCAAGAATC
GACAGTGCCCCAGTCCTCCAGAGCTCAGACCTTGGCTATGAACGTCACAAATTTCTGGAAGGAAGATGC
CATGAAGACCAAGACACACTATCGCGCTATGCAGGCAGACTGCCTGCAGAAACTACAGCGATATCTGAA
ATCCGGGGTGGCCATCAGGAGAACAGTGCCCCCCATGGTGAATGTCACCTGCAGCGAGGTCTCAGAGGG
CAACATCACCGTGACATGCAGGGCTTCCAGCTTCTATCCCCGGAATATCACACTGACCTGGCGTCAGGA
TGGGGTATCTTTGAGCCACAACACCCAGCAGTGGGGGGATGTCCTGCCTGATGGGAATGGAACCTACCA
GACCTGGGTGGCCACCAGGATTCGCCAAGGAGAGGAGCAGAGGTTCACCTGCTACATGGAACACAGCGG
GAATCACGGCACTCACCCTCCCAGAGGGCCCACAATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACC
TAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCT
GAGCCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAGGATGACCCAGATGTCCAGATCAGCTGGNN
NNNN 
 
GAATTC: EcoRI restriction site 
 
TCATGA: BspHI restriction site 
 
 
Alignment  
 
Query  44    ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCG  103 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1     ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCG  60 
 
Query  104   GAGCCCCACAGTCTTCGTTACAACCTCATGGTGCTGTCCCAGGATGGATCTGTGCAGTCA  163 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61    GAGCCCCACAGTCTTCGTTACAACCTCATGGTGCTGTCCCAGGATGGATCTGTGCAGTCA  120 
 
Query  164   GGGTTTCTCGCTGAGGGACATCTGGATGGTCAGCCCTTCCTGCGCTATGACAGGCAGAAA  223 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121   GGGTTTCTCGCTGAGGGACATCTGGATGGTCAGCCCTTCCTGCGCTATGACAGGCAGAAA  180 
 
Query  224   CGCAGGGCAAAGCCCCAGGGACAGTGGGCAGAAAATGTCCTGGGAGCTAAGACCTGGGAC  283 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181   CGCAGGGCAAAGCCCCAGGGACAGTGGGCAGAAAATGTCCTGGGAGCTAAGACCTGGGAC  240 
 
Query  284   ACAGAGACCGAGGACTTGACAGAGAATGGGCAAGACCTCAGGAGGACCCTGACTCATATC  343 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241   ACAGAGACCGAGGACTTGACAGAGAATGGGCAAGACCTCAGGAGGACCCTGACTCATATC  300 
 
Query  344   AAGGACCAGAAAGGAGGCTTGCATTCCCTCCAGGAGATTAGGGTCTGTGAGATCCATGAA  403 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301   AAGGACCAGAAAGGAGGCTTGCATTCCCTCCAGGAGATTAGGGTCTGTGAGATCCATGAA  360 
 
Query  404   GACAGCAGCACCAGGGGCTCCCGGCATTTCTACTACGATGGGGAGCTCTTCCTCTCCCAA  463 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361   GACAGCAGCACCAGGGGCTCCCGGCATTTCTACTACGATGGGGAGCTCTTCCTCTCCCAA  420 
 
Query  464   AACCTGGAGACTCAAGAATCGACAGTGCCCCAGTCCTCCAGAGCTCAGACCTTGGCTATG  523 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421   AACCTGGAGACTCAAGAATCGACAGTGCCCCAGTCCTCCAGAGCTCAGACCTTGGCTATG  480 
 
Query  524   AACGTCACAAATTTCTGGAAGGAAGATGCCATGAAGACCAAGACACACTATCGCGCTATG  583 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  481   AACGTCACAAATTTCTGGAAGGAAGATGCCATGAAGACCAAGACACACTATCGCGCTATG  540 
 
 
 
 
EcoRI 
 
 
345 
 
Query  584   CAGGCAGACTGCCTGCAGAAACTACAGCGATATCTGAAATCCGGGGTGGCCATCAGGAGA  643 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  541   CAGGCAGACTGCCTGCAGAAACTACAGCGATATCTGAAATCCGGGGTGGCCATCAGGAGA  600 
 
Query  644   ACAGTGCCCCCCATGGTGAATGTCACCTGCAGCGAGGTCTCAGAGGGCAACATCACCGTG  703 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  601   ACAGTGCCCCCCATGGTGAATGTCACCTGCAGCGAGGTCTCAGAGGGCAACATCACCGTG  660 
 
Query  704   ACATGCAGGGCTTCCAGCTTCTATCCCCGGAATATCACACTGACCTGGCGTCAGGATGGG  763 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  661   ACATGCAGGGCTTCCAGCTTCTATCCCCGGAATATCACACTGACCTGGCGTCAGGATGGG  720 
 
Query  764   GTATCTTTGAGCCACAACACCCAGCAGTGGGGGGATGTCCTGCCTGATGGGAATGGAACC  823 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  721   GTATCTTTGAGCCACAACACCCAGCAGTGGGGGGATGTCCTGCCTGATGGGAATGGAACC  780 
 
Query  824   TACCAGACCTGGGTGGCCACCAGGATTCGCCAAGGAGAGGAGCAGAGGTTCACCTGCTAC  883 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  781   TACCAGACCTGGGTGGCCACCAGGATTCGCCAAGGAGAGGAGCAGAGGTTCACCTGCTAC  840 
 
Query  884   ATGGAACACAGCGGGAATCACGGCACTCACCCTCCCAGAGGGCCCACAATCAAGCCCTGT  943 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  841   ATGGAACACAGCGGGAATCACGGCACTCACCCTCCCAGAGGGCCCACAATCAAGCCCTGT  900 
 
Query  944   CCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCT  1003 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  901   CCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCT  960 
 
Query  1004  CCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTG  1063 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  961   CCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTG  1020 
 
Query  1064  GATGTGAGCGAGGATGACCCAGATGTCCAGATCAGCTGG  1102 
             ||||||||||||||||||||||||||||||||||||||| 
Sbjct  1021  GATGTGAGCGAGGATGACCCAGATGTCCAGATCAGCTGG  1059 
 
 
 
 
 
9.3 Human ULBP1 sequence  
The human ULBP1 mRNA sequence (NCBI Reference Sequence: NM_025218.2) is 
presented below. It consists of a leader peptide (L), α1, α2 (but not α 3) domains and GPI anchor signal. 
The sequence encoding for extracellular region includes L, α1 and α2 and it is 609 bp in length 
(Cosman et al, 2001). It starts from position 44 bp and ends at position 652.  
 
GGGAACCATC AGCGCCTCCT GTCCACGGAG CTCCAGGTCT ACAATGGCAG CGGCCGCCAG 
CCCCGCGTTC CTTCTGTGCC TCCCGCTTCT GCACCTGCTG TCTGGCTGGT CCCGGGCAGG 
ATGGGTCGAC ACACACTGTC TTTGCTATGA CTTCATCATC ACTCCTAAGT CCAGACCTGA 
ACCACAGTGG TGTGAAGTTC AAGGCCTGGT GGATGAAAGG CCTTTTCTTC ACTATGACTG 
TGTTAACCAC AAGGCCAAAG CCTTTGCTTC TCTGGGGAAG AAAGTCAATG TCACAAAAAC 
CTGGGAAGAA CAAACTGAAA CACTAAGAGA CGTGGTGGAT TTCCTTAAAG GGCAACTGCT 
TGACATTCAA GTGGAGAATT TAATACCCAT TGAGCCCCTC ACCCTGCAGG CCAGGATGTC 
TTGTGAGCAT GAAGCCCATG GACACGGCAG AGGATCTTGG CAGTTCCTCT TCAATGGACA 
GAAGTTCCTC CTCTTTGACT CAAACAACAG AAAGTGGACA GCACTTCATC CTGGAGCCAA 
GAAGATGACA GAGAAGTGGG AGAAGAACAG GGATGTGACC ATGTTCTTCC AGAAGATTTC 
ACTGGGGGAT TGTAAGATGT GGCTTGAAGA ATTTTTGATG TACTGGGAAC AAATGCTGGA 
TCCAACAAAA CCACCCTCTC TGGCCCCAGG CACAACCCAA CCCAAGGCCA TGGCCACCAC 
CCTCAGTCCC TGGAGCCTTC TCATCATCTT CCTCTGCTTC ATTCTAGCTG GCAGATGAGG 
AGAGTTGTTT AGAGTGACAG GTGGAAAGTG ATATCAAGAA GCCTCTGTTA GCCTGGTCTG 
GGTCCTGCTC TCCCTTCAGG GAGGCCGCCT GTCTACTCAC CACTGTGCCT TTCTGGAAAG 
CAGGAGTTCA AGCCTTAGCA AGCCCAGAGG CCCCCAGCAG ACGATGAGGA CATTGTCGGC 
TCAACATCTC AGGCCACTCA TTACCTTCGC TCATGATCCC AGCAGCCATT TTTCTTAACA 
CCTTCTGCCA CTTTCTGTCG GTGCTAATGG ATGGAACTCC TGCACAAGTT TTAACTGAAC 
...................................................... 
AATTAAACAC TGTATAATGG AAAAAAAAAA AAAAAAAAAA (3160 bp) 
 
 
BspHI 
 
 
346 
 
Red:     Leader sequence = 147 nucleotides 
Blue:    Alpha 1 domain = 306 nucleotides 
Green: Alpha 2 domain = 156 nucleotides 
 
9.3.1 Recombinant hULBP1-mFc1 sequence (1308 bp) 
ATGGCAGCGGCCGCCAGCCCCGCGTTCCTTCTGTGCCTCCCGCTTCTGCACCTGCTGTCTGGCTGGTCC
CGGGCAGGATGGGTCGACACACACTGTCTTTGCTATGACTTCATCATCACTCCTAAGTCCAGACCTGAA
CCACAGTGGTGTGAAGTTCAAGGCCTGGTGGATGAAAGGCCTTTTCTTCACTATGACTGTGTTAACCAC
AAGGCCAAAGCCTTTGCTTCTCTGGGGAAGAAAGTCAATGTCACAAAAACCTGGGAAGAACAAACTGAA
ACACTAAGAGACGTGGTGGATTTCCTTAAAGGGCAACTGCTTGACATTCAAGTGGAGAATTTAATACCC
ATTGAGCCCCTCACCCTGCAGGCCAGGATGTCTTGTGAGCATGAAGCCCATGGACACGGCAGAGGATCT
TGGCAGTTCCTCTTCAATGGACAGAAGTTCCTCCTCTTTGACTCAAACAACAGAAAGTGGACAGCACTT
CATCCTGGAGCCAAGAAGATGACAGAGAAGTGGGAGAAGAACAGGGATGTGACCATGTTCTTCCAGAAG
ATTTCACTGGGGGATTGTAAGATGTGGCTTGAAGAATTTTTGATGTACTGGGAACAACCCAGAGGGCCC
ACAATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATC
TTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTGGAT
GTGAGCGAGGATGACCCAGATGTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACAGCTCAG
ACACAAACCCATAGAGAGGATTACAACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCACCAG
GACTGGATGAGTGGCAAGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATCGAGAGA
ACCATCTCAAAACCCAAAGGGTCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGAAGAAGAG
ATGACTAAGAAACAGGTCACTCTGACCTGCATGGTCACAGACTTCATGCCTGAAGACATTTACGTGGAG
TGGACCAACAACGGGAAAACAGAGCTAAACTACAAGAACACTGAACCAGTCCTGGACTCTGATGGTTCT
TACTTCATGTACAGCAAGCTGAGAGTGGAAAAGAAGAACTGGGTGGAAAGAAATAGCTACTCCTGTTCA
GTGGTCCACGAGGGTCTGCACAATCACCACACGACTAAGAGCTTCTCCCGGACTCCGGGTAAATGA  
 
Black:  Leader sequence = 147 bp 
Red:    Sequence encodes for extracellular portion of hULBP1 protein = 462 bp. 
Blue:   Sequence encoding for Fc region of mIgG2A = 699 bp 
TCATGA: BspHI restriction site 
 
 
Translation  
MAAAASPAFLLCLPLLHLLSGWSRAGWVDTHCLCYDFIITPKSRPEPQWCEVQGLVDERPFLHYDCVNHK
AKAFASLGKKVNVTKTWEEQTETLRDVVDFLKGQLLDIQVENLIPIEPLTLQARMSCEHEAHGHGRGSWQ
FLFNGQKFLLFDSNNRKWTALHPGAKKMTEKWEKNRDVTMFFQKISLGDCKMWLEEFLMYWEQPRGPTIK
PCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTH
REDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQ
VTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGL
HNHHTTKSFSRTPGK 
 
Black: Leader protein sequence 
Red:    Extracellular portion of ULBP1 protein  
Blue:  Fc portion of mIgG2A 
Molecular weight = 49859.29 
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9.3.1.1  Alignment of the cloned nucleotide sequence to hULBP1-mFc1 sequence 
 
Results of sequencing  
NNNGNNNNNACGCTNNNCCTNNCCNNCTTGNTCAANNNTANGTNNNNNNGTTTTCTGTTNTGCGCCGTTACAGANNN
AAGCTGTGACCGGGCGCNTACCTGAGATCACCGGTGAATTCATGGCAGCGGCCGCCAGCCCCGCGTTCCTTCTGTGC
CTCCCGCTTCTGCACCTGCTGTCTGGCTGGTCCCGGGCAGGATGGGTCGACACACACTGTCTTTGCTATGACTTCAT
CATCACTCCTAAGTCCAGACCTGAACCACAGTGGTGTGAAGTTCAAGGCCTGGTGGATGAAAGGCCTTTTCTTCACT
ATGACTGTGTTAACCACAAGGCCAAAGCCTTTGCTTCTCTGGGGAAGAAAGTCAATGTCACAAAAACCTGGGAAGAA
CAAACTGAAACACTAAGAGACGTGGTGGATTTCCTTAAAGGGCAACTGCTTGACATTCAAGTGGAGAATTTAATACC
CATTGAGCCCCTCACCCTGCAGGCCAGGATGTCTTGTGAGCATGAAGCCCATGGACACGGCAGAGGATCTTGGCAGT
TCCTCTTCAATGGACAGAAGTTCCTCCTCTTTGACTCAAACAACAGAAAGTGGACAGCACTTCATCCTGGAGCCAAG
AAGATGACAGAGAAGTGGGAGAAGAACAGGGATGTGACCATGTTCTTCCAGAAGATTTCACTGGGGGATTGTAAGAT
GTGGCTTGAAGAATTTTTGATGTACTGGGAACAACCCNGANNGCCCNN 
GTGGCTTGAAGAATTTTTGATGTACTGGGAACAACCCAGAGGGCCCACAATCAAGCCCTGTCCTCCATGCAAATGCC
CAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTG
AGCCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAGGATGACCCAGATGTCCAGATCAGCTGGTTTGTGAACAA
CGTGGAAGTACACACAGCTCAGACACAAACCCATAGAGAGGATTACAACAGTACTCTCCGGGTGGTCAGTGCCCTCC
CCATCCAGCACCAGGACTGGATGAGTGGCAAGGAGTNCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATC
GAGAGAACCATCTCAAAACCCAAAGGGTCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGAAGAAGAGAT
GACTAAGAAACAGGTCACTCTGACCTGCATGGTCACAGACTTCATGCCTGAAGACATTTACGTGGAGTGGACCAACA
ACGGGAAAACAGAGCTAAACTACAAGAACACTGAACCAGTCCNNNACT 
 
 
Alignment 
 
Query  119   ATGGCAGCGGCCGCCAGCCCCGCGTTCCTTCTGTGCCTCCCGCTTCTGCACCTGCTGTCT  178 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1     ATGGCAGCGGCCGCCAGCCCCGCGTTCCTTCTGTGCCTCCCGCTTCTGCACCTGCTGTCT  60 
 
Query  179   GGCTGGTCCCGGGCAGGATGGGTCGACACACACTGTCTTTGCTATGACTTCATCATCACT  238 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61    GGCTGGTCCCGGGCAGGATGGGTCGACACACACTGTCTTTGCTATGACTTCATCATCACT  120 
 
Query  239   CCTAAGTCCAGACCTGAACCACAGTGGTGTGAAGTTCAAGGCCTGGTGGATGAAAGGCCT  298 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121   CCTAAGTCCAGACCTGAACCACAGTGGTGTGAAGTTCAAGGCCTGGTGGATGAAAGGCCT  180 
 
Query  299   TTTCTTCACTATGACTGTGTTAACCACAAGGCCAAAGCCTTTGCTTCTCTGGGGAAGAAA  358 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181   TTTCTTCACTATGACTGTGTTAACCACAAGGCCAAAGCCTTTGCTTCTCTGGGGAAGAAA  240 
 
Query  359   GTCAATGTCACAAAAACCTGGGAAGAACAAACTGAAACACTAAGAGACGTGGTGGATTTC  418 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241   GTCAATGTCACAAAAACCTGGGAAGAACAAACTGAAACACTAAGAGACGTGGTGGATTTC  300 
 
Query  419   CTTAAAGGGCAACTGCTTGACATTCAAGTGGAGAATTTAATACCCATTGAGCCCCTCACC  478 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301   CTTAAAGGGCAACTGCTTGACATTCAAGTGGAGAATTTAATACCCATTGAGCCCCTCACC  360 
 
Query  479   CTGCAGGCCAGGATGTCTTGTGAGCATGAAGCCCATGGACACGGCAGAGGATCTTGGCAG  538 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361   CTGCAGGCCAGGATGTCTTGTGAGCATGAAGCCCATGGACACGGCAGAGGATCTTGGCAG  420 
 
Query  539   TTCCTCTTCAATGGACAGAAGTTCCTCCTCTTTGACTCAAACAACAGAAAGTGGACAGCA  598 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421   TTCCTCTTCAATGGACAGAAGTTCCTCCTCTTTGACTCAAACAACAGAAAGTGGACAGCA  480 
 
Query  599   CTTCATCCTGGAGCCAAGAAGATGACAGAGAAGTGGGAGAAGAACAGGGATGTGACCATG  658 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  481   CTTCATCCTGGAGCCAAGAAGATGACAGAGAAGTGGGAGAAGAACAGGGATGTGACCATG  540 
 
Query  659   TTCTTCCAGAAGATTTCACTGGGGGATTGTAAGATGTGGCTTGAAGAATTTTTGATGTAC  718 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  541   TTCTTCCAGAAGATTTCACTGGGGGATTGTAAGATGTGGCTTGAAGAATTTTTGATGTAC  600 
 
Query  719   TGGGAACAACCCAGAGGGCCCACAATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACCT  778 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  601   TGGGAACAACCCAGAGGGCCCACAATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACCT  660 
 
Query  779   AACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAGATCAAGGATGTACTCATG  838 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  661   AACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAGATCAAGGATGTACTCATG  720 
 
BspHI 
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Query  839   ATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAGGATGACCCAGAT  898 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  721   ATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAGGATGACCCAGAT  780 
 
Query  899   GTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACAGCTCAGACACAAACCCAT  958 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  781   GTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACAGCTCAGACACAAACCCAT  840 
 
Query  959   AGAGAGGATTACAACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCACCAGGAC  1018 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  841   AGAGAGGATTACAACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCACCAGGAC  900 
 
Query  1019  TGGATGAGTGGCAAGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATC  1078 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  901   TGGATGAGTGGCAAGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATC  960 
 
Query  1079  GAGAGAACCATCTCAAAACCCAAAGGGTCAGTAAGAGCTCCACAGGTATATGTCTTGCCT  1138 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  961   GAGAGAACCATCTCAAAACCCAAAGGGTCAGTAAGAGCTCCACAGGTATATGTCTTGCCT  1020 
 
Query  1139  CCACCAGAAGAAGAGATGACTAAGAAACAGGTCACTCTGACCTGCATGGTCACAGACTTC  1198 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1021  CCACCAGAAGAAGAGATGACTAAGAAACAGGTCACTCTGACCTGCATGGTCACAGACTTC  1080 
 
Query  1199  ATGCCTGAAGACATTTACGTGGAGTGGACCAACAACGGGAAAACAGAGCTAAACTACAAG  1258 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1081  ATGCCTGAAGACATTTACGTGGAGTGGACCAACAACGGGAAAACAGAGCTAAACTACAAG  1140 
 
Query  1259  AACACTGAACCAGTCC  1274 
             |||||||||||||||| 
Sbjct  1141  AACACTGAACCAGTCC  1156 
 
 
 
9.3.2 Recombinant hULBP1-m-Fc2 sequence (1221 bp) 
ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCGTGTGAAGTT
CAAGGCCTGGTGGATGAAAGGCCTTTTCTTCACTATGACTGTGTTAACCACAAGGCCAAAGCCTTTGCT
TCTCTGGGGAAGAAAGTCAATGTCACAAAAACCTGGGAAGAACAAACTGAAACACTAAGAGACGTGGTG
GATTTCCTTAAAGGGCAACTGCTTGACATTCAAGTGGAGAATTTAATACCCATTGAGCCCCTCACCCTG
CAGGCCAGGATGTCTTGTGAGCATGAAGCCCATGGACACGGCAGAGGATCTTGGCAGTTCCTCTTCAAT
GGACAGAAGTTCCTCCTCTTTGACTCAAACAACAGAAAGTGGACAGCACTTCATCCTGGAGCCAAGAAG
ATGACAGAGAAGTGGGAGAAGAACAGGGATGTGACCATGTTCTTCCAGAAGATTTCACTGGGGGATTGT
AAGATGTGGCTTGAAGAATTTTTGATGTACTGGGAACAACCCAGAGGGCCCACAATCAAGCCCTGTCCT
CCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAGATCAAG
GATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAGGATGACCCA
GATGTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACAGCTCAGACACAAACCCATAGAGAG
GATTACAACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCACCAGGACTGGATGAGTGGCAAG
GAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATCGAGAGAACCATCTCAAAACCCAAA
GGGTCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGAAGAAGAGATGACTAAGAAACAGGTC
ACTCTGACCTGCATGGTCACAGACTTCATGCCTGAAGACATTTACGTGGAGTGGACCAACAACGGGAAA
ACAGAGCTAAACTACAAGAACACTGAACCAGTCCTGGACTCTGATGGTTCTTACTTCATGTACAGCAAG
CTGAGAGTGGAAAAGAAGAACTGGGTGGAAAGAAATAGCTACTCCTGTTCAGTGGTCCACGAGGGTCTG
CACAATCACCACACGACTAAGAGCTTCTCCCGGACTCCGGGTAAATGA 
 
Green: IL-2 leader sequence = 60 bp. 
Red:   Sequence encodes for extracellular portion of ULBP1 protein = 462 
Blue:   Sequences encoding for Fc region of mIgG2A = 699 bp. 
GAATTC: EcoRI restriction site 
TCATGA: BspHI restriction site  
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Translation  
 
MYRMQLLSCIALSLALVTNSCEVQGLVDERPFLHYDCVNHKAKAFASLGKKVNVTKTWEEQTETLRDVVD
FLKGQLLDIQVENLIPIEPLTLQARMSCEHEAHGHGRGSWQFLFNGQKFLLFDSNNRKWTALHPGAKKMT
EKWEKNRDVTMFFQKISLGDCKMWLEEFLMYWEQPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVL
MISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKC
KVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNY
KNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK 
 
Green: IL-2 Leader protein sequence 
Red:    Extracellular portion of ULBP1 protein  
 
 
9.3.2.1  Alignment of the cloned nucleotide sequence to hULBP1-mFc2 sequence 
 
Results of sequencing  
NNNNGCCGGCNNTCCANGCTTTGCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTT
CTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACCTGAGATCACCGGCGAAGGAGGGCCACCATG
TACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCGTGTGAAGTTCAA
GGCCTGGTGGATGAAAGGCCTTTTCTTCACTATGACTGTGTTAACCACAAGGCCAAAGCCTTTGCTTCT
CTGGGGAAGAAAGTCAATGTCACAAAAACCTGGGAAGAACAAACTGAAACACTAAGAGACGTGGTGGAT
TTCCTTAAAGGGCAACTGCTTGACATTCAAGTGGAGAATTTAATACCCATTGAGCCCCTCACCCTGCAG
GCCAGGATGTCTTGTGAGCATGAAGCCCATGGACACGGCAGAGGATCTTGGCAGTTCCTCTTCAATGGA
CAGAAGTTCCTCCTCTTTGACTCAAACAACAGAAAGTGGACAGCACTTCATCCTGGAGCCAAGAAGATG
ACAGAGAAGTGGGAGAAGAACAGGGATGTGACCATGTTCTTCCAGAAGATTTCACTGGGGGATTGTAAG
ATGTGGCTTGAAGAATTTTTGATGTACTGGGAACAACCCAGAGGGCCCACAATCAAGCCCTGTCCTCCA
TGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAGATCAAGGAT
GTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAGGATGACCCAGAT
GTCCAGANNGNTN 
 
 
Alignment  
 
Query  136  ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCG  195 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCG  60 
 
Query  196  TGTGAAGTTCAAGGCCTGGTGGATGAAAGGCCTTTTCTTCACTATGACTGTGTTAACCAC  255 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   TGTGAAGTTCAAGGCCTGGTGGATGAAAGGCCTTTTCTTCACTATGACTGTGTTAACCAC  120 
 
Query  256  AAGGCCAAAGCCTTTGCTTCTCTGGGGAAGAAAGTCAATGTCACAAAAACCTGGGAAGAA  315 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AAGGCCAAAGCCTTTGCTTCTCTGGGGAAGAAAGTCAATGTCACAAAAACCTGGGAAGAA  180 
 
Query  316  CAAACTGAAACACTAAGAGACGTGGTGGATTTCCTTAAAGGGCAACTGCTTGACATTCAA  375 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CAAACTGAAACACTAAGAGACGTGGTGGATTTCCTTAAAGGGCAACTGCTTGACATTCAA  240 
 
Query  376  GTGGAGAATTTAATACCCATTGAGCCCCTCACCCTGCAGGCCAGGATGTCTTGTGAGCAT  435 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  GTGGAGAATTTAATACCCATTGAGCCCCTCACCCTGCAGGCCAGGATGTCTTGTGAGCAT  300 
 
Query  436  GAAGCCCATGGACACGGCAGAGGATCTTGGCAGTTCCTCTTCAATGGACAGAAGTTCCTC  495 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  GAAGCCCATGGACACGGCAGAGGATCTTGGCAGTTCCTCTTCAATGGACAGAAGTTCCTC  360 
 
Query  496  CTCTTTGACTCAAACAACAGAAAGTGGACAGCACTTCATCCTGGAGCCAAGAAGATGACA  555 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTCTTTGACTCAAACAACAGAAAGTGGACAGCACTTCATCCTGGAGCCAAGAAGATGACA  420 
 
Query  556  GAGAAGTGGGAGAAGAACAGGGATGTGACCATGTTCTTCCAGAAGATTTCACTGGGGGAT  615 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GAGAAGTGGGAGAAGAACAGGGATGTGACCATGTTCTTCCAGAAGATTTCACTGGGGGAT  480 
Blue:  Fc portion of mIgG2A 
Molecular weight = 46602.6 Daltons 
 
 
EcoRI 
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Query  616  TGTAAGATGTGGCTTGAAGAATTTTTGATGTACTGGGAACAACCCAGAGGGCCCACAATC  675 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  481  TGTAAGATGTGGCTTGAAGAATTTTTGATGTACTGGGAACAACCCAGAGGGCCCACAATC  540 
 
Query  676  AAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTC  735 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  541  AAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTC  600 
 
Query  736  ATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGT  795 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  601  ATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGT  660 
 
Query  796  GTGGTGGTGGATGTGAGCGAGGATGACCCAGATGTCCAGA  835 
            |||||||||||||||||||||||||||||||||||||||| 
Sbjct  661  GTGGTGGTGGATGTGAGCGAGGATGACCCAGATGTCCAGA  700 
 
 
 
9.4 Human ULBP2 sequence  
The human ULBP2 sequence (NCBI Reference Sequence: NM_025217.2) is submitted 
below. Like ULBP1, ULPB2 consists of a leader peptide (L), α1, α2 domains, and GPI anchor signal 
(Cosman et al, 2001). The sequence encoding for extracellular region includes L, α1 and α2 and it is 
609 bp in length (Cosman et al, 2001). It starts from position 73 bp and ends at position 682.  
 
AAAACCTTGA GGTGATTCAT CTTCCAGGCT CTCCTTCCAT CAAGTCTCTC CTCCCTAGCG 
CTCTGGGTCC TTAATGGCAG CAGCCGCCGC TACCAAGATC CTTCTGTGCC TCCCGCTTCT 
GCTCCTGCTG TCCGGCTGGT CCCGGGCTGG GCGAGCCGAC CCTCACTCTC TTTGCTATGA 
CATCACCGTC ATCCCTAAGT TCAGACCTGG ACCACGGTGG TGTGCGGTTC AAGGCCAGGT 
GGATGAAAAG ACTTTTCTTC ACTATGACTG TGGCAACAAG ACAGTCACAC CTGTCAGTCC 
CCTGGGGAAG AAACTAAATG TCACAACGGC CTGGAAAGCA CAGAACCCAG TACTGAGAGA 
GGTGGTGGAC ATACTTACAG AGCAACTGCG TGACATTCAG CTGGAGAATT ACACACCCAA 
GGAACCCCTC ACCCTGCAGG CCAGGATGTC TTGTGAGCAG AAAGCTGAAG GACACAGCAG 
TGGATCTTGG CAGTTCAGTT TCGATGGGCA GATCTTCCTC CTCTTTGACT CAGAGAAGAG 
AATGTGGACA ACGGTTCATC CTGGAGCCAG AAAGATGAAA GAAAAGTGGG AGAATGACAA 
GGTTGTGGCC ATGTCCTTCC ATTACTTCTC AATGGGAGAC TGTATAGGAT GGCTTGAGGA 
CTTCTTGATG GGCATGGACA GCACCCTGGA GCCAAGTGCA GGAGCACCAC TCGCCATGTC 
CTCAGGCACA.............        TCCCAAAAAA AAAAAAAAAA AA (1362 bp)    
 
Red:    Leader sequence = 1  nucleotides 
Blue:   Alpha 1 domain = 3  nucleotides 
Green: Alpha 2 domain = 152 nucleotides 
 
 
9.4.1 Recombinant hULBP2-mFc1 sequence  
 
ATGGCAGCAGCCGCCGCTACCAAGATCCTTCTGTGCCTCCCGCTTCTGCTCCTGCTGTCCGGCTGGTCC
CGGGCTGGGCGAGCCGACCCTCACTCTCTTTGCTATGACATCACCGTCATCCCTAAGTTCAGACCTGGA
CCACGGTGGTGTGCGGTTCAAGGCCAGGTGGATGAAAAGACTTTTCTTCACTATGACTGTGGCAACAAG
ACAGTCACACCTGTCAGTCCCCTGGGGAAGAAACTAAATGTCACAACGGCCTGGAAAGCACAGAACCCA
GTACTGAGAGAGGTGGTGGACATACTTACAGAGCAACTGCGTGACATTCAGCTGGAGAATTACACACCC
AAGGAACCCCTCACCCTGCAGGCCAGGATGTCTTGTGAGCAGAAAGCTGAAGGACACAGCAGTGGATCT
TGGCAGTTCAGTTTCGATGGGCAGATCTTCCTCCTCTTTGACTCAGAGAAGAGAATGTGGACAACGGTT
CATCCTGGAGCCAGAAAGATGAAAGAAAAGTGGGAGAATGACAAGGTTGTGGCCATGTCCTTCCATTAC
TTCTCAATGGGAGACTGTATAGGATGGCTTGAGGACTTCTTGATGGGCATGGACAGCCCCAGAGGGCCC
ACAATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATC
TTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTGGAT
GTGAGCGAGGATGACCCAGATGTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACAGCTCAG
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ACACAAACCCATAGAGAGGATTACAACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCACCAG
GACTGGATGAGTGGCAAGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATCGAGAGA
ACCATCTCAAAACCCAAAGGGTCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGAAGAAGAG
ATGACTAAGAAACAGGTCACTCTGACCTGCATGGTCACAGACTTCATGCCTGAAGACATTTACGTGGAG
TGGACCAACAACGGGAAAACAGAGCTAAACTACAAGAACACTGAACCAGTCCTGGACTCTGATGGTTCT
TACTTCATGTACAGCAAGCTGAGAGTGGAAAAGAAGAACTGGGTGGAAAGAAATAGCTACTCCTGTTCA
GTGGTCCACGAGGGTCTGCACAATCACCACACGACTAAGAGCTTCTCCCGGACTCCGGGTAAATGA  
(1308 bp)  
 
Black:  Leader sequence = 147 bp 
Red:   Sequence encodes for extracellular portion of hULBP2 protein = 462 bp 
Blue:  Sequence encoding for Fc region of mIgG2A = 699 bp. 
TCATGA: BspHI restriction site 
 
Translation  
MAAAAATKILLCLPLLLLLSGWSRAGRADPHSLCYDITVIPKFRPGPRWCAVQGQVDEKTFLHYDCGNKT
VTPVSPLGKKLNVTTAWKAQNPVLREVVDILTEQLRDIQLENYTPKEPLTLQARMSCEQKAEGHSSGSWQ
FSFDGQIFLLFDSEKRMWTTVHPGARKMKEKWENDKVVAMSFHYFSMGDCIGWLEDFLMGMDSPRGPTIK
PCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTH
REDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQ
VTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGL
HNHHTTKSFSRTPGK 
 
Black: Leader protein sequence 
Red:    Extracellular portion of ULBP2 protein  
 
 
9.4.1.1  Alignment of the cloned nucleotide sequence to hULBP2-mFc1 sequence 
 
Results of sequencing  
GAATTCATGGCAGCAGCCGCCGCTACCAAGATCCTTCTGTGCCTCCCGCTTCTGCTCCTGCTGTCCGGC
TGGTCCCGGGCTGGGCGAGCCGACCCTCACTCTCTTTGCTATGACATCACCGTCATCCCTAAGTTCAGA
CCTGGACCACGGTGGTGTGCGGTTCAAGGCCAGGTGGATGAAAAGACTTTTCTTCACTATGACTGTGGC
AGCAAGACAGTCACACCTGTCAGTCCCCTGGGGAAGAAACTAAATGTCACAACGGCCTGGAAAGCACAG
AACCCAGTACTGAGAGAGGTGGTGGACATACTTACAGAGCAACTGCGTGACATTCAGCTGGAGAATTAC
ACACCCAAGGAACCCCTCACCCTGCAGGCCAGGATGTCTTGTGAGCAGAAAGCTGAAGGACACAGCAGT
GGATCTTGGCAGTTCAGTTTCGATGGGCAGATCTTCCCCCTCTTTGACTCAGAGAAGAGAATGTGGACA
ACGGTTCATCCTGGAGCCAGAAAGATGAAAGAAAAGTGGGAGAATGACAAGGTTGTGGCCATGTCCTTC
CATTACTTCTCAATGGGAGACTGTATAGGATGGCTTGAGGACTTCTTGATGGGCATGGACAGCCCCAGA
GGGCCCACAATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTC
TTCATCTTCCCTCCAAAGATCAANNATGNNCNNNTNAN 
TTCNNNNNCCNNNNAANNNNCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTG
GTGGATGTGAGCGAGGATGACCCAGATGTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACA
GCTCAGACACAAACCCATAGAGAGGATTACAACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAG
CACCAGGACTGGATGAGTGGCAAGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATC
GAGAGAACCATCTCAAAACCCAAAGGGTCAGTAAGAGCTCC   
              
 
 
GAATTC: EcoRI restriction site 
TCATGA: BspHI restriction site  
Blue:  Fc portion of mIgG2A 
Molecular weight = 49244.13 Daltons 
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Alignment  
 
Query  7     ATGGCAGCAGCCGCCGCTACCAAGATCCTTCTGTGCCTCCCGCTTCTGCTCCTGCTGTCC  66 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1     ATGGCAGCAGCCGCCGCTACCAAGATCCTTCTGTGCCTCCCGCTTCTGCTCCTGCTGTCC  60 
 
Query  67    GGCTGGTCCCGGGCTGGGCGAGCCGACCCTCACTCTCTTTGCTATGACATCACCGTCATC  126 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61    GGCTGGTCCCGGGCTGGGCGAGCCGACCCTCACTCTCTTTGCTATGACATCACCGTCATC  120 
 
Query  127   CCTAAGTTCAGACCTGGACCACGGTGGTGTGCGGTTCAAGGCCAGGTGGATGAAAAGACT  186 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121   CCTAAGTTCAGACCTGGACCACGGTGGTGTGCGGTTCAAGGCCAGGTGGATGAAAAGACT  180 
 
Query  187   TTTCTTCACTATGACTGTGGCAGCAAGACAGTCACACCTGTCAGTCCCCTGGGGAAGAAA  246 
             |||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||| 
Sbjct  181   TTTCTTCACTATGACTGTGGCAACAAGACAGTCACACCTGTCAGTCCCCTGGGGAAGAAA  240 
 
Query  247   CTAAATGTCACAACGGCCTGGAAAGCACAGAACCCAGTACTGAGAGAGGTGGTGGACATA  306 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241   CTAAATGTCACAACGGCCTGGAAAGCACAGAACCCAGTACTGAGAGAGGTGGTGGACATA  300 
 
Query  307   CTTACAGAGCAACTGCGTGACATTCAGCTGGAGAATTACACACCCAAGGAACCCCTCACC  366 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301   CTTACAGAGCAACTGCGTGACATTCAGCTGGAGAATTACACACCCAAGGAACCCCTCACC  360 
 
Query  367   CTGCAGGCCAGGATGTCTTGTGAGCAGAAAGCTGAAGGACACAGCAGTGGATCTTGGCAG  426 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361   CTGCAGGCCAGGATGTCTTGTGAGCAGAAAGCTGAAGGACACAGCAGTGGATCTTGGCAG  420 
 
Query  427   TTCAGTTTCGATGGGCAGATCTTCCCCCTCTTTGACTCAGAGAAGAGAATGTGGACAACG  486 
             ||||||||||||||||||||||||| |||||||||||||||||||||||||||||||||| 
Sbjct  421   TTCAGTTTCGATGGGCAGATCTTCCTCCTCTTTGACTCAGAGAAGAGAATGTGGACAACG  480 
 
Query  487   GTTCATCCTGGAGCCAGAAAGATGAAAGAAAAGTGGGAGAATGACAAGGTTGTGGCCATG  546 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  481   GTTCATCCTGGAGCCAGAAAGATGAAAGAAAAGTGGGAGAATGACAAGGTTGTGGCCATG  540 
 
Query  547   TCCTTCCATTACTTCTCAATGGGAGACTGTATAGGATGGCTTGAGGACTTCTTGATGGGC  606 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  541   TCCTTCCATTACTTCTCAATGGGAGACTGTATAGGATGGCTTGAGGACTTCTTGATGGGC  600 
 
Query  607   ATGGACAGCCCCAGAGGGCCCACAATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACCT  666 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  601   ATGGACAGCCCCAGAGGGCCCACAATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACCT  660 
 
Query  667   AACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAGATCAAGGATGTACTCATG  726 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  661   AACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAGATCAAGGATGTACTCATG  720 
 
Query  727   ATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAGGATGACCCAGAT  786 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  721   ATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAGGATGACCCAGAT  780 
 
Query  787   GTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACAGCTCAGACACAAACCCAT  846 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  781   GTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACAGCTCAGACACAAACCCAT  840 
 
Query  847   AGAGAGGATTACAACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCACCAGGAC  906 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  841   AGAGAGGATTACAACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCACCAGGAC  900 
 
Query  907   TGGATGAGTGGCAAGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATC  966 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  901   TGGATGAGTGGCAAGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATC  960 
 
Query  967   GAGAGAACCATCTCAAAACCCAAAGGGTCAGTAAGAGCTCC  1007 
             ||||||||||||||||||||||||||||||||||||||||| 
Sbjct  961   GAGAGAACCATCTCAAAACCCAAAGGGTCAGTAAGAGCTCC  1001 
 
 
 
 
BspHI 
 
 
 
353 
 
9.4.2 Recombinant hULBP2-mFc  sequence  
ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCGTGT
GCGGTTCAAGGCCAGGTGGATGAAAAGACTTTTCTTCACTATGACTGTGGCAACAAGACAGTCACACCT
GTCAGTCCCCTGGGGAAGAAACTAAATGTCACAACGGCCTGGAAAGCACAGAACCCAGTACTGAGAGAG
GTGGTGGACATACTTACAGAGCAACTGCGTGACATTCAGCTGGAGAATTACACACCCAAGGAACCCCTC
ACCCTGCAGGCCAGGATGTCTTGTGAGCAGAAAGCTGAAGGACACAGCAGTGGATCTTGGCAGTTCAGT
TTCGATGGGCAGATCTTCCTCCTCTTTGACTCAGAGAAGAGAATGTGGACAACGGTTCATCCTGGAGCC
AGAAAGATGAAAGAAAAGTGGGAGAATGACAAGGTTGTGGCCATGTCCTTCCATTACTTCTCAATGGGA
GACTGTATAGGATGGCTTGAGGACTTCTTGATGGGCATGGACAGCCCCAGAGGGCCCACAATCAAGCCC
TGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAG
ATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAGGAT
GACCCAGATGTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACAGCTCAGACACAAACCCAT
AGAGAGGATTACAACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCACCAGGACTGGATGAGT
GGCAAGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATCGAGAGAACCATCTCAAAA
CCCAAAGGGTCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGAAGAAGAGATGACTAAGAAA
CAGGTCACTCTGACCTGCATGGTCACAGACTTCATGCCTGAAGACATTTACGTGGAGTGGACCAACAAC
GGGAAAACAGAGCTAAACTACAAGAACACTGAACCAGTCCTGGACTCTGATGGTTCTTACTTCATGTAC
AGCAAGCTGAGAGTGGAAAAGAAGAACTGGGTGGAAAGAAATAGCTACTCCTGTTCAGTGGTCCACGAG
GGTCTGCACAATCACCACACGACTAAGAGCTTCTCCCGGACTCCGGGTAAATGA (1 21 bp)  
 
Green: hIL-2 leader sequence = 60 bp 
Red:   Sequence encoding for extracellular portion of ULBP  protein = 4  
Blue:   Sequence encoding for Fc region of mIgG2A = 699 bp 
 
Translation  
MYRMQLLSCIALSLALVTNSCAVQGQVDEKTFLHYDCGNKTVTPVSPLGKKLNVTTAWKAQNPVLREVV
DILTEQLRDIQLENYTPKEPLTLQARMSCEQKAEGHSSGSWQFSFDGQIFLLFDSEKRMWTTVHPGARK
MKEKWENDKVVAMSFHYFSMGDCIGWLEDFLMGMDSPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIK
DVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGK
EFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGK
TELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK 
 
Green: IL-2 Leader protein sequence 
Red:    Extracellular portion of ULBP2 protein  
Blue:  Fc portion of mIgG2A 
Molecular weight = 46106.91 Daltons 
 
9.4.2.1  Alignment of the cloned nucleotide sequence to hULBP2-mFc2 sequence 
 
Results of sequencing 
NNTNNNNNTGTGACCGGCGCCTACCTGAGATCACCGGCGAAGGAGGGCCACCATGTACAGGATGCAACT
CCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCGTGTGCGGTTCAAGGCCAGGTGGATGA
AAAGACTTTTCTTCACTATGACTGTGGCAACAAGACAGTCACACCTGTCAGTCCCCTGGGGAAGAAACT
AAATGTCACAACGGCCTGGAAAGCACAGAACCCAGTACTGAGAGAGGTGGTGGACATACTTACAGAGCA
ACTGCGTGACATTCAGCTGGAGAATTACACACCCAAGGAACCCCTCACCCTGCAGGCCAGGATGTCTTG
TGAGCAGAAAGCTGAAGGACACAGCAGTGGATCTTGGCAGTTCAGTTTCGATGGGCAGATCTTCCTCCT
CTTTGACTCAGAGAAGAGAATGTGGACAACGGTTCATCCTGGAGCCAGAAAGATGAAAGAAAAGTGGGA
GAATGACAAGGTTGTGGCCATGTCCTTCCATTACTTCTCAATGGGAGACTGTATAGGATGGCTTGAGGA
CTTCTTGATGGGCATGGACAGCCCCAGAGGGCCCACAATCAAGCCCTGTCCTCCATGCAAATGCCCAGC
ACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTC
CCTGAGCCCCATAGTCACATGTGTGNTGG 
 
GAATTC: EcoRI restriction site  TCATGA: BspHI restriction site 
 
 
354 
 
Alignment  
 
Query  53   ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCG  112 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCG  60 
 
Query  113  TGTGCGGTTCAAGGCCAGGTGGATGAAAAGACTTTTCTTCACTATGACTGTGGCAACAAG  172 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   TGTGCGGTTCAAGGCCAGGTGGATGAAAAGACTTTTCTTCACTATGACTGTGGCAACAAG  120 
 
Query  173  ACAGTCACACCTGTCAGTCCCCTGGGGAAGAAACTAAATGTCACAACGGCCTGGAAAGCA  232 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  ACAGTCACACCTGTCAGTCCCCTGGGGAAGAAACTAAATGTCACAACGGCCTGGAAAGCA  180 
 
Query  233  CAGAACCCAGTACTGAGAGAGGTGGTGGACATACTTACAGAGCAACTGCGTGACATTCAG  292 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CAGAACCCAGTACTGAGAGAGGTGGTGGACATACTTACAGAGCAACTGCGTGACATTCAG  240 
 
Query  293  CTGGAGAATTACACACCCAAGGAACCCCTCACCCTGCAGGCCAGGATGTCTTGTGAGCAG  352 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  CTGGAGAATTACACACCCAAGGAACCCCTCACCCTGCAGGCCAGGATGTCTTGTGAGCAG  300 
 
Query  353  AAAGCTGAAGGACACAGCAGTGGATCTTGGCAGTTCAGTTTCGATGGGCAGATCTTCCTC  412 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  AAAGCTGAAGGACACAGCAGTGGATCTTGGCAGTTCAGTTTCGATGGGCAGATCTTCCTC  360 
 
Query  413  CTCTTTGACTCAGAGAAGAGAATGTGGACAACGGTTCATCCTGGAGCCAGAAAGATGAAA  472 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTCTTTGACTCAGAGAAGAGAATGTGGACAACGGTTCATCCTGGAGCCAGAAAGATGAAA  420 
 
Query  473  GAAAAGTGGGAGAATGACAAGGTTGTGGCCATGTCCTTCCATTACTTCTCAATGGGAGAC  532 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GAAAAGTGGGAGAATGACAAGGTTGTGGCCATGTCCTTCCATTACTTCTCAATGGGAGAC  480 
 
Query  533  TGTATAGGATGGCTTGAGGACTTCTTGATGGGCATGGACAGCCCCAGAGGGCCCACAATC  592 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  481  TGTATAGGATGGCTTGAGGACTTCTTGATGGGCATGGACAGCCCCAGAGGGCCCACAATC  540 
 
Query  593  AAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTC  652 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  541  AAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTC  600 
 
Query  653  ATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGT  712 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  601  ATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGT  660 
 
Query  713  GTGNTGG  719 
            ||| ||| 
Sbjct  661  GTGGTGG  667 
 
 
 
9.5 Human ULBP3 sequence  
The human ULBP3 sequence (NCBI Reference Sequence: NM_024518.1) is presented 
below. It consists of a leader peptide (L), extracellular segment (α1 and α2 domains) and GPI anchor 
signal (Cosman et al, 2001). The sequence encoding for extracellular region includes L, α1 and α2 and it 
is 612 bp in length (Cosman et al, 2001). It starts from position 1 bp and ends at position 612.  
ATGGCAGCGG CCGCCAGCCC CGCGATCCTT CCGCGCCTCG CGATTCTTCC GTACCTGCTA 
TTCGACTGGT CCGGGACGGG GCGGGCCGAC GCTCACTCTC TCTGGTATAA CTTCACCATC 
ATTCATTTGC CCAGACATGG GCAACAGTGG TGTGAGGTCC AGAGCCAGGT GGATCAGAAG 
AATTTTCTCT CCTATGACTG TGGCAGTGAC AAGGTCTTAT CTATGGGTCA CCTAGAAGAG 
CAGCTGTATG CCACAGATGC CTGGGGAAAA CAACTGGAAA TGCTGAGAGA GGTGGGGCAG 
AGGCTCAGAC TGGAACTGGC TGACACTGAG CTGGAGGATT TCACACCCAG TGGACCCCTC 
ACGCTGCAGG TCAGGATGTC TTGTGAGTGT GAAGCCGATG GATACATCCG TGGATCTTGG 
CAGTTCAGCT TCGATGGACG GAAGTTCCTC CTCTTTGACT CAAACAACAG AAAGTGGACA 
GTGGTTCACG CTGGAGCCAG GCGGATGAAA GAGAAGTGGG AGAAGGATAG CGGACTGACC 
ACCTTCTTCA AGATGGTCTC AATGAGAGAC TGCAAGAGCT GGCTTAGGGA CTTCCTGATG 
CACAGGAAGA AGAGGCTGGA ACCCACAGCA CCACCCACCA TGGCCCCAGG CTTAGCTCAA 
CCCAAAGCCA TAGCCACCAC CCTCAGTCCC TGGAGCTTCC TCATCATCCT CTGCTTCATC 
CTCCCTGGCA TCTGA (735 bp) 
 
EcoRI 
 
BspHI 
 
 
355 
 
Red:    Leader sequence = 150 nucleotides 
Blue:   Alpha 1 domain = 310 nucleotides 
Green: Alpha 2 domain = 152 nucleotides 
 
 
9.5.1 Recombinant hULBP3-mFc1 sequence  
ATGGCAGCGGCCGCCAGCCCCGCGATCCTTCCGCGCCTCGCGATTCTTCCGTACCTGCTATTCGACTGG
TCCGGGACGGGGCGGGCCGACGCTCACTCTCTCTGGTATAACTTCACCATCATTCATTTGCCCAGACAT
GGGCAACAGTGGTGTGAGGTCCAGAGCCAGGTGGATCAGAAGAATTTTCTCTCCTATGACTGTGGCAGT
GACAAGGTCTTATCTATGGGTCACCTAGAAGAGCAGCTGTATGCCACAGATGCCTGGGGAAAACAACTG
GAAATGCTGAGAGAGGTGGGGCAGAGGCTCAGACTGGAACTGGCTGACACTGAGCTGGAGGATTTCACA
CCCAGTGGACCCCTCACGCTGCAGGTCAGGATGTCTTGTGAGTGTGAAGCCGATGGATACATCCGTGGA
TCTTGGCAGTTCAGCTTCGATGGACGGAAGTTCCTCCTCTTTGACTCAAACAACAGAAAGTGGACAGTG
GTTCACGCTGGAGCCAGGCGGATGAAAGAGAAGTGGGAGAAGGATAGCGGACTGACCACCTTCTTCAAG
ATGGTCTCAATGAGAGACTGCAAGAGCTGGCTTAGGGACTTCCTGATGCACAGGAAGAAGCCCAGAGGG
CCCACAATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTC
ATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTG
GATGTGAGCGAGGATGACCCAGATGTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACAGCT
CAGACACAAACCCATAGAGAGGATTACAACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCAC
CAGGACTGGATGAGTGGCAAGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATCGAG
AGAACCATCTCAAAACCCAAAGGGTCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGAAGAA
GAGATGACTAAGAAACAGGTCACTCTGACCTGCATGGTCACAGACTTCATGCCTGAAGACATTTACGTG
GAGTGGACCAACAACGGGAAAACAGAGCTAAACTACAAGAACACTGAACCAGTCCTGGACTCTGATGGT
TCTTACTTCATGTACAGCAAGCTGAGAGTGGAAAAGAAGAACTGGGTGGAAAGAAATAGCTACTCCTGT
TCAGTGGTCCACGAGGGTCTGCACAATCACCACACGACTAAGAGCTTCTCCCGGACTCCGGGTAAATGA 
(1311 bp) 
 
Black:  Leader sequence = 150 bp 
Red:   Ssequence encoding for the extracellular portion of hULBP3 protein = 462 bp 
Blue:  Sequence encoding for Fc region of mIgG2A = 699 bp 
TCATGA: BspHI restriction site  
 
Translation  
MAAAASPAILPRLAILPYLLFDWSGTGRADAHSLWYNFTIIHLPRHGQQWCEVQSQVDQKNFLSYDCGSD
KVLSMGHLEEQLYATDAWGKQLEMLREVGQRLRLELADTELEDFTPSGPLTLQVRMSCECEADGYIRGSW
QFSFDGRKFLLFDSNNRKWTVVHAGARRMKEKWEKDSGLTTFFKMVSMRDCKSWLRDFLMHRKKPRGPTI
KPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQT
HREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKK
QVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEG
LHNHHTTKSFSRTPGK 
 
Black: Leader protein sequence 
Red:    Extracellular portion of ULBP3 protein  
Blue:  Fc portion of mIgG2A 
Molecular weight = 49966.2 Daltons 
 
 
 
 
 
 
 
356 
 
9.5.1.1  Alignment of the cloned nucleotide sequence to hULBP3-mFc1 sequence 
 
Results of sequencing 
NAATTGAANCGGGTGCNNNNNNNNGGTNGGCNNNGGGGTAAANTGGAAAGTGANGTNGNGTACNGNNCNNNTTTTNN
CNNGGGTGGGGGNNNNACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGNGTTTGCCGCCAGA
ACACAGCTGAAGCTTCGAGNNGCTCGCATNTNTCCTTCACGCGCCCGCCGCCCTACCTGAGGCCGCCANCCACGCCG
GTTGAGTCGCGTTCTGCCGCCTCCCGCNTGTGGTGCCTCNTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCA
GGTCGAGACCGGGCCTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCNCCACGCTTTGCCTGACC
CTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATNCAAGCTGTGACCGGCGCCTAC
CTGAGATCACCGGTGAATTCATGGCAGCGGCCGCCAGCCCCGCGATCCTTCCGCGCCTCGCGATTCTTCCGTACCTG
CTATTCGACTGGTCCGGGACGGGGCGGGCCGACGCTCACTCTCTCTGGTATAACTTCACCATCATTCATTTGCCCAG
ACATGGGCAACAGTGGTGTGAGGTCCAGAGCNNNNTGGATNNNNANN 
NNATGGNNAANNNNNNNGTNNNNNNCAGAGCCAGGTGGATCAGAAGAATTTTCTCTCCTATGACTGTGGCAGTGACA
AGGTCTTATCTATGGGTCACCTAGAAGAGCAGCTGTATGCCACAGATGCCTGGGGAAAACAACTGGAAATGCTGAGA
GAGGTGGGGCAGAGGCTCAGACTGGAACTGGCTGACACTGAGCTGGAGGATTTCACACCCAGTGGACCCCTCACGCT
GCAGGTCAGGATGTCTTGTGAGTGTGAAGCCGATGGATACATCCGTGGATCTTGGCAGTTCAGCTTCGATGGACGGA
AGTTCCTCCTCTTTGACTCAAACAACAGAAAGTGGACAGTGGTTCACGCTGGAGCCAGGCGGATGAAAGAGAAGTGG
GAGAAGGATAGCGGACTGACCACCTTCTTCAAGATGGTCTCAATGAGAGACTGCAAGAGCTGGCTTAGGGACTTCCT
GATGCACAGGAAGAAGCCCAGAGGGCCCACAATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGG
GTGGACCATCCGTCTTCATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCNNANCCCNANNNNNNNNN 
 
Alignment 
Query  483   ATGGCAGCGGCCGCCAGCCCCGCGATCCTTCCGCGCCTCGCGATTCTTCCGTACCTGCTA  542 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1     ATGGCAGCGGCCGCCAGCCCCGCGATCCTTCCGCGCCTCGCGATTCTTCCGTACCTGCTA  60 
 
Query  543   TTCGACTGGTCCGGGACGGGGCGGGCCGACGCTCACTCTCTCTGGTATAACTTCACCATC  602 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61    TTCGACTGGTCCGGGACGGGGCGGGCCGACGCTCACTCTCTCTGGTATAACTTCACCATC  120 
 
Query  603   ATTCATTTGCCCAGACATGGGCAACAGTGGTGTGAGGTCCAGAGCCAGGTGGATCAGAAG  662 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121   ATTCATTTGCCCAGACATGGGCAACAGTGGTGTGAGGTCCAGAGCCAGGTGGATCAGAAG  180 
 
Query  663   AATTTTCTCTCCTATGACTGTGGCAGTGACAAGGTCTTATCTATGGGTCACCTAGAAGAG  722 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181   AATTTTCTCTCCTATGACTGTGGCAGTGACAAGGTCTTATCTATGGGTCACCTAGAAGAG  240 
 
Query  723   CAGCTGTATGCCACAGATGCCTGGGGAAAACAACTGGAAATGCTGAGAGAGGTGGGGCAG  782 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241   CAGCTGTATGCCACAGATGCCTGGGGAAAACAACTGGAAATGCTGAGAGAGGTGGGGCAG  300 
 
Query  783   AGGCTCAGACTGGAACTGGCTGACACTGAGCTGGAGGATTTCACACCCAGTGGACCCCTC  842 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301   AGGCTCAGACTGGAACTGGCTGACACTGAGCTGGAGGATTTCACACCCAGTGGACCCCTC  360 
 
Query  843   ACGCTGCAGGTCAGGATGTCTTGTGAGTGTGAAGCCGATGGATACATCCGTGGATCTTGG  902 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361   ACGCTGCAGGTCAGGATGTCTTGTGAGTGTGAAGCCGATGGATACATCCGTGGATCTTGG  420 
 
Query  903   CAGTTCAGCTTCGATGGACGGAAGTTCCTCCTCTTTGACTCAAACAACAGAAAGTGGACA  962 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421   CAGTTCAGCTTCGATGGACGGAAGTTCCTCCTCTTTGACTCAAACAACAGAAAGTGGACA  480 
 
Query  963   GTGGTTCACGCTGGAGCCAGGCGGATGAAAGAGAAGTGGGAGAAGGATAGCGGACTGACC  1022 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  481   GTGGTTCACGCTGGAGCCAGGCGGATGAAAGAGAAGTGGGAGAAGGATAGCGGACTGACC  540 
 
Query  1023  ACCTTCTTCAAGATGGTCTCAATGAGAGACTGCAAGAGCTGGCTTAGGGACTTCCTGATG  1082 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  541   ACCTTCTTCAAGATGGTCTCAATGAGAGACTGCAAGAGCTGGCTTAGGGACTTCCTGATG  600 
 
Query  1083  CACAGGAAGAAGCCCAGAGGGCCCACAATCAAGCCCTGTCCTCCATGCAAATGCCCAGCA  1142 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  601   CACAGGAAGAAGCCCAGAGGGCCCACAATCAAGCCCTGTCCTCCATGCAAATGCCCAGCA  660 
 
Query  1143  CCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAGATCAAGGATGTACTC  1202 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  661   CCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAGATCAAGGATGTACTC  720 
 
 
 
357 
 
 
 
 
Query  1203  ATGATCTCC  1211 
             ||||||||| 
Sbjct  721   ATGATCTCC  729 
 
 
 
9.5.2 Recombinant hULBP3-mFc2 sequence  
ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCGTGT
GAGGTCCAGAGCCAGGTGGATCAGAAGAATTTTCTCTCCTATGACTGTGGCAGTGACAAGGTCTTATCT
ATGGGTCACCTAGAAGAGCAGCTGTATGCCACAGATGCCTGGGGAAAACAACTGGAAATGCTGAGAGAG
GTGGGGCAGAGGCTCAGACTGGAACTGGCTGACACTGAGCTGGAGGATTTCACACCCAGTGGACCCCTC
ACGCTGCAGGTCAGGATGTCTTGTGAGTGTGAAGCCGATGGATACATCCGTGGATCTTGGCAGTTCAGC
TTCGATGGACGGAAGTTCCTCCTCTTTGACTCAAACAACAGAAAGTGGACAGTGGTTCACGCTGGAGCC
AGGCGGATGAAAGAGAAGTGGGAGAAGGATAGCGGACTGACCACCTTCTTCAAGATGGTCTCAATGAGA
GACTGCAAGAGCTGGCTTAGGGACTTCCTGATGCACAGGAAGAAGCCCAGAGGGCCCACAATCAAGCCC
TGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAG
ATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAGGAT
GACCCAGATGTCCAGATCAGCTGGTTTGTGAACAACGTGGAAGTACACACAGCTCAGACACAAACCCAT
AGAGAGGATTACAACAGTACTCTCCGGGTGGTCAGTGCCCTCCCCATCCAGCACCAGGACTGGATGAGT
GGCAAGGAGTTCAAATGCAAGGTCAACAACAAAGACCTCCCAGCGCCCATCGAGAGAACCATCTCAAAA
CCCAAAGGGTCAGTAAGAGCTCCACAGGTATATGTCTTGCCTCCACCAGAAGAAGAGATGACTAAGAAA
CAGGTCACTCTGACCTGCATGGTCACAGACTTCATGCCTGAAGACATTTACGTGGAGTGGACCAACAAC
GGGAAAACAGAGCTAAACTACAAGAACACTGAACCAGTCCTGGACTCTGATGGTTCTTACTTCATGTAC
AGCAAGCTGAGAGTGGAAAAGAAGAACTGGGTGGAAAGAAATAGCTACTCCTGTTCAGTGGTCCACGAG
GGTCTGCACAATCACCACACGACTAAGAGCTTCTCCCGGACTCCGGGTAAATGA 
 
Green: hIL-2 leader sequence = 60 bp. 
Red:    Sequence encodes for the extracellular portion of ULBP3 protein = 462 
Blue:   Sequence encoding for Fc region of mIgG2A = 699 bp. 
GAATTC: EcoRI restriction site 
TCATGA: BspHI restriction site  
 
Translation  
MYRMQLLSCIALSLALVTNSCEVQSQVDQKNFLSYDCGSDKVLSMGHLEEQLYATDAWGKQLEMLREVG
QRLRLELADTELEDFTPSGPLTLQVRMSCECEADGYIRGSWQFSFDGRKFLLFDSNNRKWTVVHAGARR
MKEKWEKDSGLTTFFKMVSMRDCKSWLRDFLMHRKKPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIK
DVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGK
EFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGK
TELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK 
 
Green:  hIL-2 Leader protein sequence 
Red:    Extracellular portion of ULBP3 protein  
Blue:  Fc portion of mIgG2A 
Molecular weight = 46546.94 Daltons 
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9.5.2.1  Alignment of the cloned nucleotide sequence to hULBP3-mFc2 sequence 
 
Results of sequencing 
 
AAGCTGTGACCGGCGCCTACCTGAGATCACCGGCGAAGGAGGGCCACCATGTACAGGATGCAACTCCTG
TCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCGTGTGAGGTCCAGAGCCAGGTGGATCAGAAG
AATTTTCTCTCCTNNNNNNGTGNNNN 
AATTTTCTCTCCTATGACTGTGGCAGTGACAAGGTCTTATCTATGGGTCACCTAGAAGAGCAGCTGTAT
GCCACAGATGCCTGGGGAAAACAACTGGAAATGCTGAGAGAGGTGGGGCAGAGGCTCAGACTGGAACTG
GCTGACACTGAGCTGGAGGATTTCACACCCAGTGGACCCCTCACGCTGCAGGTCAGGATGTCTTGTGAG
TGTGAAGCCGATGGATACATCCGTGGATCTTGGCAGTTCAGCTTCGATGGACGGAAGTTCCTCCTCTTT
GACTCAAACAACAGAAAGTGGACAGTGGTTCACGCTGGAGCCAGGCGGATGAAAGAGAAGTGGGAGAAG
GATAGCGGACTGACCACCTTCTTCAAGATGGTCTCAATGAGAGACTGCAAGAGCTGGCTTAGGGACTTC
CTGATGCACAGGAAGAAGCCCAGAGGGCCCACAATCAAGCCCTGTCCTCCATGCAAATGCCCAGCACCT
AACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTG
AGCCCCATAGTCACATGTGTGGTGGTGGATGTGAGCGAGGATGACCCAGATGTCCAGATCAGCTGGTTT
GTGAACAACGTGGAAGTACACACAGCTCAGACACAAACCCATAGAGAGGATTACAACAGTACTCTCCGG
GTGGTCAGTGCCCTCCCCATCCAGCACCAGGACTGGATGAGTGGCAAGGAGTTCAAATGCAAGGTCAAC
AACAAAGACCT 
 
 
Alignment 
 
Query  49   ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCG  108 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1    ATGTACAGGATGCAACTCCTGTCTTGCATTGCACTAAGTCTTGCACTTGTCACGAATTCG  60 
 
Query  109  TGTGAGGTCCAGAGCCAGGTGGATCAGAAGAATTTTCTCTCCTATGACTGTGGCAGTGAC  168 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   TGTGAGGTCCAGAGCCAGGTGGATCAGAAGAATTTTCTCTCCTATGACTGTGGCAGTGAC  120 
 
Query  169  AAGGTCTTATCTATGGGTCACCTAGAAGAGCAGCTGTATGCCACAGATGCCTGGGGAAAA  228 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  AAGGTCTTATCTATGGGTCACCTAGAAGAGCAGCTGTATGCCACAGATGCCTGGGGAAAA  180 
 
Query  229  CAACTGGAAATGCTGAGAGAGGTGGGGCAGAGGCTCAGACTGGAACTGGCTGACACTGAG  288 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  CAACTGGAAATGCTGAGAGAGGTGGGGCAGAGGCTCAGACTGGAACTGGCTGACACTGAG  240 
 
Query  289  CTGGAGGATTTCACACCCAGTGGACCCCTCACGCTGCAGGTCAGGATGTCTTGTGAGTGT  348 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  CTGGAGGATTTCACACCCAGTGGACCCCTCACGCTGCAGGTCAGGATGTCTTGTGAGTGT  300 
 
Query  349  GAAGCCGATGGATACATCCGTGGATCTTGGCAGTTCAGCTTCGATGGACGGAAGTTCCTC  408 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  GAAGCCGATGGATACATCCGTGGATCTTGGCAGTTCAGCTTCGATGGACGGAAGTTCCTC  360 
 
Query  409  CTCTTTGACTCAAACAACAGAAAGTGGACAGTGGTTCACGCTGGAGCCAGGCGGATGAAA  468 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  CTCTTTGACTCAAACAACAGAAAGTGGACAGTGGTTCACGCTGGAGCCAGGCGGATGAAA  420 
 
Query  469  GAGAAGTGGGAGAAGGATAGCGGACTGACCACCTTCTTCAAGATGGTCTCAATGAGAGAC  528 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  GAGAAGTGGGAGAAGGATAGCGGACTGACCACCTTCTTCAAGATGGTCTCAATGAGAGAC  480 
 
Query  529  TGCAAGAGCTGGCTTAGGGACTTCCTGATGCACAGGAAGAAGCCCAGAGGGCCCACAATC  588 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  481  TGCAAGAGCTGGCTTAGGGACTTCCTGATGCACAGGAAGAAGCCCAGAGGGCCCACAATC  540 
 
Query  589  AAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTC  648 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  541  AAGCCCTGTCCTCCATGCAAATGCCCAGCACCTAACCTCTTGGGTGGACCATCCGTCTTC  600 
 
Query  649  ATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGT  708 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  601  ATCTTCCCTCCAAAGATCAAGGATGTACTCATGATCTCCCTGAGCCCCATAGTCACATGT  660 
 
Query  709  GTGGTGGTGGATGTGAGCGAGGATGACCCAGATGTCCAGATCAGCTGGTTTGTGAACAAC  768 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  661  GTGGTGGTGGATGTGAGCGAGGATGACCCAGATGTCCAGATCAGCTGGTTTGTGAACAAC  720 
 
EcoRI 
 
BspHI 
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Query  769  GTGGAAGTACACACAGCTCAGACACAAACCCATAGAGAGGATTACAACAGTACTCTCCGG  828 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  721  GTGGAAGTACACACAGCTCAGACACAAACCCATAGAGAGGATTACAACAGTACTCTCCGG  780 
 
Query  829  GTGGTCAGTGCCCTCCCCATCCAGCACCAGGACTGGATGAGTGGCAAGGAGTTCAAATGC  888 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  781  GTGGTCAGTGCCCTCCCCATCCAGCACCAGGACTGGATGAGTGGCAAGGAGTTCAAATGC  840 
 
Query  889  AAGGTCAACAACAAAGACCT  908 
            |||||||||||||||||||| 
Sbjct  841  AAGGTCAACAACAAAGACCT  860 
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